

Friday, December 28, 2018



Volume 49 No. 12

NOTICE – Items in this issue will be listed online weekly and printed monthly.

### 1-800 FLOWERS.COM, INC.

Earnings, 3 mos. to (Consol. – \$000):

	09/30/18	10/01/17
Total Revenues	169,496	157,349
Cost & expenses	184,619	168,868
Deprec., depl. & amort.	7,843	8,084
Operating income	(22,966)	(19,603)
Interest expense	990	1,031
Other income (expense), net	274	260
Net before taxes	(23,682)	(20,374)
Income taxes	(6,416)	(7,152)
<b>Net income</b>	<b>(17,266)</b>	<b>(13,222)</b>
Earnings common share		
Primary	\$(0.27)	\$(0.20)
Fully Diluted	\$(0.27)	\$(0.20)
Common Shares:		
Full Diluted	64,620	64,954
Year-end	64,434	64,692

### Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	27,016	
Inventories	160,680	
Current assets	244,429	
Net property & equip.	160,350	
Total assets	540,605	
Liabilities:		
Current liabilities	114,877	
Long-term debt	89,617	
Stockholders' equity	295,984	
Net current assets	129,552	

### 1347 PROPERTY INSURANCE HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	42,241	26,994
Cost & expenses	31,424	20,620
Operating income	(24)	(1,493)
Net before taxes	(24)	(1,493)
Income taxes	4	(397)
<b>Net income</b>	<b>(28)</b>	<b>(1,096)</b>
Balance for common	(786)	(1,096)
Earnings common share		
Primary	\$(0.13)	\$(0.18)
Fully Diluted	\$(0.13)	\$(0.18)
Common Shares:		
Full Diluted	5,988	5,958
Year-end	5,992	5,985

### ACACIA RESEARCH CORP

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	82,303,000	61,944,000
Cost & expenses	118,132,000	81,886,000
Operating income	(35,829,000)	(19,942,000)
Other income (expense), net	(52,127,000)	146,151,000
Gains or losses	(5,539,000)	7,287,000
Net before taxes	(92,699,000)	134,919,000
Income taxes	782,000	2,935,000
<b>Net income</b>	<b>(93,481,000)</b>	<b>131,984,000</b>
Earnings common share		
Primary	\$(1.87)	\$2.62
Fully Diluted	\$(1.87)	\$2.61
Common Shares:		
Full Diluted	50,080,234	50,684,725
Year-end	49,639,319	48,875,374

### ACHILLION PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	57,739	65,221
Operating income	(57,739)	(65,221)
Interest income	4,093	3,225
Interest expense	25	37
<b>Net income</b>	<b>(53,671)</b>	<b>(62,033)</b>
Earnings common share		
Primary	\$(0.39)	\$(0.45)
Fully Diluted	\$(0.39)	\$(0.45)
Common Shares:		
Full Diluted	138,344	136,947
Year-end	138,589	

### ACLARIS THERAPEUTICS INC

**Acquisition Completed** On Nov. 30, 2018, Co. acquired the worldwide rights to RHOFADÉ (oxymetazoline hydrochloride) cream, 1%, which includes an exclusive license to the Rhofade Licensed Patents pursuant to the License Agreement, as well as additional intellectual property (the "Acquisition"), from Allergan Sales, LLC ("Allergan"), a wholly-owned subsidiary of Allergan, Plc., for total cash consideration of approximately \$66,100,000, consisting of approximately \$59,600,000 paid to Allergan and \$6,500,000 placed in escrow. Co. has also agreed to pay Allergan a one-time payment of \$5,000,000 upon the achievement of a specified development milestone related to the potential development of an additional dermatology product. In addition, Co. has agreed to pay Allergan specified royalty payments, ranging from a mid-single digit percentage to a mid-teen percentage of net sales, subject to specified reductions, limitations and other adjustments, on a country-by-country basis until the date that the patent rights related to a particular product, such as RHOFADÉ, have expired or, if later, Nov. 30, 2028. In addition, Co. has agreed to assume the obligation to pay specified royalties and milestone payments under agreements with Aspect Pharmaceuticals, LLC and Vicept Therapeutics, Inc. Members of Co.'s management team, including Neal Walker, Frank Ruffo, Christopher Powala and Stuart Shanler, as well as Stephen Tullman, the chairman of Co.'s board of directors, were former stockholders of Vicept Therapeutics, Inc., and Dr. Shanler was also a member of Aspect Pharmaceuticals, LLC. In their capacities as current or former holders of equity interests in these entities, these individuals may be entitled to receive a portion of the potential future payments payable by Co.

### ACM RESEARCH INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	53,795	19,314
Cost & expenses	49,964	22,379
Operating income	3,831	(3,065)
Interest income	20	7
Interest expense	364	197
Other income (expense), net	1,448	(511)
Net before taxes	4,935	(3,766)
Income taxes	647	471
<b>Net income</b>	<b>4,288</b>	<b>(4,237)</b>
Earnings common share		
Primary	\$0.27	\$(0.72)
Fully Diluted	\$0.24	\$(0.72)
Common Shares:		
Full Diluted	17,816	5,148
Year-end	15,988	7,151

### ADAMAS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	20,731	3
Cost & expenses	110,454	59,046
Operating income	(89,723)	(59,043)
Interest expense	15,324	2,406
Net before taxes	(60,184)	(61,818)
Income taxes		(51)

	2018	2017
<b>Net income</b>	<b>(102,116)</b>	<b>(60,133)</b>
Earnings common share		
Primary	\$(3.82)	\$(2.69)
Fully Diluted	\$(3.82)	\$(2.69)
Common Shares:		
Full Diluted	26,728	22,390
Year-end	27,336	22,716

### ADVANTAGE TECHNOLOGIES GROUP, INC.

**Interest Sale Completed** On Nov. 29, 2018, Co. sold its property located at 1221 E. Houston Street, Broken Arrow, Oklahoma, 74012, which served as Co.'s headquarters, to David Chymiak, LLC, a company controlled by David Chymiak, the Chief Technology Officer, director and a substantial shareholder of Co., for a cash purchase price of \$5,000,000.

### ADTRAN, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Net Sales	389,189,000	540,064,000
Cost & expenses	430,828,000	498,525,000
Operating income	(41,639,000)	41,539,000
Interest expense	398,000	417,000
Other income (expense), net	11,249,000	(1,427,000)
Gains or losses	5,400,000	2,869,000
Net before taxes	(22,784,000)	45,421,000
Income taxes	(11,889,000)	10,471,000
<b>Net income</b>	<b>(10,895,000)</b>	<b>34,950,000</b>
Earnings common share		
Primary	\$(0.23)	\$0.73
Fully Diluted	\$(0.23)	\$0.72
Common Shares:		
Full Diluted	47,927,000	48,618,000
Year-end	47,711,000	48,003,000

### ADURO BIOTECH INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	12,329	13,483
Cost & expenses	85,244	91,446
Operating income	(73,358)	(78,376)
Other income (expense), net	(15)	(197)
Net before taxes	(69,481)	(76,145)
Income taxes	(444)	(10,414)
<b>Net income</b>	<b>(69,037)</b>	<b>(65,731)</b>
Earnings common share		
Primary	\$(0.88)	\$(0.92)
Fully Diluted	\$(0.88)	\$(0.92)
Common Shares:		
Full Diluted	78,607	71,529
Year-end	79,370	

### ADVANCED EMISSIONS SOLUTIONS INC

**Acquisition Completed** On Dec. 7, 2018, Co. acquired 100% of the equity interests of ADA Carbon Solutions, LLC from Energy Capital Partners I, LP, Energy Capital Partners I-A, LP, Energy Capital Partners I-B IP, LP, Energy Capital Partners I (Crowfoot IP), LP, and Carbon Solutions Management, LLC for a total purchase price of \$75,000,000 plus fees. This amount was financed through funding in the form of a \$70,000,000 term loan, less original issue discount of \$2,100,000, and \$8,600,000 of assumed capital leases.

### ADVERUM BIOTECHNOLOGIES INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	62,864	44,640
Operating income	(61,322)	(43,252)
Other income (expense), net	3,104	1,894
Net before taxes	(58,218)	
Income taxes	(1,250)	

<b>Net income</b> .....	(56,968)	(41,358)
Earnings common share		
Primary .....	\$(0.94)	\$(0.97)
Fully Diluted .....	\$(0.94)	\$(0.97)
Common Shares:		
Full Diluted .....	60,856	42,849
Year-end .....	62,826	.....

**AEROVIRONMENT, INC.****Earnings, 6 mos. to (Consol. - \$000):**

	10/27/18	10/28/17
Total Revenues .....	151,022	100,162
Cost & expenses .....	130,180	97,762
Operating income .....	20,842	2,400
Interest income .....	1,974	944
Other income (expense), net .....	9,679	(51)
Equity earnings .....	1,354	.....
Net before taxes .....	32,495	3,293
Income taxes .....	3,778	137
Income contin. oper. ....	27,363	3,156
Income discount. oper. ....	6,003	(1,521)
<b>Net income</b> .....	33,366	1,635
Earnings common share		
Primary .....	\$1.41	\$0.08
Fully Diluted .....	\$1.39	\$0.08
Common Shares:		
Full Diluted .....	24,059	23,716
Year-end .....	23,928	.....

**AGILE THERAPEUTICS INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses .....	15,809,000	20,824,000
Operating income .....	(15,809,000)	(20,824,000)
Interest income .....	289,000	187,000
Interest expense .....	955,000	1,509,000
Gains or losses .....	29,000	82,000
Net before taxes .....	(16,446,000)	.....
Income taxes .....	(477,000)	.....
<b>Net income</b> .....	(15,969,000)	(22,064,000)
Earnings common share		
Primary .....	\$(0.47)	\$(0.74)
Fully Diluted .....	\$(0.47)	\$(0.74)
Common Shares:		
Full Diluted .....	34,295,240	29,847,972
Year-end .....	34,377,329	34,158,004

**AGNC INVESTMENT CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses .....	836,000	402,000
<b>Net income</b> .....	933,000	386,000
Balance for common .....	906,000	357,000
Earnings common share		
Primary .....	\$2.16	\$1.03
Fully Diluted .....	\$2.16	\$1.03
Common Shares:		
Full Diluted .....	420,100	347,600
Year-end .....	477,800	391,300

**AIRBORNE WIRELESS NETWORK****Annual Report****Consolidated Income Statement, Years Ended Aug. 31 (\$):**

	2018	2017	2016
		(revised)	(revised)
Marketing & branding expenses ...	9,314,045	1,794,919	.....
Depreciation expenses .....	10,469	4,562	.....
General & administrative expenses .....	1,280,448	358,707	5,531
Management fees .....	111,000	38,135	.....
Professional fees .....	5,141,969	2,155,756	90,483
Research & development expenses .....	1,902,452	1,086,599	.....
Salaries & wages expenses .....	1,129,725	608,282	.....
Stock based compensation expenses .....	49,727,493	30,376,431	72,309
Total operating expenses .....	68,617,601	36,423,391	168,323

Operating income (loss) .....	(68,617,601)	(36,423,391)	(168,323)
Interest expense .....	6,517,537	150	.....
Net change in fair value of derivative liabilities including day one losses .....	(1,548,086)	.....	.....
Loss on related party loan conversion .....	.....	489,418	.....
Total other income (expense) .....	(8,065,623)	(489,568)	.....
<b>Net income (loss)</b> .....	(76,683,224)	(36,912,959)	(168,323)
Weighted average shares outstanding			
- basic .....	43,996	2,793	3,756
Weighted average shares outstanding			
- diluted .....	43,996	2,793	3,756
Year end shares outstanding .....	684,342	3,022	2,470
Net income (loss) per share - basic .....	\$(1,743.00)	\$(13,217.00)	\$0.00
Net income (loss) per share - diluted .....	\$(1,743.00)	\$(13,217.00)	\$0.00
Number of full time employees .....	8	7	8
Number of part time employees .....	1	1	.....
Total number of employees .....	9	8	.....
Number of common stockholders .....	309	321	2,016

□ Reclassified to conform with 2018 presentation; □ Adjusted for 1-for-30,000 stock split, August 27, 2018; □ As of October 31, 2018; □ As of November 9, 2017; □ As of March 22, 2017; □ Approximately; □ As of November 8, 2018; □ As of October 31, 2017; □ As of February 8, 2017

**Consolidated Balance Sheet, Years Ended Aug. 31 (\$):**

	2018	2017
		(revised)
Cash & cash equivalents .....	155,988	217,694
Legal & regulatory fees .....	255,500	94,573
Marketing & branding .....	712,900	164,667
Rent expense .....	22,550	22,250
Professional fees .....	28,700	3,794
Prepaid expenses & other assets .....	1,019,650	285,284
Total current assets .....	1,175,638	502,978
Equipment & furniture .....	30,383	16,327
Computer equipment .....	19,258	13,583
Property & equipment, gross .....	49,641	29,910
Accumulated depreciation .....	15,031	4,562
Property & equipment, net .....	34,610	25,348
Total assets .....	1,210,248	528,326
Trade payables .....	4,796,784	334,132
Credit card payable .....	37,675	56,501
Payroll liabilities .....	.....	25,636
Other payable .....	74,960	5,480
Accounts payable & accrued liabilities .....	4,909,419	421,749
Accrued interest .....	67,157	.....
Convertible notes payable .....	976,229	.....
Derivative liabilities .....	4,494,698	.....
Total current liabilities .....	10,447,503	421,749
Total liabilities .....	10,447,503	421,749
Series A convertible preferred stock .....	1	.....
Common stock .....	684	3
Additional paid-in capital (deficiency) .....	104,574,113	37,235,403
Retained earnings (accumulated deficit) .....	(113,812,053)	(37,128,829)
Total stockholders' equity (deficit) .....	(9,237,255)	106,577

□ Reclassified to conform with 2018 presentation; □ Unamor-

tized debt discount - convertible notes payable: \$863,851

**Recent Dividends:****1. Airborne Wireless Network common.**

No dividends paid.

**Annual Dividends:****1. Airborne Wireless Network common.**

No dividends paid.

**AIRBORNE WIRELESS NETWORK****Auditor's Report Auditor's Report**

The following is an excerpt from the Report of Independent Auditors, Pinnacle Accountancy Group of Utah, as it appeared in Co.'s 2018 10-K: "In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of August 31, 2018 and 2017, and the results of its operations and its cash flows for each of the years in the two-year period ended August 31, 2018, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, because of the effect of the material weaknesses described in the following paragraph on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of August 31, 2018, based on criteria established in Internal Control-Integrated Framework (2013) issued by COSO. A material weakness is a control deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. The following material weaknesses have been identified and included in management's assessment. During the fiscal year ending August 31, 2018, it was noted that material weaknesses existed in the financial reporting in the following: 1) Management override of controls, 2) absent or inadequate segregation of duties within a significant account or process, and 3) inadequate design of monitoring controls used to assess the design and operating effectiveness of the entity's internal control over time. These material weaknesses were considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2018 financial statements, and our opinion on internal control over financial reporting does not affect our opinion on these financial statements. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has suffered recurring losses and has no operations which raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**AKEBIA THERAPEUTICS INC**

**Merger Completed** On Dec. 12, 2018, Co.'s subsidiary Alpha Therapeutics Merger Sub, Inc. merged with and into Keryx Biopharmaceuticals, Inc. ("Keryx"), with Keryx became a wholly owned subsidiary of Co. (the "Merger"). As a result of the Merger, each issued and outstanding share of common stock of Keryx, \$0.001 par value per share, was converted into 0.37433 of a share of Common Stock, and cash in lieu of fractional shares. The issuance of Common Stock in connection with the Merger was registered under the Securities Act of 1933, as amended, pursuant to Co.'s registration statement on Form S-4 (File No. 333-227622) filed with the United States Securities and Exchange Commission (the "SEC") on Oct. 1, 2018, as amended on Oct. 25, 2018 and Oct. 29, 2018, and declared effective on Oct. 30, 2018.

**ALASKA COMMUNICATIONS SYSTEMS GROUP INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues .....	173,779	171,970
Cost & expenses .....	129,049	130,690
Deprec., depl. & amort. ....	25,336	27,124
Operating income .....	19,394	14,156
Interest expense .....	10,191	11,335
Other income (expense), net .....	79	(7,988)
Net before taxes .....	9,356	(5,140)
Income taxes .....	2,080	(1,886)
<b>Net income</b> .....	7,276	(3,254)
Earnings common share		
Primary .....	\$0.14	\$(0.06)
Fully Diluted .....	\$0.14	\$(0.06)
Common Shares:		
Full Diluted .....	53,887	52,159
Year-end .....	53,184	52,447

**ALDER BIOPHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	209,160	236,601
Operating income	(209,160)	(235,918)
Interest income	6,634	1,686
Interest expense	12,322	
Other income (expense), net	(1,658)	49
Equity earnings	222	463
Foreign currency	388	124
<b>Net income</b>	<b>(216,340)</b>	<b>(234,522)</b>
Balance for common	(250,464)	(234,522)
Earnings common share		
Primary	\$(3.68)	\$(4.25)
Fully Diluted	\$(3.68)	\$(4.25)
Common Shares:		
Full Diluted	68,016	55,168
Year-end	68,267	67,716

**ALIMERA SCIENCES, INC.****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	31,856	26,770
Cost & expenses	39,657	35,472
Operating income	(9,742)	(10,714)
Other income (expense), net	(1,766)	188
Foreign currency	18	(6)
Net before taxes	(15,030)	(14,684)
Income taxes	104	93
<b>Net income</b>	<b>(15,134)</b>	<b>(14,777)</b>
Balance for common	23,196	(14,777)
Earnings common share		
Primary	\$0.26	\$(0.22)
Fully Diluted	\$0.26	\$(0.22)
Common Shares:		
Full Diluted	70,504	66,273
Year-end	70,038	69,105

**ALLAKOS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	30,208	15,808
Operating income	(30,208)	(15,808)
Other income (expense), net	(154)	(110)
Net before taxes	(16,634)	(16,634)
Income taxes	(966)	(966)
<b>Net income</b>	<b>(29,010)</b>	<b>(15,668)</b>
Earnings common share		
Primary	\$(2.34)	\$(10.35)
Fully Diluted	\$(2.34)	\$(10.35)
Common Shares:		
Full Diluted	12,406	1,514
Year-end	42,113	

**ALLIANCE RESOURCE PARTNERS LP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,471,017	1,312,989
Cost & expenses	943,812	865,343
Operating income	323,011	253,537
Interest income	121	82
Interest expense	30,653	28,904
Other income (expense), net	23,921	5,110
Net before taxes	316,400	229,825
Income taxes	(2)	(3)
<b>Net income</b>	<b>316,402</b>	<b>229,828</b>
Earnings common share		
Primary	\$2.35	\$2.32
Fully Diluted	\$2.35	\$2.32
Common Shares:		
Full Diluted	131,091	87,925
Year-end	130,712	130,704

**ALLIED MOTION TECHNOLOGIES INC**

**Acquisition Completed** On Dec. 6, 2018, Co. acquired 100% of the issued and outstanding common units of TCI, LLC ("TCI"), a company that designs and manufactures peripheral products for the electronic power conversion industry worldwide, from the members of TCI in a transaction valued at \$64,100,000.

**ALPHATEC HOLDINGS INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	66,351,000	75,456,000
Cost & expenses	80,545,000	80,335,000
Operating income	(14,745,000)	(5,395,000)
Net before taxes	(19,928,000)	(11,072,000)

Income taxes	(1,697,000)	57,000
Income contin. oper.	(18,231,000)	(11,129,000)
<b>Net income</b>	<b>(18,347,000)</b>	<b>(11,349,000)</b>
Earnings common share		
Primary	\$(0.56)	\$(1.00)
Fully Diluted	\$(0.56)	\$(0.98)
Common Shares:		
Full Diluted	32,658,000	11,349,000
Year-end	43,151,000	15,148,000

**ALPINE IMMUNE SCIENCES INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	705	1,603
Cost & expenses	27,090	11,788
Operating income	(26,385)	(10,185)
Interest expense	243	76
Other income (expense), net		6,539
Net before taxes	(25,657)	(3,461)
Income taxes	(305)	4
<b>Net income</b>	<b>(25,352)</b>	<b>(3,465)</b>
Balance for common	(25,352)	(3,465)
Earnings common share		
Primary	\$(1.83)	\$(0.87)
Fully Diluted	\$(1.83)	\$(0.87)
Common Shares:		
Full Diluted	13,848	3,990
Year-end	13,852	13,882

**ALTAIR ENGINEERING INC**

**Acquisition Completed** On Dec. 13, 2018, Co. acquired Datawatch Corporation, a Delaware corporation ("Datawatch") as its new subsidiary through the merger of Dallas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary Co. ("Purchaser") with and into Datawatch, with Datawatch surviving the merger (the "Merger"). In accordance with the terms of the Merger Agreement, Purchaser commenced a tender offer purchased all of Datawatch's issued and outstanding shares of common stock, par value \$0.01 per share (the "Shares"), at a purchase price of \$13.10 per Share, net to seller in cash (the "Offer Price"), without interest and less any applicable withholding taxes (the "Offer"). According to the depository for the Offer, as of the expiration of the Offer, 8,954,113 Shares (excluding Shares with respect to which notices of guaranteed delivery were delivered) were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 70% of the outstanding Shares and a sufficient number of Shares such that the minimum tender condition to the Offer was satisfied. In addition, the depository has advised Parent that notices of guaranteed delivery have been delivered with respect to 2,162,329 additional Shares, representing approximately 17% of the outstanding Shares. All other conditions to the Offer were satisfied or waived. As a result, on December 13, 2018, promptly after the expiration of the Offer, Purchaser irrevocably accepted for payment all Shares that were validly tendered and not validly withdrawn pursuant to the Offer and payment for such Shares has been made to the depository, which will act as agent for tendering stockholders whose Shares have been accepted for payment, in accordance with the terms of the Offer. The aggregate consideration to be paid by Co. and Purchaser in the Offer and Merger is approximately \$176,000,000, without giving effect to related transaction fees and expenses. Co. provided Purchaser with the necessary funds to fund the Offer and the Merger from available cash on hand and a drawdown on Co.'s existing credit facility.

**ALTAIR ENGINEERING INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	281,168	243,466
Net Sales	239,130	202,654
Cost & expenses	260,088	270,255
Operating income	15,415	(30,076)
Interest expense	92	1,793
Other income (expense), net	1,314	184
Foreign currency	732	(1,022)
Net before taxes	17,369	(32,707)
Income taxes	4,629	6,353
<b>Net income</b>	<b>12,740</b>	<b>(39,060)</b>
Earnings common share		
Primary	\$0.19	\$(0.78)
Fully Diluted	\$0.17	\$(0.78)
Common Shares:		
Full Diluted	74,182	50,374
Year-end	70,291	51,300

**ALTIMMUNE INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	7,742,514	7,929,484
Cost & expenses	23,230,943	47,410,185
Operating income	(15,488,429)	(39,480,701)
Interest income	78,306	19,538
Interest expense	169,737	160,103
Other income (expense), net	(2,401,793)	(499,634)
Net before taxes	(17,981,653)	(40,120,900)
Income taxes	(3,318,124)	(2,526,499)
<b>Net income</b>	<b>(14,663,529)</b>	<b>(37,594,401)</b>
Balance for common	(17,190,804)	(39,719,542)
Earnings common share		
Primary	\$(17.48)	\$(102.76)
Fully Diluted	\$(17.48)	\$(102.76)
Common Shares:		
Full Diluted	983,651	386,524
Year-end	1,725,630	520,903

**ALTRA INDUSTRIAL MOTION CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	706,191	653,415
Cost & expenses	637,725	591,331
Operating income	68,466	62,084
Interest expense	5,857	5,547
Other income (expense), net	(5,302)	(1,827)
Net before taxes	57,307	54,710
Income taxes	16,986	15,723
<b>Net income</b>	<b>40,321</b>	<b>38,987</b>
Earnings common share		
Primary	\$1.39	\$1.35
Fully Diluted	\$1.38	\$1.34
Common Shares:		
Full Diluted	29,178	29,001
Year-end	29,168	29,054

**AMERICA'S CAR-MART INC****Earnings, 6 mos. to Oct 31(Consol. - \$):**

	2018	2017
Total Revenues	331,186,000	295,536,000
Cost & expenses	301,975,000	273,927,000
Deprec., depl. & amort.	1,964,000	2,187,000
Operating income	27,247,000	19,422,000
Net before taxes	27,247,000	19,422,000
Income taxes	5,083,000	6,461,000
<b>Net income</b>	<b>22,164,000</b>	<b>12,961,000</b>
Balance for common	22,144,000	12,941,000
Earnings common share		
Primary	\$3.21	\$1.74
Fully Diluted	\$3.11	\$1.69
Common Shares:		
Full Diluted	7,129,451	7,661,668
Year-end	6,822,763	7,177,213

**AMERICAN OUTDOOR BRANDS CORP****Earnings, 6 mos. to Oct 31(Consol. - \$):**

	2018	2017
Net Sales	300,536,000	277,448,000
Cost & expenses	275,735,000	272,659,000
Operating income	24,801,000	4,789,000
Interest expense	4,274,000	5,354,000
Other income (expense), net	(9,000)	1,295,000
Net before taxes	20,518,000	730,000
Income taxes	6,208,000	(337,000)
<b>Net income</b>	<b>14,310,000</b>	<b>1,067,000</b>
Earnings common share		
Primary	\$0.26	\$0.02
Fully Diluted	\$0.26	\$0.02
Common Shares:		
Full Diluted	55,047,000	54,800,000
Year-end	54,538,910	54,114,090

**AMERICAN RAILCAR INDUSTRIES INC**

**Merger Completed** On Dec. 5, 2018, STL Parent Corp. ("Parent"), a wholly-owned subsidiary of ITE Rail Fund L.P., which was managed by ITE Management L.P., an investment firm targeting industrial and transportation assets and companies, through a wholly-owned subsidiary, ("Merger Sub"), merged with and into Co., with continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each share of the common stock, par value \$0.01 per share, of Co. issued and outstanding immediately prior to the Effective Time

(each, a "Share") was cancelled and each such Share (other than (i) Shares owned by Parent, Merger Sub or any of their respective subsidiaries or affiliates (other than Co.), (ii) Shares owned by Co. or Co.'s subsidiaries, and (iii) Shares owned by holders who properly exercised appraisal rights under North Dakota law) was converted into the right to receive \$70.00 in cash, without interest, less applicable withholding taxes (the "Merger Consideration"). In addition, pursuant to the Merger Agreement, at the Effective Time, each vested stock appreciation right granted under Co.'s 2005 Equity Incentive Plan, as amended and restated, that was outstanding and unexercised immediately prior to the Effective Time ("Co. SARs") was cancelled in exchange for the right to receive from Parent or its subsidiaries (including Co. as the surviving corporation in the Merger) a lump sum cash payment calculated pursuant to the terms of the Merger Agreement. In addition, any Co. SAR which had an exercise or base price per share of Common Stock that was greater than or equal to the per share Merger Consideration and any Co. SAR (or any portion thereof) that was unvested in accordance with its terms at the closing of the Merger was cancelled at the Effective Time for no consideration or payment.

**AMERICAN SOFTWARE INC****Earnings, 6 mos. to Oct 31(Consol. – \$000):**

	2018	2017
Total Revenues	55,432	53,222
Cost & expenses	53,105	45,968
Operating income	2,133	6,863
Other income (expense), net	(464)	558
Net before taxes	2,696	8,138
Income taxes	68	2,933
<b>Net income</b>	<b>2,628</b>	<b>5,205</b>
Earnings common share		
Primary	\$0.09	\$0.17
Fully Diluted	\$0.08	\$0.17
Common Shares:		
Full Diluted	31,412	30,110
Year-end	30,954	30,121

**AMERICAN WOODMARK CORP.****Earnings, 6 mos. to Oct 31(Consol. – \$000):**

	2018	2017
Net Sales	853,840	551,596
Cost & expenses	777,849	489,947
Operating income	75,991	61,649
Interest expense	18,368	105
Other income (expense), net	325	1,291
Net before taxes	57,948	62,835
Income taxes	14,693	20,799
<b>Net income</b>	<b>43,255</b>	<b>42,036</b>
Earnings common share		
Primary	\$2.47	\$2.59
Fully Diluted	\$2.46	\$2.58
Common Shares:		
Full Diluted	17,590	16,319
Year-end	17,405	16,104

**AMKOR TECHNOLOGY INC.****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Net Sales	3,235,195	3,056,553
Cost & expenses	3,052,432	2,760,031
Operating income	182,763	296,522
Other income (expense), net	2,325	(4,781)
Net before taxes	128,109	219,924
Income taxes	27,438	53,404
<b>Net income</b>	<b>100,671</b>	<b>166,520</b>
Earnings common share		
Primary	\$0.41	\$0.68
Fully Diluted	\$0.41	\$0.68
Common Shares:		
Full Diluted	239,783	239,610
Year-end	239,374	

**AMYRIS INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	61,058	62,857
Cost & expenses	130,390	136,078
Operating income	(69,332)	(73,221)
Interest expense	25,687	29,219
Other income (expense), net	(63,265)	31,779
Net before taxes	(70,661)	(70,661)
Income taxes	(49)	(49)
<b>Net income</b>	<b>(158,284)</b>	<b>(70,612)</b>

Balance for common	(159,357)	(90,455)
Earnings common share		
Primary	\$(2.86)	\$(3.32)
Fully Diluted	\$(2.86)	\$(3.32)
Common Shares:		
Full Diluted	55,736	27,281
Year-end	64,090	38,762

**ANAPTYSBIO INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	52,059	28,630
Operating income	(47,059)	(21,630)
Interest income	3,851	762
Interest expense	1,287	1,319
Other income (expense), net	(167)	(1,022)
<b>Net income</b>	<b>(44,662)</b>	<b>(23,209)</b>
Earnings common share		
Primary	\$(1.86)	\$(1.24)
Fully Diluted	\$(1.86)	\$(1.24)
Common Shares:		
Full Diluted	23,961	18,668
Year-end	26,749	20,496

**ANDERSONS INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	2,209,495	2,701,903
Operating income	23,225	(19,630)
Net before taxes	23,225	(19,630)
Income taxes	5,668	7,505
<b>Net income</b>	<b>17,557</b>	<b>(27,135)</b>
Balance for common	17,732	(27,208)
Earnings common share		
Primary	\$0.63	\$(0.96)
Fully Diluted	\$0.62	\$(0.96)
Common Shares:		
Full Diluted	28,487	28,327
Year-end	28,501	28,351

**ANGI HOMESERVICES INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	853,249	513,173
Cost & expenses	741,363	610,536
Operating income	46,021	(113,953)
Other income (expense), net	2,975	2,100
Net before taxes	40,097	(117,391)
Income taxes	(598)	(71,095)
<b>Net income</b>	<b>40,695</b>	<b>(46,296)</b>
Earnings common share		
Primary	\$0.08	\$(0.11)
Fully Diluted	\$0.08	\$(0.11)
Common Shares:		
Full Diluted	511,630	414,978
Year-end	481,977	476,045

**ANIKA THERAPEUTICS INC.****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	78,599,000	84,032,000
Cost & expenses	66,612,000	48,031,000
Operating income	11,987,000	36,001,000
Net before taxes	12,894,000	36,336,000
<b>Net income</b>	<b>11,004,000</b>	<b>23,749,000</b>
Earnings common share		
Primary	\$0.76	\$1.63
Fully Diluted	\$0.74	\$1.58
Common Shares:		
Full Diluted	14,820,000	15,065,000
Year-end	14,211,000	14,662,000

**APELLIS PHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Cost & expenses	90,728,168	32,774,215
Operating income	(90,728,168)	(32,774,215)
Other income (expense), net	(86,575)	(8,796)
Foreign currency	(426,191)	
<b>Net income</b>	<b>(91,042,720)</b>	<b>(32,750,198)</b>
Earnings common share		
Primary	\$(1.69)	\$(3.88)
Fully Diluted	\$(1.69)	\$(3.88)
Common Shares:		

Full Diluted	53,770,400	8,432,983
Year-end	56,242,571	8,472,903

**APOLLO ENDOSURGERY INC****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	45,672,000	48,170,000
Cost & expenses	63,508,000	59,289,000
Operating income	(23,247,000)	(16,563,000)
Interest expense	2,980,000	3,529,000
Other income (expense), net	(1,085,000)	283,000
Net before taxes	(27,312,000)	(19,809,000)
Income taxes	122,000	168,000
<b>Net income</b>	<b>(27,434,000)</b>	<b>(19,977,000)</b>
Earnings common share		
Primary	\$(1.44)	\$(1.62)
Fully Diluted	\$(1.44)	\$(1.62)
Common Shares:		
Full Diluted	19,080,400	12,310,426
Year-end	21,893,174	17,290,347

**APPLIED GENETIC TECHNOLOGIES CORP****Earnings, 3 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	14,034	10,315
Cost & expenses	13,278	11,982
Operating income	756	(1,667)
Gains or losses	471	270
Equity earnings	8	
Net before taxes	1,227	
Income taxes	19	
<b>Net income</b>	<b>1,200</b>	<b>(1,397)</b>
Earnings common share		
Primary	\$0.07	\$(0.08)
Fully Diluted	\$0.07	\$(0.08)
Common Shares:		
Full Diluted	18,158	18,088
Year-end	18,130	18,093

**Consolidated Balance Sheet Items, as of (\$000):**

	2018
Assets:	
Cash & equivalents	26,472
Current assets	108,186
Net property & equip.	5,016
Total assets	117,328
Liabilities:	
Current liabilities	25,025
Stockholders' equity	78,939
Net current assets	83,161

**APPLIED MATERIALS, INC.****Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	10/28/18	10/29/17	10/30/16
Net sales	17,253,000	14,537,000	10,825,000
Cost of products sold	9,436,000	8,005,000	6,314,000
Gross profit	7,817,000	6,532,000	4,511,000
Research, development & engineering expenses	2,019,000	1,774,000	1,540,000
Marketing & selling expenses	521,000	456,000	429,000
General & administrative expenses	481,000	434,000	390,000
Total operating expenses	3,021,000	2,664,000	2,359,000
Income (loss) from operations	4,796,000	3,868,000	2,152,000
Interest expense	234,000	198,000	155,000
Interest & other income, net	132,000	61,000	16,000
Income (loss) before income taxes	4,694,000	3,731,000	2,013,000
- United States	439,000	514,000	199,000
Income (loss) before income taxes - foreign	4,255,000	3,217,000	1,814,000
Income (loss) before income taxes	4,694,000	3,731,000	2,013,000
Current provision for (benefit from)			

income taxes - United States	1,035,000	67,000	(36,000)
Current provision for (benefit from) income taxes - foreign	126,000	233,000	351,000
Current provision for (benefit from) income taxes - state	22,000	9,000	(2,000)
Total current provision for (benefit from) income taxes	1,183,000	309,000	313,000
Deferred provision for (benefit from) income taxes - United States	151,000	(11,000)	55,000
Deferred provision for (benefit from) income taxes - foreign	57,000	(7,000)	(89,000)
Deferred provision for (benefit from) income taxes - state	(10,000)	6,000	13,000
Total deferred provision for (benefit from) income taxes	198,000	(12,000)	(21,000)
Provision (benefit) for income taxes	1,381,000	297,000	292,000
<b>Net income (loss)</b>	<b>3,313,000</b>	<b>3,434,000</b>	<b>1,721,000</b>
Weighted average shares outstanding - basic	1,013,000	1,073,000	1,107,000
Weighted average shares outstanding - diluted	1,026,000	1,084,000	1,116,000
Year end shares outstanding	967,000	1,060,000	1,078,000
Net earnings (loss) per share - basic	\$3.27	\$3.20	\$1.56
Net earnings (loss) per share - diluted	\$3.23	\$3.17	\$1.54
Cash dividends declared per common share	\$0.70	\$0.40	\$0.40
Number of full time employees	...	...	15,600
Number of temporary employees	...	...	1,100
Total number of employees	21,000	18,400	16,700
Number of common stockholders	2,854	2,898	3,062

As is; Approximately; As of December 7, 2018; As of December 8, 2017; As of December 8, 2016

**Consolidated Balance Sheet, Years Ended (\$000):**

	10/28/18	10/29/17 (revised)
Cash & cash equivalents	3,440,000	5,010,000
Short-term investments	590,000	2,266,000
Accounts receivable, gross	2,598,000	2,372,000
Less: allowance for doubtful accounts	33,000	34,000
Accounts receivable, net	2,565,000	2,338,000
Customer service spares	989,000	595,000
Raw materials	1,020,000	603,000
Work-in-process	505,000	468,000
Finished goods	1,208,000	1,264,000
Inventories	3,722,000	2,930,000
Prepaid income taxes & income taxes receivable	40,000	57,000
Prepaid expenses & other current assets	390,000	317,000
Total current assets	10,747,000	12,918,000
Long-term investments	1,568,000	1,143,000
Land & improvements	245,000	160,000
Buildings & improvements	1,448,000	1,315,000
Demonstration &		

manufacturing equipment	1,282,000	1,129,000
Furniture, fixtures & other equipment	634,000	572,000
Construction in progress	203,000	135,000
Gross property, plant & equipment	3,812,000	3,311,000
Accumulated depreciation	2,405,000	2,245,000
Property, plant & equipment, net	1,407,000	1,066,000
Goodwill	3,368,000	3,368,000
Purchased technology & other intangible assets, net	213,000	412,000
Deferred income taxes & other assets	470,000	512,000
Total assets	17,773,000	19,419,000
Accounts payable	996,000	945,000
Compensation & employee benefits	639,000	666,000
Warranty	209,000	199,000
Dividends payable	193,000	106,000
Income taxes payable	136,000	112,000
Other accrued taxes	112,000	70,000
Interest payable	38,000	38,000
Other accounts payable, notes payable & accrued expenses	398,000	314,000
Accounts payable & accrued expenses	2,721,000	2,450,000
Customer deposits	444,000	381,000
Deferred revenue	903,000	1,284,000
Total current liabilities	4,068,000	4,115,000
Senior notes	5,350,000	5,350,000
Total unamortized discount	(11,000)	(12,000)
Total unamortized debt issuance costs	(30,000)	(34,000)
Long-term debt	5,309,000	5,304,000
Income taxes payable	1,254,000	392,000
Defined & postretirement benefit plans	177,000	160,000
Other liabilities	126,000	99,000
Total liabilities	10,934,000	10,070,000
Common stock	10,000	11,000
Additional paid-in capital	7,274,000	7,056,000
Retained earnings	20,874,000	18,258,000
Treasury stock	21,194,000	15,912,000
Unrealized gain (loss) on investments, net	7,000	53,000
Unrealized gain (loss) on derivative instruments qualifying as cash flow hedges	(9,000)	(11,000)
Defined & postretirement benefit plans	(137,000)	(120,000)
Cumulative translation adjustments	14,000	14,000
Accumulated other comprehensive income (loss)	(125,000)	(64,000)
Total stockholders' equity	6,839,000	9,349,000

Reclassified to conform with 2018 presentation

Recent Dividends:

**1. Applied Materials, Inc. common.**

ExDate	Amt	Declared	Record	Payable
02/13/2015	0.10	12/08/2014	02/18/2015	03/11/2015
05/19/2015	0.10	03/09/2015	05/21/2015	06/11/2015
08/18/2015	0.10	06/05/2015	08/20/2015	09/10/2015
11/17/2015	0.10	09/10/2015	11/19/2015	12/10/2015
02/23/2016	0.10	12/07/2015	02/25/2016	03/17/2016
05/24/2016	0.10	03/10/2016	05/26/2016	06/16/2016
08/23/2016	0.10	06/09/2016	08/25/2016	09/15/2016
11/22/2016	0.10	09/08/2016	11/25/2016	12/15/2016
02/17/2017	0.10	12/01/2016	02/22/2017	03/15/2017
05/23/2017	0.10	03/09/2017	05/25/2017	06/15/2017
08/22/2017	0.10	06/08/2017	08/24/2017	09/14/2017
11/22/2017	0.10	09/07/2017	11/24/2017	12/14/2017
02/20/2018	0.10	12/15/2017	02/21/2018	03/14/2018
05/23/2018	0.20	02/14/2018	05/24/2018	06/14/2018
08/22/2018	0.20	06/07/2018	08/23/2018	09/13/2018

11/21/2018	0.20	09/06/2018	11/23/2018	12/13/2018
------------	------	------------	------------	------------

**Annual Dividends:**  
**1. Applied Materials, Inc. common.**  
2015.....0.40 2016.....0.40 2017.....0.40  
2018.....0.70

**APEVO THERAPEUTICS INC**  
**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	16,721	11,840
Cost & expenses	54,794	48,968
Operating income	(38,073)	(37,128)
Other income (expense), net	(1,592)	(1,356)
Net before taxes	(39,665)	(38,484)
Income taxes	(1,587)	(1,587)
<b>Net income</b>	<b>(39,561)</b>	<b>16,733</b>
Earnings common share		
Primary	\$(1.77)	\$0.79
Fully Diluted	\$(1.77)	\$0.79
Common Shares:		
Full Diluted	22,431	21,138
Year-end	22,677	21,427

**APTINYX INC**  
**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	5,535	3,778
Cost & expenses	45,713	28,749
Operating income	(40,178)	(24,971)
Other income (expense), net	990	129
<b>Net income</b>	<b>(39,188)</b>	<b>(24,842)</b>
Earnings common share		
Primary	\$(2.48)	\$(4.82)
Fully Diluted	\$(2.48)	\$(4.82)
Common Shares:		
Full Diluted	15,789	5,159
Year-end	33,229	.....

**AQUINOX PHARMACEUTICALS INC**  
**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	25,000,000	.....
Cost & expenses	52,324,000	34,587,000
Operating income	(27,324,000)	(34,587,000)
Interest income	1,093,000	720,000
Other income (expense), net	(467,000)	(48,000)
<b>Net income</b>	<b>(26,698,000)</b>	<b>(33,915,000)</b>
Earnings common share		
Primary	\$(1.14)	\$(1.45)
Fully Diluted	\$(1.14)	\$(1.45)
Common Shares:		
Full Diluted	23,513,489	23,444,181
Year-end	23,537,368	23,464,930

**ARAVIVE INC**  
**New Accountant** On Nov. 29, 2018, Co. dismissed PricewaterhouseCoopers LLP and engaged BDO USA, LLP as its new independent public accounting firm.

**ARSANIS INC**  
**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	36,413	24,527
Operating income	(36,413)	(24,527)
Interest income	637	90
Interest expense	785	1,806
Other income (expense), net	2,898	3,553
<b>Net income</b>	<b>(33,663)</b>	<b>(22,690)</b>
Balance for common	(33,663)	(22,726)
Earnings common share		
Primary	\$(2.35)	\$(44.22)
Fully Diluted	\$(2.35)	\$(44.22)
Common Shares:		
Full Diluted	14,305	514
Year-end	14,315	.....

**ASCENA RETAIL GROUP INC**  
**Earnings, 3 mos. to (Consol. - \$):**

		11/03/18	10/28/17
Net Sales	.....	1,591,800,000	1,589,700,000
Cost & expenses	.....	1,470,900,000	1,459,800,000
Deprec., depl. & amort.	.....	82,000,000	90,000,000
Operating income	.....	38,900,000	39,900,000
Interest expense	.....	26,000,000	26,600,000

Net before taxes	13,700,000	13,500,000
Income taxes	7,800,000	6,900,000
<b>Net income</b>	<b>5,900,000</b>	<b>6,600,000</b>
Earnings common share		
Primary	\$0.03	\$0.03
Fully Diluted	\$0.03	\$0.03
Common Shares:		
Full Diluted	201,200,000	195,400,000
Year-end	197,400,000	196,000,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	198,900,000	
Inventories	829,600,000	
Current assets	1,283,000,000	
Net property & equip.	1,154,400,000	
Total assets	3,688,700,000	
Liabilities:		
Current liabilities	998,800,000	
Long-term debt	1,331,200,000	
Stockholders' equity	813,200,000	
Net current assets	284,200,000	

**ASTEC INDUSTRIES, INC.****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Net Sales	854,595	872,364
Cost & expenses	871,593	834,821
Operating income	(16,998)	37,543
Interest income	678	1,067
Interest expense	488	638
Other income (expense), net	954	816
Gains or losses	(96)	3
Net before taxes	(15,950)	38,791
Income taxes	(2,301)	12,055
<b>Net income</b>	<b>(13,649)</b>	<b>26,736</b>
Earnings common share		
Primary	\$(0.58)	\$1.17
Fully Diluted	\$(0.58)	\$1.16
Common Shares:		
Full Diluted	23,009	23,180
Year-end	22,798	23,070

**ATHENEX INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	67,829	23,170
Cost & expenses	169,201	104,802
Operating income	(101,372)	(81,632)
Other income (expense), net		(15,411)
Net before taxes	(101,835)	(103,053)
Income taxes	(286)	(52)
<b>Net income</b>	<b>(101,549)</b>	<b>(103,001)</b>
Earnings common share		
Primary	\$(1.42)	\$(2.18)
Fully Diluted	\$(1.42)	\$(2.18)
Common Shares:		
Full Diluted	63,807	47,238
Year-end	66,889	57,995

**ATRION CORP.****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	117,522	112,571
Cost & expenses	84,133	79,590
Operating income	33,389	32,981
Other income (expense), net	1,177	807
Gains or losses	(1,153)	
Net before taxes	33,413	33,788
Income taxes	6,907	5,841
<b>Net income</b>	<b>26,506</b>	<b>27,947</b>
Earnings common share		
Primary	\$14.30	\$15.16
Fully Diluted	\$14.27	\$15.06
Common Shares:		
Full Diluted	1,857	1,856
Year-end	1,853	1,836

**ATYR PHARMA INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	26,857	35,945
Operating income	(26,857)	(35,945)
Other income (expense), net	(1,336)	(788)
<b>Net income</b>	<b>(28,193)</b>	<b>(36,733)</b>

Earnings common share		
Primary	\$(0.95)	\$(1.50)
Fully Diluted	\$(0.95)	\$(1.50)
Common Shares:		
Full Diluted	29,832	24,463
Year-end	29,866	29,716

**AUTODESK INC.****Earnings, 9 mos. to Oct 31 (Consol. - \$000):**

	2018	2017
Total Revenues	1,832,500	1,502,800
Cost & expenses	1,886,000	1,814,700
Operating income	(65,300)	(327,200)
Other income (expense), net	11,500	5,000
Gains or losses	9,500	(9,500)
Foreign currency	5,200	(1,200)
Net before taxes	(75,700)	(359,000)
Income taxes	69,800	34,400
<b>Net income</b>	<b>(145,500)</b>	<b>(393,400)</b>
Earnings common share		
Primary	\$(0.67)	\$(1.79)
Fully Diluted	\$(0.67)	\$(1.79)
Common Shares:		
Full Diluted	218,700	219,700
Year-end	219,009	220,267

**AVIAT NETWORKS, INC.****Earnings, 3 mos. to (Consol. - \$000):**

	09/28/18	09/29/17
Total Revenues	60,504	56,182
Cost & expenses	62,018	57,408
Operating income	(1,514)	(1,226)
Interest income	51	58
Interest expense	5	6
Other income (expense), net		(30)
Net before taxes	(1,468)	(1,204)
Income taxes	(718)	(639)
<b>Net income</b>	<b>(750)</b>	<b>(565)</b>
Balance for common	(750)	(657)
Earnings common share		
Primary	\$(0.14)	\$(0.12)
Fully Diluted	\$(0.14)	\$(0.12)
Common Shares:		
Full Diluted	5,366	5,316
Year-end	5,351	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		
Cash & equivalents	28,397	
Inventories	8,682	
Current assets	125,306	
Net property & equip.	16,889	
Total assets	159,191	
Liabilities:		
Current liabilities	83,171	
Stockholders' equity	62,324	
Net current assets	42,135	

**AVROBIO INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	29,567	10,956
Operating income	(29,567)	(10,956)
Interest income	1,038	22
Other income (expense), net	(1,811)	(118)
<b>Net income</b>	<b>(30,340)</b>	<b>(11,052)</b>
Balance for common	(32,583)	(11,099)
Earnings common share		
Primary	\$(3.28)	\$(5.01)
Fully Diluted	\$(3.28)	\$(5.01)
Common Shares:		
Full Diluted	9,946	2,216
Year-end	23,759	

**AXONICS MODULATION TECHNOLOGIES INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016
Net revenues	128,118	
Cost of goods sold	117,944	
Gross profit (loss)	10,174	
Research & development expenses	12,332,046	12,510,280
General & administrative		

expenses	4,822,541	4,457,275
Sales & marketing expenses	1,029,915	516,076
Total operating expenses	18,184,502	17,483,631
Income (loss) from operations	(18,174,328)	(17,483,631)
Interest income	200,579	84,020
Gain (loss) on disposal of property & equipment	(65,397)	
State income tax expense	890	800
Other expenses	20,822	291
<b>Net income (loss)</b>	<b>(18,060,858)</b>	<b>(17,400,702)</b>
Weighted average shares		
outstanding - basic	2,564,964	2,313,526
Weighted average shares outstanding - diluted	2,564,964	2,313,526
Year end shares		
outstanding	2,776,583	2,329,612
Net earnings (loss) per share - basic		
	\$(7.04)	\$(7.52)
Net earnings (loss) per share - diluted		
	\$(7.04)	\$(7.52)
Total number of employees		
	172	
Number of common stockholders		
	189	

□ As of September 30, 2018; □ As of June 30, 2018

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016
Cash & cash equivalents	24,397,548	8,208,663
Inventory	1,541,325	
Prepayments & other current assets	979,668	520,181
Total current assets	26,918,541	8,728,844
Research & development equipment		
	783,254	796,928
Computer hardware & software		
	545,189	457,480
Tools & molds	876,717	393,502
Leasehold improvements	296,614	296,614
Furniture & fixtures	181,258	160,364
Total property & equipment, gross	2,683,032	2,104,888
Less: Accumulated depreciation & amortization		
	1,152,643	937,573
Property & equipment, net	1,530,389	1,167,315
Intangible assets, net	540,687	655,515
Other assets	422,057	304,327
Total assets	29,411,674	10,856,001
Accounts payable	1,615,722	630,306
Accrued liabilities	789,296	854,688
Total current liabilities	2,405,018	1,484,994
Lease liability, net of current portion		
	134,986	301,512
Total liabilities	2,540,004	1,786,506
Series A convertible preferred stock		
	14,020,451	14,020,451
Series B-1 convertible preferred stock		
	13,757,424	13,757,424
Series B-2 convertible preferred stock		
	17,572,351	17,572,351
Series C convertible preferred stock		
	16,875,554	
Noncontrolling interest in Axonics Europe, S.A.S.		
	31,066,420	13,150,330
Common stock	278	233
Additional paid-in capital		
	2,900,419	1,842,755
Stock subscription receivable		
	(1,752,700)	(1,178,404)
Retained earnings (accumulated deficit)		
	(67,165,950)	(49,105,092)
Accumulated other comprehensive income (loss)		
	(402,577)	(990,553)
Total shareholders' (deficit)/equity		
	(66,420,530)	(49,431,061)

**Recent Dividends:**

1. Axonics Modulation Technologies Inc common.

No dividends paid.

**Annual Dividends:****1. Axonics Modulation Technologies Inc common.**

No dividends paid.

**AXONICS MODULATION TECHNOLOGIES INC****Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Total Revenues	12,239	
Cost & expenses	15,156,677	8,642,553
Operating income	(15,144,438)	(8,642,553)
Interest income	275,732	41,511
Interest expense	377,965	
Other income (expense), net	(5,661)	(6,003)
<b>Net income</b>	<b>(15,252,332)</b>	<b>(8,607,045)</b>
Earnings common share		
Primary	\$(5.43)	\$(3.60)
Fully Diluted	\$(5.43)	\$(3.60)
Common Shares:		
Full Diluted	2,811,183	2,389,066
Year-end	2,825,303	

**AXSOME THERAPEUTICS INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	23,396,262	20,720,187
Operating income	(23,396,262)	(20,720,187)
Other income (expense), net	2,906,418	207,114
<b>Net income</b>	<b>(21,368,449)</b>	<b>(21,512,891)</b>
Earnings common share		
Primary	\$(0.83)	\$(0.97)
Fully Diluted	\$(0.83)	\$(0.97)
Common Shares:		
Full Diluted	25,875,783	22,270,885
Year-end	26,458,662	23,665,532

**BARRETT BUSINESS SERVICES, INC.****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	702,866	675,706
Cost & expenses	680,150	654,720
Operating income	19,488	17,997
Interest expense	574	197
Other income (expense), net	15	28
Gains or losses	6,455	3,084
Net before taxes	25,384	20,912
Income taxes	4,178	6,228
<b>Net income</b>	<b>21,206</b>	<b>14,684</b>
Earnings common share		
Primary	\$2.89	\$2.02
Fully Diluted	\$2.77	\$1.95
Common Shares:		
Full Diluted	7,652	7,539
Year-end	7,381	

**BEACON ROOFING SUPPLY INC****Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$000):**

	2018	2017	2016
Net sales	6,418,311	4,376,670	4,127,109
Cost of products sold	4,824,990	3,300,731	3,114,040
Gross profit	1,593,321	1,075,939	1,013,069
Selling, general & administrative expense	1,187,192	743,376	707,893
Depreciation expense	60,318	34,002	31,876
Total operating expense	1,388,695	859,843	808,085
Income from operations	204,626	216,096	204,984
Amortization expense	141,185	82,465	68,316
Interest expense, financing costs, & other	136,544	52,751	58,452
Income (loss) before provision for income taxes	68,082	163,345	146,532
Current federal income taxes	(4,435)	52,718	23,403
Current foreign			

income taxes	492	1,366	1,183
Current state income taxes	3,516	8,975	2,426
Total current income taxes	(427)	63,059	27,012
Deferred federal income taxes (benefit)	(35,249)	(656)	25,935
Deferred foreign income taxes (benefit)	(173)	...	321
Deferred state income taxes (benefit)	5,305	78	3,347
Total deferred income taxes (benefit)	(30,117)	(578)	29,603
Provision for income taxes	(30,544)	62,481	56,615
<b>Net income (loss)</b>	<b>98,626</b>	<b>100,864</b>	<b>89,917</b>
Dividends on preferred shares	18,000	...	...
Net income (loss) attributable to common shareholders	80,626	100,864	89,917
Weighted average shares outstanding - basic	68,013	60,316	59,424
Weighted average shares outstanding - diluted	69,191	61,344	60,418
Year end shares outstanding	68,136	67,701	59,891
Net income (loss) per share - basic	\$1.07	\$1.67	\$1.51
Net income (loss) per share - diluted	\$1.05	\$1.64	\$1.49
Total number of employees	8,356	5,406	5,042
Number of common stockholders	89	94	137
Foreign currency translation adjustments	(2,687)	3,706	1,024

Reclassified to conform with 2018 presentation; Shares increased due to the effect of issuance of common stock withheld for taxes and in connection with Roofing Supply Company, LLC (RSG) acquisition; As is; As of October 31, 2018; As of October 31, 2017; As of October 31, 2016

**Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):**

	2018	2017
Cash & cash equivalents	129,927	138,250
Accounts receivables, gross	1,108,117	716,356
Less: allowance for doubtful accounts	17,584	11,829
Accounts receivable, net	1,090,533	704,527
Inventories, net	936,047	551,924
Vendor rebates	199,725	193,071
Other prepaid expenses & other current assets	44,635	16,067
Total current assets	2,400,867	1,603,839
Land & buildings	82,991	41,791
Equipment	419,385	293,489
Furniture & fixtures	34,901	23,140
Property & equipment, gross	537,277	358,420
Less: accumulated depreciation & amortization	256,870	202,291
Property & equipment, net	280,407	156,129
Goodwill	2,491,779	1,251,986
Intangibles, net	1,334,366	429,069
Other assets, net	1,243	8,534
Total assets	6,508,662	3,449,557
Accounts payable	880,872	503,697
Accrued expenses	611,539	261,297
Current portions of long-term debt	19,661	14,141
Total current liabilities	1,512,072	779,135

Borrowings under revolving lines of credit, net	92,442	3,205
Long-term debt, net	2,494,725	721,268
Deferred income taxes, net	106,994	138,383
Long-term obligations under equipment financing and other, net	13,639	23,213
Other long-term liabilities	5,290	2,547
Total liabilities	4,225,162	1,667,751
Convertible preferred stock	399,195	...
Common stock	681	677
Additional paid-in capital	1,067,040	1,047,506
Retained earnings (accumulated deficit)	833,834	748,186
Foreign currency translation	(17,250)	(14,563)
Accumulated other comprehensive income (loss)	(17,250)	(14,563)
Total stockholders' equity	1,884,305	1,781,806

Reclassified to conform with 2018 presentation

**Recent Dividends:****1. Beacon Roofing Supply Inc preferred.**

No dividends paid.

**2. Beacon Roofing Supply Inc common.**

No dividends paid.

**Annual Dividends:****1. Beacon Roofing Supply Inc preferred.**

No dividends paid.

**2. Beacon Roofing Supply Inc common.**

No dividends paid.

**BERRY PETROLEUM CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	306,211	264,286
Cost & expenses	222,214	183,480
Operating income	18,479	23,001
Interest expense	26,828	12,482
Other income (expense), net	23,192	(1,001)
Net before taxes	18,479	23,001
Income taxes	3,145	9,189
<b>Net income</b>	<b>15,334</b>	<b>13,812</b>
Balance for common	(82,608)	1,131
Earnings common share		
Primary	\$(1.59)	\$0.03
Fully Diluted	\$(1.59)	\$0.03
Common Shares:		
Full Diluted	51,900	40,602
Year-end	81,365	

**BGC PARTNERS INC**

**Spin-Off Completed** On Nov. 30, 2018, Co. completed its previously announced distribution of all of the shares of Newmark Group, Inc. ("Newmark") held by Co. to its stockholders. Co. distributed these Newmark shares through a special pro rata stock dividend (the "Spin-Off" or the "Distribution"). Based on the number of shares of Co. Class A common stock outstanding as of the close of business on Nov. 23, 2018 (the "Record Date"), stockholders of Co. Class A common stock received 0.463895 of a share of Newmark Class A common stock in the Distribution for every one share of Co. Class A common stock held as of the Record Date. Following the Spin-Off, Co. no longer held any shares of Newmark.

**BIOCRYST PHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	17,924,000	21,296,000
Cost & expenses	86,882,000	60,846,000
Operating income	(68,958,000)	(39,550,000)
Interest expense	6,762,000	6,334,000
Gains or losses	334,000	(892,000)
<b>Net income</b>	<b>(73,820,000)</b>	<b>(46,239,000)</b>
Earnings common share		
Primary	\$(0.73)	\$(0.58)
Fully Diluted	\$(0.73)	\$(0.58)
Common Shares:		

Full Diluted	100,955,000	79,749,000
Year-end	109,625,000	98,389,000

**BIOSPECIFICS TECHNOLOGIES CORP.****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	23,108,264	20,742,243
Cost & expenses	6,915,310	7,865,860
Operating income	16,192,954	12,876,383
Interest income	851,334	436,210
Other income (expense), net	96,663	40,651
Net before taxes	17,140,951	13,353,244
Income taxes	3,271,366	4,669,569
<b>Net income</b>	<b>13,869,585</b>	<b>8,683,675</b>
Earnings common share		
Primary	\$1.92	\$1.21
Fully Diluted	\$1.89	\$1.19
Common Shares:		
Full Diluted	7,327,029	7,325,602
Year-end	7,283,528	7,164,233

**BJ'S RESTAURANTS INC****Earnings, 9 mos. to (Consol. - \$):**

	10/02/18	10/03/17
Total Revenues	836,425,000	770,642,000
Cost & expenses	740,282,000	692,480,000
Deprec., depl. & amort.	52,760,000	51,231,000
Operating income	43,383,000	26,931,000
Interest expense	3,826,000	3,178,000
Other income (expense), net	220,000	1,474,000
Net before taxes	39,777,000	25,227,000
Income taxes	(348,000)	3,933,000
<b>Net income</b>	<b>40,125,000</b>	<b>21,294,000</b>
Earnings common share		
Primary	\$1.92	\$0.98
Fully Diluted	\$1.87	\$0.97
Common Shares:		
Full Diluted	21,500,000	22,032,000
Year-end	21,260,000	20,746,000

**BLINK CHARGING CO****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	1,767,182	1,735,493
Cost & expenses	10,981,677	6,975,859
Operating income	(9,214,495)	(5,240,366)
Other income (expense), net	9,477,510	(93,478,969)
Gains or losses		(97,152)
<b>Net income</b>	<b>(1,164,630)</b>	<b>101,134,331</b>
Balance for common	(28,128,456)	103,508,631
Earnings common share		
Primary	\$(1.33)	\$(52.04)
Fully Diluted	\$(1.47)	\$(52.04)
Common Shares:		
Full Diluted	19,113,426	1,989,022
Year-end	25,564,103	4,812,632

**BLUEKNIGHT ENERGY PARTNERS LP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	261,311	137,691
Cost & expenses	242,003	112,410
Operating income	19,308	25,281
Other income (expense), net		61
Gains or losses	2,225	5,284
Net before taxes	8,850	19,831
Income taxes	215	147
<b>Net income</b>	<b>8,635</b>	<b>19,684</b>
Earnings common share		
Primary	\$(0.25)	\$.....
Fully Diluted	\$(0.25)	\$.....
Common Shares:		
Full Diluted	40,331	38,164
Year-end	41,612	39,467

**BSQUARE CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	56,575	61,342
Cost & expenses	64,903	66,466
Operating income	(8,328)	(5,124)
Other income (expense), net	156	148
Net before taxes	(8,172)	(4,976)
Income taxes	32	(150)

<b>Net income</b>	(8,204)	(4,826)
Earnings common share		
Primary	\$(0.65)	\$(0.38)
Fully Diluted	\$(0.65)	\$(0.38)
Common Shares:		
Full Diluted	12,697	12,578
Year-end	12,747	12,625

**CABOT MICROELECTRONICS CORP****Annual Report****Consolidated Income Statement, Years Ended Sept. 30****(\$000):**

	2018	2017	2016
Revenue	590,123	507,179	430,449
Cost of goods sold	276,018	253,050	220,247
Gross profit	314,105	254,129	210,202
Research, development & technical expense	51,950	55,658	58,532
Selling & marketing expense	25,044	30,846	27,717
General & administrative expense	76,993	55,637	49,445
Total operating expenses	153,987	142,141	135,694
Operating income	160,118	111,988	74,508
Interest expense	2,905	4,529	4,723
Interest income	4,409	2,351	949
Other income (expense)	89	(438)	(296)
Income (loss) before income taxes	161,711	109,372	70,438
expense (benefit) - domestic	46,254	33,272	7,130
Income (loss) before income taxes expense (benefit) - foreign	115,457	76,100	63,308
Income (loss) before income taxes expense (benefit) - U.S. federal & state income taxes	14,698	8,606	609
expense (benefit) - current			
U.S. federal & state income taxes expense (benefit) - deferred	10,347	1,550	(1,465)
Foreign income taxes expense (benefit) - current	26,135	13,422	11,737
Foreign income taxes expense (benefit) - deferred	488	(1,158)	(292)
Total foreign income taxes expense (benefit)	26,623	12,264	11,445
Provision for (benefit from) income taxes	51,668	22,420	10,589
<b>Net income (loss)</b>	<b>110,043</b>	<b>86,952</b>	<b>59,849</b>
Less: income attributable to participating securities	123	256	361
Net income available to common shareholders	109,920	86,696	59,488
Weighted average shares outstanding - basic	25,518	25,015	24,077
Weighted average shares outstanding - diluted	26,243	25,512	24,477
Year end shares outstanding	25,506	25,283	24,517
Earnings per share - basic	\$4.31	\$3.47	\$2.47
Earnings per share - diluted	\$4.19	\$3.40	\$2.43
Dividends per share	\$1.40	\$0.78	\$0.54

Total number of employees	1,219	1,179	1,145
Number of common stockholders	598	659	727
Foreign currency translation adjustments	679	(6,746)	15,996

□ As is; □ As of October 31, 2018; □ As of October 31, 2017; □ As of October 31, 2016; □ Approximately

**Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):**

	2018	2017
Cash & cash equivalents	352,921	397,890
Accounts receivable, gross	77,786	66,540
Less allowance for doubtful accounts	1,900	1,747
Accounts receivable, net	75,886	64,793
Raw materials	35,150	36,415
Work in process	8,117	7,365
Finished goods	28,659	28,093
Inventories	71,926	71,873
Prepaid expenses & other current assets	22,048	16,426
Total current assets	522,781	550,982
Land	17,525	17,823
Buildings	103,601	104,057
Machinery & equipment	195,434	187,649
Furniture & fixtures	7,575	6,770
Information systems	34,271	32,748
Capital lease	1,200	...
Construction in progress	17,001	10,439
Total property, plant & equipment	376,607	359,486
Less accumulated depreciation	265,204	253,125
Property, plant & equipment, net	111,403	106,361
Goodwill	101,083	101,932
Other intangible assets, net	35,202	42,710
Defered income taxes	5,840	21,598
Auction rate securities (ARS)	...	5,319
Long-term contract asset	1,548	2,115
Other long-term assets	1,979	2,154
Other long-term investments	1,137	929
Total assets	780,973	834,100
Accounts payable	18,171	17,624
Current portion of long-term debt	...	10,938
Accrued compensation	35,367	35,332
Income taxes payable	18,045	9,717
Dividends payable	10,822	5,314
Acquisition & integration related	2,701	...
Goods & services received, not yet invoiced	1,954	2,172
Deferred revenue & customer advances	4,894	1,559
Taxes, other than income taxes	1,976	1,688
Current portion of long-term contract liability	1,487	1,500
Other accrued expenses, income taxes payable & other current liabilities	5,737	5,369
Total current liabilities	101,154	91,213
Long-term debt, net of current portion	...	132,997
Deferred income taxes	81	63
Other long-term liabilities	13,046	14,790
Total liabilities	114,281	239,063
Common stock	36	35
Capital in excess of par value of common stock	622,498	580,938
Retained earnings (accumulated deficit)	471,673	397,881



Foreign currency translation	5,918	5,239
Cash flow hedges	(17)	46
Pension & other postretirement liabilities	(1,362)	(1,336)
Accumulated other comprehensive income (loss)	4,539	3,949
Treasury stock at cost	432,054	387,766
Total stockholders' equity	666,692	595,037

☐ Reclassified to conform with 2018 presentation; ☐ Less prepaid debt issuance cost - long-term debt, net of current portion: \$441,000

**Recent Dividends:****1. Cabot Microelectronics Corp common.**

ExDate	Amt	Declared	Record	Payable
03/15/2016	0.18	01/07/2016	03/17/2016	04/15/2016
06/21/2016	0.18	06/06/2016	06/23/2016	07/29/2016
09/29/2016	0.18	09/22/2016	10/03/2016	10/28/2016
12/21/2016	0.18	12/08/2016	12/23/2016	01/30/2017
03/21/2017	0.20	03/07/2017	03/23/2017	04/28/2017
06/21/2017	0.20	06/05/2017	06/23/2017	07/28/2017
09/22/2017	0.20	09/12/2017	09/25/2017	10/30/2017
12/21/2017	0.20	12/11/2017	12/22/2017	01/30/2018
03/22/2018	0.40	03/05/2018	03/23/2018	04/30/2018
06/22/2018	0.40	06/12/2018	06/25/2018	07/30/2018
10/05/2018	0.40	09/26/2018	10/09/2018	10/30/2018

**Annual Dividends:****1. Cabot Microelectronics Corp common.**

2016	0.54	2017	0.78	2018	1.40
------	------	------	------	------	------

**CADIZ INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	7,364	8,747
Operating income	(7,229)	(8,632)
Other income (expense), net	(3,501)	(3,501)
Net before taxes	(18,239)	(26,786)
Income taxes	4	3
<b>Net income</b>	(18,243)	(26,789)
Earnings common share		
Primary	\$(0.77)	\$(1.19)
Fully Diluted	\$(0.77)	\$(1.19)
Common Shares:		
Full Diluted	23,809	22,471
Year-end	24,453	22,530

**CAESARS ENTERTAINMENT CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	6,276,000	2,967,000
Cost & expenses	4,794,000	2,236,000
Operating income	639,000	383,000
Interest expense	1,005,000	409,000
Other income (expense), net	338,000	(2,319,000)
Net before taxes	(28,000)	(2,345,000)
Income taxes	(134,000)	34,000
<b>Net income</b>	106,000	(2,379,000)
Earnings common share		
Primary	\$0.15	\$(15.97)
Fully Diluted	\$0.15	\$(15.97)
Common Shares:		
Full Diluted	697,000	148,000
Year-end	669,733	

**CAFEPRESS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	42,120	51,491
Cost & expenses	49,427	61,803
Operating income	(7,307)	(10,312)
Interest income	240	137
Interest expense	11	11
Other income (expense), net	(626)	20
Net before taxes	(10,166)	(10,166)
Income taxes	1	1
<b>Net income</b>	(7,693)	(10,167)

Earnings common share		
Primary	\$(0.45)	\$(0.61)
Fully Diluted	\$(0.45)	\$(0.61)
Common Shares:		
Full Diluted	17,037	16,736
Year-end	17,153	16,861

**CALYXT INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	234	322
Cost & expenses	19,721	19,298
Operating income	(19,487)	(18,976)
Foreign currency	(30)	(159)
<b>Net income</b>	(19,429)	(19,131)
Earnings common share		
Primary	\$(0.65)	\$(0.89)
Fully Diluted	\$(0.65)	\$(0.89)
Common Shares:		
Full Diluted	30,041	21,616
Year-end	32,463	27,693

**CANCER GENETICS, INC.****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	20,643,000	21,598,000
Cost & expenses	38,838,000	30,700,000
Operating income	(18,195,000)	(9,102,000)
Interest income	21,000	37,000
Interest expense	1,282,000	797,000
Other income (expense), net	2,848,000	(4,087,000)
Net before taxes	(13,949,000)	(13,949,000)
Income taxes	(970,000)	(970,000)
<b>Net income</b>	(16,608,000)	(12,979,000)
Earnings common share		
Primary	\$(0.61)	\$(0.65)
Fully Diluted	\$(0.61)	\$(0.65)
Common Shares:		
Full Diluted	27,156,000	20,059,000
Year-end	27,726,000	24,252,000

**CANTERBURY PARK HOLDING CORP (NEW)****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	47,103,183	44,956,390
Cost & expenses	40,819,593	39,497,549
Operating income	4,387,867	3,589,793
Net before taxes	4,413,890	3,626,971
Income taxes	1,066,000	1,444,753
<b>Net income</b>	3,347,890	2,182,218
Earnings common share		
Primary	\$0.75	\$0.50
Fully Diluted	\$0.74	\$0.50
Common Shares:		
Full Diluted	4,514,015	4,395,534
Year-end	4,506,354	4,398,303

**CARBONITE INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	219,442	177,770
Cost & expenses	209,818	188,855
Operating income	1,109	(12,620)
Interest income	803	364
Interest expense	8,894	5,011
Other income (expense), net	48	1,129
Net before taxes	(6,934)	(16,138)
Income taxes	(13,777)	(13,750)
<b>Net income</b>	6,843	(2,388)
Earnings common share		
Primary	\$0.23	\$(0.09)
Fully Diluted	\$0.21	\$(0.09)
Common Shares:		
Full Diluted	32,762	27,714
Year-end	34,550	

**CARDIOVASCULAR SYSTEMS, INC****Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	56,266	49,676
Cost & expenses	59,234	51,428
Operating income	(2,968)	(1,752)
Interest expense	424	432
Net before taxes	(2,855)	(1,944)

Income taxes	33	33
<b>Net income</b>	(2,888)	(1,977)
Earnings common share		
Primary	\$(0.09)	\$(0.06)
Fully Diluted	\$(0.09)	\$(0.06)
Common Shares:		
Full Diluted	33,425	32,969
Year-end	34,703	34,136

**Consolidated Balance Sheet Items, as of (\$000):**

	2018	2017
Assets:		
Cash & equivalents	113,370	113,370
Inventories	18,095	18,095
Current assets	164,538	164,538
Net property & equip.	27,388	27,388
Total assets	200,310	200,310
Liabilities:		
Current liabilities	36,261	36,261
Long-term debt	21,045	21,045
Stockholders' equity	133,979	133,979
Net current assets	128,277	128,277

**CARDLYTICS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	102,865	91,099
Cost & expenses	130,503	103,700
Operating income	(30,109)	(14,904)
Interest income	526	62
Interest expense	3,521	6,489
Other income (expense), net	(8,372)	5,746
<b>Net income</b>	(41,476)	(15,585)
Balance for common	(41,633)	(20,968)
Earnings common share		
Primary	\$(2.29)	\$(6.68)
Fully Diluted	\$(2.29)	\$(6.68)
Common Shares:		
Full Diluted	18,150	3,140
Year-end	21,411	3,547

**CAREDX INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	53,060	35,821
Cost & expenses	66,223	51,828
Operating income	(13,163)	(16,007)
Other income (expense), net	(27,431)	(4,595)
Net before taxes	(44,121)	(24,768)
Income taxes	(1,095)	(837)
<b>Net income</b>	(43,026)	(23,931)
Earnings common share		
Primary	\$(1.26)	\$(1.09)
Fully Diluted	\$(1.26)	\$(1.09)
Common Shares:		
Full Diluted	34,134	21,765
Year-end	38,784	

**CAREER EDUCATION CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	435,791	453,317
Cost & expenses	377,627	418,525
Operating income	51,115	23,424
Other income (expense), net	225	489
Net before taxes	53,343	24,901
Income taxes	11,527	11,143
Income contin. oper.	41,816	13,758
<b>Net income</b>	41,110	12,485
Earnings common share		
Primary	\$0.59	\$0.18
Fully Diluted	\$0.58	\$0.18
Common Shares:		
Full Diluted	71,425	70,660
Year-end	69,761	69,094

**CARLYLE GROUP LP (THE)****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	2,275,500	2,668,400
Cost & expenses	1,848,600	2,007,500
Operating income	438,900	737,300
Gains or losses	12,000	76,400
Net before taxes	438,900	737,300
Income taxes	36,800	17,700
<b>Net income</b>	402,100	719,600

Balance for common	108,900	185,200
Earnings common share		
Primary	\$1.06	\$2.06
Fully Diluted	\$0.96	\$1.90
Common Shares:		
Full Diluted	112,854	97,538
Year-end	107,748	

**CAS MEDICAL SYSTEMS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Net Sales	16,117,627	13,641,661
Cost & expenses	19,365,697	18,796,852
Operating income	(3,248,070)	(5,155,191)
Interest expense	1,168,298	799,056
Net before taxes	(5,954,247)	(5,954,247)
Income taxes	(1,782,777)	(1,782,777)
Income contin. oper.	(4,171,470)	(4,171,470)
Income discont. oper.		3,310,873
<b>Net income</b>	<b>(4,416,368)</b>	<b>(860,597)</b>
Balance for common	(5,682,719)	(2,042,050)
Earnings common share		
Primary	\$(0.20)	\$(0.07)
Fully Diluted	\$(0.20)	\$(0.07)
Common Shares:		
Full Diluted	27,731,691	27,230,471
Year-end	28,943,711	28,230,697

**CASEY'S GENERAL STORES, INC.**

Earnings, 6 mos. to Oct 31(Consol. - \$):

	2018	2017
Total Revenues	5,126,437,000	247,484,000
Cost & expenses	4,826,523,000	971,677,000
Deprec., depl. & amort.	120,196,000	106,526,000
Operating income	179,718,000	169,281,000
Net before taxes	179,718,000	169,281,000
Income taxes	42,879,000	63,605,000
<b>Net income</b>	<b>136,839,000</b>	<b>105,676,000</b>
Earnings common share		
Primary	\$3.73	\$2.77
Fully Diluted	\$3.70	\$2.75
Common Shares:		
Full Diluted	36,997,631	38,487,907
Year-end	36,604,006	37,612,821

**CATABASIS PHARMACEUTICALS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	20283	21,882
Cost & expenses	(20,283)	(21,632)
Operating income	252	128
Interest expense	100	381
Other income (expense), net	321	18
<b>Net income</b>	<b>(19,810)</b>	<b>(21,867)</b>
Earnings common share		
Primary	\$(0.45)	\$(1.03)
Fully Diluted	\$(0.45)	\$(1.03)
Common Shares:		
Full Diluted	43,604	21,164
Year-end	71,038	

**CBAK ENERGY TECHNOLOGY INC**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	14,952,470	27,806,113
Cost & expenses	24,771,125	37,702,711
Operating income	(9,818,655)	(9,896,598)
Other income (expense), net	11,725,697	(127,751)
<b>Net income</b>	<b>1,907,042</b>	<b>(10,024,349)</b>
Earnings common share		
Primary	\$0.07	\$(0.45)
Fully Diluted	\$0.07	\$(0.45)
Common Shares:		
Full Diluted	26,723,880	22,174,315
Year-end	26,647,478	

**CBTX INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	67,361	60,783
Operating income	41,161	35,754
Net before taxes	41,161	35,754
Income taxes	7,984	10,140

<b>Net income</b>	33,177	25,614
Earnings common share		
Primary	\$1.34	\$1.16
Fully Diluted	\$1.33	\$1.16
Common Shares:		
Full Diluted	25,007	22,144
Year-end	24,859	

**CCOM GROUP INC**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Net Sales	77,831,952	68,371,062
Cost & expenses	75,813,451	67,116,271
Operating income	2,018,501	1,254,791
Interest expense	564,567	488,618
Other income (expense), net	207,410	155,622
Net before taxes	1,661,344	921,795
Income taxes	303,739	200,604
<b>Net income</b>	<b>1,357,605</b>	<b>721,191</b>
Earnings common share		
Primary	\$0.14	\$0.08
Fully Diluted	\$0.14	\$0.07
Common Shares:		
Full Diluted	9,439,540	9,439,540
Year-end	9,154,928	9,154,928

**CELSIUS HOLDINGS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	37,923,619	27,023,123
Cost & expenses	48,157,551	29,933,699
Operating income	(10,233,932)	(2,910,576)
Interest expense	122,944	122,195
<b>Net income</b>	<b>(10,356,876)</b>	<b>(3,032,771)</b>
Balance for common	(10,526,370)	(3,306,514)
Earnings common share		
Primary	\$(0.21)	\$(0.08)
Fully Diluted	\$(0.21)	\$(0.08)
Common Shares:		
Full Diluted	49,675,624	43,990,367
Year-end	51,124,946	45,679,093

**CENTRAL GARDEN & PET CO****Annual Report**

Consolidated Income Statement, Years Ended (\$000):

	09/29/18	09/30/17	09/24/16
Net sales	2,215,362	2,054,478	(revised) 1,829,017
Cost of goods sold & occupancy	1,539,986	1,421,670	1,275,967
Gross profit	675,376	632,808	553,050
Selling, general & administrative expenses	508,040	476,696	421,864
Intangible asset impairment			1,828
Operating income (loss)	167,336	156,112	129,358
Interest expense	39,196	28,209	42,847
Interest income	3,145	147	140
Other income (expense), net	(3,860)	(1,621)	(17,013)
Income (loss) before income taxes & noncontrolling interest	127,425	126,429	69,638
Current income tax expense (benefit) - federal	5,728	32,755	18,592
Current income tax expense (benefit) - state	2,319	3,034	2,140
Current income tax expense (benefit) - foreign	91	121	110
Total current income tax expense (benefit)	8,138	35,910	20,842
Deferred income tax expense (benefit) - federal	(3,676)	11,227	2,796
Deferred income tax expense (benefit) - state	(1,162)	(1,038)	463

Deferred income tax expense (benefit) - foreign	5	600	(48)
Total deferred income tax expense (benefit)	(4,833)	10,789	3,211
Income taxes expense (benefit)	3,305	46,699	24,053
<b>Net income (loss) including noncontrolling interest</b>	<b>124,120</b>	<b>79,730</b>	<b>45,585</b>
Net income attributable to noncontrolling interest	(526)	(902)	(1,071)
Net income (loss) attributable to Central Garden & Pet Company	123,594	78,828	44,514
Weighted average shares outstanding - basic	51,716	50,230	48,964
Weighted average shares outstanding - diluted	53,341	51,820	51,075
Year end shares outstanding	57,751	51,832	51,069
Net income (loss) per share - basic	\$2.39	\$1.57	\$0.91
Net income (loss) per share - diluted	\$2.32	\$1.52	\$0.87
Number of full time employees	4,900	4,000	3,400
Number of part time employees	500	100	200
Total number of employees	5,400	4,100	3,600
Number of common stockholders	86	95	96
Number of class A common stockholders	156	315	322
Number of class B common stockholders	5	5	5
Foreign currency translation adjustments			(1,458)

Reclassified to conform with 2017 presentation; As is; Approximately; As of November 16, 2018; As of November 17, 2017; As of November 18, 2016; Common par value; Reclassified to conform with 2018 presentation

Consolidated Balance Sheet, Years Ended (\$000):

	09/29/18	09/30/17
Cash & cash equivalents	482,106	32,397
Restricted cash	10,899	12,645
Accounts receivable, gross	300,033	259,304
Less: allowance for doubtful accounts	24,125	21,436
Accounts receivable, net	275,908	237,868
Raw materials	117,539	116,591
Work in progress	35,691	16,394
Finished goods	263,845	241,420
Supplies	10,748	7,696
Inventories	427,823	382,101
Prepaid expenses & other current assets	20,562	18,045
Total current assets	1,217,298	683,056
Land	14,183	8,942
Buildings & improvements	154,787	131,280
Transportation equipment	9,348	7,141
Machine & warehouse equipment	227,727	207,878
Capitalized software	114,878	117,360
Office furniture & equipment	27,734	27,355
Assets under construction	24,015	13,451
Plant, property & equipment, gross	572,672	513,407
Less: accumulated depreciation &		

amortization	355,025	332,494
Plant, property & equipment, net	217,647	180,913
Goodwill	281,177	256,275
Other intangible assets, net	152,265	116,067
Other assets	38,822	70,595
Total assets	1,907,209	1,306,906
Accounts payable	110,259	103,283
Accrued expenses	102,583	116,549
Current portion of long-term debt	122	375
Total current liabilities	212,964	220,207
Senior notes	700,000	400,000
Unamortized debt issuance costs	(8,425)	(4,840)
Other notes payable	578	493
Less current portion	122	375
Long-term debt	692,031	395,278
Deferred income taxes & other long-term obligations	49,380	54,279
Common stock	121	122
Class A common stock	439	380
Class B stock	16	16
Additional paid-in capital	590,168	396,790
Retained earnings (accumulated deficit)	362,923	239,329
Accumulated other comprehensive income (loss)	(1,218)	(951)
Total Central Garden & Pet shareholders' equity	952,449	635,686
Noncontrolling interest	385	1,456
Total equity	952,834	637,142

□ Reclassified to conform with 2018 presentation

#### Recent Dividends:

1. Central Garden & Pet Co class B common.  
No dividends paid.
2. Central Garden & Pet Co series B preferred.  
No dividends paid.
3. Central Garden & Pet Co common.  
No dividends paid.
4. Central Garden & Pet Co non-voting class A common.  
No dividends paid.

#### Annual Dividends:

1. Central Garden & Pet Co class B common.  
No dividends paid.
2. Central Garden & Pet Co series B preferred.  
No dividends paid.
3. Central Garden & Pet Co common.  
No dividends paid.
4. Central Garden & Pet Co non-voting class A common.  
No dividends paid.

#### CEREBAIN BIOTECH CORP

##### Earnings, 3 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	251,229	359,380
Operating income	140,000	
Other income (expense), net	(232,487)	(31,668)
Net income	(537,299)	(431,483)
Balance for common	(537,299)	(431,483)
Earnings common share		
Primary	\$(0.06)	\$(0.05)
Fully Diluted	\$(0.06)	\$(0.05)
Common Shares:		
Full Diluted	9,143,951	8,003,532
Year-end	10,109,347	8,319,347

##### Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	38,633	
Current assets	59,317	
Total assets	59,317	
Liabilities:		
Current liabilities	3,179,706	
Long-term debt	2,949,229	
Stockholders' equity	(6,069,618)	
Net current assets	(3,120,389)	

#### CERUS CORP.

##### Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	95,343	79,387
Operating income	(39,530)	(46,679)
Interest expense	2,926	2,122
Other income (expense), net	1,288	3,722
Foreign currency	(22)	(59)
Net before taxes	(41,190)	(45,138)
Income taxes	169	3,961
Net income	(41,359)	(49,099)
Earnings common share		
Primary	\$(0.32)	\$(0.46)
Fully Diluted	\$(0.32)	\$(0.46)
Common Shares:		
Full Diluted	130,199	106,159
Year-end	135,689	114,086

#### CHEMPIO DIAGNOSTICS INC

##### Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	25,814,251	18,027,354
Cost & expenses	30,552,135	22,425,638
Operating income	(4,737,884)	(4,398,284)
Interest income	42,985	24,956
Net income	(4,694,899)	(4,373,328)
Earnings common share		
Primary	\$(0.34)	\$(0.36)
Fully Diluted	\$(0.34)	\$(0.36)
Common Shares:		
Full Diluted	13,872,055	12,293,781
Year-end	14,173,620	12,318,570

#### CHIASMA INC

##### Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	23,947,000	20,978,000
Operating income	(23,947,000)	(20,978,000)
Other income (expense), net	785,000	556,000
Net before taxes	(23,162,000)	(20,422,000)
Income taxes	24,000	301,000
Net income	(23,186,000)	(20,723,000)
Earnings common share		
Primary	\$(0.95)	\$(0.85)
Fully Diluted	\$(0.95)	\$(0.85)
Common Shares:		
Full Diluted	24,385,328	24,361,479
Year-end	24,430,543	24,376,827

#### CHILDREN'S PLACE INC (THE)

##### Earnings, 9 mos. to (Consol. - \$000):

	11/03/18	10/28/17
Net Sales	1,407,526	1,300,303
Cost & expenses	1,258,435	1,142,191
Operating income	97,686	109,652
Interest expense	2,641	1,772
Net before taxes	95,612	109,223
Income taxes	6,675	14,627
Net income	88,937	94,596
Earnings common share		
Primary	\$5.33	\$5.36
Fully Diluted	\$5.24	\$5.19
Common Shares:		
Full Diluted	16,982	18,223
Year-end	16,256	17,443

#### CHINA XD PLASTICS CO., LTD

##### Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	925,007,293	862,814,803
Cost & expenses	837,136,311	771,254,104
Operating income	87,870,982	91,560,699
Interest income	3,607,136	4,028,299
Interest expense	37,562,666	32,865,939
Other income (expense), net	4,001,746	5,418,498
Gains or losses	(520,981)	(584,724)
Net before taxes	63,460,545	62,837,410
Income taxes	8,171,625	10,735,971
Net income	55,288,920	52,101,439
Balance for common	41,925,055	39,185,522
Earnings common share		
Primary	\$0.83	\$0.79
Fully Diluted	\$0.83	\$0.79
Common Shares:		
Full Diluted	50,629,824	49,555,096
Year-end	50,448,841	

#### CIDARA THERAPEUTICS INC

##### Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	46,687	42,262
Operating income	(46,687)	(42,262)
Other income (expense), net	(434)	
Net income	(46,674)	(42,300)
Balance for common	(57,003)	(42,300)
Earnings common share		
Primary	\$(2.35)	\$(2.51)
Fully Diluted	\$(2.35)	\$(2.51)
Common Shares:		
Full Diluted	24,254	16,831
Year-end	27,751	16,866

#### CINEDIGM CORP

##### Earnings, 6 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	26,822	31,518
Cost & expenses	21,203	21,621
Operating income	(1,336)	(895)
Other income (expense), net	(28)	(3,324)
Net before taxes	(6,631)	(12,235)
Income taxes	139	382
Net income	(6,770)	(12,617)
Balance for common	(6,924)	(12,778)
Earnings common share		
Primary	\$(0.18)	\$(1.07)
Fully Diluted	\$(0.18)	\$(1.07)
Common Shares:		
Full Diluted	37,668	11,959
Year-end	35,069	

#### CITI TRENDS INC

##### Earnings, 9 mos. to (Consol. - \$):

	11/03/18	10/28/17
Net Sales	568,395,000	543,098,000
Cost & expenses	537,831,000	516,175,000
Operating income	16,314,000	13,060,000
Interest income	979,000	617,000
Net before taxes	17,179,000	13,565,000
Income taxes	3,152,000	4,238,000
Net income	14,027,000	9,327,000
Earnings common share		
Primary	\$1.06	\$0.66
Fully Diluted	\$1.06	\$0.65
Common Shares:		
Full Diluted	13,269,405	14,270,000
Year-end	12,927,252	13,738,788

#### CLARUS CORP (NEW)

##### Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	154,834	118,010
Cost & expenses	150,451	123,199
Operating income	4,383	(5,189)
Other income (expense), net	31	435
Net before taxes	3,394	(5,702)
Income taxes	(359)	990
Net income	3,753	(6,692)
Earnings common share		
Primary	\$0.13	\$(0.22)
Fully Diluted	\$0.12	\$(0.22)
Common Shares:		
Full Diluted	30,162	30,015
Year-end	29,850	30,041

#### CLEARFIELD INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Sept. 30 (\$):

	2018	2017	2016
		(revised)	(revised)
Net sales	77,651,354	73,947,619	75,287,726
Cost of sales	46,654,570	43,683,360	42,417,478
Gross profit (loss)	30,996,784	30,264,259	32,870,248
Selling, general & administrative expenses	25,925,933	24,952,376	22,138,556
Income (loss) from operations	5,070,851	5,311,883	10,731,692
Interest income	457,101	273,930	157,402
Income (loss) before income taxes	5,527,952	5,585,813	10,889,094
Current federal			



OR Laser loans	158	...
Current portion of long-term obligations	5,072	5,078
Accounts payable	70,292	75,860
Income taxes payable	114,145	103,206
Accrued payroll & benefits	55,704	72,327
Accrued expenses & other current liabilities	36,859	34,215
Warranty reserve	40,220	36,149
Current liabilities held for sale	...	7,021
Customer deposits	19,933	20,052
Deferred revenue	30,613	65,237
Total current liabilities	372,838	419,145
Term loans	420,309	589,001
OR Laser loans	402	...
Long-term taxes payable	36,336	35,866
Deferred compensation	40,895	34,160
Deferred tax liabilities	26,339	45,373
Deferred revenue	5,091	4,765
Asset retirement obligations liability	4,529	5,382
Defined benefit plan liabilities	37,528	39,454
Other long-term liabilities	1,238	1,390
Common stock	242	245
Additional paid-in capital	78,700	171,403
Accumulated other comprehensive income (loss)	2,833	19,906
Retained earnings (accumulated deficit)	1,232,689	971,710
Total stockholders' equity (deficit)	1,314,464	1,163,264

**Recent Dividends:****1. Coherent Inc common.**

No dividends paid.

**Annual Dividends:****1. Coherent Inc common.**

No dividends paid.

**COLLECTORS UNIVERSE INC****Earnings, 3 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	17,495	19,753
Cost & expenses	14,668	15,231
Operating income	2,827	4,522
Net before taxes	2,830	4,553
Income taxes	699	919
<b>Net income</b>	2,131	3,633
Earnings common share		
Primary	\$0.24	\$0.42
Fully Diluted	\$0.24	\$0.41
Common Shares:		
Full Diluted	8,962	8,765
Year-end	9,060	8,921

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	2017
Cash & equivalents	12,194	12,194
Inventories	2,512	2,512
Current assets	18,661	18,661
Net property & equip.	8,190	8,190
Total assets	32,804	32,804
Liabilities:		
Current liabilities	11,671	11,671
Long-term debt	2,250	2,250
Stockholders' equity	15,098	15,098
Net current assets	6,990	6,990

**COLUMBIA SPORTSWEAR CO.****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Net Sales	1,884,728	1,690,064
Cost & expenses	1,686,514	1,536,457
Operating income	198,214	153,607
Other income (expense), net	372	203
Net before taxes	206,334	156,621
Income taxes	44,735	37,950
<b>Net income</b>	161,599	118,671
Earnings common share		

Primary	\$2.22	\$1.61
Fully Diluted	\$2.19	\$1.59
Common Shares:		
Full Diluted	70,685	70,390
Year-end	69,270	69,863

**COMMUNICATIONS SYSTEMS, INC.****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Net Sales	47,103,837	63,280,980
Cost & expenses	53,402,035	73,461,243
Operating income	(6,298,198)	(10,180,263)
Other income (expense), net	263,890	78,888
Gains or losses	10,904	(32,024)
Net before taxes	(6,052,178)	(10,195,238)
Income taxes	(6,092)	(67,014)
<b>Net income</b>	(6,046,086)	(10,128,224)
Earnings common share		
Primary	\$(0.66)	\$(1.13)
Fully Diluted	\$(0.66)	\$(1.13)
Common Shares:		
Full Diluted	9,093,609	8,934,235
Year-end	9,149,877	8,963,516

**COMSCORE INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	310,172	300,623
Cost & expenses	400,895	490,627
Operating income	(115,429)	(215,673)
Interest expense	11,711	554
Other income (expense), net	(827)	12,486
Foreign currency	(181)	(1,523)
Net before taxes	(128,148)	(205,264)
Income taxes	3,916	4,223
<b>Net income</b>	(132,064)	(209,487)
Earnings common share		
Primary	\$(2.32)	\$(3.65)
Fully Diluted	\$(2.32)	\$(3.65)
Common Shares:		
Full Diluted	56,877	57,442
Year-end	58,900	57,289

**COMTECH TELECOMMUNICATIONS CORP.****Earnings, 3 mos. to Oct 31(Consol. – \$):**

	2018	2017
Net Sales	160,844,000	121,569,000
Cost & expenses	149,262,000	116,078,000
Operating income	7,293,000	222,000
Interest expense	2,669,000	2,588,000
Other income (expense), net	(3,217,000)	...
Net before taxes	1,341,000	(2,405,000)
Income taxes	(2,127,000)	(745,000)
<b>Net income</b>	3,468,000	(1,660,000)
Earnings common share		
Primary	\$0.14	\$(0.07)
Fully Diluted	\$0.14	\$(0.07)
Common Shares:		
Full Diluted	24,375,000	23,797,000
Year-end	23,905,527	23,607,194

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	2017
Cash & equivalents	42,943,000	42,943,000
Inventories	89,569,000	89,569,000
Current assets	304,900,000	304,900,000
Net property & equip.	28,543,000	28,543,000
Total assets	866,940,000	866,940,000
Liabilities:		
Current liabilities	142,595,000	142,595,000
Long-term debt	193,986,000	193,986,000
Stockholders' equity	506,096,000	506,096,000
Net current assets	162,305,000	162,305,000

**CONATUS PHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	26,177,000	26,572,000
Cost & expenses	40,449,000	39,715,000
Operating income	(14,272,000)	(13,143,000)
Interest expense	561,000	473,000
Other income (expense), net	(1,000)	(72,000)
<b>Net income</b>	(14,104,000)	(13,040,000)
Earnings common share		
Primary	\$(0.47)	\$(0.46)

Fully Diluted	\$(0.47)	\$(0.46)
Common Shares:		
Full Diluted	30,118,000	28,104,000
Year-end	30,262,000	30,005,462

**CONIFER HOLDINGS INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	74,861	70,287
Cost & expenses	79,497	92,549
Operating income	(4,636)	(22,262)
Net before taxes	(4,636)	(22,262)
Income taxes	52	(410)
<b>Net income</b>	(4,451)	(21,763)
Earnings common share		
Primary	\$(0.52)	\$(2.85)
Fully Diluted	\$(0.52)	\$(2.85)
Common Shares:		
Full Diluted	8,532	7,648
Year-end	8,603	8,518

**CONNIS INC****Earnings, 9 mos. to Oct 31(Consol. – \$000):**

	2018	2017
Total Revenues	1,116,831	1,095,645
Net Sales	855,943	857,506
Cost & expenses	1,009,342	1,025,418
Operating income	107,489	70,227
Interest expense	47,484	62,142
Other income (expense), net	(1,773)	(2,907)
Net before taxes	58,232	5,178
Income taxes	13,859	1,916
<b>Net income</b>	44,373	3,262
Earnings common share		
Primary	\$1.40	\$0.10
Fully Diluted	\$1.38	\$0.10
Common Shares:		
Full Diluted	32,252	31,457
Year-end	31,727	31,365

**CONRAD INDUSTRIES INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	136,511	142,680
Cost & expenses	139,555	140,830
Operating income	(3,044)	1,850
Interest expense	343	383
Other income (expense), net	7,557	330
Net before taxes	4,170	1,797
Income taxes	1,425	512
<b>Net income</b>	2,745	1,285
Earnings common share		
Primary	\$0.55	\$0.25
Fully Diluted	\$0.55	\$0.25
Common Shares:		
Full Diluted	5,018	5,086
Year-end	5,018	5,057

**CONSTELLATION PHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	40,612	27,200
Operating income	(40,612)	(27,200)
Interest income	859	111
Interest expense	228	799
Other income (expense), net	...	4,443
<b>Net income</b>	(39,981)	(23,445)
Balance for common	(39,981)	(36,787)
Earnings common share		
Primary	\$(5.45)	\$(38.43)
Fully Diluted	\$(5.45)	\$(38.43)
Common Shares:		
Full Diluted	7,332	957
Year-end	25,784	...

**CONVERGEONE HOLDINGS INC****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	1,102,106,000	...
Cost & expenses	1,033,502,000	235,155
Operating income	33,183,000	(235,155)
Interest income	118,000	732,299
Interest expense	50,097,000	...
Other income (expense), net	12,327,000	7,435

Net before taxes	(4,469,000)	504,579
Income taxes	(20,312,000)	169,029
<b>Net income</b>	<b>15,843,000</b>	<b>335,550</b>
Balance for common	(171,204,000)	
Earnings common share		
Primary	\$(2.53)	\$(0.04)
Fully Diluted	\$(2.53)	\$(0.04)
Common Shares:		
Full Diluted	67,538,373	4,864,925
Year-end	75,331,363	5,581,597

**COPART INC****Earnings, 3 mos. to Oct 31(Consol. - \$):**

	2018	2017
Total Revenues	461,368,000	419,168,000
Cost & expenses	309,928,000	295,226,000
Operating income	151,440,000	123,942,000
Interest income	960,000	197,000
Interest expense	4,651,000	5,595,000
Other income (expense), net	1,037,000	(4,416,000)
Net before taxes	148,786,000	114,128,000
Income taxes	34,703,000	36,568,000
<b>Net income</b>	<b>114,083,000</b>	<b>77,560,000</b>
Earnings common share		
Primary	\$0.49	\$0.34
Fully Diluted	\$0.47	\$0.32
Common Shares:		
Full Diluted	244,826,000	238,791,000
Year-end	234,008,162	231,218,619

**Consolidated Balance Sheet Items, as of (\$):**

	2018
Assets:	
Cash & equivalents	320,309,000
Inventories	19,734,000
Current assets	763,222,000
Net property & equip.	1,188,088,000
Total assets	2,381,788,000
Liabilities:	
Current liabilities	254,808,000
Long-term debt	398,642,000
Stockholders' equity	1,671,760,000
Net current assets	508,414,000

**CORIUM INTERNATIONAL INC**

**Merger Completed** On Nov. 26, 2018, Gurnet Holding Co. ("Parent"), an affiliate of Gurnet Point Capital (GPC), a private investment firm focused on the healthcare and life sciences sectors, wholly-owned subsidiary, Gurnet Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, Parent acquired all the shares of Co.'s outstanding common stock, par value \$0.001 (the "Shares" and each, a "Share"), at a purchase price of (i) \$12.50 per Share in cash (the "Closing Amount"), before deduction of applicable withholding taxes and without interest, plus (ii) one non-transferable contingent value right per Share, which represented the contractual right to receive \$0.50 per share in cash (the "CVR Amount" and together with the Closing Amount, the "Merger Consideration"), before deduction of applicable withholding taxes and without interest, following approval by the FDA of the New Drug Application for Corlex Donepezil on or prior to Mar. 31, 2020. In addition, (i) each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (1) an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess of (A) the Closing Amount over (B) the per share exercise price of such option plus (2) one CVR for each Share issuable under such option, (ii) each vested restricted stock unit ("RSU") corresponding to Shares that had not yet settled was cancelled and converted into the right to receive (1) an amount in cash equal to the product of (x) the number of Shares issuable under such RSU multiplied by (y) the Closing Amount plus (2) one CVR for each Share issuable under such RSU, (iii) each unvested option that was unexercised, unexercised and outstanding was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess of (A) the Closing Amount over (B) the per share exercise price of such option, and (iv) each unvested RSU outstanding that had not yet been settled was converted into and substituted for the right to receive an amount equal to the product of (x) the number of Shares issuable under such RSU multiplied by (y) the Closing Amount. The payments in respect of unvested options and unvested RSUs shall be paid over the remaining vesting periods of such awards (with full acceleration of any unvested portion

thereof if, within 12 months following the Effective Time, the employee was terminated without cause or the employee resigns for good reason) and subject to generally the same terms and conditions as applied to the awards prior to the Effective Time. Co.'s Employee Stock Purchase Plan was terminated prior to the Effective Time.

**COUPA SOFTWARE INC**

**Acquisition Completed** On Dec. 7, 2018, Co. acquired all the outstanding equity securities of Hiperos, LLC ("Hiperos") and GTCR/Opus Blocker Corp. ("Blocker" and, together with Hiperos, the "Targets"), from GTCR Fund X/C LP ("Fund X/C"), GTCR/Opus Splitter LP ("Splitter"), and Opus Global Holdings, LLC ("Parent" and, together with Fund X/C and Splitter, the "Sellers") for approximately \$95,000,000 in cash.

**COUPA SOFTWARE INC****Earnings, 9 mos. to Oct 31(Consol. - \$000):**

	2018	2017
Total Revenues	185,458	133,028
Cost & expenses	218,069	168,933
Operating income	(32,611)	(35,905)
Interest expense	9,276	12
Net before taxes	(40,325)	(34,644)
Income taxes	(1,372)	438
<b>Net income</b>	<b>(38,953)</b>	<b>(35,082)</b>
Earnings common share		
Primary	\$(0.68)	\$(0.67)
Fully Diluted	\$(0.68)	\$(0.67)
Common Shares:		
Full Diluted	57,030	52,388
Year-end	59,324	54,734

**CRACKER BARREL OLD COUNTRY STORE, INC.****Earnings, 3 mos. to (Consol. - \$):**

	11/02/18	10/27/17
Total Revenues	733,543,000	710,368,000
Cost & expenses	671,865,000	639,530,000
Operating income	61,678,000	70,838,000
Interest expense	4,349,000	3,618,000
Net before taxes	57,329,000	67,220,000
Income taxes	10,122,000	20,840,000
<b>Net income</b>	<b>47,207,000</b>	<b>46,380,000</b>
Earnings common share		
Primary	\$1.97	\$1.93
Fully Diluted	\$1.96	\$1.92
Common Shares:		
Full Diluted	24,073,722	24,105,187
Year-end	24,034,375	23,994,793

**Consolidated Balance Sheet Items, as of (\$):**

	2018
Assets:	
Cash & equivalents	101,631,000
Inventories	181,569,000
Current assets	325,734,000
Net property & equip.	1,157,979,000
Total assets	1,559,597,000
Liabilities:	
Current liabilities	376,304,000
Long-term debt	400,000,000
Stockholders' equity	600,178,000
Net current assets	(50,570,000)

**CREDITRISKMONITOR.COM, INC.****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	10,331,106	9,963,078
Cost & expenses	10,713,404	10,259,458
Deprac., depl. & amort.	138,670	143,132
Operating income	(520,968)	(439,512)
Other income (expense), net	88,354	29,932
Net before taxes	(432,614)	(409,580)
Income taxes	(79,195)	(62,483)
<b>Net income</b>	<b>(511,809)</b>	<b>(472,063)</b>
Earnings common share		
Primary	\$(0.03)	\$(0.03)
Fully Diluted	\$(0.03)	\$(0.03)
Common Shares:		
Full Diluted	10,722,401	10,722,401
Year-end	10,722,401	10,722,401

**CRINETICS PHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,647	1,517
Cost & expenses	20,926	8,143
Operating income	(19,279)	(6,626)

Interest income	749	20
Interest expense		7
Other income (expense), net	(90)	(23)
<b>Net income</b>	<b>(18,620)</b>	<b>(6,636)</b>
Earnings common share		
Primary	\$(2.29)	\$(5.00)
Fully Diluted	\$(2.29)	\$(5.00)
Common Shares:		
Full Diluted	8,131	1,326
Year-end	24,035	

**CSI COMPRESSCO LP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	300,595	212,465
Cost & expenses	235,929	161,476
Deprac., depl. & amort.	52,496	51,860
Operating income	(31,218)	(27,595)
Other income (expense), net	(4,285)	5,179
Net before taxes	(31,218)	(27,595)
Income taxes	2,058	2,191
<b>Net income</b>	<b>(33,276)</b>	<b>(29,786)</b>
Earnings common share		
Primary	\$(0.81)	\$(0.85)
Fully Diluted	\$(0.81)	\$(0.85)
Common Shares:		
Full Diluted	40,511	34,467
Year-end	43,269	35,496

**CSW INDUSTRIALS INC****Earnings, 6 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	181,190	173,721
Cost & expenses	146,241	142,498
Operating income	34,949	31,223
Interest expense	805	1,302
Other income (expense), net	820	619
Net before taxes	34,964	30,540
Income taxes	8,534	11,103
Income contin. oper.	26,430	19,437
<b>Net income</b>	<b>26,830</b>	<b>15,816</b>
Earnings common share		
Primary	\$1.71	\$1.00
Fully Diluted	\$1.70	\$0.99
Common Shares:		
Full Diluted	15,790	15,935
Year-end	15,286	

**CUMBERLAND PHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	27,243,859	29,500,843
Cost & expenses	30,425,485	30,867,276
Operating income	(5,128,083)	(3,178,022)
Interest income	398,420	216,849
Interest expense	59,520	70,646
Net before taxes	(4,789,183)	(3,031,819)
Income taxes	12,477	4,196,192
<b>Net income</b>	<b>(4,801,660)</b>	<b>(7,228,011)</b>
Earnings common share		
Primary	\$(0.30)	\$(0.45)
Fully Diluted	\$(0.30)	\$(0.45)
Common Shares:		
Full Diluted	15,645,230	15,973,737
Year-end	15,555,865	15,781,736

**CUMULUS MEDIA INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	377,258	841,801
Cost & expenses	301,644	683,412
Operating income	57,093	110,779
Interest income	20	106
Interest expense	28,579	103,742
Other income (expense), net	(3,157)	(1,127)
Net before taxes	25,377	6,016
Income taxes	7,684	6,465
<b>Net income</b>	<b>17,693</b>	<b>(449)</b>
Balance for common	17,693	(449)
Earnings common share		
Primary	\$0.88	\$(0.02)
Fully Diluted	\$0.88	\$(0.02)
Common Shares:		
Full Diluted	20,052	29,306
Year-end	16,468	29,306

**CYMABAY THERAPEUTICS INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	4,793	21,762
Cost & expenses	51,950	(16,969)
Operating income	(51,950)	2,882
Interest income	336	846
Other income (expense), net	(3,695)	(4,996)
<b>Net income</b>	<b>(53,099)</b>	<b>(22,514)</b>
Earnings common share		
Primary	\$(0.93)	\$(0.71)
Fully Diluted	\$(0.93)	\$(0.71)
Common Shares:		
Full Diluted	57,298	31,849
Year-end	59,439	43,847

**DAKTRONICS INC.****Earnings, 6 mos. to** (Consol. – \$000):

	10/27/18	10/28/17
Net Sales	326,880	342,037
Cost & expenses	313,821	320,874
Operating income	13,059	21,163
Interest income	385	362
Interest expense	41	133
Other income (expense), net	(220)	58
Net before taxes	13,183	21,450
Income taxes	3	5,889
<b>Net income</b>	<b>13,180</b>	<b>15,561</b>
Earnings common share		
Primary	\$0.29	\$0.35
Fully Diluted	\$0.29	\$0.35
Common Shares:		
Full Diluted	44,994	44,696
Year-end	45,032	

**DATATRAK INTERNATIONAL INC.****Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	5,532,593	5,595,639
Cost & expenses	4,902,362	5,241,183
Deprec., depl. & amort.	490,798	480,718
Operating income	139,433	(126,262)
Interest income	2,388	2,039
Interest expense	2,584	129,440
Gains or losses	2,680	
<b>Net income</b>	<b>141,917</b>	<b>(253,663)</b>
Earnings common share		
Primary	\$0.06	\$(0.14)
Fully Diluted	\$0.06	\$(0.14)
Common Shares:		
Full Diluted	2,330,302	1,837,518
Year-end	2,304,275	2,267,286

**DAVE & BUSTERS ENTERTAINMENT INC****Earnings, 9 mos. to** (Consol. – \$000):

	11/04/18	10/29/17
Total Revenues	933,517	834,878
Cost & expenses	726,382	637,114
Operating income	120,006	123,317
Other income (expense), net		(718)
Net before taxes	110,600	116,526
Income taxes	22,815	31,217
<b>Net income</b>	<b>87,785</b>	<b>85,309</b>
Earnings common share		
Primary	\$2.23	\$2.05
Fully Diluted	\$2.18	\$1.99
Common Shares:		
Full Diluted	40,257	42,889
Year-end	38,791	40,927

**DECISION DIAGNOSTICS CORP****Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Net Sales	1,642,666	1,181,075
Cost & expenses	3,162,856	2,600,299
Operating income	(1,520,189)	(1,419,224)
Other income (expense), net	(195,877)	(34,515)
Gains or losses		(176,137)
<b>Net income</b>	<b>(1,866,553)</b>	<b>(1,800,469)</b>
Balance for common	(1,866,553)	(1,800,469)
Earnings common share		
Primary	\$(0.01)	\$(0.02)
Fully Diluted	\$(0.01)	\$(0.02)

Common Shares:

Full Diluted	129,749,768	92,209,047
Year-end	131,420,082	101,271,675

**DEL FRISCO'S RESTAURANT GROUP INC****Earnings, 9 mos. to** (Consol. – \$000):

	09/25/18	09/05/17
Total Revenues	254,367	193,404
Cost & expenses	256,213	179,171
Operating income	(16,580)	2,391
Other income (expense), net	(533)	(53)
Net before taxes	(42,336)	1,978
Income taxes	255	595
Income contin. oper.	(42,591)	1,383
Income discont. oper.	(25,645)	2,241
<b>Net income</b>	<b>(68,236)</b>	<b>3,624</b>
Earnings common share		
Primary	\$(3.00)	\$0.17
Fully Diluted	\$(3.00)	\$0.16
Common Shares:		
Full Diluted	22,776	22,180
Year-end	33,321	

**DENALI THERAPEUTICS INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	124,578	66,600
Operating income	(121,094)	(66,600)
<b>Net income</b>	<b>(113,773)</b>	<b>(65,298)</b>
Earnings common share		
Primary	\$(1.24)	\$(6.77)
Fully Diluted	\$(1.24)	\$(6.77)
Common Shares:		
Full Diluted	92,057	9,644
Year-end	93,974	

**DESTINATION MATERNITY CORP****Earnings, 9 mos. to** (Consol. – \$):

	11/03/18	10/28/17
Net Sales	292,459,000	301,060,000
Cost & expenses	296,683,000	309,251,000
Operating income	(4,224,000)	(8,191,000)
Net before taxes	(7,757,000)	(11,180,000)
Income taxes	168,000	259,000
<b>Net income</b>	<b>(7,925,000)</b>	<b>(11,439,000)</b>
Earnings common share		
Primary	\$(0.57)	\$(0.83)
Fully Diluted	\$(0.57)	\$(0.83)
Common Shares:		
Full Diluted	13,867,000	13,777,000
Year-end	14,447,524	14,610,827

**DESTINATION XL GROUP INC****Earnings, 9 mos. to** (Consol. – \$000):

	11/03/18	10/28/17
Net Sales	342,606	332,454
Cost & expenses	324,416	322,058
Deprec., depl. & amort.	21,867	23,337
Operating income	(3,677)	(12,941)
Interest expense	2,642	2,497
Net before taxes	(6,319)	(15,438)
Income taxes	(19)	64
<b>Net income</b>	<b>(6,300)</b>	<b>(15,502)</b>
Earnings common share		
Primary	\$(0.13)	\$(0.32)
Fully Diluted	\$(0.13)	\$(0.32)
Common Shares:		
Full Diluted	49,068	48,966
Year-end	49,453	48,670

**DIAMONDBACK ENERGY, INC.**

**Merger Completed** On Nov. 29, 2018, Co.'s wholly-owned subsidiary, Sidewinder Merger Sub Inc. ("Merger Sub"), merged with and into Energen Corp. ("Energen"), Energen continuing as the surviving corporation and became a wholly-owned subsidiary of Co. As the result of the merger, each share of common stock, par value \$0.01 per share, of Energen ("Energen Common Stock") (other than shares held in treasury by Energen, shares owned by Co. or Merger Sub or shares with respect to which dissenters' rights have been validly exercised in accordance with Alabama law) issued and outstanding immediately prior to the Effective Time was converted into the right to receive 0.6442 of a share of common stock, par value \$0.01 per share, of Co. ("Co. Common Stock"), plus cash in lieu of any fractional shares that otherwise

would have been issued (the "Merger Consideration"). In addition, at the Effective Time, (1) each outstanding stock option of Energen was converted into a stock option of equivalent value relating to shares of Co. Common Stock on the terms set forth in the Merger Agreement, (2) each stock appreciation right in respect of Energen Common Stock was converted into a stock appreciation right of equivalent value relating to shares of Co. Common Stock on the terms set forth in the Merger Agreement, (3) each outstanding performance share award of Energen with a performance period that is scheduled to terminate on Dec. 31, 2018 became fully vested and was converted into the Merger Consideration with respect to each share subject to such award and (4) each outstanding time-vesting restricted stock unit award of Energen and (other than as provided in clause (3)) each performance share award of Energen was converted into a time-vesting Co. restricted stock unit award of equivalent value on the terms set forth in the Merger Agreement. Performance goals applicable to Energen performance share awards were deemed satisfied at the greater of target and actual performance as of the Effective Time, as determined in accordance with the Merger Agreement.

**DICERNA PHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	75,498	44,819
Operating income	(70,863)	(44,819)
Interest income	1,020	360
Interest expense	399	
<b>Net income</b>	<b>(70,242)</b>	<b>(44,459)</b>
Balance for common	(70,242)	(57,336)
Earnings common share		
Primary	\$(1.32)	\$(2.76)
Fully Diluted	\$(1.32)	\$(2.76)
Common Shares:		
Full Diluted	53,038	20,809
Year-end	61,889	20,848

**DIGI INTERNATIONAL INC****Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$):**

	2018	2017	2016
		(revised)	(revised)
Revenue - hardware product	191,050,000	166,480,000	196,101,000
Revenue - service & solutions	37,316,000	15,154,000	6,904,000
Total revenue	228,366,000	181,634,000	203,005,000
Cost of hardware product	96,332,000	85,369,000	97,776,000
Cost of service & solutions	20,280,000	7,647,000	4,662,000
Amortization	2,871,000	1,444,000	887,000
Total cost of sales	119,483,000	94,460,000	103,325,000
Gross profit	108,883,000	87,174,000	99,680,000
Sales & marketing expenses	44,517,000	33,955,000	33,847,000
Research & development expenses	33,178,000	28,566,000	30,955,000
General & administrative expenses	28,565,000	13,331,000	17,026,000
Restructuring charges (benefit), net	301,000	2,515,000	747,000
Total operating expenses	106,561,000	78,367,000	82,575,000
Operating income (loss)	2,322,000	8,807,000	17,105,000
Interest income	445,000	656,000	545,000
Interest expense	25,000	48,000	291,000
Other income (expense), net	48,000	76,000	(669,000)
Total other income (expense), net	468,000	684,000	(415,000)
Income before income taxes - United States	(2,887,000)	5,170,000	9,841,000
Income before income taxes - international	5,677,000	4,321,000	6,849,000
Income (loss) from continuing operations, before income taxes	2,790,000	9,491,000	16,690,000

Current federal income tax provision (benefit) ...	526,000	312,000	(141,000)	Other current assets	2,613,000	3,032,000	Operating income	24,361,000	(12,770,000)
Current state income tax provision (benefit) ...	57,000	165,000	139,000	Assets held for sale	5,220,000	...	Interest income	2,000	2,000
Current foreign income tax provision (benefit) ...	1,412,000	1,756,000	2,099,000	Total current assets	163,044,000	174,360,000	Other income (expense), net	(1,039,000)	(965,000)
Deferred U.S. income tax provision (benefit) ...	(668,000)	(1,454,000)	1,260,000	Marketable securities, long-term	...	4,753,000	Net before taxes	22,226,000	(14,936,000)
Deferred foreign income tax provision (benefit) ...	160,000	(654,000)	(145,000)	Land	570,000	1,800,000	Income taxes	7,024,000	1,956,000
Income tax provision (benefit) ...	1,487,000	125,000	3,212,000	Buildings	2,338,000	10,522,000	<b>Net income</b>	15,202,000	(16,892,000)
Income from continuing operations	1,303,000	9,366,000	13,478,000	Improvements	1,698,000	3,445,000	Balance for common	14,859,000	(16,892,000)
Income (loss) from discontinued operations, after income taxes	...	...	3,230,000	Equipment	15,803,000	17,133,000	Earnings common share		
<b>Net income (loss)</b>	1,303,000	9,366,000	16,708,000	Purchased software	3,966,000	3,571,000	Primary	\$1.02	\$(1.18)
Weighted average shares outstanding - basic	27,083,000	26,432,000	25,760,000	Furniture & fixtures	3,350,000	3,473,000	Fully Diluted	\$1.02	\$(1.18)
Weighted average shares outstanding - diluted	27,652,000	27,099,000	26,311,000	Property, equipment & improvements, at cost	27,725,000	39,944,000	Common Shares:		
Year end shares outstanding	27,427,502	26,571,415	26,040,378	Less accumulated depreciation & amortization	21,455,000	27,143,000	Full Diluted	14,518,765	14,333,452
Earnings (loss) per share from continuing operations, basic	\$0.05	\$0.35	\$0.52	Property, equipment, & improvements, net	6,270,000	12,801,000	Year-end	14,813,907	14,769,342
Earnings (loss) per share from discontinued operations, basic	...	...	\$0.13	Identifiable intangible assets, net	39,320,000	11,800,000	<b>DOCUSIGN INC</b>		
<b>Net earnings (loss) per share - basic</b>	\$0.05	\$0.35	\$0.65	Goodwill	154,535,000	131,995,000	<b>Earnings, 9 mos. to Oct 31(Consol. - \$000):</b>		
Earnings (loss) per share from continuing operations, diluted	\$0.05	\$0.35	\$0.51	Deferred tax assets	6,665,000	9,211,000	2018	2017	
Earning (loss) per share from discontinued operations, diluted	...	...	\$0.12	Other assets	1,291,000	269,000	Total Revenues	501,237	369,630
<b>Net earnings (loss) per share - diluted</b>	\$0.05	\$0.35	\$0.64	Total assets	371,125,000	345,189,000	Cost & expenses	864,932	415,018
Total number of employees	516	514	515	Accounts payable	12,911,000	6,240,000	Operating income	(363,695)	(45,388)
Number of common stockholders	117	118	129	Accrued compensation	8,190,000	4,325,000	Interest expense	3,743	474
Foreign currency translation adjustments	(865,000)	...	(2,107,000)	Accrued warranty	1,172,000	987,000	Other income (expense), net	4,165	699
				Accrued professional fees	1,367,000	928,000	Net before taxes	(363,273)	(45,163)
				Accrued restructuring	453,000	1,656,000	Income taxes	(3,059)	761
				Unearned revenue	2,579,000	1,343,000	<b>Net income</b>	(360,214)	(45,924)
				Contingent consideration on acquired businesses	5,890,000	388,000	Earnings common share		
				Other current liabilities	2,413,000	2,113,000	Primary	\$(2.90)	\$(1.49)
				Total current liabilities	34,975,000	17,980,000	Fully Diluted	\$(2.90)	\$(1.49)
				Income taxes payable	851,000	877,000	Common Shares:		
				Deferred tax liabilities	334,000	534,000	Full Diluted	124,343	31,604
				Contingent consideration on acquired businesses	4,175,000	6,000,000	Year-end	157,255	...
				Other non-current liabilities	510,000	654,000	<b>DOMO INC</b>		
				Total liabilities	40,845,000	26,045,000	<b>Earnings, 9 mos. to Oct 31(Consol. - \$000):</b>		
				Common stock	338,000	330,000	2018	2017	
				Additional paid-in capital	255,936,000	245,528,000	Total Revenues	103,056	78,451
				Retained earnings (accumulated deficit)	151,748,000	150,478,000	Cost & expenses	219,395	213,761
				Accumulated other comprehensive income (loss)	(23,526,000)	(22,659,000)	Operating income	(116,339)	(135,310)
				Treasury stock, at cost	54,216,000	54,533,000	Other income (expense), net	(7,188)	251
				Total stockholders' equity	330,280,000	319,144,000	Net before taxes	(123,527)	(135,059)
							Income taxes	909	296
							<b>Net income</b>	(124,436)	(135,355)
							Earnings common share		
							Primary	\$(9.61)	\$(85.45)
							Fully Diluted	\$(9.61)	\$(85.45)
							Common Shares:		
							Full Diluted	12,954	1,584
							Year-end	26,338	...
							<b>DORCHESTER MINERALS LP</b>		
							<b>Earnings, 9 mos. to Sep 30(Consol. - \$000):</b>		
							2018	2017	
							Total Revenues	50,944	37,760
							Cost & expenses	7,474	7,122
							<b>Net income</b>	36,606	24,195
							Earnings common share		
							Primary	\$1.09	\$0.75
							Fully Diluted	\$1.09	\$0.75
							Common Shares:		
							Full Diluted	32,280	31,222
							Year-end	32,280	32,280
							<b>DOVA PHARMACEUTICALS INC</b>		
							<b>Earnings, 9 mos. to Sep 30(Consol. - \$000):</b>		
							2018	2017	
							Total Revenues	7,513	...
							Cost & expenses	59,516	20,040
							Operating income	(52,003)	(20,040)
							<b>Net income</b>	(52,949)	(20,654)
							Earnings common share		
							Primary	\$(1.91)	\$(1.03)
							Fully Diluted	\$(1.91)	\$(1.03)
							Common Shares:		
							Full Diluted	27,668	20,014
							Year-end	28,204	25,652
							<b>DRONE AVIATION HOLDING CORP</b>		
							<b>Earnings, 9 mos. to Sep 30(Consol. - \$):</b>		
							2018	2017	
							Net Sales	995,838	474,634
							Cost & expenses	4,695,811	7,715,816
							Operating income	(3,699,973)	(7,241,182)
							Interest expense	244,283	1,558,389
							Other income (expense), net	...	1,149,647

□ Reclassified to conform with 2017 presentation; □ As of November 15, 2018; □ As of November 17, 2017; □ As of December 9, 2016

#### Consolidated Balance Sheet, Years Ended Sept. 30 (\$):

	2018	2017 (revised)
Cash & cash equivalents	58,014,000	78,222,000
Marketable securities	4,736,000	32,015,000
Accounts receivable, gross	54,451,000	31,365,000
Less allowance for doubtful accounts	1,074,000	341,000
Less reserve for future returns & pricing adjustments	(2,560,000)	(2,169,000)
Accounts receivable, net	50,817,000	28,855,000
Raw materials	22,047,000	24,050,000
Work in process	525,000	484,000
Finished goods	19,072,000	5,704,000
Inventories	41,644,000	30,238,000
Receivable from sale of business	...	1,998,000

	2018	2017
Total Revenues	78,252,000	78,320,000
Cost & expenses	80,330,000	80,753,000
Operating income	(3,147,000)	(3,554,000)
Other income (expense), net	(155,000)	(946,000)
Net before taxes	(3,865,000)	(5,074,000)
Income taxes	(940,000)	7,357,000
Income contin. oper.	(2,925,000)	(12,431,000)
<b>Net income</b>	2,330,000	(13,747,000)
Earnings common share		
Primary	\$0.12	\$(0.69)
Fully Diluted	\$0.12	\$(0.69)
Common Shares:		
Full Diluted	20,129,000	19,974,000
Year-end	20,230,628	...
<b>DMC GLOBAL INC</b>		
<b>Earnings, 9 mos. to Sep 30(Consol. - \$):</b>		
2018	2017	
Net Sales	236,111,000	138,314,000
Cost & expenses	209,385,000	148,050,000

□ Reclassified to conform with 2018 presentation

#### Recent Dividends:

1. Digi International Inc common.

No dividends paid.

#### Annual Dividends:

1. Digi International Inc common.

No dividends paid.

#### DIGIRAD CORP

**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	78,252,000	78,320,000
Cost & expenses	80,330,000	80,753,000
Operating income	(3,147,000)	(3,554,000)
Other income (expense), net	(155,000)	(946,000)
Net before taxes	(3,865,000)	(5,074,000)
Income taxes	(940,000)	7,357,000
Income contin. oper.	(2,925,000)	(12,431,000)
<b>Net income</b>	2,330,000	(13,747,000)
Earnings common share		
Primary	\$0.12	\$(0.69)
Fully Diluted	\$0.12	\$(0.69)
Common Shares:		
Full Diluted	20,129,000	19,974,000
Year-end	20,230,628	...

#### DMC GLOBAL INC

**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	236,111,000	138,314,000
Cost & expenses	209,385,000	148,050,000



<b>Net income</b> .....	(3,944,256)	(7,649,924)	Operating income .....	39,893,000	8,953,781	Selling, general, & administrative expenses .....	21,232,000	22,246,000	20,734,000
Earnings common share			Interest income .....		21,032	Research & development expenses .....	15,387,000	12,542,000	9,921,000
Primary .....	\$(0.43)	\$(0.86)	Interest expense .....	11,284,000	10,997,118	Impairments .....	...	506,000	...
Fully Diluted .....	\$(0.43)	\$(0.86)	Net before taxes .....	28,609,000	(2,022,305)	Recovery of previously incurred litigation related fees & expenses from arbitration award .....	...	...	(2,599,000)
Common Shares:			Income taxes .....	6,821,000	(1,296,578)	Loss (gain) from change in estimate on ARO obligation ...	(145,000)	45,000	...
Full Diluted .....	9,182,470	8,880,168	<b>Net income</b> .....	21,788,000	(725,727)	Gain (loss) on sale of assets .....	(34,000)	456,000	41,000
Year-end .....	9,182,470	9,182,470	Earnings common share			Total operating expenses .....	36,798,000	34,793,000	28,015,000
<b>DROPBOX INC</b>			Primary .....	\$0.79	\$(0.03)	Operating income (loss) .....	(18,311,000)	7,741,000	2,939,000
<b>Earnings, 9 mos. to Sep 30</b> (Consol. - \$000):			Fully Diluted .....	\$0.78	\$(0.03)	Interest income (expense), net .....	733,000	245,000	88,000
	2018	2017	Common Shares:			Foreign exchange gain (loss) .....	(434,000)	82,000	(394,000)
Total Revenues .....	1,015,800	801,300	Full Diluted .....	27,935,614	27,885,839	Other income (expense) .....	110,000	316,000	...
Cost & expenses .....	1,497,800	877,700	Year-end .....	27,801,599	27,133,041	Total other income (expense) .....	409,000	643,000	(306,000)
Operating income .....	(482,000)	(76,400)	<b>EIDOS THERAPEUTICS INC</b>			Income (loss) from continuing operations before income taxes - domestic .....	(16,752,000)	10,632,000	1,735,000
Other income (expense), net .....	6,100	13,000	<b>Earnings, 9 mos. to Sep 30</b> (Consol. - \$000):			Income (loss) from continuing operations before income taxes - foreign .....	(1,150,000)	(2,248,000)	898,000
Net before taxes .....	(472,700)	(72,800)		2018	2017	Income (loss) from continuing operations before income tax expense (benefit) .....	(17,902,000)	8,384,000	2,633,000
Income taxes .....	2,700	1,200	Cost & expenses .....	28,018	6,905	Federal income tax benefit (expense) - current .....	(502,000)	135,000	...
<b>Net income</b> .....	(475,400)	(74,000)	Operating income .....	(28,018)	(6,905)	Federal income tax benefit (expense) .....	(502,000)	135,000	...
Earnings common share			Other income (expense), net .....	(8,358)	75	State income tax benefit (expense) - current .....	53,000	28,000	(117,000)
Primary .....	\$(1.39)	\$(0.38)	<b>Net income</b> .....	(36,376)	(6,830)	State income tax benefit (expense) .....	53,000	28,000	(117,000)
Fully Diluted .....	\$(1.39)	\$(0.38)	Earnings common share			Foreign income tax benefit (expense) - current .....	...	...	131,000
Common Shares:			Primary .....	\$(2.28)	\$(1.95)	Foreign income tax benefit (expense) .....	...	...	131,000
Full Diluted .....	342,000	195,500	Fully Diluted .....	\$(2.28)	\$(1.95)	Income tax expense (benefit) .....	(449,000)	163,000	14,000
Year-end .....	421,257	...	Common Shares:			Income (loss) from continuing operations before income tax expense (benefit) .....	(17,453,000)	8,221,000	2,619,000
<b>DULUTH HOLDINGS INC</b>			Full Diluted .....	15,976	3,505	Income (loss) from discontinued operations, net of tax .....	...	14,000	5,647,000
<b>Earnings, 9 mos. to</b> (Consol. - \$000):			Year-end .....	36,712	...	<b>Net income (loss)</b> .....	(17,453,000)	8,235,000	8,266,000
	10/28/18	10/29/17	<b>EIGER BIOPHARMACEUTICALS INC</b>			Weighted average shares outstanding - basic .....	27,266,000	26,659,000	25,979,000
Net Sales .....	317,561	253,642	<b>Earnings, 9 mos. to Sep 30</b> (Consol. - \$000):			Weighted average shares outstanding - diluted .....	27,266,000	27,544,000	26,518,000
Cost & expenses .....	310,485	246,116		2018	2017	Year end shares outstanding .....	27,577,000	27,028,000	26,244,000
Operating income .....	7,076	7,526	Net Sales .....	34,954	30,935	Income (loss) per share - continuing operations - basic .....	\$(0.64)	\$0.31	\$0.10
Other income (expense), net .....	168	175	Operating income .....	(34,954)	(30,935)	Income (loss) per share - discontinued .....			
Net before taxes .....	3,606	6,502	Interest income .....	654	321				
Income taxes .....	913	2,480	Interest expense .....	1,574	1,129				
<b>Net income</b> .....	2,693	4,022	Other income (expense), net .....	(16)	188				
Earnings common share			<b>Net income</b> .....	(35,890)	(31,555)				
Primary .....	\$0.08	\$0.12	Earnings common share						
Fully Diluted .....	\$0.08	\$0.12	Primary .....	\$(2.92)	\$(3.77)				
Common Shares:			Fully Diluted .....	\$(2.92)	\$(3.77)				
Full Diluted .....	32,402	32,297	Common Shares:						
Year-end .....	32,587	32,464	Full Diluted .....	12,291	8,367				
<b>DUO WORLD INC</b>			Year-end .....	19,096	10,516				
<b>Earnings, 6 mos. to Sep 30</b> (Consol. - \$):			<b>ELECTRO SCIENTIFIC INDUSTRIES INC</b>						
	2018	2017	<b>Earnings, 6 mos. to</b> (Consol. - \$000):						
Total Revenues .....	328,881	381,138		09/29/18	09/30/17				
Cost & expenses .....	1,108,294	1,187,217	Net Sales .....	196,541	143,651				
Operating income .....	(792,730)	(820,222)	Cost & expenses .....	144,457	135,736				
Interest expense .....	99,516	36,156	Operating income .....	52,084	7,915				
Other income (expense), net .....	2,965	(1,469)	Net before taxes .....	52,919	7,502				
Gains or losses .....	14	32	Income taxes .....	4,941	340				
Foreign currency .....	(27,103)	3,453	<b>Net income</b> .....	47,978	7,162				
<b>Net income</b> .....	(916,370)	(854,361)	Earnings common share						
Earnings common share			Primary .....	\$1.39	\$0.21				
Primary .....	\$(0.01)	\$(0.01)	Fully Diluted .....	\$1.34	\$0.21				
Fully Diluted .....	\$(0.01)	\$(0.01)	Common Shares:						
Common Shares:			Full Diluted .....	35,916	34,716				
Full Diluted .....	111,283,919	89,128,172	Year-end .....	34,699	34,067				
Year-end .....	65,738,320	164,466,616	<b>ELECTRONICS FOR IMAGING, INC.</b>						
<b>DXP ENTERPRISES, INC.</b>			<b>Earnings, 9 mos. to Sep 30</b> (Consol. - \$000):						
<b>Earnings, 9 mos. to Sep 30</b> (Consol. - \$000):				2018	2017				
	2018	2017	Total Revenues .....	758,072	724,097				
Net Sales .....	905,191	741,155	Cost & expenses .....	709,577	665,737				
Cost & expenses .....	857,169	716,152	Operating income .....	13,694	23,531				
Operating income .....	48,022	25,003	Interest expense .....	14,739	14,538				
Other income (expense), net .....	1,318	324	Net before taxes .....	225	11,795				
Net before taxes .....	33,381	12,754	Income taxes .....	(1,868)	795				
Income taxes .....	8,962	2,880	<b>Net income</b> .....	2,093	11,000				
<b>Net income</b> .....	24,419	9,874	Earnings common share						
Balance for common .....	24,442	10,166	Primary .....	\$0.05	\$0.24				
Earnings common share			Fully Diluted .....	\$0.05	\$0.23				
Primary .....	\$1.39	\$0.58	Common Shares:						
Fully Diluted .....	\$1.33	\$0.56	Full Diluted .....	45,388	47,102				
Common Shares:			Year-end .....	44,243	46,447				
Full Diluted .....	18,387	18,242	<b>EMCORE CORP.</b>						
Year-end .....	17,570	17,389	<b>Annual Report</b>						
<b>ECHO GLOBAL LOGISTICS INC</b>			<b>Consolidated Income Statement, Years Ended Sept. 30</b> (\$):						
<b>Earnings, 9 mos. to Sep 30</b> (Consol. - \$):				2018	2017				
	2018	2017							
Total Revenues .....	1,856,723,000	395,368,478	Revenue .....	85,617,000	122,895,000				
Cost & expenses .....	1,789,662,000	362,275,938	Cost of revenue .....	67,130,000	80,361,000				
Deprec., depl. & amort. ....	27,168,000	24,138,759	Gross profit (loss) ....	18,487,000	42,534,000				

operations - basic . . . . .			\$0.22
Net income (loss) per share - basic . . . . .	\$(0.64)	\$0.31	\$0.32
Income (loss) per share - continuing operations - diluted . . . . .	\$(0.64)	\$0.30	\$0.10
Income (loss) per share - discontinued operations - diluted . . . . .			\$0.21
Net income (loss) per share - diluted . . . . .	\$(0.64)	\$0.30	\$0.31
Total number of employees . . . . .	2391	2364	2589
Number of common stockholders . . . . .	292	290	295
Foreign currency translation adjustments . . . . .	324,000	(18,000)	

□ Reclassified to conform with 2018 presentation; □ Approximately; □ As of November 29, 2018; □ As of November 30, 2017; □ As of November 30, 2016

#### Consolidated Balance Sheet, Years Ended Sept. 30 (\$):

	2018	2017 (revised)
Cash & cash equivalents . . . . .	63,117,000	68,333,000
Restricted cash . . . . .	78,000	421,000
Less: allowance for doubtful accounts . . . . .	548,000	22,000
Accounts receivable, net . . . . .	19,275,000	22,265,000
Raw materials . . . . .	11,857,000	15,826,000
Work in-process . . . . .	5,402,000	6,586,000
Finished goods . . . . .	5,024,000	5,413,000
Inventory, gross . . . . .	22,283,000	27,825,000
Less: non-current portion . . . . .	1,433,000	2,686,000
Inventory, net . . . . .	20,850,000	25,139,000
Prepaid expenses & other current assets . . . . .	12,730,000	8,527,000
Total current assets . . . . .	116,050,000	124,685,000
Equipment . . . . .	36,625,000	31,507,000
Furniture & fixtures . . . . .	1,109,000	1,109,000
Computer hardware & software . . . . .	2,928,000	2,974,000
Leasehold improvements . . . . .	2,049,000	2,330,000
Construction in progress . . . . .	3,648,000	4,539,000
Property, plant, & equipment, gross . . . . .	46,359,000	42,459,000
Less: accumulated depreciation . . . . .	28,143,000	25,824,000
Property, plant, & equipment, net . . . . .	18,216,000	16,635,000
Non-current inventory . . . . .	1,433,000	2,686,000
Other non-current assets . . . . .	199,000	78,000
Total assets . . . . .	135,898,000	144,084,000
Accounts payable . . . . .	12,997,000	11,818,000
Accrued compensation . . . . .	3,065,000	3,904,000
Accrued warranty . . . . .	642,000	684,000
Accrued professional fees . . . . .	604,000	653,000
Customer deposits . . . . .	22,000	20,000
Deferred revenue . . . . .	368,000	
Accrued income & other taxes . . . . .	7,593,000	2,920,000
Severance & restructuring accruals . . . . .	82,000	628,000
Other accrued expenses & current liabilities . . . . .	1,829,000	1,016,000
Total current liabilities . . . . .	27,202,000	21,643,000
Asset retirement obligations . . . . .	1,809,000	1,638,000
Other long-term liabilities . . . . .	82,000	29,000
Total liabilities . . . . .	29,093,000	23,310,000
Common stock . . . . .	734,066,000	730,906,000
Treasury stock, at cost . . . . .	47,721,000	47,721,000
Accumulated other comprehensive income (loss) . . . . .	885,000	561,000
Retained earnings (accumulated deficit) . . . . .	(580,425,000)	(562,972,000)
Total shareholders'		

equity (deficit) . . . . .	106,805,000	120,774,000
□ Reclassified to conform with 2018 presentation; □ As reported by the Company		

#### Recent Dividends:

##### 1. EMCORE Corp. common.

No dividends paid.

#### Annual Dividends:

##### 1. EMCORE Corp. common.

No dividends paid.

#### ENCORE WIRE CORP.

##### Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Net Sales . . . . .	968,956,000	862,956,000
Cost & expenses . . . . .	901,059,000	805,990,000
Operating income . . . . .	67,897,000	56,966,000
Net before taxes . . . . .	69,229,000	57,150,000
Income taxes . . . . .	16,109,000	18,621,000
Net income . . . . .	53,120,000	38,529,000
Earnings common share		
Primary . . . . .	\$2.55	\$1.86
Fully Diluted . . . . .	\$2.54	\$1.85
Common Shares:		
Full Diluted . . . . .	20,910,000	20,835,000
Year-end . . . . .	20,855,148	20,812,748

#### ENDOCYTE INC

##### Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues . . . . .	116,175	57,500
Cost & expenses . . . . .	34,934,033	47,294,024
Operating income . . . . .	(34,817,858)	(47,236,524)
Other income (expense), net . . . . .	(49,353)	2,328
Net income . . . . .	(32,774,814)	(46,500,131)
Earnings common share		
Primary . . . . .	\$(0.50)	\$(1.09)
Fully Diluted . . . . .	\$(0.50)	\$(1.09)
Common Shares:		
Full Diluted . . . . .	65,648,006	42,525,693
Year-end . . . . .	81,323,300	47,859,381

#### ENDOLOGIX INC.

##### Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues . . . . .	121,780	137,154
Cost & expenses . . . . .	166,276	170,069
Operating income . . . . .	(44,496)	(32,915)
Interest income . . . . .	7	80
Interest expense . . . . .	18,895	16,119
Other income (expense), net . . . . .	9,902	(2,587)
Net before taxes . . . . .	(53,482)	(51,541)
Income taxes . . . . .	277	338
Net income . . . . .	(53,759)	(51,879)
Earnings common share		
Primary . . . . .	\$(0.64)	\$(0.62)
Fully Diluted . . . . .	\$(0.64)	\$(0.62)
Common Shares:		
Full Diluted . . . . .	84,487	83,225
Year-end . . . . .	85,465	

#### ENERGY RECOVERY INC

##### Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Cost & expenses . . . . .	47,777	40,082
Operating income . . . . .	8,559	4,909
Other income (expense), net . . . . .	(66)	(150)
Net before taxes . . . . .	9,535	5,369
Income taxes . . . . .	(10,140)	546
Net income . . . . .	19,675	4,823
Earnings common share		
Primary . . . . .	\$0.37	\$0.09
Fully Diluted . . . . .	\$0.36	\$0.09
Common Shares:		
Full Diluted . . . . .	55,382	55,571
Year-end . . . . .	53,775	

#### ENGLOBAL CORP.

##### Earnings, 9 mos. to (Consol. - \$):

	09/29/18	09/30/17
Total Revenues . . . . .	41,314,000	41,336,000
Cost & expenses . . . . .	43,290,000	44,974,000
Operating income . . . . .	(1,976,000)	(3,638,000)
Interest expense . . . . .	14,000	95,000

Other income (expense), net . . . . .	(367,000)	57,000
Net before taxes . . . . .	(2,357,000)	(3,676,000)
Income taxes . . . . .	31,000	10,250,000
Net income . . . . .	(2,388,000)	(13,926,000)
Earnings common share		
Primary . . . . .	\$(0.09)	\$(0.51)
Fully Diluted . . . . .	\$(0.09)	\$(0.51)
Common Shares:		
Full Diluted . . . . .	27,511,000	27,257,000
Year-end . . . . .	27,509,317	27,513,574

#### ENPHASE ENERGY INC.

##### Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues . . . . .	223,870	206,492
Cost & expenses . . . . .	227,277	243,738
Operating income . . . . .	(3,407)	(37,246)
Interest expense . . . . .	7,031	5,979
Other income (expense), net . . . . .	(1,077)	1,771
Net before taxes . . . . .	(11,515)	(41,454)
Income taxes . . . . .	821	798
Net income . . . . .	(12,336)	(42,252)
Earnings common share		
Primary . . . . .	\$(0.13)	\$(0.52)
Fully Diluted . . . . .	\$(0.13)	\$(0.52)
Common Shares:		
Full Diluted . . . . .	97,257	81,993
Year-end . . . . .	106,322	85,217

#### ENTASIS THERAPEUTICS HOLDINGS INC

##### Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues . . . . .	5,000	
Cost & expenses . . . . .	33,955	21,443
Operating income . . . . .	(28,955)	(21,443)
Interest income . . . . .	47	18
Other income (expense), net . . . . .	4,507	674
Net before taxes . . . . .	(24,401)	
Income taxes . . . . .	472	
Net income . . . . .	(24,873)	(20,751)
Balance for common . . . . .	(34,015)	(20,751)
Earnings common share		
Primary . . . . .	\$(113.22)	\$(25,183.25)
Fully Diluted . . . . .	\$(113.22)	\$(25,183.25)
Common Shares:		
Full Diluted . . . . .	300	1
Year-end . . . . .	13,098	

#### ENTEGR A FINANCIAL CORP

##### Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Cost & expenses . . . . .	38,311	31,591
Operating income . . . . .	12,517	8,337
Net before taxes . . . . .	12,517	8,337
Income taxes . . . . .	2,325	2,464
Net income . . . . .	10,192	5,873
Earnings common share		
Primary . . . . .	\$1.48	\$0.91
Fully Diluted . . . . .	\$1.45	\$0.90
Common Shares:		
Full Diluted . . . . .	7,024	6,542
Year-end . . . . .	6,892	6,459

#### EPIZYME INC.

##### Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues . . . . .	12,000	10,000
Cost & expenses . . . . .	115,795	109,478
Operating income . . . . .	(103,795)	(99,478)
Interest income . . . . .	3,121	1,353
Other income (expense), net . . . . .	(11)	(18)
Net income . . . . .	(100,685)	(98,143)
Earnings common share		
Primary . . . . .	\$(1.45)	\$(1.67)
Fully Diluted . . . . .	\$(1.45)	\$(1.67)
Common Shares:		
Full Diluted . . . . .	69,472	58,837
Year-end . . . . .	69,576	69,237

#### EQUILLIUM INC

##### Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Cost & expenses	4,387,489	1,072,248
Operating income	(4,387,489)	(1,072,248)
Interest income	57,470	
Interest expense	2,329,296	22,192
Other income (expense), net	(1,599,267)	(61,078)
<b>Net income</b>	<b>(8,258,582)</b>	<b>(1,155,518)</b>
Earnings common share		
Primary	\$(0.76)	\$(0.16)
Fully Diluted	\$(0.76)	\$(0.16)
Common Shares:		
Full Diluted	10,835,483	7,127,537
Year-end	11,130,446	

**ESPERION THERAPEUTICS INC (NEW)****Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Cost & expenses	143,936,000	130,286,000
Operating income	(143,936,000)	130,286,000
Other income (expense), net	2,165,000	1,189,000
<b>Net income</b>	<b>(141,771,000)</b>	<b>129,097,000</b>
Earnings common share		
Primary	\$(5.30)	\$(5.57)
Fully Diluted	\$(5.30)	\$(5.57)
Common Shares:		
Full Diluted	26,732,733	23,161,847
Year-end	26,804,300	26,187,531

**ETON PHARMACEUTICALS INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017
Research & development expenses	3,930
General & administrative expenses	3,220
Total operating expenses	7,150
Income (loss) from operations	(7,150)
Interest & other income, net	35
Change in fair value of warrant liability	41
Income (loss) before income taxes	(7,156)
<b>Net income (loss)</b>	<b>(7,156)</b>
Accrued dividends on redeemable convertible preferred stock	643
Deemed dividends for accretion of redeemable convertible preferred stock issuance costs	840
Net income (loss) attributable to common stockholders	(8,639)
Weighted average shares outstanding - basic	3,453
Weighted average shares outstanding - diluted	3,453
Year end shares outstanding	6,000
Net earnings (loss) per share - basic	\$(2.50)
Net earnings (loss) per share - diluted	\$(2.50)
Number of full time employees	10
Number of common stockholders	9

□ From April 27, 2017 (inception); ▢ As Is; ▣ As of June 30, 2018

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017
Cash & cash equivalents	13,156
Prepaid expenses	136
Total current assets	13,292
Other long-term assets, net	32
Computer hardware & software	46
Furniture & fixtures	42
Leasehold improvements	42
Property & equipment, gross	130
Less: Accumulated depreciation	11
Property & equipment, net	119
Total assets	13,443
Accounts payable	539
Accrued liabilities	254
Total current liabilities	793
Warrant liability	520
Total liabilities	1,313
Redeemable convertible preferred stock - Series A	19,004
Common stock	6
Additional paid-in capital	1,759
Retained earnings (accumulated deficit)	(8,639)

Total stockholders' equity (deficit)	(6,874)
--------------------------------------	---------

**Recent Dividends:****1. Eton Pharmaceuticals Inc common.**

No dividends paid.

**Annual Dividends:****1. Eton Pharmaceuticals Inc common.**

No dividends paid.

**ETON PHARMACEUTICALS INC****Earnings, 6 mos. to Jun 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	5,661	2,184
Operating income	(5,661)	(2,184)
Other income (expense), net	(439)	
<b>Net income</b>	<b>(6,100)</b>	<b>(2,184)</b>
Balance for common	(7,528)	(2,275)
Earnings common share		
Primary	\$(1.80)	\$(0.69)
Fully Diluted	\$(1.80)	\$(0.69)
Common Shares:		
Full Diluted	4,173	3,285
Year-end	6,219	

**EVERBRIDGE INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	105,266	75,177
Cost & expenses	138,948	89,280
Operating income	(33,682)	(14,103)
Interest income	1,316	234
Interest expense	4,736	5
Other income (expense), net	(237)	(61)
Net before taxes	(37,339)	(13,935)
Income taxes	371	(65)
<b>Net income</b>	<b>(37,710)</b>	<b>(13,870)</b>
Earnings common share		
Primary	\$(1.30)	\$(0.50)
Fully Diluted	\$(1.30)	\$(0.50)
Common Shares:		
Full Diluted	28,918	27,720
Year-end	29,625	28,203

**EVERSPIN TECHNOLOGIES INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	37,136	25,813
Cost & expenses	51,063	41,785
Operating income	(13,927)	(15,972)
Other income (expense), net	315	(163)
<b>Net income</b>	<b>(14,274)</b>	<b>(16,719)</b>
Earnings common share		
Primary	\$(0.88)	\$(1.35)
Fully Diluted	\$(0.88)	\$(1.35)
Common Shares:		
Full Diluted	16,131	12,425
Year-end	17,066	12,746

**EVINE LIVE INC****Earnings, 9 mos. to (Consol. - \$):**

	11/03/18	10/28/17
Net Sales	439,018,000	455,504,000
Cost & expenses	443,797,000	452,119,000
Operating income	(9,460,000)	(1,406,000)
Interest income	28,000	10,000
Other income (expense), net		(1,134,000)
Net before taxes	(12,123,000)	(6,496,000)
Income taxes	60,000	(206,000)
<b>Net income</b>	<b>(12,183,000)</b>	<b>(6,290,000)</b>
Earnings common share		
Primary	\$(0.18)	\$(0.10)
Fully Diluted	\$(0.18)	\$(0.10)
Common Shares:		
Full Diluted	65,907,301	63,400,368
Year-end	66,363,845	65,261,231

**EVO PAYMENTS INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	413,931	366,165
Cost & expenses	384,808	282,180
Operating income	(32,185)	28,506
Interest income	1,622	951
Interest expense	47,453	46,516

Other income (expense), net	6,421	473
Net before taxes	(71,595)	(16,586)
Income taxes	7,974	14,734
<b>Net income</b>	<b>(79,569)</b>	<b>(31,320)</b>
Earnings common share		
Primary	\$(0.60)	\$
Fully Diluted	\$(0.60)	\$
Common Shares:		
Full Diluted	17,901	
Year-end	81,128	

**EVOLUS INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	33,627	8,650
Operating income	(33,634)	(8,868)
Interest expense	750	4
Net before taxes	(34,384)	(8,872)
Income taxes	41	56
<b>Net income</b>	<b>(34,425)</b>	<b>(8,928)</b>
Earnings common share		
Primary	\$(1.47)	\$(0.54)
Fully Diluted	\$(1.47)	\$(0.54)
Common Shares:		
Full Diluted	23,417	16,527
Year-end	27,275	16,527

**EXELIXIS INC****Earnings, 9 mos. to (Consol. - \$000):**

	09/28/18	09/29/17
Total Revenues	625,224	332,405
Cost & expenses	297,971	203,926
Operating income	327,253	128,479
Interest income	8,099	3,497
Interest expense	1	8,679
Other income (expense), net	369	(3,638)
Net before taxes	335,720	119,659
Income taxes	5,739	3,921
<b>Net income</b>	<b>329,981</b>	<b>115,738</b>
Earnings common share		
Primary	\$1.11	\$0.39
Fully Diluted	\$1.05	\$0.37
Common Shares:		
Full Diluted	313,200	311,555
Year-end	298,882	

**EXLSERVICE HOLDINGS INC****Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	648,209,000	564,435,000
Cost & expenses	561,110,000	479,521,000
Deprec., depl. & amort.	35,185,000	28,489,000
Operating income	51,914,000	56,425,000
Other income (expense), net	65,000	401,000
Gains or losses	7,007,000	6,777,000
Equity earnings	176,000	
Foreign currency	3,414,000	1,905,000
Net before taxes	59,841,000	65,445,000
Income taxes	6,796,000	7,202,000
<b>Net income</b>	<b>52,869,000</b>	<b>58,243,000</b>
Earnings common share		
Primary	\$1.53	\$1.72
Fully Diluted	\$1.50	\$1.66
Common Shares:		
Full Diluted	35,217,814	35,048,672
Year-end	34,253,291	33,804,962

**EXP WORLD HOLDINGS INC**

**Acquisition Completed** On Nov. 29, 2018, Co.'s newly formed subsidiary, eXp World Technologies, LLC ("Purchaser"), acquired from VirBELA LLC ("Seller"), a company that develops and operates social virtual reality platform for business and education sector, substantially all the assets owned and used by Seller in the design of software that includes a proprietary 3D virtual reality platform that allows users to connect with avatars, voice and text chat, collaborative web-browsers, and embedded learning simulations and games (the "Business"), for a purchase price of \$11,000,000, of which \$7,000,00 was paid in cash at closing (subject to a holdback of \$500,000 to secure Seller's performance of certain post-closing obligations), and the balance in shares of Co.'s common stock (the "Share Consideration"). Purchaser also agreed to assume certain liabilities of Seller as specified in the Purchase Agreement. The Share Consideration was issuable in four installments valued at \$1,000,000 each. The number of shares issuable on each issuance date would be determined based on the

closing price of Co.'s common stock on the last business day prior to the applicable issuance date. The first installment of 97,371 shares was issued on the closing date and the balance of the Share Consideration would be issued on the first, second and third anniversaries thereof.

**EXPONENT INC.**

Earnings, 9 mos. to (Consol. - \$000):

	09/28/18	09/29/17
Total Revenues	287,380	259,517
Cost & expenses	222,710	205,261
Operating income	64,670	54,256
Other income (expense), net	4,875	6,660
Net before taxes	71,358	61,788
Income taxes	15,140	16,778
<b>Net income</b>	<b>56,218</b>	<b>45,010</b>
Earnings common share		
Primary	\$1.06	\$0.85
Fully Diluted	\$1.04	\$0.83
Common Shares:		
Full Diluted	54,181	53,952
Year-end	52,052	51,620

**EXTRACTION OIL & GAS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	772,571	390,266
Cost & expenses	152,085	212,550
Deprec., depl. & amort.	310,296	213,483
Operating income	310,190	(35,767)
Interest expense	103,229	33,761
Other income (expense), net	3,094	1,709
Gains or losses	(175,752)	46,423
Net before taxes	34,303	(21,396)
Income taxes	12,300	(7,556)
<b>Net income</b>	<b>22,003</b>	<b>(13,840)</b>
Balance for common	6,105	(25,996)
Earnings common share		
Primary	\$0.03	\$(0.15)
Fully Diluted	\$0.03	\$(0.15)
Common Shares:		
Full Diluted	175,269	171,838
Year-end	175,376	

**EZCORP, INC.****Annual Report**

Consolidated Income Statement, Years Ended Sept. 30 (\$000):

	2018	2017	2016
Merchandise sales	438,372	414,838	409,107
Jewelry scrapping sales	60,752	51,189	50,113
Pawn service charges	305,936	273,080	261,800
Other revenues	8,455	8,847	9,485
Total revenues	813,515	747,954	730,505
Merchandise cost of goods sold	276,618	266,525	258,271
Jewelry scrapping cost of goods sold	52,290	43,931	42,039
Other cost of revenues	1,697	1,988	1,965
Net revenues	482,910	435,510	428,230
Operations expense	334,649	304,636	301,387
Administrative expense	53,653	53,254	68,101
Depreciation & amortization expense	25,484	23,661	26,542
Gain (loss) on sale or disposal of assets	(463)	(359)	(1,106)
Restructuring expense			1,921
Total operating expenses	414,249	381,910	399,057
Operating income (loss)	68,661	53,600	29,173
Interest expense	27,834	27,803	16,477
Interest income	17,041	12,103	81
Equity in net income (loss) of unconsolidated affiliate	5,529	4,916	(255)

Impairment of investments	11,712	...	10,957
Other income (expense)	5,391	423	(1,202)
Income (loss) from continuing operations before income taxes - domestic	29,001	29,740	(17)
Income (loss) from continuing operations before income taxes - foreign	28,075	13,499	380
Income (loss) from continuing operations before income taxes	57,076	43,239	363
Current federal income tax expense (benefit)	(26)	1,092	11,120
Current state & foreign income tax expense (benefit)	9,470	6,359	3,193
Total current income tax expense (benefit)	9,444	7,451	14,313
Deferred federal income tax expense (benefit)	9,076	5,190	(3,766)
Deferred state & foreign income tax expense (benefit)	(371)	(1,435)	(1,186)
Total deferred income tax expense (benefit)	8,705	3,755	(4,952)
Income tax expense (benefit)	18,149	11,206	9,361
Income (loss) from continuing operations, net of tax	38,927	32,033	(8,998)
Income (loss) from discontinued operations, net of tax	(856)	(1,825)	(79,432)
<b>Net income (loss)</b>	<b>38,071</b>	<b>30,208</b>	<b>(88,430)</b>
Net income (loss) attributable to noncontrolling interest	988	1,650	7,686
Net income (loss) attributable to EZCORP, Inc.	39,059	31,858	(80,744)
Weighted average shares outstanding - basic	54,456	54,260	54,427
Weighted average shares outstanding - diluted	57,896	54,368	54,427
Year end shares outstanding	54,585	54,398	54,099
Earnings (loss) per share from continuing operations - basic	\$0.73	\$0.62	\$(0.15)
Earnings (loss) per share from discontinued operations - basic	\$(0.01)	\$(0.03)	\$(1.34)
Net earnings (loss) per share - basic	\$0.72	\$0.59	\$(1.49)
Earnings (loss) per share from continuing operations - diluted	\$0.69	\$0.62	\$(0.15)
Earnings (loss) per share from discontinued operations - diluted	\$(0.01)	\$(0.03)	\$(1.34)
Net earnings (loss) per share - diluted	\$0.68	\$0.59	\$(1.49)

Number of class A common stockholders	300	85	85
Number of class B common stockholders	1	1	1
Foreign currency translation adjustments	(2,688)	5,701	(14,580)

Reclassified to conform with 2017 presentation; As is; As of November 10, 2018; As of November 10, 2017; As of November 30, 2016

**Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):**

	2018	2017
Cash & cash equivalents	286,015	164,393
Pawn loans	198,463	169,242
Gross pawn service charges receivable	49,629	42,117
Less: allowance for uncollectible pawn service charges receivable	11,311	10,569
Pawn service charges receivable, net	38,318	31,548
Gross inventory	176,198	161,212
Less inventory reserves	9,201	6,801
Inventory, net	166,997	154,411
Notes receivable, net	34,199	32,598
Prepaid expenses & other current assets	9,402	9,250
Accounts receivable & other current assets	20,933	19,515
Restricted cash	267	...
2019 convertible notes hedges	2,552	...
Prepaid expenses & other current assets	33,154	28,765
Total current assets	757,146	580,957
Investment in unconsolidated affiliate	49,500	43,319
Land, gross	4	4
Buildings & improvements, gross	97,236	80,828
Less accumulated depreciation - buildings & improvements	60,459	55,077
Furniture & equipment, gross	119,975	105,319
Less accumulated depreciation - furniture & equipment	85,737	78,581
Software, gross	34,178	34,022
Less accumulated depreciation - software	33,177	32,623
In progress, gross	1,629	4,067
Property & equipment, gross	253,022	224,240
Less accumulated depreciation	179,373	166,281
Property & equipment, net	73,649	57,959
Goodwill	297,448	254,760
Intangible assets, net	54,923	32,420
Notes receivable, net	3,226	28,377
Deferred tax asset, net	7,165	16,856
Other assets	3,863	9,715
Total assets	1,246,920	1,024,363
Current maturities of long-term debt, net	190,181	...
Trade accounts payable	10,500	13,064
Accrued payroll	6,294	4,860
Bonus accrual	12,406	9,010
Other payroll related expenses	2,963	3,922
Accrued interest	3,835	2,212
Accrued rent & property taxes	12,106	11,357
Deferred revenues	2,661	2,483
Other accrued expenses	4,064	8,310
Income taxes payable	1,161	1,465
Unrecognized tax benefits	1,810	4,860
Customer layaway deposits	11,824	11,032
Total current liabilities	259,805	72,575

Convertible notes	511,250	338,750	Income (loss) before income taxes				Total assets	2,605,476	2,476,489
Convertible notes embedded derivative	2,552	6,591	- international	162,424	122,648	84,153	Accounts payable	57,757	50,760
Unsecured notes	1,304	...	Income (loss) before income taxes	603,760	575,517	549,891	Accrued payroll & benefits	104,815	109,088
Less current portion	197,748	...	Current U.S. federal income taxes	78,454	113,105	129,728	Accrued sales & marketing	2,743	6,654
Long-term debt, gross	317,358	345,341	Current state income taxes	9,800	10,381	16,821	Accrued restructuring	8,268	7,741
Less debt discounts & issuance costs	(90,656)	(60,534)	Current foreign income taxes	41,040	34,679	31,015	Income tax accruals	17,795	15,519
Long-term debt, net	226,702	284,807	Total current income taxes	129,294	158,165	177,564	Other tax accruals	9,861	13,429
Deferred tax liability, net	8,817	...	Deferred U.S. federal income taxes	21,259	964	9,770	Other accrued liabilities	37,497	34,948
Other long-term liabilities	6,890	7,055	Deferred state income taxes	725	99	(1,029)	Accrued liabilities	180,979	187,379
Total liabilities	502,214	364,437	Deferred foreign income taxes	(1,207)	(4,472)	(2,269)	Deferred revenue	715,697	696,404
Class A non-voting common stock	516	514	Total deferred income taxes	20,777	(3,409)	6,472	Total current liabilities	954,433	934,543
Class B voting common stock	30	30	Provision (benefit) for income taxes	150,071	154,756	184,036	Other long-term liabilities	65,892	44,589
Additional paid-in capital	397,927	348,532	<b>Net income (loss)</b>	453,689	420,761	365,855	Deferred revenue, long-term	299,624	267,902
Retained earnings (accumulated deficit)	392,180	351,666	Weighted average shares outstanding - basic	61,262	64,173	67,433	Deferred tax liabilities	35	63
Accumulated other comprehensive income (loss)	(42,616)	(38,367)	Weighted average shares outstanding - diluted	62,013	64,775	67,984	Total long-term liabilities	365,551	312,554
EZCORP, Inc. stockholders' equity	748,037	662,375	Year end shares outstanding	60,215	62,594	65,315	Common stock	20,427	17,627
Noncontrolling interest	(3,331)	(2,449)	Net income (loss) per share - basic	\$7.41	\$6.56	\$5.43	Accumulated other comprehensive income (loss)	(22,178)	(17,997)
Total equity	744,706	659,926	Net income (loss) per share - diluted	\$7.32	\$6.50	\$5.38	Retained earnings (accumulated deficit)	1,287,243	1,229,762

□ Reclassified to conform with 2018 presentation

#### Recent Dividends:

##### 1. EZCORP, Inc. class A non-voting common.

No dividends paid.

##### 2. EZCORP, Inc. class B voting common.

No dividends paid.

##### 3. EZCORP, Inc. class A non-voting common, subject to possible redemption.

No dividends paid.

#### Annual Dividends:

##### 1. EZCORP, Inc. class A non-voting common.

No dividends paid.

##### 2. EZCORP, Inc. class B voting common.

No dividends paid.

##### 3. EZCORP, Inc. class A non-voting common, subject to possible redemption.

No dividends paid.

#### F5 NETWORKS, INC.

##### Annual Report

##### Consolidated Income Statement, Years Ended Sept. 30 (\$000):

	2018	2017	2016
		(revised)	(revised)
Products revenues	960,108	964,662	944,469
Services revenues	1,201,299	1,125,379	1,050,565
Total net revenues	2,161,407	2,090,041	1,995,034
Cost of products revenues	181,061	176,032	166,624
Cost of services revenues	180,420	177,453	170,581
Total cost of net revenues	361,481	353,485	337,205
Gross profit (loss)	1,799,926	1,736,556	1,657,829
Sales & marketing expenses	664,135	652,239	628,743
Research & development expenses	366,084	350,365	334,227
General & administrative expenses	160,382	156,887	138,431
Litigation expense	...	391	9,051
Restructuring charges	18,426	12,718	...
Total operating expenses	1,209,027	1,172,600	1,110,452
Income (loss) from operations	590,899	563,956	547,377
Other income (expense), net	12,861	11,561	2,514
Income (loss) before income taxes - United States	441,336	452,869	465,738

##### Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):

	2018	2017
		(revised)
Cash & cash equivalents	424,707	673,228
Short-term investments	614,705	343,700
Accounts receivable, gross	297,392	293,739
Less: allowances for doubtful accounts	2,040	1,815
Accounts receivable, net	295,352	291,924
Finished goods	21,339	20,280
Raw materials	9,229	9,554
Inventories	30,568	29,834
Other current assets	52,326	67,538
Total current assets	1,417,658	1,406,224
Computer equipment	194,847	177,235
Office furniture & equipment	31,625	32,781
Leasehold improvements	107,615	88,410
Property & equipment, gross	334,087	298,426
Less accumulated depreciation & amortization	189,045	176,006
Property & equipment, net	145,042	122,420
Long-term investments	411,184	284,802
Deferred tax assets	33,441	53,303
Goodwill	555,965	555,965
Acquired & developed technology & software development costs	17,641	25,085
Intangible assets	13,618	17,469
Restricted cash & deposits	10,927	11,221

□ As is; □ As of November 15, 2018; □ As of October 30, 2017; □ As of October 28, 2016

□ Reclassified to conform with 2018 presentation

#### Recent Dividends:

##### 1. F5 Networks, Inc. common.

No dividends paid.

#### Annual Dividends:

##### 1. F5 Networks, Inc. common.

No dividends paid.

#### FAMOUS DAVE'S OF AMERICA INC.

##### Earnings, 9 mos. to (Consol. - \$):

	09/30/18	10/01/17
Total Revenues	41,455,000	52,063,000
Cost & expenses	35,400,000	57,156,000
Operating income	5,072,000	(7,404,000)
Interest income	79,000	20,000
Interest expense	422,000	510,000
Net before taxes	4,729,000	(7,894,000)
Income taxes	937,000	(2,910,000)
Income contin. oper.	...	(4,984,000)
<b>Net income</b>	3,792,000	(4,323,000)
Earnings common share		
Primary	\$0.45	\$(0.62)
Fully Diluted	\$0.45	\$(0.62)
Common Shares:		
Full Diluted	8,459,000	6,955,000
Year-end	9,092,000	...

#### FARMER BROS. CO.

##### Earnings, 3 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Net Sales	147,440	131,713
Cost & expenses	149,518	129,868
Operating income	(2,078)	1,845
Other income (expense), net	657	1,755
Net before taxes	(4,273)	1,433
Income taxes	(1,287)	592
<b>Net income</b>	(2,986)	841
Balance for common	(3,118)	841
Earnings common share		
Primary	\$(0.18)	\$0.05
Fully Diluted	\$(0.18)	\$0.05
Common Shares:		
Full Diluted	16,887	16,802
Year-end	16,978	16,843

##### Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	5,503
Inventories	115,572
Current assets	194,144
Net property & equip.	191,138
Total assets	503,251
Liabilities:	
Current liabilities	212,962
Long-term debt	46
Stockholders' equity	222,588



	2018	2017
Total Revenues .....	979	899
Cost & expenses .....	823	706
Operating income .....	142	182
Other income (expense), net .....	1	1
Net before taxes .....	143	183
Income taxes .....	36	67
<b>Net income</b> .....	108	116
Earnings common share		
Primary .....	\$1.28	\$1.37
Fully Diluted .....	\$1.28	\$1.37
Common Shares:		
Full Diluted .....	85	85
Year-end .....	85	

**FULGENT GENETICS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues .....	15,678	14,449
Cost & expenses .....	19,719	15,861
Operating income .....	(4,041)	(1,412)
Equity earnings .....	701	277
Net before taxes .....	(3,705)	(1,028)
Income taxes .....	(852)	(419)
<b>Net income</b> .....	(3,554)	(886)
Earnings common share		
Primary .....	\$(0.20)	\$(0.05)
Fully Diluted .....	\$(0.20)	\$(0.05)
Common Shares:		
Full Diluted .....	17,931	17,713
Year-end .....	18,057	17,771

**FUNKO INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales .....	452,849	346,610
Cost & expenses .....	390,870	301,087
Operating income .....	33,067	22,768
Interest expense .....	17,230	23,768
Other income (expense), net .....	(2,594)	145
Net before taxes .....	13,243	(855)
Income taxes .....	2,049	1,046
<b>Net income</b> .....	11,194	(1,901)
Earnings common share		
Primary .....	\$0.14	\$.....
Fully Diluted .....	\$0.13	\$.....
Common Shares:		
Full Diluted .....	25,124	
Year-end .....	48,366	

**FUTURE FINTECH GROUP INC**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues .....	1,658,911	10,179,416
Cost & expenses .....	25,626,178	23,748,629
Operating income .....	(23,967,267)	(13,569,213)
Interest income .....	8,289	2,032
Interest expense .....	1,260,671	738,705
Other income (expense), net .....	(7,492)	3,013,337
Net before taxes .....		(11,292,549)
Income taxes .....		258,260
<b>Net income</b> .....	(25,227,141)	(11,550,809)
Earnings common share		
Primary .....	\$(1.27)	\$(3.04)
Fully Diluted .....	\$(1.26)	\$(3.00)
Common Shares:		
Full Diluted .....	18,907,150	4,814,052
Year-end .....	26,071,083	5,173,187

**G-III APPAREL GROUP LTD.**

Earnings, 9 mos. to Oct 31(Consol. - \$000):

	2018	2017
Net Sales .....	2,309,423	2,092,040
Cost & expenses .....	2,094,235	1,932,239
Deprec., depl. & amort. ....	28,868	27,480
Operating income .....	186,320	132,321
Other income (expense), net .....	(303)	(2,935)
Net before taxes .....	153,864	98,120
Income taxes .....	39,877	35,454
<b>Net income</b> .....	113,987	62,666
Earnings common share		
Primary .....	\$2.32	\$1.29
Fully Diluted .....	\$2.26	\$1.27
Common Shares:		

Full Diluted .....	50,345	49,410
Year-end .....	49,356	49,081

**G1 THERAPEUTICS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses .....	63,200,000	43,687,000
Operating income .....	(63,200,000)	(43,687,000)
Other income (expense), net .....	2,003,000	547,000
<b>Net income</b> .....	(61,197,000)	(43,140,000)
Balance for common .....	(61,197,000)	(47,897,000)
Earnings common share		
Primary .....	\$(1.91)	\$(3.24)
Fully Diluted .....	\$(1.91)	\$(3.24)
Common Shares:		
Full Diluted .....	32,006,978	14,772,621
Year-end .....	37,139,303	28,369,679

**GAIA INC (NEW)**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues .....	31,462,000	19,864,000
Cost & expenses .....	56,298,000	38,899,000
Operating income .....	(24,836,000)	(19,035,000)
Net before taxes .....	(24,539,000)	(18,885,000)
Income taxes .....	(1,826,000)	(760,000)
Income discount oper. ....		429,000
<b>Net income</b> .....	(22,713,000)	(17,696,000)
Earnings common share		
Primary .....	\$(1.33)	\$(1.17)
Fully Diluted .....	\$(1.33)	\$(1.17)
Common Shares:		
Full Diluted .....	17,048,000	15,157,000
Year-end .....	17,900,139	15,168,072

**GAMING PARTNERS INTERNATIONAL CORP**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues .....	66,248,000	59,822,000
Cost & expenses .....	60,694,000	55,233,000
Operating income .....	5,554,000	4,589,000
Other income (expense), net .....	26,000	(18,000)
Foreign currency .....	(184,000)	152,000
Net before taxes .....	5,278,000	4,538,000
Income taxes .....	1,305,000	1,350,000
<b>Net income</b> .....	3,973,000	3,188,000
Earnings common share		
Primary .....	\$0.50	\$0.40
Fully Diluted .....	\$0.50	\$0.40
Common Shares:		
Full Diluted .....	8,025,000	8,061,000
Year-end .....	7,965,655	7,932,094

**GCI LIBERTY INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues .....	504,840	16,000
Cost & expenses .....	389,414	48,000
Deprec., depl. & amort. ....	143,257	2,000
Operating income .....	(27,831)	(34,000)
Other income (expense), net .....	17,732	(147,000)
Gains or losses .....	(4,328)	1,186,000
Net before taxes .....	(95,731)	960,000
Income taxes .....	61,224	303,000
<b>Net income</b> .....	(156,955)	657,000
Earnings common share		
Primary .....	\$(1.45)	\$7.73
Fully Diluted .....	\$(1.45)	\$7.64
Common Shares:		
Full Diluted .....	107,693	86,000
Year-end .....	108,515	85,597

**GEMPHIRE THERAPEUTICS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses .....	19,504	26,557
Operating income .....	(19,504)	(26,557)
Other income (expense), net .....	(1)	(5)
<b>Net income</b> .....	(19,981)	(26,669)
Earnings common share		
Primary .....	\$(1.46)	\$(2.60)
Fully Diluted .....	\$(1.46)	\$(2.60)
Common Shares:		
Full Diluted .....	13,651	10,253
Year-end .....	14,265	10,633

**GENERAL FINANCE CORP**

Earnings, 3 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues .....	97,792,000	76,917,000
Net Sales .....	39,474,000	27,285,000
Cost & expenses .....	71,586,000	61,144,000
Deprec., depl. & amort. ....	10,001,000	10,126,000
Operating income .....	16,205,000	5,647,000
Interest income .....	48,000	15,000
Interest expense .....	8,625,000	5,822,000
Other income (expense), net .....	(4,959,000)	(1,202,000)
Net before taxes .....	2,669,000	(1,362,000)
Income taxes .....	1,915,000	(518,000)
<b>Net income</b> .....	754,000	(844,000)
Balance for common .....	(168,000)	(965,000)
Earnings common share		
Primary .....	\$(0.01)	\$(0.04)
Fully Diluted .....	\$(0.01)	\$(0.04)
Common Shares:		
Full Diluted .....	27,391,220	26,611,688
Year-end .....	30,243,872	26,611,688

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents .....	9,542,000
Inventories .....	38,530,000
Current assets .....	113,820,000
Net property & equip. ....	22,241,000
Total assets .....	708,302,000
Liabilities:	
Current liabilities .....	79,261,000
Long-term debt .....	406,122,000
Stockholders' equity .....	178,340,000
Net current assets .....	34,559,000

**GEOSPACE TECHNOLOGIES CORP****Annual Report****Consolidated Income Statement, Years Ended Sept. 30**

(\$000):

	2018	2017	2016
		(revised)	(revised)
Revenue - products ...	53,885	60,055	46,530
Revenue - rental equipment .....	21,863	13,666	15,530
Total revenue .....	75,748	73,721	62,060
Cost of revenue - products .....	52,422	79,548	63,608
Cost of revenue - rental equipment .....	12,354	14,856	17,815
Total cost of revenue .....	64,776	94,404	81,423
Gross profit (loss) ....	10,972	(20,683)	(19,363)
Selling, general & administrative expenses .....	19,874	20,238	21,533
Research & development expenses .....	10,832	13,782	13,851
Bad debt expense (recovery) .....	1,009	(380)	763
Income (loss) from operations .....	(20,743)	(54,323)	(55,510)
Interest expense .....	336	39	26
Interest income .....	1,083	653	376
Foreign exchange gains (losses) .....	324	(339)	(113)
Other income (expense), net .....	(120)	(60)	(60)
Total other income (expense), net .....	951	215	177
Income (loss) before income taxes			
- United States .....	(19,231)	(50,757)	(45,506)
Income (loss) before income taxes - foreign .....	(561)	(3,351)	(9,827)
Income (loss) before income taxes ..	(19,792)	(54,108)	(55,333)
Current provision (benefit) for income taxes - federal .....	(613)	2,422	(13,726)
Current provision (benefit) for income taxes -			

foreign	51	286	148	Deferred income tax assets, net	246	259	Common Shares:		
Current provision (benefit) for income taxes - state	...	...	6	Non-current financing receivables	4,740	8,195	Full Diluted	15,181,760	11,512,968
Total current provision (benefit) for income taxes	(562)	2,708	(13,572)	Prepaid income taxes	54	450	Year-end	16,070,616	13,485,025
Deferred provision (benefit) for income taxes - federal	...	...	2,881	Other assets	213	629	<b>GLOWPOINT INC</b>		
Deferred provision (benefit) for income taxes - foreign	(18)	(25)	1,328	Total assets	199,080	205,696	<b>Earnings, 9 mos. to Sep 30</b> (Consol. - \$):		
Total deferred provision (benefit) for income taxes	(18)	(25)	4,209	Accounts payable trade	4,106	2,599	Total Revenues	9,698,000	11,417,000
Income tax expense (benefit)	(580)	2,683	(9,363)	Accrued product warranty	688	508	Cost & expenses	13,131,000	12,496,000
<b>Net income (loss)</b>	(19,212)	(56,791)	(45,970)	Accrued compensated absences	1,329	1,287	Operating income	(4,029,000)	(2,449,000)
Weighted average shares outstanding - basic	13,251	13,134	13,045	Accrued legal & professional fees	434	194	Other income (expense), net	(415,000)	8,065,000
Weighted average shares outstanding - diluted	13,251	13,134	13,045	Accrued payroll	960	682	Net before taxes	5,616,000	
Year end shares outstanding	13,601	13,438	13,328	Accrued property & sales taxes	1,977	2,383	Income taxes	(230,000)	
Earnings (loss) per share - basic	\$(1.45)	\$(4.32)	\$(3.52)	Accrued medical claims	450	550	<b>Net income</b>	(4,444,000)	5,846,000
Earnings (loss) per share - diluted	\$(1.45)	\$(4.32)	\$(3.52)	Other accrued expenses & other current liabilities	988	734	Balance for common	(4,453,000)	5,837,000
Number of full time employees	726	707	785	Deferred revenue	3,752	1,568	Earnings common share		
Number of common stockholders	136	123	127	Income tax payable	51	...	Primary	\$(0.09)	\$0.16
Foreign currency translation adjustments	(1,365)	1,754	(2,984)	Total current liabilities	14,735	10,505	Fully Diluted	\$(0.09)	\$0.15
				Contingent earn-out liability	7,713	...	Common Shares:		
				Deferred income tax liabilities	45	37	Full Diluted	47,489,000	38,078,000
				Total liabilities	22,493	10,542	Year-end	47,908,000	36,130,000
				Common stock	136	134	<b>GOGO INC</b>		
				Additional paid-in capital	86,116	83,733	<b>Earnings, 9 mos. to Sep 30</b> (Consol. - \$000):		
				Retained earnings (accumulated deficit)	105,954	125,517	Total Revenues	676,540	511,080
				Unrealized gains (losses) on available-for-sale securities	(82)	(58)	Cost & expenses	593,323	464,094
				Foreign currency translation adjustments	(15,537)	(14,172)	Deprec., depl. & amort.	100,447	96,821
				Accumulated other comprehensive income (loss)	(15,619)	(14,230)	Operating income	(17,230)	(49,835)
				Total stockholder's equity	176,587	195,154	Interest income	3,307	1,999
							Interest expense	91,938	81,754
							Other income (expense), net	59	(322)
							Net before taxes	(105,802)	(129,912)
							Income taxes	(3,459)	945
							<b>Net income</b>	(102,343)	(130,857)
							Balance for common	(102,343)	(130,857)
							Earnings common share		
							Primary	\$(1.28)	\$(1.65)
							Fully Diluted	\$(1.28)	\$(1.65)
							Common Shares:		
							Full Diluted	79,948	79,340
							Year-end	87,458	86,773

□ As is; □ Approximately; □ As of October 31, 2018; □ As of November 15, 2017; □ As of October 31, 2016

□ Reclassified to conform with 2018 presentation; □ Net of allowance - Non-current financing receivables: \$1,849,000; □ Net of allowance - Non-current financing receivables: \$1,020,000

**Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):**

	2018	2017	(revised)
Cash & cash equivalents	11,934	15,092	
Short-term investments	25,471	36,137	
Trade accounts receivable	15,776	10,830	
Allowance for doubtful accounts	1,453	1,395	
Trade accounts receivable, net	14,323	9,435	
Financing receivables	4,258	3,055	
Income tax receivable	...	273	
Inventories	18,812	20,752	
Prepaid expenses & other current assets	1,856	1,623	
Total current assets	76,654	86,367	
Rental equipment, primarily wireless recording equipment	76,245	55,734	
Accumulated depreciation & impairment - rental equipment	36,700	39,272	
Rental equipment, net	39,545	16,462	
Land & land improvements	8,552	8,572	
Buildings & building improvements	31,070	31,034	
Machinery & equipment	52,523	53,185	
Furniture & fixtures	1,362	1,352	
Transportation equipment	31	31	
Tools & molds	2,256	2,181	
Construction in progress	503	1,135	
Property, plant & equipment, gross	96,297	97,490	
Accumulated depreciation	62,673	60,091	
Property, plant & equipment, net	33,624	37,399	
Goodwill	4,343	...	
Other intangible assets	8,006	...	
Non-current inventories	31,655	55,935	

**Recent Dividends:**  
1. Geospace Technologies Corp common. No dividends paid.

**Annual Dividends:**  
1. Geospace Technologies Corp common. No dividends paid.

**GLADSTONE COMMERCIAL CORP**  
**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Total Revenues	79,538,000	69,547,000
Cost & expenses	17,201,000	17,255,000
Operating income	(67,000)	(14,000)
Interest expense	19,275,000	18,223,000
Other income (expense), net	1,911,000	4,007,000
<b>Net income</b>	9,807,000	7,403,000
Balance for common	1,304,000	(671,000)
Earnings common share		
Primary	\$0.05	\$(0.03)
Fully Diluted	\$0.05	\$(0.03)
Common Shares:		
Full Diluted	28,532,224	25,833,423
Year-end	29,809,473	...

**GLADSTONE LAND CORP**  
**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Total Revenues	28,657,000	18,310,000
Cost & expenses	13,249,000	4,759,000
Operating income	8,603,000	8,428,000
Interest expense	8,728,000	6,984,000
Other income (expense), net	(2,273,000)	(1,185,000)
Gains or losses	6,247,000	(78,000)
<b>Net income</b>	3,849,000	181,000
Balance for common	3,551,000	158,000
Earnings common share		
Primary	\$0.23	\$0.01
Fully Diluted	\$0.23	\$0.01

**GRANITE CITY FOOD & BREWERY LTD**  
**Earnings, 9 mos. to (Consol. - \$):**

	09/25/18	09/26/17
Net Sales	100,328,003	107,372,495
Cost & expenses	96,381,237	103,542,988
Deprec., depl. & amort.	5,187,083	6,038,607
Operating income	(1,240,317)	(2,209,100)
Net before taxes	(4,501,456)	(5,379,158)
Income taxes	20,866	49,442
<b>Net income</b>	(4,522,322)	(5,428,600)
Earnings common share		
Primary	\$(0.31)	\$(0.38)
Common Shares:		
Year-end	14,360,981	14,360,981

**GREAT ELM CAPITAL GROUP INC**  
**Earnings, 3 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	6,473	1,769
Cost & expenses	8,206	4,957
Operating income	(2,443)	(3,368)
Interest expense	995	98
Other income (expense), net	45	(55)
Gains or losses	905	(354)
Income contin. oper.	(1,941)	...
Income discont. oper.	(68)	...
<b>Net income</b>	(2,009)	(3,384)
Balance for common	(2,004)	(3,030)
Earnings common share		
Primary	\$(0.08)	\$(0.13)
Fully Diluted	\$(0.08)	\$(0.13)
Common Shares:		
Full Diluted	25,054	23,233
Year-end	25,143	...

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	22,788
Inventories	1,698
Current assets	45,808
Net property & equip.	875
Total assets	187,341



Liabilities:		
Current liabilities .....	19,600	
Long-term debt .....	88,260	
Stockholders' equity .....	61,340	
Net current assets .....	26,208	

**GREAT LAKES DREDGE & DOCK CORP****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues .....	501,505	510,762
Cost & expenses .....	471,022	507,789
Operating income .....	30,483	2,973
Interest expense .....	25,719	18,440
Other income (expense), net .....	(2,808)	(4,114)
Net before taxes .....	1,956	(19,581)
Income taxes .....	549	(7,555)
Income contin. oper. ....	(12,026)	
<b>Net income</b> .....	1,407	(24,723)
Earnings common share		
Primary .....	\$0.02	\$(0.40)
Fully Diluted .....	\$0.02	\$(0.40)
Common Shares:		
Full Diluted .....	63,340	61,290
Year-end .....	62,452	61,575

**GREEN PLAINS INC.**

**Interest Sale Completed** On Nov. 27, 2018, Co.'s indirect wholly-owned subsidiary, Green Plains and Green Plains II LLC, sold all the issued and outstanding capital stock of Fleischmann's Vinegar Company, Inc. to Kerry Holding Co., a holding company that manufactures prepared foods and miscellaneous food specialties, for approximately \$353,900,000 in cash and restricted cash, including net working capital adjustments.

**GREEN PLAINS PARTNERS LP****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues .....	77,495	78,743
Cost & expenses .....	27,275	28,419
Operating income .....	46,814	46,543
Interest income .....	61	61
Interest expense .....	5,253	3,941
Other income (expense), net .....	75	
Equity earnings .....	82	
Net before taxes .....	41,697	42,663
Income taxes .....	70	135
<b>Net income</b> .....	41,545	42,528
Earnings common share		
Primary .....	\$1.28	\$1.31
Fully Diluted .....	\$1.28	\$1.31
Common Shares:		
Full Diluted .....	18,780	15,914
Year-end .....	31,830	31,809

**GREENSKY INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues .....	304,942	236,073
Cost & expenses .....	177,071	134,252
Operating income .....	111,965	100,818
Interest income .....	4,714	4,158
Interest expense .....	17,391	2,363
Gains or losses .....	(1,864)	(2,052)
Net before taxes .....	110,101	
Income taxes .....	4,969	
<b>Net income</b> .....	105,132	98,766
Earnings common share		
Primary .....	\$0.31	\$.....
Fully Diluted .....	\$0.30	\$.....
Common Shares:		
Full Diluted .....	189,026	
Year-end .....	186,624	

**GRITSTONE ONCOLOGY INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses .....	47,652	24,183
Operating income .....	(47,556)	(24,183)
Interest income .....	120	175
<b>Net income</b> .....	(47,436)	(24,008)
Earnings common share		
Primary .....	\$(20.27)	\$(12.27)
Fully Diluted .....	\$(20.27)	\$(12.27)
Common Shares:		
Full Diluted .....	2,340	1,957
Year-end .....	2,490	

**GUARDANT HEALTH INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues .....	57,766	29,840
Cost & expenses .....	123,321	90,835
Operating income .....	(65,555)	(60,995)
Interest income .....	2,932	1,222
Interest expense .....	952	2,398
Other income (expense), net .....	4,587	(5,990)
Net before taxes .....	(58,988)	
Income taxes .....	3	
<b>Net income</b> .....	(58,991)	(68,161)
Balance for common .....	(59,941)	(73,935)
Earnings common share		
Primary .....	\$(4.87)	\$(5.76)
Fully Diluted .....	\$(4.87)	\$(5.76)
Common Shares:		
Full Diluted .....	12,300	12,831
Year-end .....	13,003	

**GULF RESOURCES INC****Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues .....	2,594,941	104,160,873
Cost & expenses .....	44,522,445	70,030,152
Operating income .....	(41,927,504)	34,130,721
Interest income .....	509,738	398,382
Interest expense .....	123,749	124,068
Net before taxes .....	(41,541,515)	34,405,035
Income taxes .....	(10,258,508)	9,152,597
<b>Net income</b> .....	(31,283,007)	25,252,438
Earnings common share		
Primary .....	\$(0.67)	\$0.54
Fully Diluted .....	\$(0.67)	\$0.54
Common Shares:		
Full Diluted .....	46,803,791	46,833,030
Year-end .....	46,803,791	46,803,791

**H&E EQUIPMENT SERVICES INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues .....	892,987	735,353
Cost & expenses .....	777,240	637,706
Operating income .....	115,747	97,647
Interest expense .....	47,061	41,665
Other income (expense), net .....	1,222	(24,207)
Net before taxes .....	69,908	31,775
Income taxes .....	18,345	8,045
<b>Net income</b> .....	51,563	23,730
Earnings common share		
Primary .....	\$1.45	\$0.67
Fully Diluted .....	\$1.44	\$0.67
Common Shares:		
Full Diluted .....	35,904	35,656
Year-end .....	35,735	35,650

**HALOZYME THERAPEUTICS INC****Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues .....	91,630,000	127,049,000
Cost & expenses .....	160,889,000	171,976,000
Operating income .....	(69,259,000)	(44,927,000)
Interest expense .....	14,286,000	16,526,000
Other income (expense), net .....	5,561,000	1,512,000
Net before taxes .....	(77,984,000)	(59,941,000)
Income taxes .....	220,000	970,000
<b>Net income</b> .....	(78,204,000)	(60,911,000)
Earnings common share		
Primary .....	\$(0.55)	\$(0.45)
Fully Diluted .....	\$(0.55)	\$(0.45)
Common Shares:		
Full Diluted .....	143,396,000	134,633,000
Year-end .....	144,522,000	142,301,000

**HAMILTON LANE INC****Earnings, 3 mos. to Jun 30**(Consol. – \$000):

	2018	2017
Total Revenues .....	63,362	52,701
Cost & expenses .....	37,670	28,420
Operating income .....	24,720	29,304
Interest income .....	42	316
Interest expense .....	765	1,106
Other income (expense), net .....	(249)	5,813
Net before taxes .....	24,720	29,304

Income taxes .....	1,617	3,692
<b>Net income</b> .....	23,103	25,612
Earnings common share		
Primary .....	\$0.40	\$0.30
Fully Diluted .....	\$0.39	\$0.30
Common Shares:		
Full Diluted .....	22,773	18,459
Year-end .....	48,827	47,201

**Consolidated Balance Sheet Items, as of (\$000):**

	2018	2017
Assets:		
Cash & equivalents .....	53,641	
Current assets .....	77,268	
Net property & equip. ....	5,800	
Total assets .....	306,735	
Liabilities:		
Current liabilities .....	153,284	
Stockholders' equity .....	83,535	
Net current assets .....	(76,016)	

**HAYNES INTERNATIONAL, INC.****Annual Report****Consolidated Income Statement, Years Ended Sept. 30****(\$000):**

	2018	2017	2016
			(revised)
Net revenues .....	435,326	395,209	406,359
Cost of sales .....	387,648	365,499	358,779
Gross profit .....	47,678	29,710	47,580
Selling, general & administrative expense .....	47,111	42,393	39,684
Research & technical expense ....	3,785	3,855	3,698
Operating income (loss) .....	(3,218)	(16,538)	4,198
Interest income .....	82	186	108
Interest expense .....	918	865	555
Income (loss) before income taxes			
- U.S. ....	(16,650)	(25,090)	(4,160)
Income (loss) before income taxes - foreign .....	12,596	7,873	7,911
Income (loss) before income taxes ..	(4,054)	(17,217)	3,751
Current provision for income taxes - U.S. federal .....	(7,690)	933	(4,427)
Current provision (benefit) for income taxes - foreign .....	2,404	1,652	1,368
Current provision for income taxes - state .....	(137)	401	(141)
Total current provision (benefit) for income taxes .....	(5,423)	2,986	(3,200)
Deferred provision (benefit) for income taxes - U.S. federal .....	25,141	(8,781)	4,582
Deferred provision (benefit) for income taxes - foreign .....	...	...	(105)
Deferred provision (benefit) for income taxes - state .....	(2,496)	(1,427)	(2,954)
Valuation allowance ..	475	195	408
Total deferred provision (benefit) for income taxes .....	23,120	(10,013)	1,931
Provision (benefit) for income taxes .....	17,697	(7,027)	(1,269)
<b>Net income (loss)</b> .....	(21,751)	(10,190)	5,020
Weighted average shares			
outstanding-basic ....	12,420	12,397	12,361
Weighted average shares			
outstanding-diluted ..	12,420	12,397	12,366
Year end shares			



Full Diluted	11,778	11,626
Year-end	11,785	11,762

**HOUSTON WIRE & CABLE CO****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	268,952	235,551
Cost & expenses	256,617	231,682
Operating income	10,708	1,635
Interest expense	2,156	1,492
Net before taxes	8,552	143
Income taxes	1,544	2,361
<b>Net income</b>	<b>7,008</b>	<b>(2,218)</b>
Earnings common share		
Primary	\$0.43	\$(0.14)
Fully Diluted	\$0.42	\$(0.14)
Common Shares:		
Full Diluted	16,492	16,261
Year-end	16,523	16,506

**I.D. SYSTEMS, INC. (DE)****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	41,573,000	29,791,000
Cost & expenses	44,490,000	32,707,000
Operating income	(2,917,000)	(2,916,000)
Interest income	217,000	169,000
Interest expense	150,000	248,000
Other income (expense), net	(153,000)	(1,000)
<b>Net income</b>	<b>(3,003,000)</b>	<b>(2,996,000)</b>
Earnings common share		
Primary	\$(0.18)	\$(0.21)
Fully Diluted	\$(0.18)	\$(0.21)
Common Shares:		
Full Diluted	17,121,000	14,311,000
Year-end	18,105,000	

**IDENTIV INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	56,844	43,664
Cost & expenses	59,802	46,219
Operating income	(2,958)	(2,555)
Other income (expense), net	(1,369)	977
Foreign currency	354	(202)
Net before taxes	(5,212)	(3,775)
Income taxes	121	(161)
<b>Net income</b>	<b>(5,333)</b>	<b>(3,614)</b>
Earnings common share		
Primary	\$(0.34)	\$(0.28)
Fully Diluted	\$(0.34)	\$(0.28)
Common Shares:		
Full Diluted	15,484	12,806
Year-end	15,449	14,234

**IMMERSION CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	100,112	28,117
Cost & expenses	43,465	61,323
Operating income	56,647	(33,206)
Net before taxes	57,798	(32,702)
Income taxes	313	295
<b>Net income</b>	<b>57,485</b>	<b>(32,997)</b>
Earnings common share		
Primary	\$1.89	\$(1.13)
Fully Diluted	\$1.83	\$(1.13)
Common Shares:		
Full Diluted	31,334	29,155
Year-end	30,801	29,235

**IMMUNE DESIGN CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,720	6,710
Cost & expenses	44,561	47,150
Operating income	(42,841)	(40,440)
<b>Net income</b>	<b>(41,157)</b>	<b>(39,882)</b>
Earnings common share		
Primary	\$(0.85)	\$(1.56)
Fully Diluted	\$(0.85)	\$(1.56)
Common Shares:		
Full Diluted	48,138	25,551
Year-end	48,165	25,634

**IMPERVA INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	260,677	230,635
Cost & expenses	274,914	246,566
Operating income	(15,145)	(16,513)
Other income (expense), net	2,983	633
Gains or losses		35,871
Net before taxes	(12,162)	19,991
Income taxes	19,620	768
<b>Net income</b>	<b>(31,782)</b>	<b>19,223</b>
Earnings common share		
Primary	\$(0.91)	\$0.57
Fully Diluted	\$(0.91)	\$0.56
Common Shares:		
Full Diluted	34,782	34,118
Year-end	35,151	34,013

**INDUSTRIAL LOGISTICS PROPERTIES TRUST****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	120,456	117,111
Cost & expenses	32,145	30,088
Deprec., depl. & amort.	20,915	20,476
Operating income	67,396	66,547
Interest income	134	
Interest expense	11,406	1,680
Net before taxes	56,124	64,867
Income taxes	24	33
<b>Net income</b>	<b>56,100</b>	<b>64,834</b>
Earnings common share		
Primary	\$0.88	\$1.44
Fully Diluted	\$0.88	\$1.44
Common Shares:		
Full Diluted	63,839	45,000
Year-end	65,072	

**INFORMATION SERVICES GROUP INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	207,868	202,942
Cost & expenses	192,659	187,968
Operating income	9,337	5,201
Interest expense	5,140	5,132
Foreign currency	19	(292)
Net before taxes	4,329	(129)
Income taxes	(2,200)	(681)
<b>Net income</b>	<b>6,529</b>	<b>552</b>
Earnings common share		
Primary	\$0.15	\$0.01
Fully Diluted	\$0.14	\$0.01
Common Shares:		
Full Diluted	46,349	43,344
Year-end	45,138	

**INNODATA INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	42,439,000	45,271,000
Cost & expenses	40,982,000	47,682,000
Operating income	1,457,000	(2,411,000)
Net before taxes	1,457,000	(2,411,000)
Income taxes	1,502,000	807,000
<b>Net income</b>	<b>(45,000)</b>	<b>(3,218,000)</b>
Earnings common share		
Primary	\$	\$(0.11)
Fully Diluted	\$	\$(0.11)
Common Shares:		
Full Diluted	25,877,000	25,795,000
Year-end	25,877,454	25,878,000

**INOVIO PHARMACEUTICALS INC.****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	27,979,273	33,432,852
Cost & expenses	92,571,247	94,187,964
Operating income	(64,591,974)	(60,755,112)
Other income (expense), net	360,795	227,273
Gains or losses	1,305,174	(7,275,462)
Net before taxes	(61,835,814)	
Income taxes	2,169,811	
<b>Net income</b>	<b>(64,005,625)</b>	<b>(66,699,593)</b>
Earnings common share		
Primary	\$(0.70)	\$(0.85)

Fully Diluted	\$(0.70)	\$(0.85)
---------------	----------	----------

## Common Shares:

Full Diluted	91,350,117	79,043,480
Year-end	94,472,389	90,294,937

**INSEEGO CORP****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	146,420,000	172,763,000
Cost & expenses	130,459,000	193,051,000
Operating income	13,197,000	(23,002,000)
Other income (expense), net	(554,000)	(3,408,000)
Net before taxes	(2,717,000)	(40,676,000)
Income taxes	1,185,000	1,270,000
<b>Net income</b>	<b>(3,902,000)</b>	<b>(41,946,000)</b>
Earnings common share		
Primary	\$(0.06)	\$(0.72)
Fully Diluted	\$(0.06)	\$(0.72)
Common Shares:		
Full Diluted	63,585,229	58,157,171
Year-end	73,391,361	58,259,353

**INSIGNIA SYSTEMS, INC.****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	25,119,000	18,339,000
Cost & expenses	23,788,000	20,200,000
Operating income	1,331,000	(1,861,000)
Other income (expense), net	27,000	7,000
Net before taxes	1,358,000	(1,854,000)
Income taxes	365,000	(580,000)
<b>Net income</b>	<b>993,000</b>	<b>(1,274,000)</b>
Earnings common share		
Primary	\$0.08	\$(0.10)
Fully Diluted	\$0.08	\$(0.10)
Common Shares:		
Full Diluted	12,026,000	11,698,000
Year-end	11,848,000	11,903,946

**INTEGRAL TECHNOLOGIES INC.****Earnings, 3 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	23,245	
Cost & expenses	542,618	786,268
Operating income	(5)	(12)
Interest expense	519,145	29,802
Other income (expense), net	12,048	62,050
<b>Net income</b>	<b>(1,016,397)</b>	<b>(730,775)</b>
Earnings common share		
Primary	\$	\$(0.01)
Fully Diluted	\$	\$(0.01)
Common Shares:		
Full Diluted	209,834,346	135,385,386
Year-end	202,210,516	137,327,603

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2017
Cash & equivalents	2,156
Current assets	14,560
Net property & equip.	68,442
Total assets	266,615
Liabilities:	
Current liabilities	4,133,306
Stockholders' equity	(4,125,024)
Net current assets	(4,118,746)

**INTELGENX TECHNOLOGIES CORP****Definitive Licensing, Development & Supply Agree-**

**ment** On Dec. 12, 2018, Co. announced the execution of a definitive licensing, development and supply agreement (the "Agreement") with Gensco<sup>®</sup> Pharma (Gensco<sup>®</sup>), a specialty pharmaceutical company focusing on research, development and marketing of prescription products, for the exclusive commercialization of RIZAPORT<sup>®</sup> in the United States. Upon the anticipated RIZAPORT<sup>®</sup> approval by the US Food and Drug Administration ("FDA"), the product will become the first oral thin film on the market for the treatment of migraines, and will also be the first commercialized film product developed and manufactured at Co.'s state-of-the-art facilities. Under the Agreement, Gensco<sup>®</sup> has been granted the exclusive right to commercialize Co.'s RIZAPORT<sup>®</sup> product in the United States. In return, Co. is entitled to receive royalty payments based on net profits of RIZAPORT<sup>®</sup>. Co. is also eligible to receive milestone payments upon FDA approval and product launch. The agreement also gives Gensco<sup>®</sup> exclusivity to develop the market, sell, distribute and

fully commercialize products as a Co. partner for the People's Republic of China. Terms of the transaction were not disclosed.

**INTELGEX TECHNOLOGIES CORP**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	1,173,000	3,733,000
Cost & expenses	7,421,000	4,847,000
Operating income	(6,788,000)	(1,639,000)
<b>Net income</b>	<b>(7,609,000)</b>	<b>(1,960,000)</b>
Earnings common share		
Primary	\$(0.11)	\$(0.02)
Fully Diluted	\$(0.11)	\$(0.02)
Common Shares:		
Full Diluted	69,298,321	65,885,055
Year-end	73,100,075	66,931,467

**INTELGEX TECHNOLOGIES CORP**

**Online Marketing & Corporate Communications Services** On Nov. 30, 2018, Co. announced the engagement of Focus Communications ("Focus"), a private Toronto based firm providing investor relations, corporate communications and market awareness services, to provide online marketing and corporate communications services to Co. Focus has been retained on a twelve month contract basis to advise Co. with respect to its online marketing endeavours and assisting management in developing a strategy to help expand and support corporate development initiatives. Focus would also assist Co. in increasing investor awareness by managing Co.'s corporate communications, marketing undertakings, ongoing engagement with shareholders, finance professionals and media contacts. Under the terms of the agreement, Co. would pay Focus C\$5,000 per month for an initial twelve month term and grant 100,000 stock options at an exercise price of US\$0.81.

**INTERDIGITAL INC (PA)**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	232,078	327,634
Cost & expenses	173,328	171,843
Operating income	58,750	155,791
Other income (expense), net	(8,907)	26
Net before taxes	33,614	148,460
Income taxes	(25,001)	29,413
<b>Net income</b>	<b>58,615</b>	<b>119,047</b>
Balance for common	62,038	121,791
Earnings common share		
Primary	\$1.79	\$3.52
Fully Diluted	\$1.74	\$3.40
Common Shares:		
Full Diluted	35,614	35,865
Year-end	34,442	

**INTERLINK ELECTRONICS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	7,176	8,797
Cost & expenses	6,424	6,895
Operating income	752	1,902
Other income (expense), net	66	13
Net before taxes	818	1,915
Income taxes	242	650
<b>Net income</b>	<b>576</b>	<b>1,265</b>
Earnings common share		
Primary	\$0.08	\$0.17
Fully Diluted	\$0.08	\$0.17
Common Shares:		
Full Diluted	7,129	7,418
Year-end	6,483	

**INTERSECTIONS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	115,182,000	119,631,000
Cost & expenses	108,363,000	127,229,000
Operating income	2,097,000	(11,687,000)
Other income (expense), net	(29,000)	(1,392,000)
Net before taxes	(216,000)	(14,974,000)
Income taxes	(303,000)	(23,000)
Income contin. oper.		(14,951,000)
<b>Net income</b>	<b>87,000</b>	<b>(17,400,000)</b>
Earnings common share		
Primary	\$	\$(0.73)
Fully Diluted	\$	\$(0.73)
Common Shares:		
Full Diluted	24,687,000	23,818,000
Year-end	24,397,000	

**INTRICON CORP**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Net Sales	85,657,000	68,800,000
Cost & expenses	79,587,000	66,730,000
Operating income	6,070,000	2,070,000
Interest expense	453,000	548,000
Other income (expense), net	(580,000)	(328,000)
Net before taxes	5,037,000	1,194,000
Income taxes	358,000	165,000
Income contin. oper.		1,029,000
<b>Net income</b>	<b>4,679,000</b>	<b>737,000</b>
Earnings common share		
Primary	\$0.65	\$0.24
Fully Diluted	\$0.56	\$0.23
Common Shares:		
Full Diluted	8,360,000	7,179,000
Year-end	8,640,000	

**INVO BIOSCIENCE, INC.**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	2,459,996	644,202
Operating income	(2,120,611)	(443,412)
Gains or losses		(40,869)
<b>Net income</b>	<b>(2,304,711)</b>	<b>(500,695)</b>
Earnings common share		
Primary	\$(0.02)	\$
Fully Diluted	\$(0.02)	\$
Common Shares:		
Full Diluted	146,052,444	141,103,908
Year-end	147,454,700	141,681,268

**IONIS PHARMACEUTICALS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	407,559	346,387
Cost & expenses	479,716	309,140
Operating income	(72,157)	37,247
Interest expense	33,332	33,966
Other income (expense), net	(145)	(11,217)
Gains or losses	18,711	7,504
Net before taxes	(86,923)	(432)
Income taxes	824	1,184
<b>Net income</b>	<b>(87,747)</b>	<b>(1,616)</b>
Earnings common share		
Primary	\$(0.33)	\$0.13
Fully Diluted	\$(0.33)	\$0.13
Common Shares:		
Full Diluted	132,518	125,858
Year-end	137,506	

**IRIDIUM COMMUNICATIONS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	390,843,000	332,577,000
Cost & expenses	197,952,000	146,499,000
Operating income	41,795,000	129,426,000
Other income (expense), net	(277,000)	(163,000)
Net before taxes	4,223,000	132,174,000
Income taxes	10,025,000	40,195,000
<b>Net income</b>	<b>(5,802,000)</b>	<b>91,979,000</b>
Balance for common	(13,854,000)	80,402,000
Earnings common share		
Primary	\$(0.13)	\$0.82
Fully Diluted	\$(0.13)	\$0.72
Common Shares:		
Full Diluted	107,840,000	126,839,000
Year-end	111,321,000	

**IRONWOOD PHARMACEUTICALS INC**

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	215,947	204,068
Cost & expenses	452,723	301,480
Operating income	(244,887)	(100,150)
Interest expense	28,138	27,164
Other income (expense), net	3,996	(3,200)
<b>Net income</b>	<b>(266,875)</b>	<b>(129,022)</b>
Earnings common share		
Primary	\$(1.75)	\$(0.87)
Fully Diluted	\$(1.75)	\$(0.87)
Common Shares:		
Full Diluted	152,143	148,695
Year-end	153,782	149,692

**J&J SNACK FOODS CORP.**

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	09/29/18	09/30/17	09/24/16
Net sales	1,138,265	1,084,224	992,781
Cost of goods sold	801,979	753,201	688,314
Gross profit (loss)	336,286	331,023	304,467
Marketing expenses	95,405	94,394	85,963
Distribution			
expenses	92,281	81,824	73,114
Administrative			
expenses	37,757	36,843	32,299
Other expense			
(income)	68	(145)	281
Total operating			
expenses	225,511	212,916	191,657
Operating income			
(loss)	110,775	118,107	112,810
Investment income	6,267	5,289	4,132
Interest expense &			
other expenses	(1,110)	1,196	123
Earnings (loss)			
before income taxes	118,152	122,200	116,819
Current U.S.			
federal income tax			
expense (benefit)	16,591	27,142	25,126
Current foreign			
income tax expense			
(benefit)	2,512	2,770	2,433
Current state			
income tax expense			
(benefit)	5,836	5,227	5,622
Total current			
income tax expense			
(benefit)	24,939	35,139	33,181
Deferred U.S.			
federal income tax			
expense (benefit)	(14,613)	6,857	6,444
Deferred foreign			
income tax expense			
(benefit)	514	(422)	(145)
Deferred state			
income tax expense			
(benefit)	3,716	1,452	1,364
Total deferred			
income tax expense			
(benefit)	(10,383)	7,887	7,663
Income taxes	14,556	43,026	40,844
<b>Net earnings</b>			
(losses)	103,596	79,174	75,975
Weighted average			
shares outstanding			
- basic	18,694	18,707	18,649
Weighted average			
shares outstanding			
- diluted	18,817	18,816	18,769
Year end shares			
outstanding	18,754	18,663	18,668
Net earnings (loss)			
per share - basic	\$5.54	\$4.23	\$4.07
Net earnings (loss)			
per share - diluted	\$5.51	\$4.21	\$4.05
Cash dividends			
declared per common			
share		\$1.68	
Number of full time			
employees	4,500	4,200	3,600
Number of			
beneficiary			
stockholders	18,000	15,000	15,400
Foreign currency			
translation			
adjustments	(2,738)	3,745	

For 53 weeks; Reclassified to conform with 2017 presentation; Includes share-based compensation expense - Cost of goods sold: \$862,000; Includes share-based compensation expense - Cost of goods sold: \$720,000; Includes share-based compensation expense - Cost of goods sold: \$609,000; Includes share-based compensation expense - Marketing:

\$1,339,000; <sup>(7)</sup> Includes share-based compensation expense - Marketing: \$1,038,000; <sup>(8)</sup> Includes share-based compensation expense - Marketing: \$924,000; <sup>(9)</sup> Includes share-based compensation expense - Distribution: \$76,000; <sup>(10)</sup> Includes share-based compensation expense - Distribution: \$72,000; <sup>(11)</sup> Includes share-based compensation expense - Distribution: \$48,000; <sup>(12)</sup> Includes share-based compensation expense - Administrative: \$1,581,000; <sup>(13)</sup> Includes share-based compensation expense - Administrative: \$1,218,000; <sup>(14)</sup> Includes share-based compensation expense - Administrative: \$794,000; <sup>(15)</sup> As is; <sup>(16)</sup> Approximately

**Consolidated Balance Sheet, Years Ended (\$000):**

	09/29/18	09/30/17
Cash & cash equivalents	111,479	90,962
Marketable securities held to maturity	21,048	59,113
Accounts receivable, net	132,342	124,553
Finished goods	52,221	45,394
Raw materials	23,173	22,682
Packaging materials	9,780	8,833
Equipment parts & other inventories	27,710	26,359
Inventories	112,884	103,268
Prepaid expenses & other current assets	5,044	3,936
Total current assets	382,797	381,832
Land	2,494	2,482
Buildings	26,582	26,741
Plant machinery & equipment	290,396	257,172
Marketing equipment	290,955	278,860
Transportation equipment	8,429	8,449
Office equipment	30,752	25,302
Improvements	38,941	38,003
Construction in progress	8,468	16,880
Property, plant & equipment, at cost	697,517	653,889
Less accumulated depreciation & amortization	454,844	426,308
Property, plant & equipment, net	242,673	227,581
Goodwill	102,511	102,511
Other intangible assets, net	57,762	61,272
Marketable securities held to maturity	118,765	60,908
Marketable securities available for sale	24,743	30,260
Other assets	2,762	2,864
Total assets	932,013	867,228
Current obligations under capital leases	324	340
Accounts payable	69,592	72,729
Accrued insurance liability	11,217	10,558
Accrued liabilities	8,031	7,753
Accrued compensation expense	20,297	19,826
Dividends payable	8,438	7,838
Total current liabilities	117,899	119,044
Long-term obligations under capital leases	753	904
Deferred income taxes	52,322	62,705
Other long-term liabilities	1,948	2,253
Common stock	27,340	17,382
Foreign currency translation adjustments	(12,079)	(9,341)
Unrealized holding gain (loss) on marketable securities	85	466
Accumulated other comprehensive income (loss)	(11,994)	(8,875)
Retained earnings (accumulated deficit)	743,745	673,815
Total stockholders' equity (deficit)	759,091	682,322

**Recent Dividends:**  
1. J&J Snack Foods Corp. common.

ExDate	Amt	Declared	Record	Payable
12/19/2014	0.36	12/09/2014	12/23/2014	01/08/2015
03/11/2015	0.36	02/19/2015	03/13/2015	04/02/2015
06/11/2015	0.36	05/28/2015	06/15/2015	07/02/2015
09/11/2015	0.36	08/06/2015	09/15/2015	10/06/2015
12/18/2015	0.39	12/10/2015	12/22/2015	01/07/2016
03/11/2016	0.39	02/17/2016	03/15/2016	04/06/2016
06/13/2016	0.39	05/20/2016	06/15/2016	07/07/2016
09/13/2016	0.39	08/11/2016	09/15/2016	10/06/2016
09/13/2017	0.42	12/08/2016	12/21/2016	01/11/2017
03/13/2017	0.42	02/16/2017	03/15/2017	04/06/2017
06/19/2017	0.42	06/07/2017	06/21/2017	07/06/2017
09/13/2017	0.42	08/04/2017	09/14/2017	10/04/2017
12/12/2017	0.45	11/30/2017	12/13/2017	01/04/2018
03/14/2018	0.45	02/12/2018	03/15/2018	04/04/2018
06/13/2018	0.45	05/21/2018	06/14/2018	07/05/2018
09/13/2018	0.45	08/29/2018	09/14/2018	10/04/2018

**Annual Dividends:**  
1. J&J Snack Foods Corp. common.

Year	2015	2016	2017
2015	1.44	1.56	1.68
2018	1.80		

**JACK IN THE BOX, INC. Annual Report**

**Consolidated Income Statement, Years Ended (\$000):**

	09/30/18	<sup>(1)</sup> 10/01/17 (revised)	<sup>(2)</sup> 10/02/16 (revised)
Company restaurant sales	448,058	715,921	789,040
Franchise rental revenues	259,047	231,578	232,794
Franchise royalties & other revenues	162,585	149,792	140,424
Total revenues	869,690	1,097,291	1,162,258
Food & packaging costs	128,947	206,653	235,538
Payroll & employee benefits costs	129,089	211,611	223,019
Occupancy & other costs	71,803	124,367	129,763
Total company restaurant costs	329,839	542,631	588,320
Franchise occupancy expenses (excluding depreciation & amortization)	158,319	140,623	137,706
Franchise support & other costs	11,593	8,811	11,107
Selling, general & administrative expenses	106,649	120,640	152,147
Depreciation & amortization expenses	59,422	67,398	72,786
Restructuring costs	10,647	3,631	3,531
Costs of closed restaurants & other charges	4,803	5,736	2,457
Gains (losses) on disposition of property & equipment, net	(1,627)	(2,891)	(2,398)
Accelerated depreciation	1,130	911	1,543
Impairment charges	211		
Gains (losses) on the sale of company-operated restaurants	46,164	38,034	1,230
Total operating costs & expenses	638,076	855,238	970,765
Earnings from operations	231,614	242,053	191,493
Interest income (expense), net	(45,547)	(38,148)	(24,280)
Earnings (loss) from continuing operations & before income taxes	186,067	203,905	167,213
Current federal income taxes	51,454	79,038	23,768
Current state			

income taxes	4,922	12,368	3,679
Total current income taxes	56,376	91,406	27,447
Deferred federal income taxes (benefit)	23,462	(13,176)	28,455
Deferred state income taxes (benefit)	1,890	(2,898)	4,838
Total deferred income taxes (benefit)	25,352	(16,074)	33,293
Income taxes (benefit)	81,728	75,332	60,740
Earnings from continuing operations	104,339	128,573	106,473
Earnings (losses) from discontinued operations, net of income tax benefit	17,032	6,759	17,600
<b>Net earnings (loss)</b>	121,371	135,332	124,073
Weighted average shares outstanding - basic	28,499	30,630	33,735
Weighted average shares outstanding - diluted	28,807	30,914	34,146
Year end shares outstanding	25,736	29,432	...
Earnings (loss) per share from continuing operations - basic	\$3.66	\$4.20	\$3.16
Earnings (loss) per share from discontinued operations - basic	\$0.60	\$0.22	\$0.52
Net earnings (loss) per share - basic	\$4.26	\$4.42	\$3.68
Earnings (loss) per share from continuing operations - diluted	\$3.62	\$4.16	\$3.12
Earnings (loss) per share from discontinued operations - diluted	\$0.59	\$0.22	\$0.52
Net earnings (loss) per share - diluted	\$4.21	\$4.38	\$3.63
Cash dividends declared per common share	\$1.60	\$1.60	\$1.20
Total number of employees	<sup>(3)</sup> 5,200	...	...
Number of common stockholders	<sup>(4)</sup> 452	...	...
Foreign currency translation adjustments	6	(35)	...

<sup>(1)</sup> Restated to reflect the sale of Qdoba Restaurant Corporation as discontinued operations; <sup>(2)</sup> As is; <sup>(3)</sup> Approximately; <sup>(4)</sup> As of November 16, 2018

**Consolidated Balance Sheet, Years Ended (\$000):**

	09/30/18	<sup>(1)</sup> 10/01/17 (revised)
Cash	2,705	4,467
Trade accounts receivable	35,877	55,108
Notes receivable	11,480	988
Income tax receivable	5,637	3,273
Other accounts & other receivables	6,123	2,399
Allowances for doubtful accounts	1,695	2,159
Accounts & other receivables, net	57,422	59,609
Inventories	1,858	3,445
Prepaid income taxes	4,837	16,928
Prepaid rent	4,318	5,407
Other prepaid expenses	5,288	5,197

Prepaid expenses	14,443	27,532
Current assets held for sale	13,947	42,732
Other current assets	4,598	1,493
Total current assets	94,973	139,278
Land	105,155	112,509
Buildings	934,360	958,841
Restaurant & other equipment	129,701	173,980
Construction in progress	20,815	16,787
Property & equipment, at cost	1,190,031	1,262,117
Less accumulated depreciation & amortization	770,362	777,841
Property & equipment, net	419,669	484,276
Intangible assets, net	600	1,413
Goodwill	46,749	51,412
Non-current assets held for sale	...	280,796
Company-owned life insurance policies	109,908	110,057
Deferred tax assets	62,140	105,118
Deferred rent receivable	48,372	46,962
Other assets	40,986	15,433
Other assets, net	...	0
Total other assets	308,755	611,191
Total assets	823,397	1,234,745
Current maturities of long-term debt	31,828	64,225
Accounts payable	44,970	28,366
Accrued insurance	35,405	39,011
Accrued payroll & related taxes	29,498	23,361
Accrued advertising	952	18,493
Accrued sales & property taxes	4,555	7,275
Gift card liability	2,081	2,237
Accrued income taxes	1,387	18,961
Deferred franchise fees	375	450
Other accrued liabilities	32,669	25,266
Current liabilities held for sale	...	34,345
Total current liabilities	183,720	261,990
Revolver	730,422	497,022
Term loan	336,360	639,385
Capital lease obligations	4,403	9,940
Less current maturities of long-term debt	31,828	64,225
Less term loan debt issuance costs	(1,430)	(2,140)
Long-term debt, net of current maturities	1,037,927	1,079,982
Non-current liabilities held for sale	...	32,078
Defined benefit pension plans	69,012	107,011
Straight-line rent accrual	31,762	33,749
Other long-term liabilities	92,675	108,065
Total long-term liabilities	1,231,376	1,360,885
Common stock	821	818
Capital in excess of par value	470,826	453,432
Retained earnings (accumulated deficit)	1,561,353	1,485,820
Accumulated other comprehensive income (loss)	(94,260)	(137,761)
Treasury stock, at cost	2,530,439	2,190,439
Total stockholders' equity (deficit)	(591,699)	(388,130)

<sup>1</sup> Restated to reflect the sale of Qdoba Restaurant Corporation as discontinued operations; <sup>2</sup> Net of term loan debt issuance costs - current maturities of long-term debt: \$1,008,000; <sup>3</sup> Net of term loan debt issuance costs - current maturities of long-term debt: \$1,502,000

**Recent Dividends:****1. Jack in the Box, Inc. common.**

ExDate	Amt	Declared	Record	Payable
03/04/2015	0.20	02/18/2015	03/06/2015	03/19/2015
05/28/2015	0.30	05/07/2015	06/01/2015	06/12/2015
08/24/2015	0.30	07/30/2015	08/26/2015	09/09/2015
12/07/2015	0.30	11/12/2015	12/09/2015	12/22/2015
02/26/2016	0.30	02/12/2016	03/01/2016	03/14/2016
05/20/2016	0.30	05/05/2016	05/24/2016	06/07/2016
08/12/2016	0.30	07/28/2016	08/16/2016	08/29/2016
12/01/2016	0.40	11/17/2016	12/05/2016	12/16/2016
03/03/2017	0.40	02/21/2017	03/07/2017	03/20/2017
05/25/2017	0.40	05/11/2017	05/30/2017	06/12/2017
08/18/2017	0.40	08/03/2017	08/22/2017	09/05/2017
12/01/2017	0.40	11/17/2017	12/04/2017	12/15/2017
03/02/2018	0.40	02/19/2018	03/05/2018	03/16/2018
05/25/2018	0.40	05/11/2018	05/29/2018	06/11/2018
08/17/2018	0.40	08/03/2018	08/20/2018	09/05/2018
12/04/2018	0.40	11/15/2018	12/05/2018	12/18/2018

**Annual Dividends:****1. Jack in the Box, Inc. common.**

2015	1.10	2016	1.30	2017	1.60
2018	1.60				

**JAKKS PACIFIC INC.****Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Net Sales	435,484,000	476,483,000
Cost & expenses	463,239,000	514,061,000
Operating income	(27,755,000)	(37,578,000)
Other income (expense), net	78,000	397,000
Gains or losses	(2,514,000)	(7,000,000)
Net before taxes	(37,374,000)	(51,651,000)
Income taxes	1,708,000	890,000
Net income	(39,082,000)	(52,541,000)
Earnings common share		
Primary	\$(1.69)	\$(2.53)
Fully Diluted	\$(1.69)	\$(2.53)
Common Shares:		
Full Diluted	23,104,000	20,848,000
Year-end	29,169,913	26,987,430

**JETBLUE AIRWAYS CORP****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	5,261,000	4,123,000
Operating income	67,000	803,000
Net before taxes	18,000	743,000
Income taxes	(1,000)	273,000
Net income	19,000	470,000
Earnings common share		
Primary	\$0.06	\$1.42
Fully Diluted	\$0.06	\$1.41
Common Shares:		
Full Diluted	316,400	332,400
Year-end	305,000	...

**JOINT CORP (NEW)****Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	22,717,298	18,045,095
Cost & expenses	22,266,406	19,601,448
Deprec., depl. & amort.	1,181,661	1,550,013
Operating income	(730,769)	(3,106,366)
Other income (expense), net	(33,556)	(33,589)
Gains or losses	75,264	...
Net before taxes	(689,061)	(3,139,955)
Income taxes	(107,575)	79,277
Net income	(581,486)	(3,219,232)
Earnings common share		
Primary	\$(0.04)	\$(0.24)
Fully Diluted	\$(0.04)	\$(0.24)
Common Shares:		
Full Diluted	13,646,599	13,144,764
Year-end	13,734,008	...

**JOUNCE THERAPEUTICS INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	73,250	66,318
Operating income	(28,149)	(7,663)
Other income (expense), net	2,810	2,105
Net before taxes	(5,558)	(5,558)

Income taxes	1,521
Net income	(25,339) (7,079)
Balance for common	(25,339) (7,873)
Earnings common share	
Primary	\$(0.78) \$(0.27)
Fully Diluted	\$(0.78) \$(0.27)
Common Shares:	
Full Diluted	32,462 29,321
Year-end	32,692 32,208

**KAISER ALUMINUM CORP.****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Net Sales	1,196,500	1,044,400
Cost & expenses	1,057,400	901,800
Operating income	106,700	113,300
Interest income	200	...
Interest expense	17,000	16,400
Other income (expense), net	(4,600)	(1,700)
Invest. income	4,700	2,200
Net before taxes	90,000	97,400
Income taxes	21,900	36,800
Net income	68,100	60,600
Earnings common share		
Primary	\$4.09	\$3.55
Fully Diluted	\$4.03	\$3.49
Common Shares:		
Full Diluted	16,882	17,363
Year-end	16,547	16,905

**KALA PHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	41,153	28,735
Operating income	(41,153)	(28,735)
Interest income	848	276
Interest expense	1,214	618
Other income (expense), net	...	(1,844)
Net income	(41,519)	(30,921)
Earnings common share		
Primary	\$(1.69)	\$(4.51)
Fully Diluted	\$(1.69)	\$(4.51)
Common Shares:		
Full Diluted	24,570	6,861
Year-end	24,646	24,347

**KALVISTA PHARMACEUTICALS INC****Earnings, 6 mos. to Oct 31 (Consol. - \$000):**

	2018	2017
Total Revenues	9,311	1,223
Cost & expenses	21,211	12,613
Operating income	(11,900)	(11,390)
Interest income	293	3
Other income (expense), net	3,438	1,422
Net income	(8,334)	(9,914)
Earnings common share		
Primary	\$(0.64)	\$(1.01)
Fully Diluted	\$(0.64)	\$(1.01)
Common Shares:		
Full Diluted	12,954	9,859
Year-end	17,225	10,784

**KANDI TECHNOLOGIES GROUP INC****Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	62,690,873	59,953,751
Cost & expenses	67,546,030	90,318,674
Operating income	(4,855,157)	(30,364,923)
Other income (expense), net	3,118,849	(7,507,608)
Net before taxes	(1,736,308)	(37,872,531)
Income taxes	(370,316)	(4,130,951)
Net income	(2,106,624)	(42,003,482)
Earnings common share		
Primary	\$(0.03)	\$(0.71)
Fully Diluted	\$(0.03)	\$(0.71)
Common Shares:		
Full Diluted	51,089,047	47,913,028
Year-end	51,481,944	48,034,038

**KEMPHARM INC****Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	46,635	25,216
Operating income	(46,635)	(25,216)

Other income (expense), net .....	289	(2,381)
Net before taxes .....	(51,390)	(32,832)
Income taxes .....	(107)	(12)
<b>Net income .....</b>	<b>(51,283)</b>	<b>(32,820)</b>
Earnings common share		
Primary .....	\$(3.33)	\$(2.24)
Fully Diluted .....	\$(3.33)	\$(2.24)
Common Shares:		
Full Diluted .....	15,386	14,651
Year-end .....	16,042	14,657

**KEWAUNEE SCIENTIFIC CORPORATION**

**Earnings, 6 mos. to Oct 31(Consol. - \$000):**

	2018	2017
Net Sales .....	79,430	75,352
Cost & expenses .....	75,909	71,009
Operating income .....	3,521	4,343
Interest expense .....	182	148
Other income (expense), net .....	314	345
Net before taxes .....	3,653	4,540
Income taxes .....	783	1,583
<b>Net income .....</b>	<b>2,870</b>	<b>2,957</b>
Earnings common share		
Primary .....	\$1.03	\$1.06
Fully Diluted .....	\$1.01	\$1.04
Common Shares:		
Full Diluted .....	2,802	2,766
Year-end .....	2,744	2,721

**KEY TRONIC CORP**

**Earnings, 3 mos. to (Consol. - \$000):**

	09/29/18	09/30/17
Net Sales .....	127,472	109,217
Cost & expenses .....	124,927	108,053
Operating income .....	2,545	1,164
Interest expense .....	677	594
Net before taxes .....	1,868	570
Income taxes .....	275	138
<b>Net income .....</b>	<b>1,593</b>	<b>432</b>
Earnings common share		
Primary .....	\$0.15	\$0.04
Fully Diluted .....	\$0.15	\$0.04
Common Shares:		
Full Diluted .....	10,979	10,760
Year-end .....	10,760	10,760

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	2017
Cash & equivalents .....	1,359	99,534
Inventories .....	99,534	199,290
Current assets .....	199,290	27,606
Net property & equip. ....	27,606	101,690
Total assets .....	250,984	
Liabilities:		
Current liabilities .....	97,600	
Long-term debt .....	29,642	
Stockholders' equity .....	123,420	
Net current assets .....	101,690	

**KEYW HOLDING CORP**

**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues .....	380,572	314,708
Cost & expenses .....	363,075	317,794
Operating income .....	8,098	(11,944)
Other income (expense), net .....	(11,472)	375
Income taxes .....	(3,569)	5,039
<b>Net income .....</b>	<b>(16,779)</b>	<b>(28,960)</b>
Earnings common share		
Primary .....	\$(0.34)	\$(0.60)
Fully Diluted .....	\$(0.34)	\$(0.60)
Common Shares:		
Full Diluted .....	49,814	48,627
Year-end .....	49,859	

**KEZAR LIFE SCIENCES INC**

**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses .....	18,300	6,330
Operating income .....	(18,300)	(6,330)
Interest income .....	915	113
<b>Net income .....</b>	<b>(17,385)</b>	<b>(6,217)</b>
Earnings common share		
Primary .....	\$(2.38)	\$(10.92)
Fully Diluted .....	\$(2.38)	\$(10.92)

Common Shares:		
Full Diluted .....	7,319	569
Year-end .....	19,108	

**KIRKLAND'S INC**

**Earnings, 9 mos. to (Consol. - \$000):**

	11/03/18	10/28/17
Net Sales .....	430,924	409,503
Cost & expenses .....	439,718	416,155
Operating income .....	(14,199)	(11,741)
Interest expense .....	200	195
Other income (expense), net .....	825	448
Net before taxes .....	(13,574)	(11,488)
Income taxes .....	(3,197)	(3,919)
<b>Net income .....</b>	<b>(10,377)</b>	<b>(7,569)</b>
Earnings common share		
Primary .....	\$(0.66)	\$(0.48)
Fully Diluted .....	\$(0.66)	\$(0.48)
Common Shares:		
Full Diluted .....	15,673	15,932
Year-end .....	15,063	16,002

**KONA GRILL INC**

**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues .....	121,798	136,592
Cost & expenses .....	118,355	134,581
Operating income .....	(6,699)	(9,266)
Interest expense .....	1,845	1,214
Other income (expense), net .....	(37)	(472)
Net before taxes .....	(8,581)	(10,952)
Income taxes .....	(7)	71
<b>Net income .....</b>	<b>(8,574)</b>	<b>(11,023)</b>
Earnings common share		
Primary .....	\$(0.72)	\$(1.09)
Fully Diluted .....	\$(0.72)	\$(1.09)
Common Shares:		
Full Diluted .....	11,828	10,126
Year-end .....	13,260	10,105

**KULICKE & SOFFA INDUSTRIES, INC.**

**Annual Report**

**Consolidated Income Statement, Years Ended (\$000):**

	09/29/18	09/30/17	10/01/16
Net revenue .....	889,121	809,041	627,192
Cost of sales .....	479,680	426,947	346,156
Gross profit .....	409,441	382,094	281,036
Selling, general & administrative expenses .....	123,188	133,601	134,709
Research & development expenses .....	119,621	100,203	92,374
Impairment charges .....	...	35,207	...
Total operating expenses .....	242,809	269,011	227,083
Income (loss) from operations .....	166,632	113,083	53,953
Interest income .....	11,971	6,491	3,318
Interest expense .....	1,054	1,059	1,107
Income (loss) before income taxes - United States operations .....	25,211	(4,114)	(12,600)
Income (loss) before income taxes - foreign operations .....	152,338	122,629	68,764
Income (loss) from operations before income taxes .....	177,549	118,515	56,164
Current federal income taxes (benefit) .....	83,159	(3,975)	871
Current state income taxes .....	58	64	53
Current foreign income taxes (benefit) .....	16,980	13,290	21,841
Deferred federal income taxes (benefit) .....	23,346	(15,374)	(13,423)
Deferred state			

income taxes (benefit) .....	(2)	40	12
Deferred foreign income taxes (benefit) .....	(2,797)	(1,439)	(1,645)
Income tax expense (benefit) .....	120,744	(7,394)	7,709
Share of results of equity-method investee, net of tax .....	(129)	190	...
<b>Net income (loss) .....</b>	<b>56,676</b>	<b>126,099</b>	<b>48,455</b>
Weighted average shares outstanding - basic .....	69,380	70,906	70,477
Weighted average shares outstanding - diluted .....	70,419	72,063	70,841
Year end shares outstanding .....	67,143	70,197	70,420
Net income (loss) per share - basic .....	\$0.82	\$1.78	\$0.69
Net income (loss) per share - diluted .....	\$0.80	\$1.75	\$0.68
Cash dividends declared per share .....	\$0.24	...	...
Number of full-time employees .....	2,681	...	...
Number of part-time employees .....	231	...	...
Number of common stockholders .....	206	...	...
Foreign currency translation adjustments .....	(3,633)	...	...

□ Restated to reflect corrections of errors related to warranty expense, accrual accounts, cost of sales and accounts payable accounts due to management override of controls, and tax expense adjustments; □ As is; □ Approximately; □ As of November 16, 2018

**Consolidated Balance Sheet, Years Ended (\$000):**

	09/29/18	09/30/17
Cash & cash equivalents .....	320,630	392,410
Restricted cash .....	518	530
Short-term investments .....	293,000	216,000
Accounts & notes receivable, gross .....	243,758	198,559
Less: allowance for doubtful accounts .....	385	79
Accounts & notes receivable, net .....	243,373	198,480
Raw materials & supplies .....	63,894	44,239
Work in process .....	37,829	40,827
Finished goods .....	40,357	61,596
Inventory reserves .....	26,889	24,639
Inventories, net .....	115,191	122,023
Prepaid expenses & other current assets .....	14,561	23,939
Total current assets .....	987,273	953,382
Land .....	2,182	2,182
Buildings & building improvements .....	52,449	50,910
Leasehold improvements .....	12,728	9,882
Data processing equipment & software .....	35,469	34,700
Machinery, equipment, furniture & fixtures .....	68,666	60,143
Construction in progress .....	6,940	8,000
Property, plant & equipment, gross .....	178,434	165,817
Less: accumulated depreciation .....	102,367	98,055
Property, plant & equipment, net .....	76,067	67,762
Goodwill .....	56,550	56,318
Intangible assets, net .....	52,871	62,316
Deferred income taxes .....	9,017	27,771
Equity investments .....	1,373	1,502
Other assets .....	2,589	2,056
Total assets .....	1,185,740	1,171,107
Accounts payable .....	48,527	51,354





**Options Granted** On Nov. 28, 2018, Co. announced that it has granted stock options to new employees and consultants that enable the option holders to purchase up to 390,000 common shares of Co. at a price of US\$1.27 for a period of five years, vesting over a period of three years.

#### LLEXARIA BIOSCIENCE CORP

**Options Granted** On Dec. 11, 2018, Co. announced it continues to hire additional personnel including a new corporate controller; head of legal division and other office staff. In the New Year, Co. expected to begin hiring additional new laboratory personnel as its R&D operations intensify. As a result of the latest positions created, Co. issued 240,000 stock options with an exercise price of US\$1.06, that will vest as to 80,000 per year until Apr. 15, 2021.

#### LLEXARIA BIOSCIENCE CORP

**Wrts. Exercise Terms** On Dec. 11, 2018, Co. announced that it has received US\$110,000 from the exercise of warrants previously granted. Co. has received for exercise a total of 250,000 warrants with an exercise price of US\$0.44, previously granted. The warrant exercises were by third parties who are neither an officer nor a director of Co. No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.

#### LIFEPOINT HEALTH INC

**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	4,729,600	4,801,000
Cost & expenses	4,412,800	4,315,400
Operating income	72,900	221,600
Net before taxes	72,900	221,600
Income taxes	100	81,700
<b>Net income</b>	72,800	139,900
Earnings common share		
Primary	\$1.70	\$3.24
Fully Diluted	\$1.66	\$3.16
Common Shares:		
Full Diluted	39,600	41,100
Year-end	38,741	39,585

#### LIGHTWAVE LOGIC INC

**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Cost & expenses	4,374,026	4,032,323
Operating income	(4,374,026)	(4,032,323)
Other income (expense), net	(135,333)	(128,557)
<b>Net income</b>	(4,509,172)	(4,160,693)
Earnings common share		
Primary	\$(0.06)	\$(0.06)
Fully Diluted	\$(0.06)	\$(0.06)
Common Shares:		
Full Diluted	75,694,887	70,128,995
Year-end	77,635,666	72,194,057

#### LINCOLN EDUCATIONAL SERVICES CORP

**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	193,087	194,452
Cost & expenses	202,797	206,942
Operating income	(9,710)	(12,490)
Interest income	25	47
Interest expense	1,743	6,597
Net before taxes	(11,428)	(19,040)
Income taxes	150	150
<b>Net income</b>	(11,578)	(19,190)
Earnings common share		
Primary	\$(0.47)	\$(0.80)
Fully Diluted	\$(0.47)	\$(0.80)
Common Shares:		
Full Diluted	24,387	23,866
Year-end	24,642	

#### LIVEXLIVE MEDIA INC

**Earnings, 6 mos. to Sep 30**(Consol. - \$):

	2018	2017
Total Revenues	15,558,000	80,000
Cost & expenses	30,344,000	5,012,000
Operating income	(19,619,000)	(4,932,000)
Interest expense	1,397,000	1,394,000
Other income (expense), net	(77,000)	
Income contin. oper.		(6,326,000)
<b>Net income</b>	(21,093,000)	(7,117,000)
Earnings common share		
Primary	\$(0.41)	\$(0.20)
Fully Diluted	\$(0.41)	\$(0.20)

Common Shares:		
Full Diluted	51,739,841	35,773,359
Year-end	51,969,385	

#### LOGICBIO THERAPEUTICS INC

**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Cost & expenses	10,566	2,770
Operating income	(10,566)	(2,770)
Other income (expense), net	(158)	49
Net before taxes	(10,522)	(2,734)
Income taxes	38	48
<b>Net income</b>	(10,560)	(2,782)
Balance for common	(14,512)	(4,044)
Earnings common share		
Primary	\$(7.39)	\$(3.07)
Fully Diluted	\$(7.39)	\$(3.07)
Common Shares:		
Full Diluted	1,964	1,319
Year-end	2,176	

#### LPL FINANCIAL HOLDINGS INC.

**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	3,871,358	3,165,039
Cost & expenses	3,237,558	2,687,592
Operating income	430,194	284,680
Other income (expense), net		(22,407)
Net before taxes	430,194	284,680
Income taxes	111,033	109,915
<b>Net income</b>	319,161	174,765
Earnings common share		
Primary	\$3.59	\$1.94
Fully Diluted	\$3.49	\$1.90
Common Shares:		
Full Diluted	91,447	92,027
Year-end	86,709	90,160

#### LUMENTUM HOLDINGS INC

**Earnings, 3 mos. to** (Consol. - \$000):

	09/29/18	09/30/17
Total Revenues	354,100	243,200
Cost & expenses	297,000	240,500
Operating income	57,100	2,700
Interest income	2,700	1,500
Interest expense	5,100	4,400
Other income (expense), net	(1,800)	4,100
Foreign currency	(300)	(400)
Net before taxes	52,600	3,500
Income taxes	5,200	(3,600)
<b>Net income</b>	47,400	7,100
Balance for common	46,100	2,900
Earnings common share		
Primary	\$0.73	\$0.11
Fully Diluted	\$0.72	\$0.04
Common Shares:		
Full Diluted	63,900	64,500
Year-end	63,347	62,006

**Consolidated Balance Sheet Items, as of** (\$000):

	2018	2017
Assets:		
Cash & equivalents	459,400	
Inventories	136,600	
Current assets	1,181,100	
Net property & equip.	318,600	
Total assets	1,645,000	
Liabilities:		
Current liabilities	213,900	
Long-term debt	338,500	
Stockholders' equity	983,500	
Net current assets	967,200	

#### LUMENTUM HOLDINGS INC

**Merger Completed** On Dec. 10, 2018, Co.'s wholly-owned subsidiary, Prota Merger Sub, Inc. ("Merger Sub"), merged with and into Oclaro, Inc. ("Oclaro"), with Oclaro continuing as the surviving corporation. As the result of the merger, each outstanding share of Oclaro common stock, par value \$0.01 per share, other than shares owned by Co., Oclaro and their subsidiaries, was automatically converted into the right to receive the following consideration (collectively, the "Merger Consideration"), without interest: (1) \$5.60 in cash (the "Cash Consideration"); and (2) 0.0636 of a validly issued, fully paid and nonassessable share of Co. common stock, par value \$0.001 per share (the "Stock Consideration") (such ratio, the "Exchange Ratio"). Each Oclaro restricted stock unit award (each, an "Oclaro RSU") that did not

become vested at the Effective Time was converted into a Co. restricted stock unit award (a "Co. RSU") with the same terms and conditions, including vesting, that were applicable to such Oclaro RSU, except that the number of Co. shares subject to Co.'s RSU equals the product of (i) the number of Oclaro shares subject to such Oclaro RSU (with any performance milestones deemed achieved based on the maximum level of achievement) multiplied by (ii) the sum of (A) the Exchange Ratio plus (B) the quotient obtained by dividing the Cash Consideration by \$43.189 (Co.'s average closing price for the 10 trading days ending on Dec. 4, 2018, the third trading day prior to the Closing Date), rounded down to the nearest whole share (such sum, the "Equity Award Exchange Ratio"). Each Oclaro stock option (each, an "Oclaro Option"), whether vested or unvested, was converted into a Co. stock option (a "Co. Option") with the same terms and conditions, including vesting, that were applicable to such Oclaro Option, except that (i) the number of shares subject to the Co. Option equals the product of (A) the number of Oclaro shares subject to such Oclaro Option multiplied by (B) the Equity Award Exchange Ratio, rounded down to the nearest whole share and (ii) the exercise price of Co.'s Option equals (A) the exercise price per share of the Oclaro Option divided by (B) the Equity Award Exchange Ratio, rounded up to the nearest whole cent. Notwithstanding the foregoing, any Oclaro Option that was held by an individual who was not an Oclaro employee as of immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration for each net option share covered by such Oclaro Option, subject to applicable withholding taxes. In addition, each Oclaro restricted stock award ("Oclaro Restricted Stock Award") and Oclaro RSU that became vested as of immediately prior to the Effective Time (including each Oclaro Restricted Stock Award held by a non-employee director) was converted into the right to receive the Merger Consideration in respect of each Oclaro share underlying such award, subject to applicable withholding taxes. Each Oclaro stock appreciation right ("Oclaro SAR") was cancelled and converted into the right to receive a cash amount equal to the product of (i) the number of Oclaro shares subject to the Oclaro SAR multiplied by (ii) the positive difference of (A) the cash equivalent value of the Merger Consideration less (B) the strike price of the Oclaro SAR, subject to applicable withholding taxes.

#### MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC

**Annual Report**

**Consolidated Income Statement, Years Ended (\$000):**

	09/28/18	09/29/17	09/30/16
Revenue	570,398	698,772	544,338
Cost of revenue	324,692	371,888	262,729
Gross profit	245,706	326,884	281,609
Research & development expense	177,713	147,986	107,698
Selling, general & administrative expense	161,673	187,886	145,433
Impairment charges	6,575	4,352	11,765
Restructuring charges	6,265	2,744	3,465
Total operating expenses	352,226	342,968	268,361
Income (loss) from operations	(106,520)	(16,084)	13,248
Warrant liability gain (expense)	27,646	(2,522)	(16,431)
Interest expense, net	31,338	28,855	18,427
Other income (expense)	(45,023)	(2,044)	39
Total other income (expense), net	(48,715)	(33,421)	(34,819)
Income (loss) before income taxes - U.S.	(145,851)	(111,432)	(46,593)
Income (loss) before income taxes - foreign	(9,384)	61,927	25,022
Income (loss) before income taxes	(155,235)	(49,505)	(21,571)
Current income tax expense (benefit) - federal	(6,876)	100	(5,861)
Current income tax expense (benefit) - state	(160)	225	(766)
Current income tax			

expense (benefit) - foreign	1,642	7,307	906
Total current income tax provision (benefit)	(5,394)	7,632	(5,721)
Deferred income tax expense (benefit) - federal	75,428	(42,637)	(8,163)
Deferred income tax expense (benefit) - state	(15,526)	(4,037)	(502)
Deferred income tax expense (benefit) - foreign	(24,652)	(466)	(2,603)
Change in valuation allowance	(51,329)	140,419	(994)
Total deferred income tax provision (benefit)	(16,079)	93,279	(12,262)
Income tax expense (benefit)	(21,473)	100,911	(17,983)
Income (loss) from continuing operations	(133,762)	(150,416)	(3,588)
Income (loss) from discontinued operations	(6,215)	(19,077)	5,022
<b>Net income (loss)</b>	<b>(139,977)</b>	<b>(169,493)</b>	<b>1,434</b>
Warrant liability loss (gain)	27,646	...	...
Net income (loss) attributable to common stockholders	(167,623)	(169,493)	1,434
Weighted average shares outstanding - basic	64,741	60,704	53,364
Weighted average shares outstanding - diluted	65,311	60,704	53,364
Year end shares outstanding	65,179	64,256	53,685
Income (loss) per share from continuing operations - basic	\$(2.07)	\$(2.48)	\$(0.07)
Income (loss) per share from discontinued operations - basic	\$(0.10)	\$(0.31)	\$0.09
Income (loss) per share - basic	\$(2.16)	\$(2.79)	\$0.03
Income (loss) per share from continuing operations - diluted	\$(2.47)	\$(2.48)	\$(0.07)
Income (loss) per share from discontinued operations - diluted	\$(0.10)	\$(0.31)	\$0.09
Income (loss) per share - diluted	\$(2.57)	\$(2.79)	\$0.03
Total number of employees	1,400	1,800	1,400
Number of common stockholders	14	14	13
Foreign currency translation adjustments	(502)	(5,999)	11,320

□ Reclassified to conform with 2018 presentation; □ As is; □ As of November 9, 2018; □ As of November 10, 2017; □ As of November 11, 2016

#### Consolidated Balance Sheet, Years Ended (\$000):

	09/28/18	09/29/17 (revised)
Cash & cash equivalents	94,676	130,104
Short-term investments	98,221	84,121
Accounts receivable, gross	104,170	145,506
Less allowances - accounts receivable	6,795	9,410

Accounts receivable	97,375	136,096
Raw materials	71,408	78,999
Work-in-process	13,466	13,962
Finished goods	37,963	43,113
Inventories	122,837	136,074
Income tax receivable	17,601	18,493
Assets held for sale	4,840	35,571
Prepaid & other current assets	23,311	22,438
Total current assets	458,861	562,897
Construction in process	49,661	22,195
Machinery & equipment	174,638	160,955
Leasehold improvements	14,984	13,809
Furniture & fixtures	2,306	2,078
Capital lease assets	19,380	20,410
Computer equipment & software	17,317	16,539
Total property & equipment	278,286	235,986
Less accumulated depreciation & amortization	128,363	104,967
Property, plant & equipment, net	149,923	131,019
Goodwill	314,076	313,765
Intangible assets, net	512,785	621,092
Deferred income taxes	2,272	948
Other investments	31,094	...
Other long-term assets	13,484	7,402
Total assets	1,482,495	1,637,123
Current portion of lease payable	467	815
Current portion of long-term debt	6,885	6,885
Accounts payable	41,951	47,038
Accrued compensation & benefits	22,935	32,505
Accrued distribution costs	10,670	5,777
Accrued product warranty	5,756	3,672
Accrued professional fees	1,875	2,140
Accrued rent & utilities	1,660	1,257
Accrued contingent consideration	585	1,679
Accrued income taxes payable	415	4,184
Accrued purchase price holdback	375	1,000
Accrued restructuring costs	89	627
Other accrued liabilities	5,585	5,402
Accrued liabilities	49,945	58,243
Liabilities held for sale	...	2,144
Deferred revenue	7,757	1,994
Total current liabilities	107,005	117,119
Lease payable, less current portion	29,023	17,275
Principal balance	679,856	...
Unamortized discount	(4,625)	...
Unamortized deferred financing costs	(9,974)	...
Total term loans	665,257	...
Current portion	6,885	...
Long-term debt, less current portion	658,372	661,471
Warrant liability	13,129	40,775
Other long-term liabilities	5,902	7,937
Deferred income taxes	389	15,172
Total liabilities	813,820	859,749
Common stock	65	64
Treasury stock, at cost	330	330
Foreign currency items	2,637	3,139
Other items	(449)	(162)
Accumulated other comprehensive income (loss)	2,188	2,977
Additional paid-in capital	1,074,728	1,041,644
Retained earnings (accumulated deficit)	(407,976)	(266,981)
Total stockholders' equity (deficit)	668,675	777,374

□ Reclassified to conform with 2018 presentation

#### Recent Dividends:

1. MACOM Technology Solutions Holdings Inc common.

No dividends paid.

#### Annual Dividends:

1. MACOM Technology Solutions Holdings Inc common.

No dividends paid.

#### MANNATECH INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Net Sales	129,534,000	130,324,000
Cost & expenses	127,579,000	127,476,000
Deprec., depl. & amort.	1,521,000	1,379,000
Operating income	434,000	1,469,000
Interest income	212,000	58,000
Other income (expense), net	681,000	209,000
Net before taxes	1,327,000	1,736,000
Income taxes	3,637,000	(193,000)
<b>Net income</b>	<b>(2,310,000)</b>	<b>1,929,000</b>
Earnings common share		
Primary	\$(0.89)	\$0.71
Fully Diluted	\$(0.89)	\$0.69
Common Shares:		
Full Diluted	2,595,000	2,773,000
Year-end	2,381,244	2,708,491

#### MANNKIND CORP

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	11,827	7,215
Cost & expenses	80,692	86,567
Operating income	(68,865)	(79,352)
Interest income	305	178
Other income (expense), net	(694)	4,671
Net before taxes	(76,984)	...
Income taxes	240	...
<b>Net income</b>	<b>(77,224)</b>	<b>(84,549)</b>
Earnings common share		
Primary	\$(0.56)	\$(0.84)
Fully Diluted	\$(0.56)	\$(0.84)
Common Shares:		
Full Diluted	138,307	100,136
Year-end	159,498	...

#### MARCHEX INC

**Acquisition Completed** On Nov. 20, 2018, Co. acquired all the issued and outstanding shares of SITA Laboratories, Inc. (d/b/a CallCap) ("CallCap"), a call monitoring and analytics company, for a purchase price of \$25,000,000 in cash in connection with the closing and \$10,000,000 in value of shares of Class B common stock (the "Common Stock") of Co. calculated based on a 10 day trailing average of Co.'s Common Stock daily closing price on Nasdaq prior to the closing with 25% of such shares of Common Stock to be issued on the first, second, third and fourth annual anniversary of the closing, respectively (the "Share Purchase Agreement").

#### MARCHEX INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	62,120,000	68,444,000
Cost & expenses	64,934,000	74,142,000
Operating income	(2,814,000)	(5,698,000)
Net before taxes	(2,009,000)	(5,564,000)
Income taxes	32,000	37,000
<b>Net income</b>	<b>(2,041,000)</b>	<b>(5,601,000)</b>
Balance for common	(2,041,000)	(5,601,000)
Earnings common share		
Primary	\$(0.05)	\$(0.13)
Fully Diluted	\$(0.05)	\$(0.13)
Common Shares:		
Full Diluted	42,299,000	42,621,000
Year-end	41,854,000	43,669,270

#### MARKETAXESS HOLDINGS INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	323,121	294,862
Cost & expenses	147,270	130,018
Operating income	158,619	150,778
Other income (expense), net	(785)	(932)
Gains or losses	4,186	2,551
Net before taxes	162,020	152,397
Income taxes	34,999	37,781

Net income	127,021	114,616
Earnings common share		
Primary	\$3.44	\$3.11
Fully Diluted	\$3.36	\$3.01
Common Shares:		
Full Diluted	37,859	38,069
Year-end	37,597	37,548

translation adjustments	(21,982)	9,471	...
<sup>1</sup> Reclassified to conform with 2018 presentation; <sup>2</sup> As is; <sup>3</sup> As of October 31, 2018; <sup>4</sup> Approximately; <sup>5</sup> As of October 31, 2017; <sup>6</sup> As of October 31, 2016			

**Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):**

	2018	2017	2016
		(revised)	(revised)
Cash & cash equivalents	41,572	57,515	
Accounts receivable, gross	342,621	331,188	
Allowance for doubtful accounts	11,158	11,622	
Accounts receivable, net	331,463	319,566	
Raw materials	34,880	29,396	
Work in process	67,827	61,917	
Finished goods	77,744	80,132	
Inventories, net	180,451	171,445	
Other current assets	62,937	46,533	
Total current assets	616,423	595,059	
Investments	45,430	37,667	
Buildings	113,027	104,604	
Machinery & equipment	452,846	412,980	
Less accumulated depreciation	357,827	335,346	
Land	18,017	16,845	
Construction in progress	26,712	36,450	
Property, plant & equipment, net	252,775	235,533	
Deferred income taxes	1,837	2,456	
Other assets	66,216	51,758	
Goodwill	948,894	897,794	
Other intangible assets, net	443,910	424,382	
Total assets	2,375,485	2,244,649	
Long-term debt, current maturities	31,260	29,528	
Trade accounts payable	70,044	66,607	
Accrued compensation	51,490	62,210	
Accrued income taxes	11,413	21,386	
Other current liabilities	139,936	105,401	
Total current liabilities	304,143	285,132	
Revolving credit facilities	322,711	551,126	
Securitization facility	102,250	95,825	
Senior secured term loan	212,086	232,479	
2025 senior notes	296,176	...	
Notes payable to banks	17,895	21,831	
Short-term borrowings	4,915	4,735	
Capital lease obligations	4,569	5,134	
Less current maturities	31,260	29,528	
Long-term debt	929,342	881,602	
Accrued pension	82,035	103,273	
Postretirement benefits	17,753	19,273	
Deferred income taxes	121,519	139,430	
Other liabilities	51,979	25,680	
Total liabilities	1,506,771	1,454,390	
Class A common stock	36,334	36,334	
Additional paid-in capital	129,252	123,432	
Retained earnings	1,040,378	948,830	
Cumulative foreign currency translation	(134,960)	(112,907)	
Fair value of derivatives, net	<sup>1</sup> 8,538	<sup>2</sup> 2,415	
Minimum pension liabilities, net	<sup>3</sup> (37,876)	<sup>4</sup> (43,623)	
Accumulated other comprehensive income (loss)	(164,298)	(154,115)	
Treasury stock, at cost	173,315	164,774	
Total shareholders' equity - Matthews International Corporation	868,351	789,707	
Noncontrolling interests	363	552	
Total shareholders' equity	868,714	790,259	
<sup>1</sup> Net of tax - Fair value of derivatives: \$2,771,000; <sup>2</sup> Net of tax - Fair value of derivatives: 1,544,000; <sup>3</sup> Net of tax - Minimum pension liability: \$12,076,000; <sup>4</sup> Net of tax - Minimum pension liability: \$27,114,000			

**Recent Dividends:**

**1. Matthews International Corp class A common.**

No dividends paid.

**Annual Dividends:**

**1. Matthews International Corp class A common.**

No dividends paid.

**MEDICINOVA INC**

**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
		(revised)
Cost & expenses	15,094,577	9,620,047
Operating income	(15,094,577)	(9,620,047)
Interest income	650,013	81,709
Other income (expense), net	(19,014)	(13,783)
Net before taxes	(14,463,578)	(9,552,121)
Income taxes	3,570	8,144
<b>Net income</b>	(14,467,148)	(9,560,265)
Balance for common	(14,467,148)	(9,560,265)
Earnings common share		
Primary	\$(0.35)	\$(0.27)
Fully Diluted	\$(0.35)	\$(0.27)
Common Shares:		
Full Diluted	40,866,343	34,778,921
Year-end	41,881,306	35,672,265

**MEDIDATA SOLUTIONS, INC.**

**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
		(revised)
Total Revenues	468,509	402,616
Cost & expenses	428,227	354,819
Operating income	40,282	47,797
Interest income	6,544	4,030
Interest expense	14,422	13,117
Other income (expense), net	7,244	(7)
Net before taxes	39,648	38,703
Income taxes	2,046	8,139
<b>Net income</b>	37,602	30,564
Earnings common share		
Primary	\$0.65	\$0.54
Fully Diluted	\$0.62	\$0.51
Common Shares:		
Full Diluted	61,002	59,664
Year-end	61,194	...

**MERCER INTERNATIONAL INC**

**Acquisition Completed** On Dec. 10, 2018, Co. through its subsidiary acquired all of the issued and outstanding shares of Daishowa-Marubeni International Ltd. The total cash consideration paid by Co. in connection with the completion of the acquisition, including estimated net working capital of approximately \$77,900,000 (C\$104,200,000), was approximately \$344,700,000 (C\$461,100,000).

**MERIDIAN BIOSCIENCE INC.**

**Annual Report**

**Consolidated Income Statement, Years Ended Sept. 30 (\$):**

	2018	2017	2016
		(revised)	(revised)
Net revenues	213,571,000	200,771,000	196,082,000
Cost of sales	83,110,000	76,479,000	68,870,000
Gross profit (loss)	130,461,000	124,292,000	127,212,000
Research & development expenses	16,870,000	16,036,000	14,191,000
Selling & marketing expenses	34,468,000	32,388,000	30,056,000
General & administrative expenses	34,488,000	31,096,000	29,429,000
Restructuring costs	8,706,000	134,000	677,000
Litigations costs	4,345,000	628,000	...
Goodwill impairment charge	...	6,628,000	...
Acquisition-related costs	...	...	1,481,000
Total operating expenses	98,877,000	86,910,000	75,834,000
Operating income (loss)	31,584,000	37,382,000	51,378,000
Interest income	418,000	171,000	67,000
Interest expense	1,520,000	1,642,000	897,000
Other income (expense), net	(102,000)	518,000	96,000
Total other income (expense)	(1,204,000)	(953,000)	(734,000)
Earnings (loss)	...	...	...

before income taxes			
- domestic	27,787,000	31,885,000	44,795,000
Earnings (loss)			
before income taxes			
- foreign	2,593,000	4,544,000	5,849,000
Earnings (loss)			
before income taxes	30,380,000	36,429,000	50,644,000
Federal income taxes provision (credit)	5,067,000	12,169,000	15,046,000
State & local income taxes provision (credit)	1,066,000	1,900,000	2,421,000
Foreign income taxes provision (credit)	398,000	803,000	948,000
Income tax provision (credit)	6,531,000	14,872,000	18,415,000
<b>Net earnings (loss)</b>	<b>23,849,000</b>	<b>21,557,000</b>	<b>32,229,000</b>
Weighted average shares outstanding			
- basic	42,325,000	42,188,000	42,010,000
Weighted average shares outstanding - diluted	42,754,000	42,571,000	42,393,000
Year end shares outstanding	42,399,962	42,207,317	42,106,587
Net earnings (loss) per share - basic	\$0.56	\$0.51	\$0.77
Net earnings (loss) per share - diluted	\$0.56	\$0.51	\$0.76
Dividends per common share	\$0.50	\$0.57	\$0.80
Total number of employees	585	640	650
Number of common stockholders	635	675	525
Number of beneficiary stockholders	13,200	15,200	17,700
Foreign currency translation adjustments	(1,075,000)	1,616,000	(2,732,000)

<sup>□</sup> Reclassified to conform with 2018 presentation; <sup>□</sup> Approximately

### Consolidated Balance Sheet, Years Ended Sept. 30 (\$):

	2018	2017
Cash & equivalents	59,763,000	57,072,000
Accounts receivable, gross	32,646,000	29,413,000
Less allowances	310,000	307,000
Accounts receivable, net	32,336,000	29,106,000
Raw materials	6,689,000	6,575,000
Work-in-process	12,098,000	11,559,000
Finished goods - instruments	1,191,000	1,460,000
Finished goods - kits & reagents	22,015,000	21,899,000
Inventories	41,993,000	41,493,000
Prepaid expenses & other current assets	4,961,000	6,204,000
Total current assets	139,053,000	133,875,000
Land	1,160,000	1,162,000
Buildings & improvements	32,444,000	32,207,000
Machinery, equipment & furniture	50,606,000	48,836,000
Construction in progress	1,631,000	1,895,000
Subtotal	85,841,000	84,100,000
Less: accumulated depreciation & amortization	55,846,000	53,590,000
Net property, plant & equipment	29,995,000	30,510,000
Goodwill	54,637,000	54,926,000
Other intangible assets, net	23,113,000	26,704,000
Restricted cash	1,000,000	1,000,000
Deferred instrument costs, net	1,239,000	1,368,000
Fair value of interest rate swap	1,722,000	815,000

Deferred income taxes	130,000	158,000
Other assets	488,000	421,000
Total assets	251,377,000	249,777,000
Accounts payable	6,260,000	7,719,000
Accrued employee compensation costs	7,263,000	4,536,000
Current portion of acquisition consideration	...	2,095,000
Other accrued expenses	5,065,000	2,789,000
Current portion of long-term debt	5,250,000	4,500,000
Income taxes payable	335,000	1,248,000
Total current liabilities	24,173,000	22,887,000
Acquisition consideration	...	235,000
Post-employment benefits	2,646,000	2,468,000
Long-term debt	44,930,000	50,147,000
Long-term income taxes payable	441,000	...
Deferred income taxes	3,769,000	4,455,000
Total non-current liabilities	51,786,000	57,305,000
Additional paid-in capital	129,193,000	125,608,000
Retained earnings (accumulated deficit)	49,602,000	46,923,000
Accumulated other comprehensive income (loss)	(3,377,000)	(2,946,000)
Total shareholders' equity	175,418,000	169,585,000

### Recent Dividends:

#### 1. Meridian Bioscience Inc. common.

ExDate	Amt	Declared	Record	Payable
01/29/2015	0.20	01/21/2015	02/02/2015	02/13/2015
04/30/2015	0.20	04/23/2015	05/04/2015	05/14/2015
07/30/2015	0.20	07/23/2015	08/03/2015	08/13/2015
11/12/2015	0.20	11/04/2015	11/16/2015	11/27/2015
02/04/2016	0.20	01/27/2016	02/08/2016	02/18/2016
05/05/2016	0.20	04/28/2016	05/09/2016	05/19/2016
08/04/2016	0.20	07/28/2016	08/08/2016	08/18/2016
11/17/2016	0.20	11/10/2016	11/21/2016	12/01/2016
02/02/2017	0.13	01/25/2017	02/06/2017	02/16/2017
05/04/2017	0.13	04/27/2017	05/08/2017	05/18/2017
08/03/2017	0.13	07/27/2017	08/07/2017	08/17/2017
11/17/2017	0.13	11/09/2017	11/20/2017	11/30/2017
02/02/2018	0.13	01/25/2018	02/05/2018	02/15/2018
05/04/2018	0.13	04/26/2018	05/07/2018	05/17/2018
08/09/2018	0.13	07/24/2018	08/10/2018	08/20/2018
11/16/2018	0.13	11/08/2018	11/19/2018	11/30/2018

### Annual Dividends:

#### 1. Meridian Bioscience Inc. common.

2015	0.80	2016	0.80	2017	0.50
2018	0.50				

### MERSANA THERAPEUTICS INC

#### Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	9,405	14,284
Cost & expenses	52,279	39,551
Interest income	1,049	527
<b>Net income</b>	<b>(41,825)</b>	<b>(24,740)</b>
Balance for common	(41,825)	(24,740)
Earnings common share		
Primary	\$(1.82)	\$(2.94)
Fully Diluted	\$(1.82)	\$(2.94)
Common Shares:		
Full Diluted	22,980	8,408
Year-end	23,161	...

### MESA LABORATORIES, INC.

#### Earnings, 6 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	50,007,000	45,627,000
Cost & expenses	44,105,000	39,997,000
Operating income	5,902,000	5,630,000
Other income (expense), net	(196,000)	(1,221,000)
Net before taxes	5,706,000	4,409,000
Income taxes	482,000	539,000
<b>Net income</b>	<b>5,224,000</b>	<b>3,870,000</b>
Balance for common	5,224,000	3,870,000

Earnings common share		
Primary	\$1.36	\$1.03
Fully Diluted	\$1.30	\$0.98
Common Shares:		
Full Diluted	4,029,000	3,934,000
Year-end	3,852,747	3,779,717

### MICHAELS COMPANIES INC

#### Earnings, 9 mos. to (Consol. - \$000):

	11/03/18	10/28/17
Net Sales	3,482,835	3,471,352
Cost & expenses	3,192,454	3,090,253
Operating income	290,381	381,099
Other income (expense), net	811	(950)
Net before taxes	181,699	285,844
Income taxes	43,557	98,314
<b>Net income</b>	<b>138,142</b>	<b>187,530</b>
Earnings common share		
Primary	\$0.79	\$1.01
Fully Diluted	\$0.78	\$1.00
Common Shares:		
Full Diluted	175,851	186,775
Year-end	158,616	158,616

### MICRON TECHNOLOGY INC.

#### Earnings, 3 mos. to (Consol. - \$000):

	11/29/18	11/30/17
Cost & expenses	4,154,000	3,706,000
Operating income	3,759,000	3,097,000
Other income (expense), net	14,000	(195,000)
Foreign currency	(5,000)	(9,000)
Net before taxes	3,773,000	2,792,000
Income taxes	477,000	114,000
<b>Net income</b>	<b>3,296,000</b>	<b>2,678,000</b>
Earnings common share		
Primary	\$2.91	\$2.36
Fully Diluted	\$2.81	\$2.19
Common Shares:		
Full Diluted	1,174,000	1,225,000
Year-end	1,120,000	1,158,000

### Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	4,447,000
Inventories	3,876,000
Current assets	15,039,000
Net property & equip.	24,807,000
Total assets	44,595,000
Liabilities:	
Current liabilities	5,189,000
Long-term debt	3,734,000
Stockholders' equity	33,869,000
Net current assets	9,850,000

### MICROSTRATEGY INC.

#### Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	365,721	367,462
Cost & expenses	359,583	311,377
Operating income	6,138	56,085
Interest income	8,698	3,449
Other income (expense), net	3,665	(6,377)
Net before taxes	18,501	53,157
Income taxes	(699)	9,463
<b>Net income</b>	<b>19,200</b>	<b>43,694</b>
Earnings common share		
Primary	\$1.68	\$3.82
Fully Diluted	\$1.67	\$3.78
Common Shares:		
Full Diluted	11,502	11,567
Year-end	11,467	...

### MIDWEST HOLDING INC

#### Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	1,837,132	3,220,884
Cost & expenses	5,217,200	5,406,896
Operating income	(3,641,803)	(2,504,161)
<b>Net income</b>	<b>(3,641,803)</b>	<b>(2,504,161)</b>
Earnings common share		
Primary	\$(0.16)	\$(0.11)
Fully Diluted	\$(0.16)	\$(0.11)
Common Shares:		
Full Diluted	22,873,764	22,763,160
Year-end	22,873,764	22,764,294

**MINERVA NEUROSCIENCES INC**

<b>Earnings, 9 mos. to Sep 30(Consol. - \$):</b>		
	2018	2017
Cost & expenses	38,102,381	31,637,670
Operating income	(38,102,381)	(31,637,670)
Interest expense	110,448	509,526
Gains or losses	1,244,196	508,116
Foreign currency	178	(46,215)
<b>Net income</b>	<b>(36,968,455)</b>	<b>(31,685,295)</b>
Earnings common share		
Primary	\$(0.95)	\$(0.84)
Fully Diluted	\$(0.95)	\$(0.84)
Common Shares:		
Full Diluted	38,760,294	37,676,686
Year-end	38,846,467	38,700,693

**MIRATI THERAPEUTICS INC**

<b>Earnings, 9 mos. to Sep 30(Consol. - \$000):</b>		
	2018	2017
Total Revenues	9,467	
Cost & expenses	82,422	53,307
Operating income	(72,955)	(53,307)
Other income (expense), net	2,809	772
<b>Net income</b>	<b>(70,146)</b>	<b>(52,535)</b>
Earnings common share		
Primary	\$(2.31)	\$(2.12)
Fully Diluted	\$(2.31)	\$(2.12)
Common Shares:		
Full Diluted	30,350	24,770
Year-end	32,516	24,978

**MISONIX, INC.**

<b>Earnings, 3 mos. to Sep 30(Consol. - \$):</b>		
	2018	2017
Total Revenues	9,361,164	7,280,723
Cost & expenses	11,973,698	9,222,473
Operating income	(2,612,534)	(1,941,750)
Other income (expense), net	(18,265)	448,513
Net before taxes		(1,493,224)
Income taxes		(281,000)
<b>Net income</b>	<b>(2,610,986)</b>	<b>(1,212,224)</b>
Earnings common share		
Primary	\$(0.29)	\$(0.14)
Fully Diluted	\$(0.29)	\$(0.14)
Common Shares:		
Full Diluted	9,100,123	8,958,405
Year-end	9,481,251	9,365,666

**Consolidated Balance Sheet Items, as of (\$):**

<b>Assets:</b>		2018
Cash & equivalents		9,322,811
Inventories		4,920,350
Current assets		20,361,746
Net property & equip.		4,346,826
Total assets		28,611,347
<b>Liabilities:</b>		
Current liabilities		4,427,607
Stockholders' equity		24,170,437
Net current assets		15,934,139

**MITCHAM INDUSTRIES INC**

<b>Earnings, 9 mos. to Oct 31(Consol. - \$000):</b>		
	2018	2017
Total Revenues	30,614	37,913
Cost & expenses	39,295	48,345
Operating income	(10,497)	(12,054)
Other income (expense), net	(57)	(107)
Gains or losses	(4,905)	
Net before taxes	(15,412)	(12,138)
Income taxes	273	1,172
<b>Net income</b>	<b>(15,685)</b>	<b>(13,310)</b>
Balance for common	(16,930)	(13,940)
Earnings common share		
Primary	\$(1.40)	\$(1.15)
Fully Diluted	\$(1.40)	\$(1.15)
Common Shares:		
Full Diluted	12,100	12,082
Year-end	12,120	12,090

**MONROE CAPITAL CORP**

<b>Earnings, 9 mos. to Sep 30(Consol. - \$000):</b>		
	2018	2017
Cost & expenses	19,452	18,734
<b>Net income</b>	<b>24,097</b>	<b>19,009</b>
Earnings common share		

Primary	\$1.19	\$1.05
Fully Diluted	\$1.19	\$1.05
Common Shares:		
Full Diluted	20,301	18,081
Year-end	20,445	20,240

**MORNINGSTAR INC**

<b>Earnings, 9 mos. to Sep 30(Consol. - \$000):</b>		
	2018	2017
Total Revenues	757,200	668,600
Cost & expenses	519,500	476,600
Deprec., depl. & amort.	71,200	64,800
Operating income	166,500	127,200
Other income (expense), net	2,200	(4,000)
Gains or losses	11,400	18,600
Invest. income	5,600	
Equity earnings	1,600	1,000
Net before taxes	184,500	139,200
Income taxes	42,300	40,200
<b>Net income</b>	<b>140,600</b>	<b>98,000</b>
Earnings common share		
Primary	\$3.30	\$2.29
Fully Diluted	\$3.27	\$2.28
Common Shares:		
Full Diluted	43,000	43,100
Year-end	42,671	42,530

**MR AMAZING LOANS CORP**

<b>Earnings, 9 mos. to Sep 30(Consol. - \$):</b>		
	2018	2017
Total Revenues	1,062,835	1,288,694
Cost & expenses	2,885,371	3,759,266
Operating income	(1,826,810)	(2,475,067)
Other income (expense), net	108	(623,920)
Gains or losses	(194)	(153,514)
<b>Net income</b>	<b>(1,826,896)</b>	<b>(3,252,501)</b>
Balance for common	(1,826,896)	(3,252,501)
Earnings common share		
Primary	\$(0.10)	\$(0.30)
Fully Diluted	\$(0.10)	\$(0.30)
Common Shares:		
Full Diluted	17,459,974	10,901,436
Year-end	17,226,283	12,335,293

**MTS SYSTEMS CORP****Annual Report**

<b>Consolidated Income Statement, Years Ended (\$000):</b>			
	09/29/18	09/30/17	10/01/16
		(revised)	(revised)
Revenue - product	674,391	691,471	562,340
Revenue - service	103,641	96,484	87,807
Total revenue	778,032	787,955	650,147
Cost of sales - product	409,525	427,405	365,401
Costs of sales - service	62,978	58,272	53,342
Total cost of sales	472,503	485,677	418,743
Gross profit	305,529	302,278	231,404
Selling & marketing expenses	126,333	124,912	94,992
General & administrative expenses	79,240	87,539	69,313
Research & development expenses	34,784	34,999	25,336
Income (loss) from operations	65,172	54,828	41,763
Interest income (expense), net	(25,882)	(30,821)	(8,489)
Other income (expense), net	4,933	(996)	238
Income before income taxes - Domestic	6,139	(9,658)	5,345
Income before income taxes - Foreign	38,084	32,669	28,167
Income before income taxes	44,223	23,011	33,512
Current provision (benefit) for income taxes - federal	1,613	(1,493)	3,169

Current provision for income taxes - state	565	156	138
Current provision for income taxes - foreign	10,331	11,980	6,712
Deferred provision (benefit) for income taxes	(29,614)	(12,716)	(4,001)
Provision for income taxes	(17,105)	(2,073)	6,018
<b>Net income (loss)</b>	<b>61,328</b>	<b>25,084</b>	<b>27,494</b>
Weighted average shares outstanding - basic	19,163	19,040	16,027
Weighted average shares outstanding - diluted	19,293	19,137	16,179
Year end shares outstanding	17,856	17,760	16,660
Net income (loss) per share - basic	\$3.20	\$1.32	\$1.72
Net income (loss) per share - diluted	\$3.18	\$1.31	\$1.70
Cash dividends paid per common share	\$1.20	\$1.20	\$1.20
Total number of employees	3,400	3,500	3,500
Number of common stockholders	644	675	708
Foreign currency translation adjustments	(2,174)	3,273	(332)

□ As is; □ Approximately; □ As of November 21, 2018; □ As of November 22, 2017; □ As of April 6, 2017

**Consolidated Balance Sheet, Years Ended (\$000):**

	09/29/18	09/30/17
		(revised)
Cash & cash equivalents	71,804	108,733
Accounts receivable, gross	127,247	129,365
Less: allowance for doubtful accounts	5,004	5,371
Unbilled accounts receivable	70,474	76,914
Components, assemblies & parts	93,020	86,991
Customer projects in various stages of completion	35,675	30,225
Finished goods	10,414	10,512
Inventories	139,109	127,728
Prepaid expenses & other current assets	24,572	19,880
Total current assets	428,202	457,249
Land & improvements	2,881	2,867
Buildings & improvements	58,880	60,340
Machinery & equipment	203,647	196,621
Assets held under capital leases	2,815	2,747
Property & equipment, gross	268,223	262,575
Accumulated depreciation	177,954	162,645
Property & equipment, net	90,269	99,930
Goodwill	369,275	369,762
Other intangibles, gross	301,217	296,643
Less: accumulated amortization - other intangibles	55,079	41,564
Intangible assets, net	246,138	255,079
Other long-term assets	2,263	4,116
Deferred income taxes	3,249	3,556
Total assets	1,139,396	1,189,692
Current maturities of long-term debt	32,738	39,095
Accounts payable	47,886	47,515
Accrued payroll & related costs	43,554	49,434
Advance payments from customers	80,131	76,712
Accrued warranty costs	5,418	6,018

Accrued income taxes	4,928	4,464
Accrued dividends	5,312	5,278
Other accrued liabilities	19,146	18,873
Total current liabilities	239,113	247,389
Unsecured notes	398,706	471,843
Capital lease obligations	2,000	2,466
Total long-term debt	400,706	474,309
Less: Unamortized		
underwriting discounts,		
commissions & other		
expenses	(8,623)	(12,491)
Less: Current maturities		
of long-term Tranche B		
term loan debt	(28,600)	(33,600)
Less: Current maturities		
of long-term TEU debt	(7,290)	(9,152)
Less: current maturities		
of capital lease		
obligations	(553)	(522)
Long-term debt, less		
current maturities	355,640	418,544
Non-current deferred		
income taxes	46,482	74,981
Non-current accrued		
income taxes	6,158	5,855
Defined benefit pension		
plan obligation	9,177	8,588
Other long-term		
liabilities	4,894	5,558
Total liabilities	661,464	760,915
Common stock	4,464	4,440
Additional paid-in		
capital	171,407	163,632
Retained earnings		
(accumulated deficit)	300,585	261,258
Foreign currency		
translation adjustment	1,772	3,946
Unrealized derivative		
instrument adjustments	6,320	1,953
Defined pension benefit		
plan adjustments	(6,616)	(6,452)
Accumulated other		
comprehensive income		
(loss)	1,476	(553)
Total shareholders'		
investment	477,932	428,777

□ Reclassified to conform with 2018 presentation

#### Recent Dividends:

##### 1. MTS Systems Corp common.

ExDate	Amt	Declared	Record	Payable
03/12/2015	0.30	02/09/2015	03/16/2015	03/30/2015
06/11/2015	0.30	06/02/2015	06/15/2015	06/29/2015
09/10/2015	0.30	07/21/2015	09/14/2015	09/28/2015
12/10/2015	0.30	11/17/2015	12/14/2015	12/28/2015
03/17/2016	0.30	02/08/2016	03/21/2016	04/04/2016
06/16/2016	0.30	05/24/2016	06/20/2016	07/05/2016
09/15/2016	0.30	07/28/2016	09/19/2016	10/03/2016
12/15/2016	0.30	11/15/2016	12/19/2016	01/03/2017
03/16/2017	0.30	02/06/2017	03/20/2017	04/03/2017
06/21/2017	0.30	06/07/2017	06/23/2017	07/07/2017
09/15/2017	0.30	07/31/2017	09/18/2017	10/02/2017
12/15/2017	0.30	11/14/2017	12/18/2017	01/02/2018
03/16/2018	0.30	02/12/2018	03/19/2018	04/02/2018
06/21/2018	0.30	06/06/2018	06/22/2018	07/06/2018
09/14/2018	0.30	08/03/2018	09/17/2018	10/01/2018

#### Annual Dividends:

##### 1. MTS Systems Corp common.

2015	1.20	2016	0.90	2017	1.20
2018	1.20				

#### MUELLER (PAUL) CO

##### Earnings, 6 mos. to Jun 30(Consol. – \$000):

	2018	2017
Net Sales	108,783	77,241
Cost & expenses	105,359	75,966
Operating income	3,424	1,275
Interest expense	551	111
Other income (expense), net	(595)	(207)
Net before taxes	2,278	957
Net income	1,955	510

Earnings common share		
Primary	\$1.63	\$0.43
Fully Diluted	\$1.63	\$0.43
Common Shares:		
Year-end	1,196	1,196

#### MUELLER (PAUL) CO

##### Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	155,592	125,512
Cost & expenses	151,299	121,295
Operating income	4,293	4,217
Interest expense	733	248
Other income (expense), net	28	(35)
Net before taxes	3,588	3,934
Net income	2,779	2,316
Earnings common share		
Primary	\$2.32	\$1.94
Fully Diluted	\$2.32	\$1.94
Common Shares:		
Year-end	1,196	1,196

#### MUSTANG BIO INC

##### Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	19,373	16,056
Operating income	(19,323)	(16,056)
Interest income	431	369
Net income	(18,892)	(15,687)
Earnings common share		
Primary	\$(0.70)	\$(0.63)
Fully Diluted	\$(0.70)	\$(0.63)
Common Shares:		
Full Diluted	26,872	24,937
Year-end	27,264	27,264

#### NANOMETRICS, INC.

##### Earnings, 9 mos. to (Consol. – \$000):

	09/29/18	09/30/17
Total Revenues	247,507	180,416
Cost & expenses	191,888	156,772
Operating income	55,619	23,644
Interest income	8	6
Interest expense	253	84
Other income (expense), net	508	330
Net before taxes	55,882	23,896
Income taxes	10,258	4,492
Net income	45,624	19,404
Earnings common share		
Primary	\$1.90	\$0.77
Fully Diluted	\$1.86	\$0.75
Common Shares:		
Full Diluted	24,551	25,933
Year-end	24,216	25,567

#### NAPCO SECURITY TECHNOLOGIES, INC.

##### Earnings, 3 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	21,617	20,115
Operating income	1,759	1,059
Interest expense	7	26
Net before taxes	1,752	1,033
Income taxes	248	143
Net income	1,504	890
Earnings common share		
Primary	\$0.08	\$0.05
Fully Diluted	\$0.08	\$0.05
Common Shares:		
Full Diluted	18,776	18,879
Year-end	18,692	18,849

#### Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	7,469	7,469
Inventories	25,158	25,158
Current assets	56,861	56,861
Net property & equip.	6,969	6,969
Total assets	77,248	77,248
Liabilities:		
Current liabilities	13,125	13,125
Stockholders' equity	63,709	63,709
Net current assets	43,736	43,736

#### NATIONAL BEVERAGE CORP.

##### Earnings, 6 mos. to (Consol. – \$000):

	10/27/18	10/28/17
Net Sales	553,299	503,951
Cost & expenses	436,195	394,998
Operating income	117,104	108,953
Net before taxes	117,104	108,953
Income taxes	27,196	36,701
Net income	89,908	72,252
Earnings common share		
Primary	\$1.93	\$1.55
Fully Diluted	\$1.92	\$1.54
Common Shares:		
Full Diluted	46,923	46,921
Year-end	46,637	46,601

#### NATIONAL COMMERCE CORP

##### Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	87,986	63,082
Operating income	43,610	30,509
Net before taxes	43,610	30,509
Income taxes	10,119	9,950
Net income	33,491	20,559
Earnings common share		
Primary	\$1.75	\$1.42
Fully Diluted	\$1.71	\$1.38
Common Shares:		
Full Diluted	18,562	13,854
Year-end	20,650	14,777

#### NATIONAL INSTRUMENTS CORP.

##### Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	999,033	939,635
Cost & expenses	887,975	851,169
Operating income	111,058	88,466
Interest income	3,845	1,509
Other income (expense), net	169	(957)
Foreign currency	(2,082)	1,624
Net before taxes	112,990	90,642
Income taxes	14,474	13,949
Net income	98,516	76,693
Earnings common share		
Primary	\$0.75	\$0.59
Fully Diluted	\$0.74	\$0.59
Common Shares:		
Full Diluted	133,067	131,050
Year-end	132,433	130,745

#### NATIONAL VISION HOLDINGS INC

##### Earnings, 9 mos. to (Consol. – \$000):

	09/29/18	09/30/17
Total Revenues	1,180,932	1,053,489
Cost & expenses	1,062,631	939,031
Operating income	64,221	70,054
Interest expense	28,144	40,965
Other income (expense), net		(2,702)
Net before taxes	36,077	26,387
Income taxes	(7,863)	9,267
Net income	43,940	17,120
Earnings common share		
Primary	\$0.58	\$0.30
Fully Diluted	\$0.56	\$0.29
Common Shares:		
Full Diluted	78,571	58,281
Year-end	77,082	56,477

#### NATURAL ALTERNATIVES INTERNATIONAL, INC.

##### Earnings, 3 mos. to Sep 30(Consol. – \$):

	2018	2017
Net Sales	36,532,000	28,074,000
Cost & expenses	33,808,000	26,191,000
Operating income	2,724,000	1,883,000
Interest income	555,000	250,000
Interest expense	3,000	
Other income (expense), net	23,000	1,000
Foreign currency	(78,000)	(143,000)
Net before taxes	3,221,000	1,991,000
Income taxes	662,000	557,000
Net income	2,559,000	1,434,000
Earnings common share		
Primary	\$0.38	\$0.22
Fully Diluted	\$0.37	\$0.21
Common Shares:		
Full Diluted	6,964,942	6,831,230
Year-end	7,577,735	7,436,284

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	27,613,000	
Inventories	24,972,000	
Current assets	69,905,000	
Net property & equip.	19,277,000	
Total assets	90,102,000	
Liabilities:		
Current liabilities	15,420,000	
Stockholders' equity	71,876,000	
Net current assets	54,485,000	

**NCS MULTISTAGE HOLDINGS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	176,775	151,450
Cost & expenses	141,824	121,354
Operating income	21,663	9,561
Interest expense	1,382	3,751
Other income (expense), net	68	1,132
Foreign currency	(399)	224
Net before taxes	19,950	7,166
Income taxes	3,137	2,022
Net income	16,813	5,144
Balance for common	12,738	5,221
Earnings common share		
Primary	\$0.29	\$0.13
Fully Diluted	\$0.28	\$0.13
Common Shares:		
Full Diluted	47,254	42,537
Year-end	45,011	43,912

**NEON THERAPEUTICS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	54,927	33,454
Operating income	(54,927)	(33,454)
Interest expense	1,136	394
Other income (expense), net	(20)	
Net income	(53,811)	(33,060)
Balance for common	(60,182)	(40,569)
Earnings common share		
Primary	\$(5.55)	\$(25.33)
Fully Diluted	\$(5.55)	\$(25.33)
Common Shares:		
Full Diluted	10,834	1,602
Year-end	28,313	

**NETWORK CN INC.****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	277,940	263,366
Operating income	(277,940)	(263,366)
Interest expense	423,796	405,950
Other income (expense), net	107,500	
Net income	(594,236)	(669,316)
Earnings common share		
Primary	\$(0.07)	\$(0.08)
Fully Diluted	\$(0.07)	\$(0.08)
Common Shares:		
Full Diluted	8,393,842	8,041,995
Year-end	8,575,395	8,041,995

**NEWMARK GROUP INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,415,888	1,135,874
Cost & expenses	1,204,896	950,662
Deprec., depl. & amort.	68,587	71,377
Operating income	205,964	194,030
Other income (expense), net	99,059	75,956
Net before taxes	205,964	194,030
Income taxes	53,625	3,396
Net income	152,339	190,634
Balance for common	88,973	190,663
Earnings common share		
Primary	\$0.56	\$0.56
Fully Diluted	\$0.56	\$0.56
Common Shares:		
Full Diluted	185,559	
Year-end	154,779	

**NEWMARK GROUP INC**

**Spin-Off Completed** On Nov. 30, 2018, Co. announced that BGC Partners, Inc. ("BGC Partners" or "BGC") had completed its previously announced distribution of all of the shares of Co. held by BGC to stockholders of BGC. BGC distributed these Co. shares through a special pro rata stock dividend (the "Spin-Off" or the "Distribution"). Based on the number of shares of BGC Partners Class A common stock outstanding as of the close of business on Nov. 23, 2018 (the "Record Date"), stockholders of BGC Partners Class A common stock received 0.463895 of a share of Co. Class A common stock in the Distribution for every one share of BGC Partners Class A common stock held as of the Record Date.2 Following the Spin-Off, BGC no longer held any shares of Co.

**NEWTEK BUSINESS SERVICES CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	40,852	33,171
Deprec., depl. & amort.	358	292
Net income	(6,353)	(4,965)
Earnings common share		
Primary	\$(0.34)	\$(0.29)
Common Shares:		
Year-end	18,849	

**NEXSTAR MEDIA GROUP INC**

**Acquisition Development** On Dec. 3, 2018, Co. announced that it will acquire all outstanding shares of Tribune Media Co. ("Tribune Media"), a company that engaged in the media and entertainment business for \$46.50 per share in a cash transaction that is valued at \$6,400,000,000 including the assumption of Tribune Media's outstanding debt.

**NLIGHT INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	145,197	101,098
Cost & expenses	130,353	93,991
Operating income	14,844	7,107
Other income (expense), net	(503)	(1,840)
Net before taxes	14,414	4,220
Income taxes	2,836	3,476
Net income	11,578	744
Balance for common	7,163	
Earnings common share		
Primary	\$0.34	\$0.27
Fully Diluted	\$0.27	\$0.27
Common Shares:		
Full Diluted	26,138	2,660
Year-end	36,356	

**NORTHERN TECHNOLOGIES INTERNATIONAL CORP.****Annual Report****Consolidated Income Statement, Years Ended Aug. 31 (\$):**

	2018	2017	<sup>1</sup> 2016
		(revised)	(revised)
Net sales, excluding joint ventures	48,516,749	36,346,645	30,211,660
Net sales, to joint ventures	2,908,072	3,222,478	2,721,905
Total net sales	51,424,821	39,569,123	32,933,565
Cost of goods sold	34,165,440	26,316,511	22,320,156
Gross profit	17,259,381	13,252,612	10,613,409
Equity in income from joint ventures	7,527,383	5,898,908	4,743,831
Fees for services provided to joint ventures	6,142,139	5,452,687	5,137,710
Selling expenses	10,886,011	9,283,310	6,255,353
General & administrative expenses	8,500,490	7,807,563	8,232,369
Research & development expenses	3,524,953	2,912,393	4,724,596
Operating income (loss)	8,017,449	4,600,941	1,282,632
Interest income	99,463	43,539	42,115
Interest expense	17,962	20,382	13,261
Impairment on investment at carrying value			(1,883,668)
Income (loss) before income tax expense	8,098,950	4,624,098	(572,182)
Current state			

income taxes (benefit)	1,000	62,000	20,000
Current foreign income taxes (benefit)	671,000	754,000	647,000
Total current income taxes (benefit)	672,000	816,000	667,000
Deferred federal income taxes (benefit)	477,000	(135,000)	6,000
Deferred state income taxes (benefit)	24,000	(9,000)	...
Deferred foreign income taxes (benefit)	(297,000)	28,000	(47,000)
Total deferred income taxes (benefit)	204,000	(116,000)	(41,000)
Income tax expense (benefit)	<sup>2</sup> 876,103	<sup>3</sup> 699,519	<sup>3</sup> 626,120
Net income (loss)	7,222,847	3,924,579	(1,198,302)
Net loss (income) attributable to non-controlling interests	(521,481)	(502,453)	330,788
Net income (loss) attributable to Northern Technologies International Corp.	6,701,366	3,422,126	(867,514)
Weighted average shares outstanding-basic	4,538,838	4,528,611	4,537,504
Weighted average shares outstanding-diluted	4,685,202	4,577,359	4,537,504
Year end shares outstanding	4,541,303	4,535,018	4,533,416
Net income (loss) per share-basic	\$1.48	\$0.76	\$(0.19)
Net income (loss) per share-diluted	\$1.43	\$0.75	\$(0.19)
Cash dividends declared per common share	\$0.40	\$0.00	...
Number of full time employees	136	71	121
Number of common stockholders	167	174	175
Foreign currency translation adjustments	(1,162,755)	552,575	223,253

<sup>1</sup> Reclassified to conform with 2017 presentation; <sup>2</sup> Rounding difference, breakdown taken from the notes; <sup>3</sup> Rounding difference; breakdown taken from notes

**Consolidated Balance Sheet, Years Ended Aug. 31 (\$):**

	2018	<sup>1</sup> 2017
		(revised)
Cash & cash equivalents	4,163,023	6,360,201
Available for sale securities	3,300,110	3,766,984
Trade receivables excluding joint ventures, gross	9,970,108	5,952,631
Less allowance for doubtful accounts	50,000	40,000
Trade receivables excluding joint ventures, net	9,920,108	5,912,631
Trade receivables - trade joint ventures	761,506	691,752
Receivables - fees for services provided to joint ventures	1,357,255	1,302,944
Income taxes	273,333	137,256
Production materials	1,824,489	1,746,916
Finished goods	7,306,372	5,709,636
Inventories	9,130,861	7,456,552
Prepaid expenses	1,661,577	439,298
Total current assets	30,567,773	26,067,618

Land	310,365	310,365	Cost of product & licensing	77,086	74,004	86,379	adjustments	2,421	
Buildings & improvements	6,927,484	6,847,177	Cost of maintenance & support	58,095	54,094	54,077	As is; <sup>□</sup> Approximately; <sup>□</sup> As of October 31, 2018; <sup>□</sup> As of October 31, 2017; <sup>□</sup> As of October 31, 2016		
Machinery & equipment	4,680,072	4,171,387	Amortization of intangible assets	56,873	64,853	62,876	<b>Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):</b>		
Property & equipment, gross	11,917,921	11,328,929	Total cost of revenues	873,570	853,800	829,500	2018	2017	
Less accumulated depreciation	4,749,095	3,969,267	Gross profit (loss)	1,178,091	1,085,562	1,119,403	Cash & cash equivalents	315,963	592,299
Property & equipment, net	7,168,826	7,359,662	Research & development	305,323	266,097	271,130	Marketable securities	135,579	251,981
Investments in joint ventures	22,950,995	20,035,074	Sales & marketing	388,305	398,130	390,866	Trade accounts receivable	368,467	417,516
Deferred income taxes	1,551,536	1,756,565	General & administrative	229,774	166,677	168,473	Unbilled accounts receivable under long-term contracts	33,413	27,515
Patents & trademarks, net	1,156,257	1,322,089	Amortization of intangible assets	91,093	113,895	108,021	Less - allowance for doubtful accounts	11,724	14,333
Other assets	153,849	71,685	Acquisition-related costs, net	16,101	27,740	17,166	Less - allowance for sales returns	(11,324)	(35,306)
Total assets	63,549,236	56,612,693	Restructuring & other charges, net	63,498	61,054	25,224	Accounts receivable, net	378,832	395,392
Accounts payable	3,905,034	2,676,610	Impairment of goodwill & other intangible assets	170,941	...	...	Prepaid expenses & other current assets	98,257	88,269
Income taxes payable	70,892	...	Total operating expenses	1,265,035	1,033,593	980,880	Total current assets	928,631	1,327,941
Accrued payroll & related benefits	2,747,303	1,540,386	Income (loss) from operations	(86,944)	51,969	138,523	Marketable securities	21,932	29,844
Other accrued liabilities	1,006,953	677,621	Interest income	9,327	6,922	4,438	Land	2,400	2,400
Total current liabilities	7,730,182	4,894,617	Interest expense	137,253	156,889	132,732	Building	5,409	5,456
Common stock	90,826	90,700	Other income (expense), net	(1,865)	(21,017)	(8,490)	Machinery & equipment	164,089	144,130
Additional paid-in capital	14,619,777	14,163,509	Income (loss) before income taxes - domestic	(187,616)	(228,406)	(118,410)	Computers, software & equipment	183,904	187,732
Retained earnings (accumulated deficit)	41,963,341	37,077,483	Income (loss) before income taxes - foreign	(29,119)	109,391	120,149	Leasehold improvements	37,393	34,478
Accumulated other comprehensive income (loss)	(3,597,199)	(2,471,064)	Income (loss) before income taxes	(216,735)	(119,015)	1,739	Furniture & fixtures	18,322	19,171
Total stockholders' equity	53,076,745	48,860,628	Current income taxes (benefit) - federal	4,189	...	...	Construction in progress	2,088	9,121
Non-controlling interests	2,742,309	2,857,448	Current income taxes (benefit) - state	598	2,185	3,230	Land, building & equipment, gross	413,605	402,488
Total equity	55,819,054	51,718,076	Current income taxes (benefit) - foreign	25,623	24,941	22,981	Less: accumulated depreciation	257,711	225,940
			Total current income taxes (benefit)	30,410	27,126	26,211	Land, building & equipment, net	155,894	176,548
			Deferred income taxes (benefit) - federal	(83,319)	7,291	(7,235)	Goodwill	3,504,457	3,590,608
			Deferred income taxes (benefit) - state	2,303	1,133	(1,962)	Intangible assets, net	549,508	664,474
			Deferred income taxes (benefit) - foreign	(6,201)	(3,569)	(2,817)	Other assets	141,957	142,508
			Total deferred income taxes (benefit)	(87,217)	4,855	(12,014)	Total assets	5,302,379	5,931,923
			Provision (benefit) for income taxes	(56,807)	31,981	14,197	Current portion of long-term debt	...	376,121
			Net income (loss)	(159,928)	(150,996)	(12,458)	Contingent & deferred acquisition payments	14,211	28,860
			Weighted average shares outstanding - basic	291,318	289,348	292,129	Accounts payable	84,516	94,604
			Weighted average shares outstanding - diluted	291,318	289,348	292,129	Accrued compensation	181,992	159,951
			Year end shares outstanding	287,753	290,187	287,633	Accrued interest payable	21,326	26,285
			Net income (loss) per share - basic	\$(0.55)	\$(0.52)	\$(0.04)	Accrued cost of revenue related liabilities	32,667	20,124
			Net income (loss) per share - diluted	\$(0.55)	\$(0.52)	\$(0.04)	Accrued consulting & professional fees	21,441	12,649
			Number of full time employees	<sup>□□</sup> 10,400	<sup>□□</sup> 11,600	<sup>□□</sup> 13,200	Accrued facilities related liabilities	5,340	7,158
			Number of common stockholders	<sup>□□</sup> 605	<sup>□□</sup> 643	<sup>□□</sup> 676	Accrued sales & marketing incentives	2,904	3,655
			Foreign currency translation				Accrued sales & other taxes payable	6,602	3,125
							Other accrued expenses & other current liabilities	9,372	12,954
							Deferred revenue	383,793	366,042
							Total current liabilities	764,164	1,111,528
							Senior notes, net	<sup>□</sup> 1,091,894	<sup>□□</sup> 1,240,838
							Convertible debentures, net	<sup>□□</sup> 1,094,310	<sup>□□</sup> 1,377,740
							Deferred issuance costs related to our revolving credit facility	(843)	(1,174)
							Less: current portion	...	376,121
							Deferred revenue, net of current portion	489,177	423,929
							Deferred tax liabilities	49,931	131,320
							Other liabilities	96,250	92,481
							Total liabilities	3,584,883	4,000,541
							Common stock	291	294
							Additional paid-in capital	2,597,693	2,629,245
							Treasury stock, at cost	16,788	16,788
							Foreign currency translation adjustment	(118,220)	(94,247)
							Unrealized gains (losses) on marketable securities	(115)	77
							Net unrealized losses on post-retirement benefits	(4,528)	(7,172)

<sup>□</sup> Reclassified to conform with 2018 presentation

#### Recent Dividends:

##### 1. Northern Technologies International Corp. common.

ExDate	Amt	Declared	Record	Payable
12/07/2017	0.10	11/20/2017	12/08/2017	12/21/2017
02/06/2018	0.10	01/24/2018	02/07/2018	02/21/2018
05/08/2018	0.10	04/25/2018	05/09/2018	05/23/2018
08/07/2018	0.10	07/25/2018	08/08/2018	08/22/2018
11/06/2018	0.12	10/24/2018	11/07/2018	11/21/2018

#### Annual Dividends:

##### 1. Northern Technologies International Corp. common.

2017	0.10	2018	0.42
------	------	------	------

#### NOVAN INC

##### Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	1,955	1,908
Cost & expenses	27,003	29,755
Operating income	(25,048)	(27,847)
Interest income	242	78
Interest expense	785	786
Other income (expense), net	5,765	6
Net income	(19,826)	(28,549)
Earnings common share		
Primary	\$(0.77)	\$(1.79)
Fully Diluted	\$(0.77)	\$(1.79)
Common Shares:		
Full Diluted	25,708	15,976
Year-end	26,055	...

#### NUANCE COMMUNICATIONS INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Sept. 30 (\$000):

	2018	2017	2016
		(revised)	(revised)
Professional services & hosting	1,049,448	976,893	955,329
Product & licensing	684,230	635,391	669,227
Maintenance & support	317,983	327,078	324,347
Total revenues	2,051,661	1,939,362	1,948,903
Cost of professional services & hosting	681,516	660,849	626,168



Accumulated other comprehensive income (loss) .....	(122,863)	(101,342)
Retained earnings (accumulated deficit) .....	(740,837)	(580,027)
Total stockholders' equity (deficit) .....	1,717,496	1,931,382

□ Net of deferred issuance costs - senior notes: \$8,100,000; □ Net of unamortized premium - senior notes: \$1,000,000; □ Net of deferred issuance costs - senior notes: \$10,100,000; □ Net of unamortized discount - Convertible debentures: \$233,600,000; □ Net of deferred issuance costs - convertible debentures: \$4,800,000; □ Net of unamortized discount - Convertible debentures: \$277,600,000; □ Net of deferred issuance costs - convertible debentures: \$12,800,000

**Recent Dividends:****1. Nuance Communications Inc series B preferred.**

No dividends paid.

**2. Nuance Communications Inc common.**

No dividends paid.

**Annual Dividends:****1. Nuance Communications Inc series B preferred.**

No dividends paid.

**2. Nuance Communications Inc common.**

No dividends paid.

**NUTANIX INC****Earnings, 3 mos. to Oct 31(Consol. - \$000):**

	2018	2017
Total Revenues .....	313,283	275,552
Cost & expenses .....	408,473	334,591
Operating income .....	(95,190)	(59,039)
Other income (expense), net .....	(2,703)	(189)
Net before taxes .....	(97,893)	(59,228)
Income taxes .....	(3,628)	2,259
<b>Net income</b> .....	<b>(94,265)</b>	<b>(61,487)</b>
Earnings common share		
Primary .....	\$(0.54)	\$(0.39)
Fully Diluted .....	\$(0.54)	\$(0.39)
Common Shares:		
Full Diluted .....	175,446	156,781
Year-end .....	179,066	154,637

**Consolidated Balance Sheet Items, as of (\$000):**

	2018	2017
Assets:		
Cash & equivalents .....	399,786	
Current assets .....	1,277,020	
Net property & equip. ....	104,750	
Total assets .....	1,773,086	
Liabilities:		
Current liabilities .....	470,930	
Long-term debt .....	436,745	
Stockholders' equity .....	431,319	
Net current assets .....	806,090	

**NUTRISYSTEM INC**

**Sale Development** On Dec. 10, 2018, Co. and Tivity Health, Inc. ("Tivity"), a leading provider of fitness and health improvement programs announced that they have entered into a definitive agreement under which Tivity will acquire all of the outstanding shares of Co. for a combination of cash and stock. Under the terms of the agreement, which has been unanimously approved by the boards of directors of both companies, Co. shareholders will receive \$38.75 per share in cash and 0.2141 Tivity shares for each share of Co. common stock. The transaction values Co. at an enterprise value of \$1,300,000,000 and an equity value of \$1,400,000,000, or approximately \$47.00 per share. The implied stock consideration of \$8.25 per Co. share is based on the volume-weighted average price of Tivity's stock for the 10 days ended Dec. 3, 2018. The implied transaction consideration of \$47.00 per share represents a 30% premium based on the volume-weighted average price for Co. over the last five trading days. The transaction is expected to close in the first quarter of 2019, subject to the approval of Co. shareholders, the receipt of regulatory approval and other customary closing conditions.

**NUVETRA CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues .....	37,939	19,880
Cost & expenses .....	70,346	54,180
Operating income .....	(32,407)	(34,300)
Interest expense .....	2,772	1,190
Other income (expense), net .....	(88)	(499)
Net before taxes .....	(35,267)	(35,989)

Income taxes .....	11	9
<b>Net income</b> .....	<b>(35,278)</b>	<b>(35,998)</b>
Earnings common share		
Primary .....	\$(2.55)	\$(3.43)
Fully Diluted .....	\$(2.55)	\$(3.43)
Common Shares:		
Full Diluted .....	13,852	10,497
Year-end .....	17,574	10,746

**OCLARO INC**

**Merger Completed** On Dec. 10, 2018, Lumentum Holdings Inc. ("Lumentum") wholly-owned subsidiary, Prota Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation. As the result of the merger, each outstanding share of Co. common stock, par value \$0.01 per share, other than shares owned by Lumentum, Co. and their subsidiaries, was automatically converted into the right to receive the following consideration (collectively, the "Merger Consideration"), without interest: (1) \$5.60 in cash (the "Cash Consideration"); and (2) 0.0636 of a validly issued, fully paid and nonassessable share of Lumentum common stock, par value \$0.001 per share (the "Stock Consideration") (such ratio, the "Exchange Ratio"). Each Co. restricted stock unit award (each, a "Co. RSU") that did not become vested at the Effective Time was converted into a Lumentum restricted stock unit award (a "Lumentum RSU") with the same terms and conditions, including vesting, that were applicable to such Co. RSU, except that the number of Lumentum shares subject to the Lumentum RSU equals the product of (i) the number of Co. shares subject to such Co. RSU (with any performance milestones deemed achieved based on the maximum level of achievement) multiplied by (ii) the sum of (A) the Exchange Ratio plus (B) the quotient obtained by dividing the Cash Consideration by \$43.189 (Lumentum's average closing price for the 10 trading days ending on Dec. 4, 2018, the third trading day prior to the Closing Date), rounded down to the nearest whole share (such sum, the "Equity Award Exchange Ratio"). Each Co. stock option (each, a "Co. Option"), whether vested or unvested, was converted into a Lumentum stock option (a "Lumentum Option") with the same terms and conditions, including vesting, that were applicable to such Co. Option, except that (i) the number of shares subject to the Lumentum Option equals the product of (A) the number of Co. shares subject to such Co. Option multiplied by (B) the Equity Award Exchange Ratio, rounded down to the nearest whole share and (ii) the exercise price of the Lumentum Option equals (A) the exercise price per share of Co.'s Option divided by (B) the Equity Award Exchange Ratio, rounded up to the nearest whole cent. Notwithstanding the foregoing, any Co. Option that was held by an individual who was not an Co. employee as of immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration for each net option share covered by such Co. Option, subject to applicable withholding taxes. In addition, each Co. restricted stock award ("Co. Restricted Stock Award") and Co. RSU that became vested as of immediately prior to the Effective Time (including each Co. Restricted Stock Award held by a non-employee director) was converted into the right to receive the Merger Consideration in respect of each Co. share underlying such award, subject to applicable withholding taxes. Each Co. stock appreciation right ("Co. SAR") was cancelled and converted into the right to receive a cash amount equal to the product of (i) the number of Co. shares subject to Co.'s SAR multiplied by (ii) the positive difference of (A) the cash equivalent value of the Merger Consideration less (B) the strike price of Co.'s SAR, subject to applicable withholding taxes.

**ODONATE THERAPEUTICS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses .....	61,287	16,998
Operating income .....	(61,287)	(16,998)
Interest income .....	1,090	
<b>Net income</b> .....	<b>(60,197)</b>	<b>(16,998)</b>
Earnings common share		
Primary .....	\$(2.47)	\$(1.37)
Fully Diluted .....	\$(2.47)	\$(1.37)
Common Shares:		
Full Diluted .....	24,403	12,427
Year-end .....	26,827	

**OKTA INC****Earnings, 9 mos. to Oct 31(Consol. - \$000):**

	2018	2017
Total Revenues .....	283,783	179,495
Cost & expenses .....	375,670	267,634
Operating income .....	(91,887)	(88,139)

Other income (expense), net .....	(4,682)	872
Net before taxes .....	(96,569)	(87,267)
Income taxes .....	(1,883)	(463)
<b>Net income</b> .....	<b>(94,686)</b>	<b>(86,804)</b>
Earnings common share		
Primary .....	\$(0.89)	\$(1.13)
Fully Diluted .....	\$(0.89)	\$(1.13)
Common Shares:		
Full Diluted .....	106,587	76,950
Year-end .....	110,346	

**OLLIE'S BARGAIN OUTLET HOLDINGS INC****Earnings, 9 mos. to (Consol. - \$000):**

	11/03/18	10/28/17
Net Sales .....	847,443	720,363
Cost & expenses .....	738,775	631,851
Deprec., depl. & amort. ....	8,531	7,150
Operating income .....	100,137	81,362
Interest expense .....	1,188	3,601
Other income (expense), net .....	(100)	(397)
Net before taxes .....	98,849	77,364
Income taxes .....	13,730	19,824
<b>Net income</b> .....	<b>85,119</b>	<b>57,540</b>
Earnings common share		
Primary .....	\$1.36	\$0.94
Fully Diluted .....	\$1.29	\$0.89
Common Shares:		
Full Diluted .....	65,861	64,794
Year-end .....	62,812	61,657

**OMNICELL INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues .....	575,559	516,343
Cost & expenses .....	550,097	521,399
Operating income .....	25,462	(5,056)
Net before taxes .....	19,000	(10,048)
Income taxes .....	(3,936)	(9,341)
<b>Net income</b> .....	<b>22,936</b>	<b>(707)</b>
Earnings common share		
Primary .....	\$0.59	\$(0.02)
Fully Diluted .....	\$0.57	\$(0.02)
Common Shares:		
Full Diluted .....	40,237	37,266
Year-end .....	39,615	

**ONLINE VACATION CENTER HOLDINGS CORP****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues .....	12,839,169	11,457,254
Cost & expenses .....	11,884,881	11,281,560
Deprec., depl. & amort. ....	573,750	551,982
Operating income .....	380,538	(376,288)
Other income (expense), net .....	83,135	(1,736)
Net before taxes .....	463,673	(378,024)
Income taxes .....	129,734	(106,448)
<b>Net income</b> .....	<b>333,939</b>	<b>(271,576)</b>
Earnings common share		
Primary .....	\$0.03	\$(0.02)
Fully Diluted .....	\$0.03	\$(0.02)
Common Shares:		
Full Diluted .....	11,031,341	11,261,878
Year-end .....	8,776,327	11,261,878

**OPHTHOTECH CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues .....	209,977	209,977
Cost & expenses .....	43,554	87,113
Operating income .....	(43,554)	122,864
Other income (expense), net .....	(17)	(34)
Net before taxes .....	(41,860)	123,943
Income taxes .....	(833)	196
<b>Net income</b> .....	<b>(41,027)</b>	<b>123,747</b>
Earnings common share		
Primary .....	\$(1.13)	\$3.45
Fully Diluted .....	\$(1.13)	\$3.44
Common Shares:		
Full Diluted .....	36,181	35,984
Year-end .....	36,218	36,033

**OPTINOSE INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**



Common Shares:			
Full Diluted	17,145,000	16,830,000	
Year-end	18,318,141	17,762,694	

**PCM, INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Net Sales	1,599,842	1,622,117
Cost & expenses	1,569,851	1,610,496
Operating income	29,991	11,621
Interest expense	7,050	5,589
Other income (expense), net	377	424
Net before taxes	23,318	6,456
Income taxes	6,653	685
<b>Net income</b>	<b>16,665</b>	<b>5,771</b>

**Earnings common share**

Primary	\$1.40	\$0.46
Fully Diluted	\$1.35	\$0.43

**Common Shares:**

Full Diluted	12,343	13,325
Year-end	12,144	

**PEAK RESORTS INC**

**Acquisition Completed** On Nov. 21, 2018, Co., through its wholly owned subsidiary Snow Time Acquisition, Inc., acquired 100% of the issued and outstanding common stock of Snow Time, Inc. ("Snow Time"), a company that owns and operates three ski resorts in Pennsylvania, which included the assets and businesses of Snow Time, including Liberty Mountain Resort, Round-top Mountain Resort and Whitetail Resort, which were day and overnight drive ski resorts located in southern Pennsylvania serving the Baltimore and Washington, D.C. metropolitan areas. Such resorts included two 18-hole golf courses, a 115-room hotel and conference center and more than 20 food and beverage locations across the three resorts, among other amenities, from the stockholders of Snow Time, for approximately \$70,000,000 in cash, which was subject to customary post-closing adjustments related to prepaid services, working capital and transaction expenses as described in the Purchase Agreement, and 1,183,432 shares of Co.'s common stock with a value equal to \$6,000,000, which was determined based on a \$5.07 average closing price of the common stock for the 20 trading days immediately preceding the Acquisition closing.

**PEAK RESORTS INC****Earnings, 6 mos. to Oct 31**(Consol. – \$000):

	2018	2017
Total Revenues	14,991	16,358
Cost & expenses	33,302	33,284
Operating income	(25,043)	(23,225)
Interest expense	6,825	6,207
Other income (expense), net	47	89
Gains or losses	166	166
Net before taxes	(31,655)	(29,177)
Income taxes	(8,857)	(11,668)
<b>Net income</b>	<b>(22,798)</b>	<b>(17,509)</b>
Balance for common	(23,598)	(18,309)

**Earnings common share**

Primary	\$(1.67)	\$(1.30)
Fully Diluted	\$(1.67)	\$(1.30)

**Common Shares:**

Full Diluted	14,095	14,037
Year-end	13,982	13,982

**PENNANTPARK INVESTMENT CORPORATION****Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$):**

	2018	2017	2016 (revised)
Investment income from non-controlled, non-affiliated investments - interest	83,255,593	84,685,961	103,659,182
Investment income from non-controlled, non-affiliated investments - payment in kind	5,645,535	3,819,996	848,834

**Investment income from non-controlled, non-affiliated**

Investment income from non-controlled, non-affiliated investments - interest	83,255,593	84,685,961	103,659,182
Investment income from non-controlled, non-affiliated investments - payment in kind	5,645,535	3,819,996	848,834

investments - other income	6,981,507	7,079,034	10,945,240
Investment income from non-controlled, affiliated investments - interest	3,013,976	10,339,444	12,374,621
Investment income from non-controlled, affiliated investments - payment in kind	2,031,589	5,475,491	680,746
Investment income from non-controlled, affiliated investments - interest	4,499,350	734,163	731,381
Investment income from controlled, affiliated investments - payment in kind	2,850,498	10,790,300	12,750,302
Total investment income	108,278,048	124,534,324	142,070,827
Base management fee	17,468,376	24,218,029	24,852,898
Performance-based incentive fee	11,492,928	11,077,956	16,018,790
Interest & expenses on debt	22,818,492	26,642,113	27,601,242
Administrative services expenses	2,086,500	3,576,000	3,566,667
Other general & administrative expenses	2,504,853	2,662,640	3,605,923
Expenses before management fees waiver, provision for taxes & credit facility amendment costs	56,371,149	68,176,738	75,645,520
Management fees waiver	1,427,253	5,647,358	6,539,475
Provision (benefit) for taxes		1,700,000	2,350,000
Credit facility amendment costs		3,866,633	
<b>Net investment income (loss)</b>	<b>53,334,152</b>	<b>56,438,311</b>	<b>70,614,782</b>
Weighted average shares outstanding - basic	70,686,354	71,060,836	71,621,530
Weighted average shares outstanding - diluted	70,686,354	71,060,836	71,621,530
Year end shares outstanding	69,053,958	71,060,836	71,060,836
Net investment income per common share - basic	\$0.75	\$0.79	\$0.99
Net investment income per common share - diluted	\$0.75	\$0.79	\$0.99
Distributions declared per share	\$0.72	\$0.82	\$1.12
Total number of employees	0		
Number of common stockholders	11	12	12

Reclassified to conform with 2017 presentation; As of November 15, 2018; As of November 19, 2017; As of November 21, 2016

**Consolidated Balance Sheet, Years Ended Sept. 30 (\$):**

	2018	2017
Investments at fair value		

- non-controlled, non-affiliated investments	905,271,258	849,351,548
Investments at fair value - non-controlled, affiliated investments	78,078,331	189,674,977
Investments at fair value - controlled, affiliated investments	148,735,885	114,550,983
Total of investments at fair value	1,132,085,474	1,153,577,508
Cash & cash equivalents	19,506,154	38,202,068
Interest receivable	7,606,964	5,906,976
Prepaid expenses & other assets	920,235	4,509,289
Total assets	1,160,118,827	1,202,195,841
Distributions payable	12,429,712	12,790,950
Payable for investments purchased		1,014,000
Credit facility payable	77,645,830	76,037,341
2019 notes payable	251,322,506	255,665,000
Small Business Administration (SBA) debentures payable, net	175,373,229	194,364,653
Base management fees payable, net	4,086,831	4,845,237
Performance-based incentive fee payable, net	2,964,265	2,270,008
Interest payable on debt	6,576,393	6,876,756
Accrued other expenses	818,172	1,523,425
Total liabilities	531,216,932	555,387,370
Common stock	69,054	71,061
Paid-in capital in excess of par value	803,729,220	818,737,784
Undistributed (distributions in excess of) net investment income	6,003,360	3,333,195
Accumulated net realized gain (loss) on investments	(70,687,629)	(116,598,355)
Net unrealized appreciation (depreciation) on investments	(111,763,780)	(56,425,773)
Net unrealized depreciation (appreciation) on debt	1,551,670	(2,309,441)
Total net assets	628,901,895	646,808,471
Net assets value per share	\$9.11	\$9.10

Cost - investments at fair value - non-controlled, non-affiliated investments: \$896,720,950; Cost - investments at fair value - non-controlled, non-affiliated investments: \$824,106,322; Cost - investments at fair value - non-controlled, affiliated investments: \$91,520,908; Cost - investments at fair value - non-controlled, affiliated investments: \$185,799,943; Cost - investments at fair value - controlled, affiliated investments: \$255,574,317; Cost - investments at fair value - controlled, affiliated investments: \$200,120,407; Cost - total of investments at fair value: \$1,243,816,175; Cost - total of investments at fair value: \$1,210,026,672; Cost - cash and cash equivalents: \$19,543,625; Cost - cash and cash equivalents: \$38,182,373; Cost - credit facility payable: \$80,520,000; Cost - credit facility payable: \$79,392,900; Par - 2019 notes payable: \$250,000,000; Par - Small Business Administration (SBA) debentures payable, net: \$180,000,000; Par - Small Business Administration (SBA) debentures payable, net: \$199,000,000

**Recent Dividends:****1. PennantPark Investment Corporation common.**

ExDate	Amt	Declared	Record	Payable
12/17/2014	0.28	12/02/2014	12/19/2014	01/02/2015
03/18/2015	0.28	03/03/2015	03/20/2015	04/01/2015
06/11/2015	0.28	06/02/2015	06/15/2015	07/01/2015
09/17/2015	0.28	09/02/2015	09/21/2015	10/01/2015
12/22/2015	0.28	12/02/2015	12/24/2015	01/04/2016
03/16/2016	0.28	03/02/2016	03/18/2016	04/01/2016
06/15/2016	0.28	06/02/2016	06/20/2016	07/01/2016
09/19/2016	0.28	09/02/2016	09/21/2016	10/03/2016
12/20/2016	0.28	12/02/2016	12/22/2016	01/03/2017

03/20/2017	0.18	03/02/2017	03/22/2017	04/03/2017
06/19/2017	0.18	06/02/2017	06/21/2017	07/03/2017
09/19/2017	0.18	09/05/2017	09/20/2017	10/02/2017
12/22/2017	0.18	12/05/2017	12/26/2017	01/02/2018
03/16/2018	0.18	03/05/2018	03/19/2018	04/02/2018
06/15/2018	0.18	06/06/2018	06/18/2018	07/02/2018
09/14/2018	0.18	09/07/2018	09/17/2018	10/02/2018

**Annual Dividends:****1. PennantPark Investment Corporation common.**

2015	1.12	2016	1.12	2017	0.82
2018	0.72				

**PERFORMANT FINANCIAL CORP****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	115,938	98,760
Cost & expenses	114,286	104,659
Operating income	1,652	(5,899)
Interest income	19	
Interest expense	3,534	5,683
Net before taxes	(1,863)	(11,582)
Income taxes	882	1,668
<b>Net income</b>	<b>(2,745)</b>	<b>(13,250)</b>
Earnings common share		
Primary	\$(0.05)	\$(0.26)
Fully Diluted	\$(0.05)	\$(0.26)
Common Shares:		
Full Diluted	51,752	50,581
Year-end	52,976	

**PERNIX THERAPEUTICS HOLDINGS INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	86,383,000	104,527,000
Cost & expenses	96,729,000	81,268,000
Operating income	(24,032,000)	(31,717,000)
Interest expense	29,063,000	27,491,000
Other income (expense), net	176,000	14,612,000
Gains or losses	446,000	
Foreign currency	(864,000)	
Net before taxes	(53,337,000)	(44,596,000)
Income taxes	109,000	122,000
<b>Net income</b>	<b>(53,446,000)</b>	<b>(44,718,000)</b>
Balance for common	(43,942,000)	(44,718,000)
Earnings common share		
Primary	\$(3.55)	\$(4.31)
Fully Diluted	\$(3.55)	\$(4.31)
Common Shares:		
Full Diluted	12,377,000	10,387,000
Year-end	13,957,733	11,532,423

**PETIQ INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	417,590	214,761
Cost & expenses	404,739	201,514
Operating income	12,851	13,247
Interest expense	6,140	1,351
Other income (expense), net	(622)	14
Foreign currency	8	(152)
Net before taxes	6,097	11,758
Income taxes	754	550
<b>Net income</b>	<b>5,343</b>	<b>11,208</b>
Earnings common share		
Primary	\$0.17	\$(0.02)
Fully Diluted	\$0.17	\$(0.02)
Common Shares:		
Full Diluted	15,966	13,223
Year-end	25,767	21,491

**PHIBRO ANIMAL HEALTH CORP.****Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	200,153	193,412
Cost & expenses	177,300	171,025
Operating income	22,853	22,387
Interest expense	3,243	3,427
Foreign currency	2,635	(325)
Net before taxes	22,705	18,944
Income taxes	6,391	3,052
<b>Net income</b>	<b>16,314</b>	<b>15,892</b>
Earnings common share		
Primary	\$0.40	\$0.40

Fully Diluted	\$0.40	\$0.39
Common Shares:		
Full Diluted	40,560	40,293
Year-end	40,376	40,171
<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:	2018	
Cash & equivalents	75,860	
Inventories	185,794	
Current assets	419,793	
Net property & equip.	130,786	
Total assets	678,475	
Liabilities:		
Current liabilities	128,731	
Long-term debt	311,750	
Stockholders' equity	192,057	
Net current assets	291,062	

**PILGRIMS PRIDE CORP.****Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	09/24/17
Net Sales	8,280,995	8,025,511
Cost & expenses	7,808,944	7,108,206
Operating income	472,051	917,305
Interest income	10,665	3,600
Other income (expense), net	1,781	5,198
Foreign currency	2,802	2,500
Net before taxes	361,398	862,288
Income taxes	106,367	278,046
<b>Net income</b>	<b>255,031</b>	<b>584,242</b>
Pfd. dividends	(143)	(230)
Earnings common share		
Primary	\$1.03	\$2.25
Fully Diluted	\$1.03	\$2.25
Common Shares:		
Full Diluted	249,076	248,962
Year-end	248,980	248,753

**PIONEER POWER SOLUTIONS INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	74,024,000	77,835,000
Cost & expenses	71,062,000	73,799,000
Operating income	2,962,000	4,036,000
Other income (expense), net	(158,000)	(165,000)
Net before taxes	678,000	2,079,000
Income taxes	550,000	396,000
Income contin. oper.	128,000	1,683,000
<b>Net income</b>	<b>(1,312,000)</b>	<b>599,000</b>
Earnings common share		
Primary	\$(0.16)	\$0.08
Fully Diluted	\$(0.16)	\$0.08
Common Shares:		
Full Diluted	8,726,000	8,727,000
Year-end	8,726,045	

**PIXELWORKS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	56,015	62,189
Cost & expenses	59,328	61,180
Operating income	(3,313)	1,009
Other income (expense), net	1,272	
Net before taxes	(2,584)	281
Income taxes	396	902
<b>Net income</b>	<b>(2,980)</b>	<b>(621)</b>
Earnings common share		
Primary	\$(0.08)	\$(0.02)
Fully Diluted	\$(0.08)	\$(0.02)
Common Shares:		
Full Diluted	35,697	30,545
Year-end	36,607	34,252

**PLEXUS CORP.****Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	09/29/18	09/30/17	10/01/16
Net sales	2,873,508	2,528,052	2,556,004
Cost of sales	2,615,908	2,272,197	2,328,645
Gross profit	257,600	255,855	227,359
Selling & administrative expenses	139,317	125,947	120,886
Restructuring costs			7,034

Operating income (loss)	118,283	129,908	99,439
Interest expense	12,226	13,578	14,635
Interest income	4,696	5,042	4,242
Miscellaneous income (expense), net	(3,143)	451	(1,652)
Income (loss) before income taxes - U.S.	(53,243)	(35,209)	(26,796)
Income (loss) before income taxes - foreign	160,853	157,032	114,190
Income (loss) before income taxes	107,610	121,823	87,394
Current income tax expense (benefit) - federal	63,814	78	...
Current income tax expense (benefit) - state	234	33	(15)
Current income tax expense (benefit) - foreign	10,134	10,016	11,312
Total current income tax expense (benefit)	74,182	10,127	11,297
Deferred income tax expense (benefit) - federal	(2,958)	77	...
Deferred income tax expense (benefit) - state	(447)	38	24
Deferred income tax expense (benefit) - foreign	23,793	(481)	(354)
Total deferred income tax expense (benefit)	20,388	(366)	(330)
Income tax expense (benefit)	94,570	9,761	10,967
<b>Net income (loss)</b>	<b>13,040</b>	<b>112,062</b>	<b>76,427</b>
Weighted average shares outstanding - basic	33,003	33,612	33,374
Weighted average shares outstanding - diluted	33,919	34,553	34,098
Year end shares outstanding	31,838	33,464	33,457
Net earnings (loss) per share - basic	\$0.40	\$3.33	\$2.29
Net earnings (loss) per share - diluted	\$0.38	\$3.24	\$2.24
Number of full time employees	18,000	16,000	14,000
Number of common stockholders	420	447	478
Foreign currency translation adjustments	(3,058)	4,155	(14,035)

□ Reclassified to conform with 2018 presentation; □ Approximately; □ As is; □ As of November 12, 2018; □ As of November 13, 2017; □ As of November 14, 2016

**Consolidated Balance Sheet, Years Ended (\$000):**

	09/29/18	09/30/17
		(revised)
Cash	99,197	264,222
Money market funds & other cash equivalents	198,072	304,638
Restricted cash	417	394
Accounts receivable, gross	395,712	366,493
Allowances	885	980
Accounts receivable, net	394,827	365,513
Raw materials	579,377	477,921
Work-in-process	102,337	86,367
Finished goods	112,632	90,354
Inventories, net	794,346	654,642
Prepaid expenses & other current assets	30,302	28,046
Total current assets	1,517,161	1,617,455

Land, buildings & improvements	267,809	262,428
Machinery & equipment	364,034	348,593
Computer hardware & software	130,645	117,404
Capital assets in progress	38,469	12,790
Total property, plant & equipment, gross	800,957	741,215
Less: accumulated depreciation	459,651	426,550
Property, plant & equipment, net	341,306	314,665
Intangibles, net	8,239	...
Deferred income taxes	10,825	5,292
Other assets	55,111	38,770
Total non-current assets	415,481	358,727
Total assets	1,932,642	1,976,182
Current portion of long-term debt & capital lease obligations	5,532	286,934
Accounts payable	506,322	413,999
Customer deposits	90,782	107,837
Accrued salaries & wages	66,874	49,376
Other accrued liabilities	68,163	49,445
Total current liabilities	737,673	907,591
Borrowings under the credit facility	...	108,000
Senior notes	150,000	175,000
Capital lease & other financing obligations	39,857	30,901
Unamortized deferred financing fees	(1,240)	(794)
Total obligations	188,617	313,107
Less: current portion	5,532	286,934
Long-term accrued income taxes payable	56,130	...
Other liabilities	20,235	16,479
Total non-current liabilities	273,826	42,652
Deferred income taxes payable	14,376	...
Total liabilities	1,011,499	950,243
Common stock	526	519
Additional paid-in capital	581,488	555,297
Common stock held in treasury, at cost	711,138	574,104
Retained earnings (accumulated deficit)	1,062,246	1,049,206
Foreign currency translation adjustments	(10,540)	(7,482)
Cumulative change in fair value of derivative instruments	(1,439)	2,503
Accumulated other comprehensive income (loss)	(11,979)	(4,979)
Total shareholders' equity	921,143	1,025,939

**Recent Dividends:****1. Plexus Corp. common.**

No dividends paid.

**Annual Dividends:****1. Plexus Corp. common.**

No dividends paid.

**PRIMORIS SERVICES CORP****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	2,061,808,000	800,978,000
Cost & expenses	1,984,563,000	719,411,000
Operating income	77,245,000	81,567,000
Interest expense	11,637,000	6,605,000
Other income (expense), net	(751,000)	(52,000)
Gains or losses	...	6,066,000
Foreign currency	1,444,000	299,000
Net before taxes	67,845,000	81,686,000
Income taxes	14,633,000	28,644,000
<b>Net income</b>	<b>53,212,000</b>	<b>53,042,000</b>
Earnings common share		
Primary	\$0.88	\$0.97
Fully Diluted	\$0.87	\$0.96

Common Shares:		
Full Diluted	51,760,000	51,751,000
Year-end	51,204,959	51,448,753

**PRINCIPIA BIOPHARMA INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	43,000	1,873
Cost & expenses	34,120	22,276
Operating income	8,880	(20,403)
Interest expense	...	5,566
Other income (expense), net	(90)	102
<b>Net income</b>	<b>8,790</b>	<b>(25,867)</b>
Earnings common share		
Primary	\$(46.85)	\$(46.85)
Fully Diluted	\$(46.85)	\$(46.85)
Common Shares:		
Full Diluted	3,097	552
Year-end	23,861	...

**PROTAGENIC THERAPEUTICS INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	1,789,879	1,656,541
Operating income	(1,789,879)	(1,656,541)
Gains or losses	17,748	81,509
Invest. income	1,568	963
<b>Net income</b>	<b>(1,767,869)</b>	<b>(1,563,512)</b>
Earnings common share		
Primary	\$(0.17)	\$(0.15)
Fully Diluted	\$(0.17)	\$(0.15)
Common Shares:		
Full Diluted	10,261,419	10,261,419
Year-end	10,261,419	10,261,419

**PTC INC****Annual Report****Consolidated Income Statement, Years Ended Sept. 30****(\$000):**

	2018	2017	2016
		(revised)	(revised)
Subscription revenue	482,027	279,246	118,322
Support revenue	496,826	574,680	651,807
Total recurring software revenue	978,853	853,926	770,129
Perpetual license revenue	109,634	133,390	173,467
Total subscription, support & license revenue	1,088,487	987,316	943,596
Professional services revenue	153,337	176,723	196,937
Total revenue	1,241,824	1,164,039	1,140,533
Cost of license & subscription revenue	94,108	86,047	69,710
Cost of support revenue	88,575	92,202	85,729
Cost of software revenue	182,683	178,249	155,439
Cost of professional services revenue	143,511	150,770	170,226
Total cost of revenue	326,194	329,019	325,665
Gross margin	915,630	835,020	814,868
Sales & marketing expenses	414,524	372,946	367,465
Research & development expenses	249,774	236,059	229,331
General & administrative expenses	142,981	145,067	145,615
Amortization of acquired intangible assets	31,350	32,108	33,198
Restructuring & other charges, net	3,764	7,942	...
Restructuring charges	...	...	76,273
Total operating expenses	842,393	794,122	851,882

Operating income (loss)	73,237	40,898	(37,014)
Foreign currency gains (losses), net	(6,982)	(5,686)	(1,889)
Interest income	3,819	3,249	3,437
Interest expense	41,673	42,400	29,882
Other income (expense), net	255	2,533	(1,844)
Income (loss) before income taxes	(114,591)	(140,150)	(156,166)
Income (loss) before income taxes - foreign	143,247	138,744	88,974
Income (loss) before income taxes	28,656	(1,406)	(67,192)
Current provision for (benefit from) income taxes - federal	3,009	2,423	2,417
Current provision for (benefit from) income taxes - state	2,003	340	571
Current provision for (benefit from) income taxes - foreign	28,213	17,881	28,467
Total current provision for (benefit from) income taxes	33,225	20,644	31,455
Deferred provision for (benefit from) income taxes - federal	(12,594)	4,911	965
Deferred provision for (benefit from) income taxes - state	(445)	877	515
Deferred provision for (benefit from) income taxes - foreign	(43,517)	(34,077)	(45,662)
Total deferred provision for (benefit from) income taxes	(56,556)	(28,289)	(44,182)
Provision (benefit) for income taxes	(23,331)	(7,645)	(12,727)
<b>Net income (loss)</b>	<b>51,987</b>	<b>6,239</b>	<b>(54,465)</b>
Weighted average shares outstanding - basic	116,390	115,523	114,612
Weighted average shares outstanding - diluted	118,158	117,356	114,612
Year end shares outstanding	115,333	115,333	114,968
Net income (loss) per share - basic	\$0.45	\$0.05	\$(0.48)
Net income (loss) per share - diluted	\$0.44	\$0.05	\$(0.48)
Total number of employees	6,110	6,041	5,800
Number of common stockholders	1,138	1,209	1,299
Foreign currency translation adjustments	...	...	408

□ Reclassified to conform with 2018 presentation; □ Reclassified to conform with 2017 presentation; □ As is; □ As of November 13, 2018; □ As of November 27, 2017; □ As of November 16, 2016

**Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):**

	2018	2017
		(revised)
Cash & cash equivalents	259,946	280,003
Short term marketable securities	25,836	18,408
Accounts receivable, gross	129,904	153,361

Less allowance for doubtful accounts	607	1,062
Accounts receivable, net	129,297	152,299
Prepaid expenses	48,997	49,913
Other current assets	169,708	165,933
Total current assets	633,784	666,556
Computer hardware & software	324,765	286,380
Furniture & fixtures	20,737	21,145
Leasehold improvements	47,272	47,658
Gross property & equipment	392,774	355,183
Accumulated depreciation & amortization	312,161	291,583
Property & equipment, net	80,613	63,600
Goodwill	1,182,457	1,182,772
Acquired intangible assets, net	200,202	257,908
Long term marketable securities	30,115	31,907
Deferred tax assets	165,566	123,166
Other assets	36,285	34,475
Total assets	2,329,022	2,360,384
Accounts payable	53,473	35,160
Accrued expenses & other current liabilities	74,388	80,761
Accrued compensation & benefits	101,784	110,957
Accrued income taxes	18,044	5,735
Deferred revenue	487,590	446,296
Total current liabilities	735,279	678,909
Senior notes	500,000	500,000
Credit facility-revolver	148,125	218,125
Total debt	648,125	718,125
Unamortized debt issuance costs for the senior notes	(4,857)	(5,719)
Total debt, net of issuance costs	643,268	712,406
Long-term debt, net of current portion	643,268	712,406
Deferred tax liabilities	5,589	17,880
Deferred revenue	11,852	12,611
Other liabilities	58,445	53,142
Total liabilities	1,454,433	1,474,948
Common stock	1,180	1,153
Additional paid-in capital	1,558,403	1,609,030
Retained earnings (accumulated deficit)	(599,409)	(650,840)
Accumulated other comprehensive income (loss)	(85,585)	(73,907)
Total stockholders' equity (deficit)	874,589	885,436

**Recent Dividends:****1. PTC Inc common.**

No dividends paid.

**Annual Dividends:****1. PTC Inc common.**

No dividends paid.

**QAD, INC.****Earnings, 9 mos. to Oct 31(Consol. – \$000):**

	2018	2017
Total Revenues	250,310	224,265
Cost & expenses	244,256	224,292
Operating income	6,009	(386)
Interest income	1,913	1,101
Interest expense	488	508
Other income (expense), net	1,309	(1,399)
Net before taxes	8,743	(1,192)
Income taxes	3,251	2,701
<b>Net income</b>	5,492	(3,893)
Earnings common share		
Primary	\$0.29	\$(0.21)
Fully Diluted	\$0.26	\$(0.21)
Common Shares:		
Full Diluted	17,911	15,913
Year-end	19,625	19,243

**QUICKLOGIC CORP****Earnings, 9 mos. to (Consol. – \$):**

	09/30/18	10/01/17
Total Revenues	9,396,000	9,168,000
Cost & expenses	19,940,000	19,644,000
Operating income	(10,544,000)	(10,476,000)
Interest expense	77,000	97,000
Net before taxes	(10,595,000)	(10,575,000)
Income taxes	119,000	147,000
<b>Net income</b>	(10,714,000)	(10,722,000)
Earnings common share		
Primary	\$(0.12)	\$(0.14)
Fully Diluted	\$(0.12)	\$(0.14)
Common Shares:		
Full Diluted	87,040,000	76,267,000
Year-end	94,922,000	80,171,000

**RADISYS CORP.**

**Merger Completed** On Dec. 11, 2018, Integrated Cloud Orchestration (ICO), Inc. ("Merger Sub"), an Oregon corporation and wholly owned subsidiary of Reliance Industries Limited, a company organized and existing under the laws of India ("Reliance") merged with and into Co., with Co. surviving the Merger as a wholly owned subsidiary of Reliance (the "Merger"). As a result of the Merger, each share of common stock, no par value, of Co. (collectively, "Shares") issued and outstanding (other than shares owned by Reliance, Merger Sub or any other wholly owned subsidiary of Co. or Reliance or held in the treasury of Co., all of which were cancelled without any consideration being exchanged therefor) was cancelled and extinguished and automatically converted into the right to receive \$1.72 in cash, without interest, and less any applicable withholding taxes (the "Merger Consideration"). In addition, as of the effective time, all outstanding stock options and restricted stock unit awards were cancelled and converted into the right to receive a specified amount of cash (subject to any applicable withholding tax), without interest, based on the Merger Consideration.

**RADNET INC****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	717,935,000	686,634,000
Cost & expenses	633,083,000	604,568,000
Operating income	31,430,000	31,747,000
Interest expense	31,343,000	30,712,000
Other income (expense), net	9,534,000	8,608,000
Gains or losses		3,146,000
Net before taxes	9,621,000	12,789,000
Income taxes	2,835,000	4,177,000
<b>Net income</b>	6,786,000	8,612,000
Earnings common share		
Primary	\$0.06	\$0.16
Fully Diluted	\$0.06	\$0.16
Common Shares:		
Full Diluted	48,481,305	47,239,360
Year-end	48,334,925	47,536,958

**RAMBUS INC. (DE)****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	162,638	291,205
Cost & expenses	245,405	252,517
Operating income	(82,767)	38,688
Net before taxes	(70,425)	29,425
Income taxes	85,514	16,119
<b>Net income</b>	(155,939)	13,306
Earnings common share		
Primary	\$(1.44)	\$0.12
Fully Diluted	\$(1.44)	\$0.12
Common Shares:		
Full Diluted	108,324	113,861
Year-end	108,501	109,778

**RAVEN INDUSTRIES, INC.****Earnings, 9 mos. to Oct 31(Consol. – \$000):**

	2018	2017
Net Sales	318,646	281,494
Cost & expenses	266,874	233,746
Operating income	51,772	47,748
Other income (expense), net	6,214	(327)
Net before taxes	57,986	47,421
Income taxes	9,062	14,842
<b>Net income</b>	48,924	32,579
Earnings common share		
Primary	\$1.36	\$0.90
Fully Diluted	\$1.34	\$0.89
Common Shares:		

Full Diluted	36,439	36,477
Year-end	35,953	35,756

**REDFIN CORP****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	362,791	274,282
Cost & expenses	394,219	287,885
Operating income	(31,428)	(13,603)
Interest income	3,082	387
Interest expense	1,610	
Other income (expense), net	200	13
<b>Net income</b>	(29,756)	(13,203)
Balance for common	(29,756)	(189,118)
Earnings common share		
Primary	\$(0.35)	\$(6.37)
Fully Diluted	\$(0.35)	\$(6.37)
Common Shares:		
Full Diluted	84,327	29,678
Year-end	89,235	81,385

**REGULUS THERAPEUTICS INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	54	54
Cost & expenses	38,835	56,479
Operating income	(38,781)	(56,425)
Net before taxes		(57,596)
Income taxes		(139)
<b>Net income</b>	(40,146)	(57,457)
Earnings common share		
Primary	\$(4.62)	\$(10.52)
Fully Diluted	\$(4.62)	\$(10.52)
Common Shares:		
Full Diluted	8,689	5,463
Year-end	8,662	8,663

**REPLIMUNE GROUP INC****Earnings, 6 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	12,983	7,432
Operating income	(12,983)	(7,432)
Interest income	891	40
Other income (expense), net	(4,413)	(820)
<b>Net income</b>	(16,505)	(8,212)
Balance for common	(16,505)	(8,212)
Earnings common share		
Primary	\$(1.11)	\$(1.65)
Fully Diluted	\$(1.11)	\$(1.65)
Common Shares:		
Full Diluted	14,831	4,976
Year-end	31,554	

**RETAIL OPPORTUNITY INVESTMENTS CORP****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	220,640,000	200,506,000
Cost & expenses	68,313,000	61,541,000
Operating income	76,444,000	67,635,000
Other income (expense), net	5,890,000	
<b>Net income</b>	35,573,000	30,575,000
Earnings common share		
Primary	\$0.28	\$0.25
Fully Diluted	\$0.28	\$0.25
Common Shares:		
Full Diluted	124,410,038	121,200,615
Year-end	113,984,835	

**RETROPHIN, INC.****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Cost & expenses	195,530,000	151,374,000
Operating income	(75,055,000)	(38,614,000)
Interest income	2,905,000	2,460,000
Other income (expense), net	(17,414,000)	(7,856,000)
Net before taxes	(94,412,000)	(47,325,000)
Income taxes	811,000	(5,212,000)
<b>Net income</b>	(95,223,000)	(42,113,000)
Earnings common share		
Primary	\$(2.37)	\$(1.10)
Fully Diluted	\$(2.37)	\$(1.10)
Common Shares:		
Full Diluted	40,149,184	38,301,893
Year-end	41,167,942	39,280,702

**REVANNE THERAPEUTICS INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Total Revenues .....	3,242	225
Cost & expenses .....	107,473	84,868
Operating income .....	(104,231)	(84,643)
Interest income .....	3,099	999
Interest expense .....	44	439
Other income (expense), net .....	(776)	(597)
<b>Net income</b> .....	(101,952)	(84,680)
Earnings common share		
Primary .....	\$(2.82)	\$(2.86)
Fully Diluted .....	\$(2.82)	\$(2.86)
Common Shares:		
Full Diluted .....	36,117	29,624
Year-end .....	36,992	30,935

**RHYTHM PHARMACEUTICALS INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Cost & expenses .....	51,266	21,429
Operating income .....	(51,266)	(21,429)
Interest income .....	2,709	114
Other income (expense), net .....		(1,863)
<b>Net income</b> .....	(48,557)	(23,178)
Balance for common .....	(48,557)	(26,963)
Earnings common share		
Primary .....	\$(1.63)	\$(3.02)
Fully Diluted .....	\$(1.63)	\$(3.02)
Common Shares:		
Full Diluted .....	29,859	8,918
Year-end .....	34,383	

**RIGEL PHARMACEUTICALS INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Total Revenues .....	6,652	4,484
Cost & expenses .....	81,867	57,885
Operating income .....	(75,215)	(53,401)
Interest income .....	1,507	548
Gains or losses .....		732
<b>Net income</b> .....	(73,708)	(52,121)
Earnings common share		
Primary .....	\$(0.47)	\$(0.43)
Fully Diluted .....	\$(0.47)	\$(0.43)
Common Shares:		
Full Diluted .....	158,456	120,282
Year-end .....	166,640	146,491

**RIGNET INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Total Revenues .....	178,610	148,078
Cost & expenses .....	163,675	132,667
Deprec., depl. & amort. ....	24,756	22,867
Operating income .....	(9,821)	(7,456)
Interest expense .....	2,773	1,921
Other income (expense), net .....	(40)	62
Net before taxes .....	(12,634)	(9,315)
Income taxes .....	(11)	1,075
<b>Net income</b> .....	(12,623)	(10,390)
Earnings common share		
Primary .....	\$(0.69)	\$(0.58)
Fully Diluted .....	\$(0.69)	\$(0.58)
Common Shares:		
Full Diluted .....	18,566	17,982
Year-end .....	19,322	

**ROCKET PHARMACEUTICALS INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Cost & expenses .....	44,611	22,535
Operating income .....	(44,611)	(22,535)
Interest income .....	1,264	574
Interest expense .....	4,010	2,666
Other income (expense), net .....	158	
<b>Net income</b> .....	(47,199)	(24,627)
Earnings common share		
Primary .....	\$(1.22)	\$(3.64)
Fully Diluted .....	\$(1.22)	\$(3.64)
Common Shares:		
Full Diluted .....	38,598	6,752
Year-end .....	39,836	6,806

**ROKU INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Total Revenues .....	466,767	324,502
Cost & expenses .....	485,550	353,612
Operating income .....	(18,783)	(29,110)
Interest expense .....	220	1,286
Other income (expense), net .....	2,971	(39,910)
Net before taxes .....	(16,032)	(70,306)
Income taxes .....	(397)	144
<b>Net income</b> .....	(15,635)	(70,450)
Balance for common .....	(15,635)	(70,450)
Earnings common share		
Primary .....	\$(0.15)	\$(14.09)
Fully Diluted .....	\$(0.15)	\$(14.09)
Common Shares:		
Full Diluted .....	103,035	4,999
Year-end .....	108,799	5,638

**ROSS STORES, INC.**

<b>Earnings, 9 mos. to</b> (Consol. – \$000):	11/03/18	10/28/17
Net Sales .....	10,876,153	10,066,926
Cost & expenses .....	9,372,265	8,617,738
Operating income .....	1,503,888	1,449,188
Net before taxes .....	1,503,888	1,449,188
Income taxes .....	358,124	537,182
<b>Net income</b> .....	1,145,764	912,006
Earnings common share		
Primary .....	\$3.09	\$2.38
Fully Diluted .....	\$3.06	\$2.36
Common Shares:		
Full Diluted .....	373,936	385,823
Year-end .....	371,058	382,146

**RUBIUS THERAPEUTICS INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Cost & expenses .....	62,541	25,791
Operating income .....	(62,541)	(25,791)
Interest expense .....	259	212
Other income (expense), net .....	788	(327)
<b>Net income</b> .....	(62,012)	(26,330)
Balance for common .....	(62,012)	(26,986)
Earnings common share		
Primary .....	\$(2.33)	\$(3.42)
Fully Diluted .....	\$(2.33)	\$(3.42)
Common Shares:		
Full Diluted .....	26,662	7,900
Year-end .....	79,043	

**RUTH'S HOSPITALITY GROUP INC**

<b>Earnings, 9 mos. to</b> (Consol. – \$000):	09/30/18	09/24/17
Total Revenues .....	325,175	290,720
Net Sales .....	307,390	273,042
Cost & expenses .....	278,466	248,854
Operating income .....	32,947	30,777
Interest expense .....	1,253	521
Other income (expense), net .....	(31)	33
Net before taxes .....	31,663	30,289
Income taxes .....	4,873	9,632
Income contin. oper. ....	26,790	20,657
<b>Net income</b> .....	26,820	20,556
Earnings common share		
Primary .....	\$0.90	\$0.67
Fully Diluted .....	\$0.88	\$0.66
Common Shares:		
Full Diluted .....	30,370	31,041
Year-end .....	29,731	30,549

**SAFETY INSURANCE GROUP, INC.**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Total Revenues .....	633,596	625,548
Cost & expenses .....	552,556	552,981
Operating income .....	81,040	72,567
Net before taxes .....	81,040	72,567
Income taxes .....	16,191	21,489
<b>Net income</b> .....	64,849	51,078
Earnings common share		
Primary .....	\$4.28	\$3.38
Fully Diluted .....	\$4.24	\$3.36
Common Shares:		

Full Diluted .....	15,218	15,124
Year-end .....	15,287	15,220

**SAGA COMMUNICATIONS INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Total Revenues .....	91,891	86,685
Cost & expenses .....	78,218	73,327
Operating income .....	13,673	13,358
Interest income .....	444	
Other income (expense), net .....	25	
Net before taxes .....	13,425	12,667
Income taxes .....	4,030	5,280
Income contin. oper. ....		7,387
<b>Net income</b> .....	9,395	39,888
Balance for common .....	9,235	39,206
Earnings common share		
Primary .....	\$1.58	\$6.76
Fully Diluted .....	\$1.58	\$6.76
Common Shares:		
Full Diluted .....	5,833	5,804
Year-end .....	5,910	5,907

**SAKER AVIATION SERVICES, INC.**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$):	2018	2017
Total Revenues .....	8,236,353	8,743,913
Cost & expenses .....	7,953,017	7,994,350
Operating income .....	283,336	749,563
Interest income .....	32,703	
Interest expense .....	13,386	17,091
Other income (expense), net .....		(10,000)
Net before taxes .....	302,653	722,472
Income taxes .....	102,454	414,241
<b>Net income</b> .....	200,199	308,231
Earnings common share		
Primary .....	\$0.01	\$0.01
Fully Diluted .....	\$0.01	\$0.01
Common Shares:		
Full Diluted .....	31,424,188	34,415,005
Year-end .....	30,195,034	33,422,995

**SANMINA CORP**

<b>Annual Report</b>			
<b>Consolidated Income Statement, Years Ended (\$000):</b>			
	09/29/18	09/30/17	10/01/16
		(revised)	(revised)
Net sales .....	7,110,130	6,868,619	6,481,181
Cost of sales .....	6,646,347	6,348,708	5,966,899
Gross profit .....	463,783	519,911	514,282
Selling, general & administrative expenses .....	250,924	251,568	244,604
Research & development expenses .....	30,754	33,716	37,746
Restructuring costs .....	29,146	1,339	2,701
Goodwill impairment .....	30,610		
Amortization of intangible assets .....	2,908	3,672	3,446
Asset impairment .....		4,600	1,000
Gain (loss) on sale of long-lived assets .....		1,451	
Other operating expenses .....	2,908	6,821	4,446
Total operating expenses .....	344,342	293,444	289,497
Operating income (loss) .....	119,441	226,467	224,785
Interest income .....	1,268	1,265	680
Interest expense .....	27,734	21,934	24,911
Foreign exchange gains (losses) .....	766	4,709	(415)
Bargain purchase gain, net of tax .....			1,642
Other income (expenses), net .....	3,798	2,973	2,836
Interest & other income (expense), net .....	(21,902)	(12,987)	(20,168)
Income (loss) before income taxes - domestic .....	16,215	128,493	138,138





Fully Diluted	\$(0.34)	\$(0.41)
Common Shares:		
Full Diluted	80,751	80,254
Year-end	81,658	

**SEMTECH CORP.****Earnings, 9 mos. to (Consol. – \$000):**

	10/28/18	10/29/17
Net Sales	467,190	447,233
Cost & expenses	375,563	372,092
Operating income	71,706	54,727
Interest expense	6,745	6,107
Other income (expense), net	(28,086)	431
Net before taxes	36,875	49,051
Income taxes	(12,882)	11,124
<b>Net income</b>	<b>49,716</b>	<b>37,723</b>
Earnings common share		
Primary	\$0.75	\$0.57
Fully Diluted	\$0.73	\$0.56
Common Shares:		
Full Diluted	68,549	67,555
Year-end	65,780	66,312

**SERES THERAPEUTICS INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	17,638	29,044
Cost & expenses	96,251	90,664
Operating income	(78,613)	(61,620)
Interest income	958	1,193
<b>Net income</b>	<b>(77,655)</b>	<b>(60,427)</b>
Earnings common share		
Primary	\$(1.91)	\$(1.49)
Fully Diluted	\$(1.91)	\$(1.49)
Common Shares:		
Full Diluted	40,699	40,420
Year-end	40,844	40,513

**SESEN BIO INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	425	425
Cost & expenses	27,434	23,087
Operating income	(27,434)	(22,662)
Other income (expense), net	498	180
<b>Net income</b>	<b>(26,936)</b>	<b>(22,482)</b>
Earnings common share		
Primary	\$(0.48)	\$(0.91)
Fully Diluted	\$(0.48)	\$(0.91)
Common Shares:		
Full Diluted	56,526	24,663
Year-end	77,089	24,698

**SHOE CARNIVAL, INC.****Earnings, 9 mos. to (Consol. – \$000):**

	11/03/18	10/28/17
Net Sales	794,992	775,922
Cost & expenses	746,729	738,391
Operating income	48,263	37,531
Interest income	392	3
Interest expense	113	248
Net before taxes	48,542	37,286
Income taxes	11,766	14,462
<b>Net income</b>	<b>36,776</b>	<b>22,824</b>
Balance for common	36,624	22,496
Earnings common share		
Primary	\$2.40	\$1.38
Fully Diluted	\$2.36	\$1.38
Common Shares:		
Full Diluted	15,544	16,293
Year-end	15,570	16,952

**SIENNA BIOPHARMACEUTICALS INC****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Cost & expenses	56,729,000	34,582,000
Operating income	(56,729,000)	(34,582,000)
Other income (expense), net	2,593,000	(4,986,000)
Net before taxes	(39,568,000)	(39,568,000)
Income taxes	(212,000)	(212,000)
<b>Net income</b>	<b>(54,136,000)</b>	<b>(39,356,000)</b>
Earnings common share		
Primary	\$(2.66)	\$(6.31)
Fully Diluted	\$(2.66)	\$(6.31)

Common Shares:		
Full Diluted	20,331,000	6,233,000
Year-end	20,756,000	

**SMG INDUSTRIES INC**

**Acquisition Completed** On Dec. 7, 2018, Co. acquired one hundred percent (100%) of the issued and outstanding membership interests ("MWTS Membership Interests") of Momentum Water Transfer Services LLC, a Texas limited liability company ("MWTS") from the sole member of MWTS (the "MWTS Member") pursuant to which MWTS became Co.'s wholly owned subsidiary ("Acquisition"). As a result of the Acquisition, Co. issued 550,000 shares of its common stock, par value \$0.001 per share, paid \$361,710 in cash and issued a note to the MWTS Member in the amount of \$800,000 in exchange for all of the issued and outstanding MWTS Membership Interests. Principal and interest on the note shall be repaid in sixty (60) equal monthly payments of \$7,500.00 ("Installment Payments") and a final balloon payment for the remaining principal and accrued interest due on the maturity date. The note bears interest at a rate of 6% per annum. The note and the repayment thereof shall be secured by all of Co.'s assets, subject to prior security interests which includes the Crestmark Bank line of credit, up to \$2,000,000 of 8.5% Secured Promissory Notes to be issued by Co., and other previously issued and outstanding notes.

**SMG INDUSTRIES INC****Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	3,192,432	1,802,486
Cost & expenses	3,424,690	2,067,770
Operating income	(232,258)	(265,284)
Gains or losses	23,291	
<b>Net income</b>	<b>(408,066)</b>	<b>(342,416)</b>
Earnings common share		
Primary	\$(0.04)	\$(0.21)
Fully Diluted	\$(0.04)	\$(0.21)
Common Shares:		
Full Diluted	9,986,415	1,665,192
Year-end	11,316,690	7,700,190

**SOLID BIOSCIENCES INC****Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	53,301	39,696
Operating income	(53,301)	(39,696)
Interest income	237	165
Other income (expense), net	187	840
<b>Net income</b>	<b>(52,877)</b>	<b>(38,691)</b>
Earnings common share		
Primary	\$(1.61)	\$(1.99)
Fully Diluted	\$(1.61)	\$(1.99)
Common Shares:		
Full Diluted	32,800	12,447
Year-end	35,432	

**SONIC CORP.**

**Merger Completed** On Dec. 7, 2018, Inspire Brands, Inc. ("Parent"), a multi-brand restaurant company whose portfolio includes more than 4700 Arby's, Buffalo Wild Wings, and Rusty Taco locations worldwide, wholly-owned subsidiary, SSK Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each share of common stock, par value \$0.01 per share, of Co. (the "Common Stock"), issued and outstanding immediately prior to the Effective Time (other than shares of Common Stock (i) held in treasury by Co. or owned by any direct or indirect wholly-owned subsidiary of Co., (ii) owned by Parent or Merger Sub or any direct or indirect wholly owned subsidiary of Parent or (iii) for which appraisal rights have been properly demanded in accordance with the General Corporation Law of the State of Delaware) was cancelled and automatically converted into the right to receive \$43.50 in cash, without interest (the "Merger Consideration"), subject to the terms and conditions set forth in the Merger Agreement. In addition, each option of Co. that was outstanding and unexercised immediately prior to the Effective Time (each, a "Co. Option"), whether or not vested or exercisable, became vested and, at the Effective Time, each Co. Option that had an exercise price per share below the Merger Consideration was cancelled and converted into the right to receive a cash payment equal to the product of (i) the excess of the Merger Consideration over the exercise price per share of Co. Option and (ii) the aggregate number of shares of Common Stock issuable upon exercise of such option. Each Co. Option that had an exercise price per share equal to or greater than

the Merger Consideration was cancelled as of the Effective Time without payment of any cash consideration. In connection with the Merger, each unvested restricted stock unit of Co. that was outstanding immediately prior to the Effective Time vested and, at the Effective Time, was cancelled and converted into the right to receive a cash payment equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of Common Stock subject to such restricted stock unit.

**SONOS INC****Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	09/29/18	09/30/17	10/01/16
		(revised)	(revised)
Revenue	1,137,008	992,526	901,284
Cost of revenue	647,700	536,461	497,885
Gross profit	489,308	456,065	403,399
Research & development expense	142,109	124,394	107,729
Sales & marketing expense	270,869	270,162	258,012
General & administrative expense	85,205	77,118	68,531
Total operating expenses	498,183	471,674	434,272
Operating income (loss)	(8,875)	(15,609)	(30,873)
Interest expense, net	4,511	4,260	2,489
Other income (expense), net	(1,162)	3,361	(2,208)
Income (loss) before provision for (benefit from) income taxes	(14,548)	(16,508)	(35,570)
Current U.S. Federal income tax provision (benefit)	...	...	129
Current U.S. state income taxes	177	62	59
Current foreign income tax provision (benefit)	816	(3,791)	3,344
Total current income tax provision (benefit)	993	(3,729)	3,532
Deferred U.S. Federal income tax provision (benefit)	(168)	...	...
Deferred foreign income tax provision (benefit)	231	1,438	(888)
Deferred income taxes	63	1,438	(888)
Provision for (benefit from) income taxes	1,056	(2,291)	2,644
<b>Net income (loss)</b>	<b>(15,604)</b>	<b>(14,217)</b>	<b>(38,214)</b>
Weighted average shares outstanding-basic	65,706	56,315	53,873
Weighted average shares outstanding-diluted	65,706	56,315	53,873
Year end shares outstanding	<sup>1</sup> 100,061	58,593	54,833
Net income (loss) per share-basic	\$(0.24)	\$(0.25)	\$(0.71)
Net income (loss) per share-diluted	\$(0.24)	\$(0.25)	\$(0.71)
Number of full time employees	<sup>2</sup> 1,352	<sup>2</sup> 1,478	...
Number of stockholders	<sup>2</sup> <sup>3</sup> 521	...	...
Foreign currency translation adjustments	488	...	...

<sup>1</sup> Shares increased due to issuance of common stock upon ipo, exercise of stock options, & conversion of redeemable preferred stock; <sup>2</sup> As Is; <sup>3</sup> As of March 31, 2018; <sup>4</sup> As of November 16, 2018

**Consolidated Balance Sheet, Years Ended (\$000):**

	09/29/18	09/30/17
Cash & cash equivalents	220,930	130,595
Restricted cash	190	193
Accounts receivable, net	73,214	47,363
Finished goods	176,181	104,014
Components	17,012	9,842
Inventories	193,193	113,856
Prepaid & other current assets	10,073	9,462
Total current assets	497,600	301,469
Computer hardware & software	46,385	42,928
Furniture & fixtures	9,696	9,840
Tooling & production line test equipment	47,297	42,368
Leasehold improvements	53,962	53,479
Product displays	40,265	55,855
Property & equipment, gross	197,605	204,470
Less accumulated depreciation & amortization	112,234	109,340
Property & equipment, net	85,371	95,130
Deferred tax asset, net	941	1,107
Other noncurrent assets	3,586	2,314
Total assets	587,498	400,020
Accounts payable	195,159	114,494
Accrued advertising & marketing	11,613	10,880
Accrued taxes	4,175	4,800
Accrued inventory	4,179	22,563
Accrued manufacturing, logistics & product development	8,290	4,921
Other accrued payables	10,430	14,184
Accrued expenses	38,687	57,348
Accrued compensation	33,371	32,007
Short-term debt	6,667	...
Deferred revenue	11,615	10,920
Other current liabilities	10,858	8,497
Total current liabilities	296,357	223,266
Secured term loan	40,000	40,000
Less: unamortized debt issuance costs	(236)	(400)
Total debt before current portion	39,764	39,600
Less: Current portion	6,667	...
Long-term debt, net	33,097	39,600
Deferred revenue	39,352	34,647
Other non-current liabilities	10,334	12,139
Total liabilities	379,140	309,652
Redeemable convertible preferred stock	...	90,341
Common stock	101	59
Treasury stock	11,072	10,161
Additional paid-in capital	424,617	200,301
Retained earnings (accumulated deficit)	(203,611)	(188,007)
Accumulated other comprehensive income (loss)	(1,677)	(2,165)
Total shareholders' equity (deficit)	208,358	27

□ Reclassified to conform with 2018 presentation

#### Recent Dividends:

**1. Sonos Inc common.**  
No dividends paid.

#### Annual Dividends:

**1. Sonos Inc common.**  
No dividends paid.

#### SORL AUTO PARTS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	314,390,788	237,390,345
Operating income	30,425,177	30,199,608
Interest income	2,847,299	38,175
Interest expense	10,214,681	1,827,835
Other income (expense), net	2,214,068	824,289

Foreign currency	1,396,460	(1,193,897)
Net before taxes	26,668,323	28,040,340
Income taxes	14,974,982	4,225,404
<b>Net income</b>	11,693,341	23,814,936
Balance for common	9,411,708	21,433,443
Earnings common share		
Primary	\$0.49	\$1.11
Fully Diluted	\$0.49	\$1.11
Common Shares:		
Full Diluted	19,304,921	19,304,921
Year-end	19,304,921	19,304,921

#### SOTHERLY HOTELS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	134,707,144	116,106,987
Cost & expenses	101,832,585	90,054,545
Deprec., depl. & amort.	15,783,174	12,708,548
Operating income	17,091,385	13,343,894
Interest income	236,693	126,241
Interest expense	14,571,142	11,827,061
Other income (expense), net	(611,163)	(258,835)
Gains or losses	898,565	1,119,622
Net before taxes	3,044,338	2,503,861
Income taxes	882,045	(581,890)
<b>Net income</b>	2,162,293	3,085,751
Balance for common	(1,951,816)	597,385
Earnings common share		
Primary	\$(0.14)	\$0.04
Fully Diluted	\$(0.14)	\$0.04
Common Shares:		
Full Diluted	13,491,807	13,885,290
Year-end	14,209,378	13,823,459

#### SOTHERLY HOTELS LP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	134,707,144	116,106,987
Cost & expenses	101,832,585	90,054,545
Deprec., depl. & amort.	15,783,174	12,708,548
Operating income	17,091,385	13,343,894
Interest income	236,693	126,241
Interest expense	14,571,142	11,827,061
Other income (expense), net	287,402	782,980
Gains or losses	...	77,807
Net before taxes	3,044,338	2,503,861
Income taxes	882,045	(581,890)
<b>Net income</b>	2,162,293	3,085,751
Earnings common share		
Primary	\$(0.14)	\$0.04
Fully Diluted	\$(0.14)	\$0.04
Common Shares:		
Full Diluted	15,902,565	16,256,713
Year-end	15,987,515	...

#### SP PLUS CORP

**Acquisition Completed** On Nov. 30, 2018, Co. acquired acquire all the outstanding shares of ZWB Holdings, Inc. ("ZWB"), Rynn's Luggage Corp. ("RLC") and the direct and indirect subsidiaries of ZWB and RLC (together with ZWB and RLC, the "Target Companies"), both companies operate luggage retail stores and luggage repair facilities, from Craig Mateer (the "Seller") for \$275,000,000 in cash, subject to certain adjustments (the "Purchase Price"). On the Closing date, an aggregate of \$27,800,000 of the Purchase Price was deposited into an escrow account and would be held by an escrow agent to secure certain obligations of the Seller under the Purchase Agreement.

#### SP PLUS CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,091,200	1,198,100
Cost & expenses	1,018,900	1,117,500
Deprec., depl. & amort.	12,700	16,300
Operating income	59,600	64,300
Interest income	300	500
Interest expense	6,500	7,100
Other income (expense), net	10,100	(500)
Gains or losses	...	100
Net before taxes	63,500	57,300
Income taxes	16,900	21,300
<b>Net income</b>	46,600	36,000
Earnings common share		
Primary	\$1.97	\$1.51
Fully Diluted	\$1.95	\$1.48

Common Shares:		
Full Diluted	22,607	22,501
Year-end	22,730	22,509

#### SPARK THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	51,568,000	4,657,000
Cost & expenses	186,824,000	200,365,000
Operating income	(135,256,000)	195,708,000
Interest income	7,420,000	2,231,000
Other income (expense), net	114,291,000	...
Net before taxes	(13,545,000)	193,477,000
Income taxes	20,000	(1,816,000)
<b>Net income</b>	(13,565,000)	191,661,000
Earnings common share		
Primary	\$(0.36)	\$(5.89)
Fully Diluted	\$(0.36)	\$(5.89)
Common Shares:		
Full Diluted	37,267,942	32,516,829
Year-end	37,610,295	37,610,295

#### SPERO THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	2,274	986
Cost & expenses	33,996	28,716
Operating income	(31,722)	(27,730)
Gains or losses	...	1,547
<b>Net income</b>	(31,063)	(26,018)
Balance for common	(31,063)	(31,327)
Earnings common share		
Primary	\$(2.01)	\$(93.96)
Fully Diluted	\$(2.01)	\$(93.96)
Common Shares:		
Full Diluted	15,417	333
Year-end	18,182	335

#### SPLUNK INC

Earnings, 9 mos. to Oct 31(Consol. - \$000):

	2018	2017
Total Revenues	1,180,925	849,481
Cost & expenses	1,456,255	1,069,214
Operating income	(275,330)	(219,733)
Interest income	15,322	6,273
Interest expense	16,401	6,695
Other income (expense), net	(657)	(1,771)
Net before taxes	(277,066)	(221,926)
Income taxes	637	1,459
<b>Net income</b>	(277,703)	(223,385)
Earnings common share		
Primary	\$(1.91)	\$(1.61)
Fully Diluted	\$(1.91)	\$(1.61)
Common Shares:		
Full Diluted	145,015	139,111
Year-end	147,783	...

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	1,868,116
Current assets	3,108,068
Net property & equip.	156,502
Total assets	4,139,674
Liabilities:	
Current liabilities	809,396
Long-term debt	1,614,945
Stockholders' equity	1,421,867
Net current assets	2,298,672

#### SPORTSMAN'S WAREHOUSE HOLDINGS INC

Earnings, 9 mos. to (Consol. - \$000):

	11/03/18	10/28/17
Net Sales	606,447	566,506
Cost & expenses	579,396	536,517
Operating income	27,051	29,989
Interest expense	10,524	10,081
Net before taxes	16,527	19,908
Income taxes	3,406	8,053
<b>Net income</b>	13,121	11,855
Earnings common share		
Primary	\$0.31	\$0.28
Fully Diluted	\$0.31	\$0.28
Common Shares:		
Full Diluted	42,937	42,501
Year-end	42,938	42,579

**SRC ENERGY INC****Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Cost & expenses	106,613,000	60,115,000
Operating income	224,539,000	88,908,000
Interest income	37,000	47,000
Other income (expense), net	152,000	385,000
Gains or losses	(28,604,000)	2,324,000
Net before taxes	196,124,000	
Income taxes	18,076,000	
<b>Net income</b>	<b>178,048,000</b>	<b>91,664,000</b>
Earnings common share		
Primary	\$0.74	\$0.46
Fully Diluted	\$0.73	\$0.46
Common Shares:		
Full Diluted	243,207,058	201,326,129
Year-end	242,572,199	

**SUNPOWER CORP****Earnings, 9 mos. to (Consol. – \$000):**

	09/30/18	10/01/17
Total Revenues	1,269,248	1,142,912
Cost & expenses	1,961,410	1,434,785
Operating income	(692,162)	(291,873)
Interest income	2,280	1,961
Interest expense	77,796	65,439
Other income (expense), net	48,775	(89,108)
Equity earnings	17,059	(26,084)
Net before taxes	(718,903)	(444,459)
Income taxes	9,389	(1,073)
<b>Net income</b>	<b>(745,351)</b>	<b>(417,302)</b>
Earnings common share		
Primary	\$(4.64)	\$(2.56)
Fully Diluted	\$(4.64)	\$(2.56)
Common Shares:		
Full Diluted	140,722	139,289
Year-end	141,056	

**SURFACE ONCOLOGY INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	49,653	10,347
Cost & expenses	53,223	39,702
Operating income	(3,570)	(29,355)
Net before taxes		(28,885)
Income taxes		719
<b>Net income</b>	<b>(1,862)</b>	<b>(29,604)</b>
Balance for common	(1,873)	(29,634)
Earnings common share		
Primary	\$(0.11)	\$(12.11)
Fully Diluted	\$(0.11)	\$(12.11)
Common Shares:		
Full Diluted	17,398	2,446
Year-end	27,607	

**SURGERY PARTNERS INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	1,306,076	132,258
Cost & expenses	1,126,970	117,002
Deprec., depl. & amort.	49,379	3,330
Operating income	129,727	11,926
Interest expense	107,368	15,883
Gains or losses		1,098
Net before taxes	22,359	(2,859)
Income taxes	10,905	(211)
<b>Net income</b>	<b>11,454</b>	<b>(2,648)</b>
Balance for common	(81,937)	(27,339)
Earnings common share		
Primary	\$(1.71)	\$(0.57)
Fully Diluted	\$(1.71)	\$(0.57)
Common Shares:		
Full Diluted	48,020	48,315
Year-end	48,892	

**SUTRO BIOPHARMA INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	19,333	47,701
Cost & expenses	53,281	51,805
Operating income	(33,948)	(4,104)
Interest income	483	192
Interest expense	1,199	235
Other income (expense), net	840	(197)

<b>Net income</b>	(33,824)	(4,344)
Earnings common share		
Primary	\$(71.06)	\$(9.77)
Fully Diluted	\$(71.06)	\$(9.77)
Common Shares:		
Full Diluted	476	445
Year-end	485	

**SVMK INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	186,392	161,761
Cost & expenses	293,415	178,209
Operating income	(107,023)	(16,448)
Interest income	292	30
Interest expense	22,181	20,030
Other income (expense), net	872	7,524
Net before taxes	(129,072)	(28,528)
Income taxes	470	3,551
<b>Net income</b>	<b>(129,542)</b>	<b>(32,079)</b>
Earnings common share		
Primary	\$(1.27)	\$(0.32)
Fully Diluted	\$(1.27)	\$(0.32)
Common Shares:		
Full Diluted	101,984	100,056
Year-end	125,077	

**SYNACOR, INC.****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	104,481	94,025
Cost & expenses	103,555	97,439
Deprec., depl. & amort.	7,316	7,004
Operating income	(6,390)	(10,418)
Interest expense	265	328
Other income (expense), net	(46)	172
Gains or losses		1,902
Net before taxes	(6,701)	(8,672)
Income taxes	478	999
<b>Net income</b>	<b>(7,179)</b>	<b>(9,671)</b>
Earnings common share		
Primary	\$(0.18)	\$(0.27)
Fully Diluted	\$(0.18)	\$(0.27)
Common Shares:		
Full Diluted	38,857	35,591
Year-end	39,878	38,636

**SYNALLOY CORP.****Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Net Sales	208,167,243	148,310,548
Cost & expenses	190,431,876	147,494,908
Operating income	17,735,367	815,640
Other income (expense), net	(422,650)	349,158
Net before taxes	16,008,993	449,667
Income taxes	3,461,000	125,000
<b>Net income</b>	<b>12,547,993</b>	<b>324,667</b>
Earnings common share		
Primary	\$1.43	\$0.04
Fully Diluted	\$1.42	\$0.04
Common Shares:		
Full Diluted	8,857,804	8,713,914
Year-end	8,864,772	8,716,893

**SYNERGY PHARMACEUTICALS INC**

**Bankruptcy Proceedings** On Dec. 12, 2018, Co. and its wholly-owned subsidiary, Synergy Advanced Pharmaceuticals, Inc., a Delaware corporation ("Synergy Advanced" and together with Co., the "Debtors") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of New York (the "Court"). The Debtors have filed a motion with the Court seeking joint administration of their chapter 11 cases (the "Chapter 11 Cases") pursuant to Rule 1015(b) of the Federal Rules of Bankruptcy Procedure under the caption In re Synergy Pharmaceuticals Inc, et al. (Case No. 18-14010 (JLG)). The Debtors will continue to operate their businesses and manage their properties as debtors in possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code. To ensure their ability to continue operating in the ordinary course of business, the Debtors have filed with the Court motions seeking a variety of "first-day" relief (collectively, the "First Day Motions"), including authority to obtain debtor-in-possession financing, maintain the Debtors' cash management system, and honor certain obligations of the Debtors.

**SYNERGY PHARMACEUTICALS INC**

**Sale Development** On Dec. 12, 2018, Co. announced an agreement with Bausch Health Companies Inc. ("Bausch Health"), a pharmaceutical and medical device company through which Bausch Health would acquire substantially all of Co.'s assets, including all rights to TRULANCE (plecanatide), dolcanatide and related intellectual property, for approximately \$200,000,000 in cash, subject to certain adjustments at closing, plus the assumption of certain liabilities related to the assets to be acquired. The sale is subject to a competitive process and Co.'s receipt of higher and better offers. To facilitate the sale and address its debt obligations, Co. initiated voluntary proceedings under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York. Co. fully intends to operate its business as usual while it works to complete the sale through the Chapter 11 process.

**SYNLOGIC INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	2,409	2,333
Cost & expenses	40,931	31,239
Operating income	(38,522)	(28,906)
Interest expense	36	22
Other income (expense), net	(5)	(19)
<b>Net income</b>	<b>(36,504)</b>	<b>(28,680)</b>
Earnings common share		
Primary	\$(1.56)	\$(7.87)
Fully Diluted	\$(1.56)	\$(7.87)
Common Shares:		
Full Diluted	23,415	3,642
Year-end	25,440	16,285

**SYNOPSIS INC****Annual Report****Consolidated Income Statement, Years Ended Oct. 31 (\$000):**

	2018	2017	2016
		(revised)	(revised)
Time-based license revenue	2,303,317	2,021,812	1,910,902
Upfront license revenue	357,698	338,204	248,137
Maintenance & service revenue	460,043	364,864	263,493
Total revenue	3,121,058	2,724,880	2,422,532
Cost of license products revenue	448,430	413,203	346,825
Cost of maintenance & service	203,434	164,872	94,019
Amortization of intangible assets	84,034	76,109	102,118
Total cost of revenue	735,898	654,184	542,962
Gross margin	2,385,160	2,070,696	1,879,570
Research & development	1,084,822	908,841	856,705
Sales & marketing expenses	622,978	549,248	502,368
General & administrative expenses	262,560	196,844	165,962
Amortization of intangible assets	41,630	31,614	27,507
Restructuring charges	12,945	36,586	9,633
Total operating expenses	2,024,935	1,723,133	1,562,175
Operating income (loss)	360,225	347,563	317,395
Interest income	5,323	7,241	3,715
Interest expense	15,607	7,303	3,771
Gain (loss) on assets related to deferred compensation plan	4,636	29,606	4,400
Foreign currency exchange gain (loss)	3,557	3,354	156
Other income (expense)	5,409	2,637	7,653
Total other income (expense), net	3,318	35,535	12,153
Income (loss) before provision			



	09/30/18	10/01/17
Total Revenues	64,014	60,805
Cost & expenses	68,196	71,384
Operating income	(4,182)	(10,579)
Interest expense	665	602
Other income (expense), net	1,651	1,663
Net before taxes	(3,196)	(9,518)
Income taxes	121	70
<b>Net income</b>	<b>(3,317)</b>	<b>(9,588)</b>
Earnings common share		
Primary	\$(0.16)	\$(0.47)
Fully Diluted	\$(0.16)	\$(0.47)
Common Shares:		
Full Diluted	20,497	20,305
Year-end	21,398	21,422

**SYROS PHARMACEUTICALS INC**

**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	1,157	1,101
Cost & expenses	46,846	40,267
Operating income	(45,689)	(39,166)
Other income (expense), net	1,442	458
<b>Net income</b>	<b>(44,247)</b>	<b>(38,708)</b>
Earnings common share		
Primary	\$(1.37)	\$(1.54)
Fully Diluted	\$(1.37)	\$(1.54)
Common Shares:		
Full Diluted	32,306	25,100
Year-end	33,654	

**TABULA RASA HEALTHCARE INC**

**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	146,960	90,145
Cost & expenses	175,246	89,051
Operating income	(40,396)	(4,636)
Interest expense	415	327
Net before taxes	(40,811)	(4,963)
Income taxes	(4,107)	(6,852)
<b>Net income</b>	<b>(36,704)</b>	<b>1,889</b>
Balance for common	(36,704)	1,889
Earnings common share		
Primary	\$(1.93)	\$0.11
Fully Diluted	\$(1.93)	\$0.10
Common Shares:		
Full Diluted	18,989	18,412
Year-end	20,357	

**TANDY LEATHER FACTORY INC**

**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Net Sales	58,353,784	57,818,996
Cost & expenses	54,287,898	53,775,793
Operating income	4,065,886	4,043,203
Interest expense	223,534	143,165
Other income (expense), net	126,459	115,599
Net before taxes	3,968,811	4,015,637
Income taxes	1,376,634	1,235,226
<b>Net income</b>	<b>2,592,177</b>	<b>2,780,411</b>
Earnings common share		
Primary	\$0.28	\$0.30
Fully Diluted	\$0.28	\$0.30
Common Shares:		
Full Diluted	9,199,959	9,246,066
Year-end	9,154,208	9,270,862

**TD AMERITRADE HOLDING CORP Annual Report**

**Consolidated Income Statement, Years Ended Sept. 30 (\$):**

	2018	2017	2016
		(revised)	(revised)
Commissions & transaction fees	1,969,000,000	1,384,000,000	1,372,000,000
Bank deposit account fees	1,541,000,000	1,107,000,000	926,000,000
Net interest revenue	1,272,000,000	690,000,000	595,000,000
Investment product fees	557,000,000	423,000,000	374,000,000
Other revenues	113,000,000	72,000,000	60,000,000
Employee compensation & benefits expenses	1,555,000,000	962,000,000	839,000,000

Clearing & execution costs	189,000,000	149,000,000	136,000,000
Communications expenses	179,000,000	131,000,000	137,000,000
Occupancy & equipment costs	302,000,000	181,000,000	171,000,000
Depreciation & amortization	142,000,000	102,000,000	92,000,000
Amortization of acquired intangible assets	141,000,000	79,000,000	86,000,000
Professional services	303,000,000	260,000,000	178,000,000
Advertising	293,000,000	254,000,000	260,000,000
Other operating expenses	350,000,000	92,000,000	110,000,000
Total operating expenses	3,454,000,000	2,210,000,000	2,009,000,000
Operating income	1,998,000,000	1,466,000,000	1,318,000,000
Interest on borrowings	99,000,000	71,000,000	53,000,000
Gain on sale of investment	(11,000,000)		
Other revenues (expenses)	(1,000,000)	(1,000,000)	
Total other income (expense)	(111,000,000)	(72,000,000)	(53,000,000)
Pre-tax income	1,887,000,000	1,394,000,000	1,265,000,000
Current income taxes - federal	380,000,000	484,000,000	435,000,000
Current income taxes - state	58,000,000	49,000,000	(4,000,000)
Total current income taxes	438,000,000	533,000,000	431,000,000
Deferred income taxes - federal	(32,000,000)	(11,000,000)	(5,000,000)
Deferred income taxes - state	8,000,000		(3,000,000)
Total deferred income taxes	(24,000,000)	(11,000,000)	(8,000,000)
Provision for (benefit from) income taxes	414,000,000	522,000,000	423,000,000
<b>Net income (loss)</b>	<b>1,473,000,000</b>	<b>872,000,000</b>	<b>842,000,000</b>
Weighted average shares outstanding - basic	567,000,000	529,000,000	531,000,000
Weighted average shares outstanding - diluted	569,000,000	531,000,000	534,000,000
Year end shares outstanding	563,000,000	567,000,000	526,000,000
Earnings (loss) per share - basic	\$2.60	\$1.65	\$1.59
Earnings (loss) per share-diluted	\$2.59	\$1.64	\$1.58
Dividends declared per share	\$0.84	\$0.72	\$0.68
Number of full time employees	9,183	10,412	6,010
Number of common stockholders	604	631	655
Number of beneficial stockholders	92,000	67,000	68,000

<sup>1</sup> Reclassified to conform with 2018 presentation; <sup>2</sup> Full-time equivalent; <sup>3</sup> As of November 1, 2018; <sup>4</sup> As of November 2, 2017; <sup>5</sup> As of November 3, 2016; <sup>6</sup> Approximately

**Consolidated Balance Sheet, Years Ended Sept. 30 (\$):**

	2018	2017
		(revised)
Cash & cash equivalents	2,690,000,000	1,472,000,000
Cash & investments segregated & on deposit for regulatory purposes	3,185,000,000	10,446,000,000
Deposits paid for securities borrowed	803,000,000	1,154,000,000
Clearing organizations	545,000,000	151,000,000
Broker-dealers	14,000,000	21,000,000
Securities failed to deliver	12,000,000	8,000,000
Receivable from brokers,		

dealers & clearing organizations	1,374,000,000	1,334,000,000
Receivable from clients, gross	22,670,000,000	17,162,000,000
Allowance for doubtful accounts	54,000,000	11,000,000
Receivable from clients, net	22,616,000,000	17,151,000,000
Receivable from affiliates	151,000,000	137,000,000
Other receivables, net	304,000,000	174,000,000
Securities owned, at fair value	156,000,000	503,000,000
Investments available-for-sale, at fair value	484,000,000 <sup>1</sup>	746,000,000 <sup>2</sup>
Buildings & building components	462,000,000	351,000,000
Computer equipment	326,000,000	270,000,000
Software	178,000,000	215,000,000
Leasehold improvements	176,000,000	173,000,000
Building construction in process		101,000,000
Land	61,000,000	77,000,000
Other property & equipment	92,000,000	83,000,000
Property & equipment, gross	1,295,000,000	1,270,000,000
Less accumulated depreciation & amortization	503,000,000	518,000,000
Property & equipment at cost, net	792,000,000	752,000,000
Goodwill	4,227,000,000	4,213,000,000
Acquired intangible assets, net	1,329,000,000	1,470,000,000
Other assets	212,000,000	229,000,000
Total assets	37,520,000,000	38,627,000,000
Deposits received for securities loaned	2,914,000,000	2,449,000,000
Clearing organizations	29,000,000	32,000,000
Securities failed to receive	34,000,000	21,000,000
Broker-dealers	3,000,000	2,000,000
Payable to clients	22,884,000,000	25,107,000,000
Accounts payable & other liabilities	896,000,000	815,000,000
Payable to affiliates	45,000,000	109,000,000
Securities sold under agreements to repurchase	96,000,000	97,000,000
Senior notes	2,439,000,000	2,555,000,000
Long-term debt	2,439,000,000	2,555,000,000
Deferred income taxes	177,000,000	193,000,000
Total liabilities	29,517,000,000	31,380,000,000
Common stock	7,000,000	7,000,000
Additional paid-in capital	3,379,000,000	3,369,000,000
Retained earnings (accumulated deficit)	7,011,000,000	6,011,000,000
Treasury stock, common, at cost	2,371,000,000	2,116,000,000
Deferred compensation	(4,000,000)	(1,000,000)
Cash flow hedging instruments	(27,000,000)	(25,000,000)
Accumulated other comprehensive income (loss)	(27,000,000)	(25,000,000)
Total stockholders' equity	8,003,000,000	7,247,000,000

<sup>1</sup> Including securities pledged as collateral for repurchase agreements - Investments available-for-sale, at fair value: \$98,000,000; <sup>2</sup> Including securities pledged as collateral for repurchase agreements - Investments available-for-sale, at fair value: \$99,000,000

**Recent Dividends:**  
**1. TD Ameritrade Holding Corp common.**

ExDate	Amt	Declared	Record	Payable
02/02/2015	0.15	01/21/2015	02/04/2015	02/18/2015
04/29/2015	0.15	04/21/2015	05/01/2015	05/15/2015
07/31/2015	0.15	07/21/2015	08/04/2015	08/18/2015
11/06/2015	0.17	10/27/2015	11/10/2015	11/24/2015
02/01/2016	0.17	01/20/2016	02/03/2016	02/17/2016

04/29/2016	0.17	04/19/2016	05/03/2016	05/17/2016
08/02/2016	0.17	07/19/2016	08/04/2016	08/18/2016
11/04/2016	0.18	10/24/2016	11/08/2016	11/22/2016
01/30/2017	0.18	01/17/2017	02/01/2017	02/15/2017
04/28/2017	0.18	04/19/2017	05/02/2017	05/16/2017
07/28/2017	0.18	07/18/2017	08/01/2017	08/15/2017
11/06/2017	0.21	10/24/2017	11/07/2017	11/21/2017
02/05/2018	0.21	01/23/2018	02/06/2018	02/20/2018
05/07/2018	0.21	04/23/2018	05/08/2018	05/22/2018
08/06/2018	0.21	07/23/2018	08/07/2018	08/21/2018
11/05/2018	0.30	10/22/2018	11/06/2018	11/20/2018

Contingent consideration - fair value				
adjustments	4,252	(6,923)	2,823	
Income (loss) from operations	190,086	183,342	135,855	
Interest income	1,824	729	996	
Interest expense	17,348	12,310	12,385	
Income before income taxes - United States	180,034	166,074	113,576	
Income before income taxes - foreign	(5,472)	5,687	10,890	
Income (loss) before income taxes expense	174,562	171,761	124,466	
Current federal income tax expense (benefit)	46,840	45,604	22,277	
Current state income tax expense (benefit)	9,228	8,860	5,634	
Current foreign income tax expense (benefit)	10,897	9,337	6,651	
Total current income tax expense (benefit)	66,965	63,801	34,562	
Deferred federal income tax expense (benefit)	(22,072)	(4,251)	6,231	
Deferred state income tax expense (benefit)	(1,471)	(945)	(16)	
Deferred foreign income tax expense (benefit)	(5,817)	(4,761)	(164)	
Total deferred income tax expense (benefit)	(29,360)	(9,957)	6,051	
Income tax expense (benefit)	37,605	53,844	40,613	
<b>Net income (loss) including noncontrolling interests</b>	136,957	117,917	83,853	
Net income attributable to noncontrolling interests	(74)	(43)	(70)	
Net income (loss) attributable to Tetra Tech, Inc.	136,883	117,874	83,783	
Weighted average shares outstanding - basic	55,670	56,911	58,186	
Weighted average shares outstanding - diluted	56,598	57,913	58,966	
Year end shares outstanding	55,349	55,873	57,042	
Net earnings (loss) per share - basic	\$2.46	\$2.07	\$1.44	
Net earnings (loss) per share - diluted	\$2.42	\$2.04	\$1.42	
Cash dividends paid per share	\$0.44	\$0.38	\$0.34	
Total number of employees	17,000	16,000	16,000	
Number of common stockholders	1,400	1,394	1,484	
Foreign currency translation adjustments	(29,656)	...	...	

Billed receivables	464,062	376,287	
Unbilled receivables	397,200	404,899	
Contract retentions	13,421	39,840	
Less allowance for doubtful accounts	37,580	32,259	
Accounts receivable - net	837,103	788,767	
Prepaid expenses & other current assets	56,003	49,969	
Income taxes receivable	11,089	13,312	
Total current assets	1,050,380	1,042,023	
Land & buildings	413	3,680	
Equipment, furniture & fixtures	131,521	150,026	
Leasehold improvements	31,430	27,689	
Total property & equipment	163,364	181,395	
Less: accumulated depreciation	120,086	124,560	
Property & equipment - net	43,278	56,835	
Investments in unconsolidated joint ventures	3,370	2,700	
Goodwill	798,820	740,886	
Intangible assets - net	16,123	26,688	
Deferred income taxes	8,607	1,763	
Other long-term assets	38,843	31,850	
Total assets	1,959,421	1,902,745	
Accounts payable	160,222	177,638	
Accrued compensation	180,153	143,408	
Billings in excess of costs on uncompleted contracts	143,270	117,499	
Current portion of long-term debt	12,599	15,588	
Current contingent earn-out liabilities	13,633	2,024	
Other current liabilities	108,216	81,511	
Total current liabilities	618,093	537,668	
Deferred income taxes	30,166	43,781	
Credit facilities	277,127	356,438	
Other long-term debt	184	433	
Less: Current portion of long-term debt	12,599	15,588	
Long-term debt	264,712	341,283	
Other long-term liabilities	57,693	50,975	
Common stock	553	559	
Additional paid-in capital	148,803	193,835	
Foreign currency translations adjustment	(128,602)	(98,946)	
Gain (loss) on derivative instruments	1,252	446	
Accumulated other comprehensive income (loss)	(127,350)	(98,500)	
Retained earnings (accumulated deficit)	944,965	832,559	
Total Tetra Tech, Inc. stockholders' equity (deficit)	966,971	928,453	
Noncontrolling interests	129	171	
Total equity	967,100	928,624	

**Annual Dividends:**

**1. TD Ameritrade Holding Corp common.**

2015	0.62	2016	0.69	2017	0.75
2018	0.93				

**TECH DATA CORP.**

**Earnings, 9 mos. to Oct 31(Consol. - \$000):**

	2018	2017
Net Sales	26,774,449	23,564,444
Cost & expenses	26,446,700	23,306,268
Operating income	327,749	258,176
Interest expense	79,380	85,205
Other income (expense), net	(7,779)	1,374
Net before taxes	240,590	174,345
Income taxes	16,809	58,964
<b>Net income</b>	223,781	115,381
Earnings common share		
Primary	\$5.83	\$3.05
Fully Diluted	\$5.80	\$3.03
Common Shares:		
Full Diluted	38,559	38,105
Year-end	37,738	38,185

**TELIGENT INC (NEW)**

**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	58,742	52,289
Operating income	(9,654)	(6,854)
Other income (expense), net	(2,467)	...
Foreign currency	(2,071)	6,645
Net before taxes	(21,956)	(8,940)
Income taxes	(90)	130
<b>Net income</b>	(21,866)	(9,070)
Earnings common share		
Primary	\$(0.41)	\$(0.17)
Fully Diluted	\$(0.41)	\$(0.17)
Common Shares:		
Full Diluted	53,532	53,298
Year-end	53,763	53,392

**TESSCO TECHNOLOGIES, INC.**

**Earnings, 6 mos. to (Consol. - \$):**

	09/30/18	09/24/17
Total Revenues	309,555,500	285,094,300
Cost & expenses	305,901,300	280,560,300
Operating income	3,654,200	4,534,000
Net before taxes	3,235,000	4,308,900
Income taxes	885,800	1,852,100
<b>Net income</b>	2,349,200	2,456,800
Earnings common share		
Primary	\$0.28	\$0.29
Fully Diluted	\$0.27	\$0.29
Common Shares:		
Full Diluted	8,600,475	8,397,856
Year-end	8,439,528	8,373,585

**TETRA TECH INC**

**Annual Report**

**Consolidated Income Statement, Years Ended (\$000):**

	09/30/18	10/01/17	10/02/16
		(revised)	(revised)
Revenue	2,964,148	2,753,360	2,583,469
Subcontractor costs	(763,414)	(719,350)	(654,264)
Other costs of revenue	1,816,276	1,680,372	1,598,994
Gross profit	384,458	353,638	330,211
Selling, general & administrative expenses	190,120	177,219	171,985
Acquisition & integration expenses	...	...	19,548

**Consolidated Balance Sheet, Years Ended (\$000):**

	09/30/18	10/01/17	10/01/17
		(revised)	(revised)
Cash & cash equivalents	146,185	189,975	...

**Recent Dividends:**

**1. Tetra Tech Inc common.**

ExDate	Amt	Declared	Record	Payable
02/09/2015	0.07	01/28/2015	02/11/2015	02/26/2015
05/12/2015	0.08	04/29/2015	05/14/2015	05/29/2015
08/13/2015	0.08	07/29/2015	08/17/2015	09/04/2015
11/25/2015	0.08	11/09/2015	11/30/2015	12/11/2015
02/10/2016	0.08	01/25/2016	02/12/2016	02/26/2016
05/11/2016	0.09	04/25/2016	05/13/2016	05/27/2016
08/10/2016	0.09	07/25/2016	08/12/2016	08/31/2016
11/29/2016	0.09	11/07/2016	12/01/2016	12/14/2016
02/15/2017	0.09	01/30/2017	02/17/2017	03/03/2017
05/16/2017	0.10	05/01/2017	05/18/2017	06/02/2017
08/15/2017	0.10	08/01/2017	08/17/2017	09/01/2017
11/29/2017	0.10	11/06/2017	11/30/2017	12/15/2017
02/13/2018	0.10	01/29/2018	02/14/2018	03/02/2018
05/15/2018	0.12	04/30/2018	05/16/2018	06/01/2018

□ Reclassified to conform with 2018 presentation; □ As is; □ Approximately; □ As of October 31, 2017; □ As of November 7, 2016

08/15/2018 0.12 07/30/2018 08/16/2018 08/31/2018  
11/29/2018 0.12 11/05/2018 11/30/2018 12/14/2018

**Annual Dividends:****1. Tetra Tech Inc common.**

2015.....0.31 2016.....0.35 2017.....0.39  
2018.....0.46

**TEXAS ROADHOUSE INC****Earnings, 9 mos. to (Consol. - \$000):**

	09/25/18	09/26/17
Total Revenues	1,851,537	1,674,455
Cost & expenses	1,621,463	1,456,472
Deprec., depl. & amort.	75,492	69,236
Operating income	154,582	148,747
Other income (expense), net	1,150	1,149
Net before taxes	154,922	148,685
Income taxes	22,321	41,159
<b>Net income</b>	<b>132,601</b>	<b>107,526</b>
Earnings common share		
Primary	\$1.79	\$1.45
Fully Diluted	\$1.78	\$1.44
Common Shares:		
Full Diluted	71,906	71,449
Year-end	71,545	71,102

**THE TRADE DESK INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	316,826	205,569
Cost & expenses	258,471	165,531
Operating income	58,355	40,038
Foreign currency	(2,035)	(3,159)
Net before taxes	56,433	35,589
Income taxes	7,728	1,602
<b>Net income</b>	<b>48,705</b>	<b>33,987</b>
Earnings common share		
Primary	\$1.15	\$0.85
Fully Diluted	\$1.07	\$0.77
Common Shares:		
Full Diluted	45,460	43,919
Year-end	43,185	41,024

**TITAN MACHINERY, INC.****Earnings, 9 mos. to Oct 31(Consol. - \$):**

	2018	2017
Total Revenues	909,219,000	863,330,000
Cost & expenses	881,756,000	863,491,000
Operating income	27,463,000	(161,000)
Net before taxes	18,396,000	(11,734,000)
Income taxes	4,055,000	(3,000,000)
<b>Net income</b>	<b>14,341,000</b>	<b>(8,734,000)</b>
Balance for common	14,107,000	(8,734,000)
Earnings common share		
Primary	\$0.65	\$(0.40)
Fully Diluted	\$0.65	\$(0.40)
Common Shares:		
Full Diluted	21,806,000	21,503,000
Year-end	22,220,000	22,042,000

**TIVITY HEALTH INC**

**Acquisition Development** On Dec. 10, 2018, Co. and Nutrisystem, Inc. ("Nutrisystem"), a leading provider of weight management products and services announced that they have entered into a definitive agreement under which Co. will acquire all of the outstanding shares of Nutrisystem for a combination of cash and stock. Under the terms of the agreement, which has been unanimously approved by the boards of directors of both companies, Nutrisystem shareholders will receive \$38.75 per share in cash and 0.2141 Co. shares for each share of Nutrisystem common stock. The transaction values Nutrisystem at an enterprise value of \$1,300,000,000 and an equity value of \$1,400,000,000, or approximately \$47.00 per share. The implied stock consideration of \$8.25 per Nutrisystem share is based on the volume-weighted average price of Co.'s stock for the 10 days ended Dec. 3, 2018. The implied transaction consideration of \$47.00 per share represents a 30% premium based on the volume-weighted average price for Nutrisystem over the last five trading days. The transaction is expected to close in the first quarter of 2019, subject to the approval of Nutrisystem shareholders, the receipt of regulatory approval and other customary closing conditions.

**TIVITY HEALTH INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	453,261,000	417,588,000
Cost & expenses	348,621,000	321,054,000
Operating income	101,179,000	94,108,000
Net before taxes	93,231,000	81,941,000
Income taxes	23,856,000	29,334,000
Income contin. oper.	69,375,000	52,607,000
<b>Net income</b>	<b>70,276,000</b>	<b>55,232,000</b>
Earnings common share		
Primary	\$1.76	\$1.41
Fully Diluted	\$1.63	\$1.31
Common Shares:		
Full Diluted	43,234,000	42,253,000
Year-end	40,045,663	39,551,278

**TONIX PHARMACEUTICALS HOLDING CORP****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	18,672,000	15,748,000
Operating income	(18,672,000)	(15,748,000)
<b>Net income</b>	<b>(18,501,000)</b>	<b>(15,630,000)</b>
Earnings common share		
Primary	\$(21.50)	\$(24.90)
Fully Diluted	\$(21.50)	\$(24.90)
Common Shares:		
Full Diluted	861,604	628,706
Year-end	1,048,046	758,170

**TOWN SPORTS INTERNATIONAL HOLDINGS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	329,613	297,714
Cost & expenses	293,654	270,384
Operating income	8,003	(2,869)
Interest income	127	36
Interest expense	9,999	9,455
Other income (expense), net	262	217
Net before taxes	(1,607)	(12,071)
Income taxes	605	4,550
<b>Net income</b>	<b>(2,212)</b>	<b>(16,621)</b>
Earnings common share		
Primary	\$(0.09)	\$(0.66)
Fully Diluted	\$(0.09)	\$(0.66)
Common Shares:		
Full Diluted	25,801	25,176
Year-end	27,182	26,687

**TRANSACT TECHNOLOGIES INC.****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	42,832	43,117
Cost & expenses	37,146	37,804
Operating income	5,686	5,313
Other income (expense), net	(137)	(8)
Net before taxes	5,528	5,280
Income taxes	1,064	1,657
<b>Net income</b>	<b>4,464</b>	<b>3,623</b>
Earnings common share		
Primary	\$0.60	\$0.49
Fully Diluted	\$0.57	\$0.48
Common Shares:		
Full Diluted	7,774	7,504
Year-end	7,391	7,366

**TRANSCAT INC****Earnings, 6 mos. to (Consol. - \$):**

	09/29/18	09/23/17
Total Revenues	75,537,000	72,206,000
Cost & expenses	71,336,000	69,337,000
Operating income	4,201,000	2,869,000
Net before taxes	3,781,000	2,326,000
Income taxes	865,000	689,000
<b>Net income</b>	<b>2,916,000</b>	<b>1,637,000</b>
Earnings common share		
Primary	\$0.41	\$0.23
Fully Diluted	\$0.39	\$0.23
Common Shares:		
Full Diluted	7,486,000	7,242,000
Year-end	7,201,589	7,139,988

**TRANSLATE BIO INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	97,169	54,661
Operating income	(96,931)	(54,661)
Interest income	499	230
Other income (expense), net	(52)	59
Net before taxes	(96,484)	(54,372)
Income taxes	(5,126)	(4,020)
<b>Net income</b>	<b>(91,358)</b>	<b>(50,352)</b>
Balance for common	(92,002)	(50,891)
Earnings common share		
Primary	\$(5.13)	\$(6.62)
Fully Diluted	\$(5.13)	\$(6.62)
Common Shares:		
Full Diluted	17,949	7,682
Year-end	45,142	

**TRAVELCENTERS OF AMERICA LLC**

**Interest Sale Completed** On Dec. 5, 2018, Co. and its subsidiary, TA Operating LLC, sold 225 standalone convenience store properties, one standalone restaurant, five parcels of vacant land and certain related assets, to EG Retail (America), LLC and EG Group Ltd., a holding company that operates convenience stores-based petrol station forecourts in the United Kingdom, France, and the Benelux countries, for \$330,800,000 plus the assumption of certain liabilities pursuant to the Asset Purchase Agreement. This sales price included \$25,800,000 of estimated net working capital items.

**TRICIDA INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	74,785	26,465
Operating income	(74,785)	(26,465)
Interest expense	2,166	6
Other income (expense), net	1,987	5,731
<b>Net income</b>	<b>(74,964)</b>	<b>(20,740)</b>
Earnings common share		
Primary	\$(4.86)	\$(9.67)
Fully Diluted	\$(4.86)	\$(9.67)
Common Shares:		
Full Diluted	15,415	2,144
Year-end	42,100	

**TRUECAR INC**

**Acquisition Completed** On Dec. 7, 2018, Co., through its wholly-owned subsidiary, TrueCar Dealer Solutions, Inc. (the "Purchaser"), acquired all the outstanding equity interests of DealerScience, LLC ("DealerScience"), an automotive retail industry's provider of advanced digital retailing software tools, from Andrew Gordon ("Seller") for \$27,000,000 in cash consideration, subject to certain customary post-closing adjustments. The Purchase Agreement also provided for two potential cash earnout payments to Seller of up to \$2,500,000 each upon the achievement of certain revenue metrics in each of the first two years following the consummation of the Acquisition. As the result, DealerScience became an indirect wholly-owned subsidiary of Co.

**TUESDAY MORNING CORP****Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	227,313	218,756
Cost & expenses	234,901	230,750
Operating income	(7,588)	(11,994)
Interest expense	587	439
Other income (expense), net	190	358
Net before taxes	(7,985)	(12,075)
Income taxes	124	179
<b>Net income</b>	<b>(8,109)</b>	<b>(12,254)</b>
Balance for common	(8,109)	(12,254)
Earnings common share		
Primary	\$(0.18)	\$(0.28)
Fully Diluted	\$(0.18)	\$(0.28)
Common Shares:		
Full Diluted	44,490	44,085
Year-end	46,726	45,841

**Consolidated Balance Sheet Items, as of (\$000):**

	2018
Assets:	
Cash & equivalents	12,552
Inventories	291,932
Current assets	312,809
Net property & equip.	118,934
Total assets	435,560
Liabilities:	
Current liabilities	180,066
Long-term debt	55,600
Stockholders' equity	172,916

Net current assets	132,743	Other current liabilities	1,066	353	<b>Net income</b>	(5,302,377)	(203,285)
<b>TWIST BIOSCIENCE CORP</b>		Total current liabilities	9,477	8,678	Earnings common share		
<b>Annual Report</b>		Redeemable convertible			Primary	\$(0.03)	\$
<b>Consolidated Income Statement, Years Ended Sept. 30</b>		preferred stock warrant			Fully Diluted	\$(0.03)	\$
<b>(\$000):</b>		liability	644	383	Common Shares:		
	2017	2016	Long-term debt, net of		Full Diluted	169,553,562	153,989,270
Revenues	10,767	2,269	current portion	9,154	9,814	Year-end	170,673,138 156,697,207
Cost of revenues	24,020	9,421	Other long-term				
Research & development			liabilities	107	162	<b>UNITED NATURAL FOODS INC.</b>	
expenses	19,169	18,230	Total liabilities	19,382	19,037	<b>Earnings, 3 mos. to (Consol. - \$):</b>	
Selling, general &			Series A redeemable			10/27/18	10/28/17
administrative expense	26,060	18,274	convertible preferred			Net Sales	2,868,156,000 457,545,000
Total operating expenses	69,249	45,925	stock	9,141	9,141	Cost & expenses	2,886,994,000 402,438,000
Income (loss) from			Series B redeemable			Operating income	(18,838,000) 55,107,000
operations	(58,482)	(43,656)	convertible preferred			Interest income	146,000 91,000
Interest income	412	241	stock	25,900	25,900	Interest expense	7,671,000 3,667,000
Interest expense	905	746	Series C redeemable			Other income (expense), net	747,000 863,000
Other income (expense),			convertible preferred			Net before taxes	(25,616,000) 52,394,000
net	(55)	73	stock	36,726	36,726	Income taxes	(4,255,000) 21,889,000
Income (loss) before			Series D redeemable			Income contin. oper.	(21,361,000) .....
income taxes	(59,030)	(44,088)	convertible preferred			<b>Net income</b>	(19,291,000) 30,505,000
Provision for income			stock	127,866	62,270	Earnings common share	
taxes	280	...	Total redeemable			Primary	\$(0.38) \$0.60
<b>Net income (loss)</b>			convertible preferred			Fully Diluted	\$(0.38) \$0.60
<b>attributable to common</b>			stock	199,633	134,037	Common Shares:	
<b>stockholders</b>	(59,310)	(44,088)	Additional paid-in			Full Diluted	50,583,000 50,957,000
Weighted average shares			capital	6,228	3,689	Year-end	50,811,000 50,801,000
outstanding - basic	2,422	1,870	Accumulated other			<b>Consolidated Balance Sheet Items, as of (\$):</b>	
Weighted average shares			comprehensive income			Assets:	
outstanding - diluted	2,422	1,870	(loss)	33	9	Cash & equivalents	53,910,000
Year end shares			Retained earnings			Inventories	2,405,017,000
outstanding	3,179	3,146	(accumulated deficit)	(139,619)	(80,309)	Current assets	4,490,041,000
Net earnings (loss) per			Total shareholders'			Net property & equip.	1,543,952,000
share - basic	\$(24.49)	\$(23.58)	(deficit)/equity	(133,358)	(76,611)	Total assets	8,587,613,000
Net earnings (loss) per						Liabilities:	
share - diluted	\$(24.49)	\$(23.58)				Current liabilities	2,832,793,000
Number of full time			<b>Recent Dividends:</b>			Long-term debt	3,239,674,000
employees	221	...	<b>1. Twist Bioscience Corp common.</b>			Stockholders' equity	1,831,946,000
Number of common			No dividends paid.			Net current assets	1,657,248,000
stockholders	196	...	<b>Annual Dividends:</b>			<b>UNITED THERAPEUTICS CORP</b>	
			<b>1. Twist Bioscience Corp common.</b>			<b>Earnings, 9 mos. to Sep 30 (Consol. - \$):</b>	
			No dividends paid.				
			<b>TWIST BIOSCIENCE CORP</b>				
			<b>Earnings, 9 mos. to Jun 30 (Consol. - \$000):</b>				
				2018	2017		
			Total Revenues	17,020	7,301		
			Cost & expenses	67,875	49,160		
			Operating income	(50,855)	(41,859)		
			Interest income	590	225		
			Interest expense	927	657		
			Other income (expense), net	(76)	151		
			Net before taxes	(51,268)	(42,140)		
			Income taxes	166	161		
			<b>Net income</b>	(51,434)	(42,301)		
			Earnings common share				
			Primary	\$(18.92)	\$(17.78)		
			Fully Diluted	\$(18.92)	\$(17.78)		
			Common Shares:				
			Full Diluted	2,719	2,379		
			Year-end	3,224	.....		
			<b>ULTA BEAUTY INC</b>				
			<b>Earnings, 9 mos. to (Consol. - \$000):</b>				
				11/03/18	10/28/17		
			Net Sales	4,591,899	3,946,914		
			Cost & expenses	4,019,029	3,416,042		
			Operating income	572,870	530,872		
			Net before taxes	576,656	532,081		
			Income taxes	132,771	185,020		
			<b>Net income</b>	443,885	347,061		
			Earnings common share				
			Primary	\$7.38	\$5.62		
			Fully Diluted	\$7.35	\$5.58		
			Common Shares:				
			Full Diluted	60,432	62,198		
			Year-end	59,461	61,074		
			<b>UNITED HEALTH PRODUCTS INC</b>				
			<b>Earnings, 9 mos. to Sep 30 (Consol. - \$):</b>				
				2018	2017		
			Total Revenues	40,826	336,543		
			Cost & expenses	1,714,589	518,828		
			Operating income	(1,673,763)	(182,285)		
			Other income (expense), net	(3,628,614)	.....		
			<b>UNITI GROUP INC</b>				
			<b>Earnings, 9 mos. to Sep 30 (Consol. - \$000):</b>				
				2018	2017		
			Total Revenues	746,880	669,696		
			Cost & expenses	407,915	392,893		
			Deprec., depl. & amort.	342,311	317,404		
			Operating income	(3,346)	(40,601)		



Net before taxes	(3,346)	(40,601)
Income taxes	(5,208)	(8,976)
<b>Net income</b>	<b>1,862</b>	<b>(31,625)</b>
Balance for common	(4,357)	(37,091)
Earnings common share		
Primary	\$(0.02)	\$(0.22)
Fully Diluted	\$(0.02)	\$(0.26)
Common Shares:		
Full Diluted	175,101	166,816
Year-end	178,210	174,821

**UNIVERSAL LOGISTICS HOLDINGS INC**

**Acquisition Completed** On Dec. 7, 2018, Universal Logistics Holdings, Inc. wholly-owned subsidiary, Mason Dixon Intermodal, Inc., d/b/a Universal Intermodal Services, Inc. ("Universal Intermodal"), acquired all the issued and outstanding shares of capital stock of Deco Logistics, Inc., d/b/a Container Connection, and Oaktree Logistics, Inc. (collectively, "Container Connection"), based in Riverside, California, Container Connection of fers harbor drayage services to the Ports of Los Angeles and Long Beach for customers primarily located within the Inland Empire and Central Valley areas, it also offers warehousing, secured parking and yard space at its 18.5-acre facility, from James H. Horvitz, Robert Sweet, and The Horvitz Family Special Needs Gift Trust for \$60,000,000 which was subject to customary post-closing adjustments.

**UNIVERSAL LOGISTICS HOLDINGS INC****Earnings, 9 mos. to (Consol. - \$000):**

	09/29/18	09/30/17
Total Revenues	1,075,330	902,642
Cost & expenses	969,996	856,877
Deprec., depl. & amort.	39,448	33,663
Operating income	65,886	12,102
Other income (expense), net	1,688	1,253
Net before taxes	57,764	6,130
Income taxes	14,606	2,378
<b>Net income</b>	<b>43,158</b>	<b>3,752</b>
Earnings common share		
Primary	\$1.52	\$0.13
Fully Diluted	\$1.52	\$0.13
Common Shares:		
Full Diluted	28,396	28,440
Year-end	28,371	28,417

**UNIVERSAL STAINLESS & ALLOY PRODUCTS, INC.****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	198,864	152,369
Cost & expenses	183,659	149,170
Operating income	15,205	3,199
Other income (expense), net	690	43
Net before taxes	12,455	33
Income taxes	2,376	283
<b>Net income</b>	<b>10,079</b>	<b>(250)</b>
Earnings common share		
Primary	\$1.27	\$(0.03)
Fully Diluted	\$1.23	\$(0.03)
Common Shares:		
Full Diluted	8,167	7,221
Year-end	8,725	

**UNUM THERAPEUTICS INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	5,929	6,237
Cost & expenses	32,930	25,509
Operating income	(27,001)	(19,272)
Interest income	745	287
Other income (expense), net	330	183
<b>Net income</b>	<b>(25,926)</b>	<b>(18,802)</b>
Balance for common	(25,942)	(18,851)
Earnings common share		
Primary	\$(1.12)	\$(1.85)
Fully Diluted	\$(1.12)	\$(1.85)
Common Shares:		
Full Diluted	23,169	10,191
Year-end	29,925	

**UPLAND SOFTWARE INC**

**Acquisition Completed** On Dec. 13, 2018, Co. acquired Aestra Ltd. ("Aestra"), a leading provider of enterprise-grade email marketing, transaction and automation software. The purchase price paid for Aestra was \$56,000,000 in cash at closing, net of cash acquired, and a \$4,200,000 cash holdback payable

in 12 months (subject to indemnification claims). Co. expects the acquisition to generate annual revenue of approximately \$18,000,000, of which approximately \$16,700,000 is recurring, subject to reductions for a deferred revenue discount as a result of GAAP purchase accounting, estimated at \$100,000 for the remaining half of Dec. 2018. The acquisition is within Co.'s target range of 5-8x pro forma Adjusted EBITDA and will generate at least \$8,000,000 in Adjusted EBITDA annually once fully integrated. The acquisition will be immediately accretive to Upland's Adjusted EBITDA per share. In connection with the acquisition of Aestra, Co. amended and expanded its credit facility from \$358,900,000 to \$400,000,000. Specifically, \$61,100,000 of new term debt was drawn, taking Upland's gross debt outstanding from \$223,900,000 to \$285,000,000 with debt, net of cash on hand, now at approximately \$265,000,000 at a maximum interest rate of LIBOR + 400 basis points (currently at approximately 6.3%).

**UPLAND SOFTWARE INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	104,705	70,105
Cost & expenses	95,919	74,740
Deprec., depl. & amort.	9,589	4,111
Operating income	(803)	(8,746)
Interest expense	8,755	4,372
Other income (expense), net	(965)	(260)
Net before taxes	(10,523)	(13,378)
Income taxes	2,118	1,553
<b>Net income</b>	<b>(12,641)</b>	<b>(14,931)</b>
Earnings common share		
Primary	\$(0.63)	\$(0.83)
Fully Diluted	\$(0.63)	\$(0.83)
Common Shares:		
Full Diluted	19,917	18,043
Year-end	21,589	20,761

**UPWORK INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	186,012	147,793
Cost & expenses	195,026	145,965
Operating income	(9,014)	1,828
Interest expense	1,674	629
Other income (expense), net	(3,845)	(75)
Net before taxes	(14,533)	1,124
Income taxes	9	56
<b>Net income</b>	<b>(14,542)</b>	<b>1,068</b>
Balance for common	(14,542)	
Earnings common share		
Primary	\$(0.41)	\$(0.41)
Fully Diluted	\$(0.41)	\$(0.41)
Common Shares:		
Full Diluted	35,129	32,760
Year-end	36,945	

**UTAH MEDICAL PRODUCTS, INC.****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	32,242,000	31,213,000
Cost & expenses	17,813,000	16,775,000
Operating income	14,429,000	14,438,000
Other income (expense), net	617,000	65,000
Net before taxes	15,046,000	14,503,000
Income taxes	(116,000)	3,476,000
<b>Net income</b>	<b>15,162,000</b>	<b>11,027,000</b>
Earnings common share		
Primary	\$4.07	\$2.97
Fully Diluted	\$4.04	\$2.95
Common Shares:		
Full Diluted	3,752,000	3,734,000
Year-end	3,734,000	3,719,000

**VACCINEX INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	530	
Cost & expenses	19,250	14,907
Operating income	(18,720)	(14,907)
Interest expense	392	988
Other income (expense), net	(1,957)	(237)
<b>Net income</b>	<b>(21,069)</b>	<b>(16,132)</b>
Balance for common	(21,069)	(18,533)
Earnings common share		
Primary	\$(6.76)	\$(16.82)

Fully Diluted	\$(6.76)	\$(16.82)
Common Shares:		
Full Diluted	3,117	1,102
Year-end	11,476	

**VALERITAS HOLDINGS INC****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	19,504,000	14,464,000
Cost & expenses	50,743,000	45,708,000
Operating income	(31,239,000)	(31,244,000)
Interest expense	2,804,000	3,348,000
Other income (expense), net	(22,000)	226,000
<b>Net income</b>	<b>(34,065,000)</b>	<b>(34,366,000)</b>
Balance for common	(35,715,000)	(35,520,000)
Earnings common share		
Primary	\$(2.12)	\$(6.74)
Fully Diluted	\$(2.12)	\$(6.74)
Common Shares:		
Full Diluted	16,842,154	5,270,952
Year-end	24,950,642	7,015,636

**VERA BRADLEY INC.****Earnings, 9 mos. to (Consol. - \$000):**

	11/03/18	10/28/17
Total Revenues	297,904	322,648
Cost & expenses	282,457	323,281
Operating income	15,447	(633)
Net before taxes	16,124	(376)
Income taxes	3,986	1,121
<b>Net income</b>	<b>12,138</b>	<b>(1,497)</b>
Earnings common share		
Primary	\$0.34	\$(0.04)
Fully Diluted	\$0.34	\$(0.04)
Common Shares:		
Full Diluted	35,654	36,081
Year-end	34,856	35,670

**VERACYTE INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	66,258	52,357
Cost & expenses	84,634	72,051
Operating income	(19,176)	(20,494)
Interest expense	1,427	2,423
Other income (expense), net	709	353
<b>Net income</b>	<b>(19,894)</b>	<b>(22,564)</b>
Earnings common share		
Primary	\$(0.56)	\$(0.67)
Fully Diluted	\$(0.56)	\$(0.67)
Common Shares:		
Full Diluted	35,770	33,882
Year-end	40,536	33,978

**VERINT SYSTEMS, INC****Earnings, 9 mos. to Oct 31(Consol. - \$000):**

	2018	2017
Total Revenues	899,517	816,498
Cost & expenses	806,113	777,398
Operating income	70,683	12,373
Other income (expense), net	(582)	(2,081)
Gains or losses	3,760	292
Foreign currency	(5,372)	2,384
Net before taxes	44,065	(12,236)
Income taxes	2,153	9,504
<b>Net income</b>	<b>41,912</b>	<b>(21,740)</b>
Earnings common share		
Primary	\$0.60	\$(0.38)
Fully Diluted	\$0.59	\$(0.38)
Common Shares:		
Full Diluted	65,885	63,152
Year-end	65,272	

**VERITONE INC****Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	16,101	10,914
Cost & expenses	60,048	44,848
Operating income	(43,947)	(33,934)
Other income (expense), net	49	(8,674)
Net before taxes	(43,302)	(46,806)
Income taxes	17	5
<b>Net income</b>	<b>(43,319)</b>	<b>(46,811)</b>
Balance for common	(43,319)	(51,281)

Earnings common share		
Primary	\$(2.55)	\$(5.94)
Fully Diluted	\$(2.55)	\$(5.94)
Common Shares:		
Full Diluted	17,008	8,640
Year-end	19,328	14,956

**VERMILLION INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Total Revenues	2,131	2,323
Cost & expenses	10,640	9,824
Operating income	(8,509)	(7,501)
Other income (expense), net	(17)	(9)
<b>Net income</b>	(8,551)	(7,542)
Balance for common	(8,551)	(8,484)
Earnings common share		
Primary	\$(0.13)	\$(0.15)
Fully Diluted	\$(0.13)	\$(0.15)
Common Shares:		
Full Diluted	68,288	55,910
Year-end	75,383	59,999

**VILLAGE SUPER MARKET, INC.**

<b>Earnings, 3 mos. to</b> (Consol. – \$000):	10/27/18	10/28/17
Net Sales	401,550	387,340
Cost & expenses	385,730	375,753
Deprec., depl. & amort.	6,898	6,235
Operating income	8,922	5,352
Interest income	1,178	900
Interest expense	1,116	1,105
Net before taxes	8,984	5,147
Income taxes	2,715	2,131
<b>Net income</b>	6,269	3,016
Earnings common share		
Primary	\$0.49	\$0.23
Fully Diluted	\$0.43	\$0.21
Common Shares:		
Full Diluted	14,036	14,026
Year-end	14,369	

**Consolidated Balance Sheet Items, as of** (\$000):

Assets:	2018	
Cash & equivalents	88,834	
Inventories	39,299	
Current assets	189,546	
Net property & equip.	216,291	
Total assets	483,873	
Liabilities:		
Current liabilities	100,360	
Long-term debt	48,690	
Stockholders' equity	306,550	
Net current assets	89,186	

**VIRCO MANUFACTURING CORP.**

<b>Earnings, 9 mos. to Oct 31</b> (Consol. – \$000):	2018	2017
Net Sales	174,180	164,665
Cost & expenses	165,688	154,840
Operating income	8,492	9,825
Net before taxes	6,594	8,545
Income taxes	1,759	3,204
<b>Net income</b>	4,835	5,341
Earnings common share		
Primary	\$0.31	\$0.35
Fully Diluted	\$0.31	\$0.35
Common Shares:		
Full Diluted	15,491	15,324
Year-end	15,542	15,357

**VIRTU FINANCIAL INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$):	2018	2017
Total Revenues	1,438,303,000	563,461,000
Cost & expenses	823,118,000	545,179,000
Operating income	547,585,000	(17,421,000)
Net before taxes	547,585,000	(17,421,000)
Income taxes	75,330,000	(2,918,000)
<b>Net income</b>	472,255,000	(14,503,000)
Earnings common share		
Primary	\$2.07	\$(0.17)
Fully Diluted	\$2.04	\$(0.17)
Common Shares:		
Full Diluted	100,468,860	53,520,346
Year-end	189,421,327	187,211,676

**VISTEON CORP**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$Millions):	2018	2017
Net Sales	2,253	2,349
Cost & expenses	2,105	2,166
Operating income	169	188
Interest income	5	3
Interest expense	11	15
Other income (expense), net	27	17
Net before taxes	169	188
Income taxes	42	34
Income contin. oper.	127	154
<b>Net income</b>	129	162
Earnings common share		
Primary	\$4.06	\$4.75
Fully Diluted	\$4.02	\$4.68
Common Shares:		
Full Diluted	30	32
Year-end	29	

**VYCOR MEDICAL INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$):	2018	2017
Cost & expenses	1,807,575	1,852,997
Operating income	(852,922)	(949,211)
Other income (expense), net		(120,788)
Foreign currency	(1,402)	986
<b>Net income</b>	(897,399)	(1,101,909)
Balance for common	(1,221,769)	(1,426,279)
Earnings common share		
Primary	\$(0.06)	\$(0.08)
Fully Diluted	\$(0.06)	\$(0.08)
Common Shares:		
Full Diluted	21,258,184	17,895,269
Year-end	22,604,980	19,738,189

**WAITR HOLDINGS INC**

**Dismissal of Accountant** On Nov. 15, 2018, Co. dismissed Marcum LLP as its independent public accounting firm.

**WAITR HOLDINGS INC**

**New Accountant** On Dec. 2, 2018, Co. engaged Moss Adams LLP as its new independent public accounting firm.

**WAYSIDE TECHNOLOGY GROUP INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Net Sales	132,389	116,130
Cost & expenses	130,387	110,816
Operating income	2,002	5,314
Gains or losses	40	22
Net before taxes	2,786	5,802
Income taxes	987	1,867
<b>Net income</b>	1,799	3,935
Earnings common share		
Primary	\$0.40	\$0.87
Fully Diluted	\$0.40	\$0.87
Common Shares:		
Full Diluted	4,344	4,303
Year-end	4,498	

**WEBCO INDUSTRIES INC.**

<b>Earnings, 3 mos. to Oct 31</b> (Consol. – \$000):	2018	2017
Net Sales	137,002	114,270
Cost & expenses	123,115	108,529
Operating income	13,887	5,740
Interest expense	1,337	782
Gains or losses	(3)	243
Net before taxes	12,547	5,201
Income taxes	2,796	2,158
<b>Net income</b>	9,751	3,044
Earnings common share		
Primary	\$12.03	\$3.74
Fully Diluted	\$10.47	\$3.31
Common Shares:		
Full Diluted	932	919
Year-end	882	890

**Consolidated Balance Sheet Items, as of** (\$000):

Assets:	2018	
Cash & equivalents	6,189	
Inventories	198,563	
Current assets	274,797	
Net property & equip.	105,468	
Total assets	384,146	
Liabilities:		

Current liabilities	163,728
Long-term debt	12,000
Stockholders' equity	200,481
Net current assets	111,069

**WILLDAN GROUP INC**

<b>Earnings, 9 mos. to</b> (Consol. – \$):	09/28/18	09/29/17
Cost & expenses	171,430,000	195,585,000
Deprec., depl. & amort.	3,292,000	2,896,000
Operating income	11,092,000	10,710,000
Interest expense	75,000	88,000
Other income (expense), net	36,000	56,000
Net before taxes	11,053,000	10,678,000
Income taxes	2,224,000	1,839,000
<b>Net income</b>	8,829,000	8,839,000
Earnings common share		
Primary	\$1.00	\$1.03
Fully Diluted	\$0.95	\$0.97
Common Shares:		
Full Diluted	9,283,000	9,138,000
Year-end	8,921,000	8,764,000

**WORKDAY INC**

<b>Earnings, 9 mos. to Oct 31</b> (Consol. – \$000):	2018	2017
Total Revenues	2,033,552	1,560,570
Cost & expenses	2,376,553	1,782,458
Operating income	(343,001)	(221,888)
Other income (expense), net	38,624	6,170
Net before taxes	(318,619)	(226,355)
Income taxes	(4,722)	5,767
<b>Net income</b>	(313,897)	(232,122)
Earnings common share		
Primary	\$(1.46)	\$(1.12)
Fully Diluted	\$(1.46)	\$(1.12)
Common Shares:		
Full Diluted	215,588	206,715
Year-end	220,000	210,000

**XCEL BRANDS, INC.**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$):	2018	2017
Total Revenues	25,520,000	24,690,000
Cost & expenses	20,301,000	20,707,000
Operating income	3,896,000	2,810,000
Interest expense	810,000	1,040,000
Net before taxes	3,086,000	1,770,000
Income taxes	1,717,000	1,704,000
<b>Net income</b>	1,369,000	66,000
Earnings common share		
Primary	\$0.07	\$0.07
Fully Diluted	\$0.07	\$0.07
Common Shares:		
Full Diluted	18,310,654	18,896,418
Year-end	18,266,202	18,468,801

**XERIS PHARMACEUTICALS INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$000):	2018	2017
Cost & expenses	40,694	18,509
Operating income	(39,030)	(17,420)
Interest income	796	45
Interest expense	1,490	1
Other income (expense), net	63	(32)
<b>Net income</b>	(39,661)	(17,408)
Earnings common share		
Primary	\$(4.36)	\$(8.63)
Fully Diluted	\$(4.36)	\$(8.63)
Common Shares:		
Full Diluted	9,104	2,016
Year-end	20,756	

**XTANT MEDICAL HOLDINGS INC**

<b>Earnings, 9 mos. to Sep 30</b> (Consol. – \$):	2018	2017
Total Revenues	53,941,000	63,280,000
Cost & expenses	56,220,000	72,765,000
Operating income	(5,353,000)	(13,590,000)
Interest expense	8,156,000	10,538,000
Other income (expense), net	101,000	136,000
<b>Net income</b>	(13,408,000)	(23,992,000)
Earnings common share		
Primary	\$(1.19)	\$(15.94)

Fully Diluted	\$(1.19)	\$(15.94)
Common Shares:		
Full Diluted	11,262,642	1,505,493
Year-end	13,171,347	1,514,417

**Y-MABS THERAPEUTICS INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	29,152	9,969
Operating income	(29,152)	(9,969)
Other income (expense), net	(62)	62
<b>Net income</b>	<b>(29,214)</b>	<b>(9,907)</b>
Earnings common share		
Primary	\$(1.08)	\$(0.56)
Fully Diluted	\$(1.08)	\$(0.56)
Common Shares:		
Full Diluted	26,945	17,746
Year-end	34,194	

**YANGTZE RIVER PORT & LOGISTICS LTD****Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Cost & expenses	4,945,544	3,915,184
Operating income	(4,945,544)	(3,915,184)
Interest income	162	216
Interest expense	7,343,228	6,409,691
Other income (expense), net	(11,480)	(857)
Net before taxes	(12,300,090)	(10,325,516)
Income taxes	(841,660)	(816,048)
<b>Net income</b>	<b>(11,458,430)</b>	<b>(9,509,468)</b>
Earnings common share		
Primary	\$(0.07)	\$(0.05)
Fully Diluted	\$(0.07)	\$(0.05)
Common Shares:		
Full Diluted	175,281,297	198,000,128
Year-end	172,532,565	172,344,446

**YOGAWORKS INC****Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	45,550,867	40,002,033
Cost & expenses	63,667,010	43,752,287
Operating income	(24,587,179)	(10,280,843)
Net before taxes	(24,490,293)	(11,624,288)
Income taxes	20,580	31,074
<b>Net income</b>	<b>(24,510,873)</b>	<b>(11,655,362)</b>
Pfd. dividends		995,743
Balance for common	(24,510,873)	(12,651,105)
Earnings common share		
Primary	\$(1.49)	\$(1.51)
Fully Diluted	\$(1.49)	\$(1.51)
Common Shares:		
Full Diluted	16,401,589	8,363,916
Year-end	16,477,675	16,409,719

**ZAFGEN INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	46,431	39,641
Operating income	(46,431)	(39,641)
Interest income	1,214	740
Interest expense	1,399	157
Foreign currency	(182)	115
<b>Net income</b>	<b>(46,798)</b>	<b>(38,943)</b>
Earnings common share		
Primary	\$(1.53)	\$(1.42)
Fully Diluted	\$(1.53)	\$(1.42)
Common Shares:		
Full Diluted	30,609	27,414
Year-end	36,866	27,484

**ZAGG INC**

**Acquisition Completed** On Nov. 30, 2018, Co.'s wholly-owned subsidiary, Patriot Corporation Unlimited Company, acquired all the authorized and issued equity securities of Gear4 HK Ltd., the U.K.'s No. 1 smartphone case brand, with growing global distribution, from STRAX AB wholly-owned subsidiary, STRAX Holding GmbH ("STRAX"), for \$32,200,000, plus an amount equal to Gear4's cash balance as of the Acquisition Date, less an amount equal to Gear4's outstanding indebtedness as of the Acquisition Date, related transaction expenses, and an indemnification cash holdback of Euro1,500,000 (the "Indemnification

Holdback Cash"), together with up to Euro7,000,000 of Co.'s common stock, par value \$0.001 per share, valued as of the Acquisition Date (the "Consideration Shares"), the Indemnification Holdback Cash, and the Additional Consideration (as defined below), if any (the "Purchase Price"). The Purchase Price was subject to adjustment (up or down) based on the results of the agreed audit of Gear4's actual net sales, as defined in the Purchase Agreement, for the year ended Dec. 31, 2018. In the event Gear4's actual net sales for the year ended Dec. 31, 2018 were equal to or exceed the estimated net sales for such period, STRAX will be entitled to receive Euro5,000,000 of the Consideration Shares (the "Adjustment Holdback Shares") from Co. and a cash payment from Patriot in US dollars equal to the amount by which such actual net sales exceeds the estimated net sales. If, however, Gear4's actual net sales for the year ended Dec. 31, 2018 were less than the estimated net sales for such period, such shortfall shall be remedied, at STRAX's election, by either (i) STRAX making a cash payment to Patriot in the full amount of the shortfall, or (ii) Co.'s obligation to issue the Adjustment Holdback Shares being reduced by the full amount of the shortfall; provided that in the event the shortfall exceeds the value of the Adjustment Holdback Shares (calculated as of the Acquisition Date), STRAX would also be required to promptly pay to Patriot in US dollars the remaining amount of such shortfall. Under the Purchase Agreement, STRAX was also entitled to additional consideration (the "Additional Consideration") from Buyer if during the 2019 financial period beginning Jan. 1, 2019 and ending on Dec. 31, 2019 (the "Financial Period"), the audited Gear4 net sales, as reported under U.S. GAAP, exceeds certain targets. Specifically, if Gear4 has audited net sales of at least \$60,000,000 but less than \$90,000,000 in the Financial Period, STRAX was entitled to a total \$5,000,000 of Additional Consideration, and if Gear4 has audited net sales of at least \$90,000,000 in the Financial Period, STRAX was entitled to a total \$10,000,000 of Additional Consideration. Such Additional Consideration was required to be paid to STRAX no later than thirty (30) days from the later of (i) the filing of Co.'s audited 2019 financial statements with the U.S. Securities and Exchange Commission (the "SEC"), and (ii) in the event of any objection to Co.'s calculation of such Additional Consideration, final determination of the amount of such Additional Consideration in accordance with the procedures set forth in the Purchase Agreement.

**ZION OIL & GAS INC****Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Cost & expenses	7,121,000	6,937,000
Operating income	(7,121,000)	(6,937,000)
Other income (expense), net	521,000	(2,971,000)
Foreign currency	(111,000)	100,000
<b>Net income</b>	<b>(6,711,000)</b>	<b>(9,808,000)</b>
Earnings common share		
Primary	\$(0.11)	\$(0.20)
Fully Diluted	\$(0.11)	\$(0.20)
Common Shares:		
Full Diluted	59,312,000	50,252,000
Year-end	64,415,398	

**ZUMIEZ INC****Earnings, 9 mos. to** (Consol. – \$000):

	11/03/18	10/28/17
Net Sales	674,052	619,156
Cost & expenses	650,670	607,345
Operating income	23,382	11,811
Other income (expense), net	(308)	(798)
Net before taxes	24,089	11,297
Income taxes	8,496	4,432
<b>Net income</b>	<b>15,593</b>	<b>6,865</b>
Earnings common share		
Primary	\$0.63	\$0.28
Fully Diluted	\$0.62	\$0.28
Common Shares:		
Full Diluted	25,220	24,845
Year-end	25,532	25,252

**ZYNGA INC****Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	658,520	628,110
Cost & expenses	652,479	611,446
Operating income	6,041	16,664
Interest income	5,031	3,548
Other income (expense), net	10,020	4,231
Net before taxes	21,092	24,443
Income taxes	6,194	10,733
<b>Net income</b>	<b>14,898</b>	<b>13,710</b>

## Earnings common share

Primary	\$0.02	\$0.02
Fully Diluted	\$0.02	\$0.02
Common Shares:		
Full Diluted	890,146	895,207
Year-end	861,857	869,416

\*

*MERGENT OTC INDUSTRIAL News Reports 0027-0865* is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2018 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.